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Zusammenfassung	
Chromatinstrukturen	 modulieren	 und	 stabilisieren	 die	 transkriptionellen	 Veränderungen,	 die	
die	 umfassenden	 zellulären	 Veränderungen	 während	 der	 Embryonalentwicklung	 steuern.	
Mutationen	 in	 Chromatin-modifizierenden	 Proteinen	 können	 daher	 fötale	 Fehlentwicklungen	
zur	Folge	haben.	Die	Familie	der	Additional	sex	combs-like	(ASXL1/ASXL2/ASXL3)-Proteine	ist	
eine	Gruppe	von	transkriptionellen	Regulatoren,	die	verschiedene	Chromatinmodifikatoren	und	
Transkriptionsfaktoren	 an	 Zielgenen	 zusammenbringen.	 ASXL	 Proteine	 rekrutieren	
beispielsweise	 den	 Polycomb	 repressive	 complex	 2	 (PRC2),	 welcher	 die	 repressive	 Lysin	 27-
Trimethylierung	an	Histon	3	(H3K27me3)	katalysiert;	andererseits	bewirken	ASXL	Proteine	 in	
Kooperation	mit	BRCA1-associated	protein-1	 (BAP1)	die	De-Ubiquitinierung	von	Lysin	119	an	
Histon	 2A	 (H2AK119).	 Mutationen	 im	 humanen	 ASXL1-Gen	 sind	 mit	 Bohring-Opitz-Syndrom	
(BOS)	assoziiert,	ein	schwerer	Geburtsfehler,	der	unter	anderem	mit	neuronalen	Defiziten	und	
kraniofaziellen	 Anomalien	 einher	 geht.	 Ein	 Teil	 dieser	 Symptome	 deutet	 auf	 eine	
Entwicklungsstörung	 der	 Neuralleistenzellen	 (NLZ)	 hin,	 eine	 multipotente,	 migratorische	
Vorläuferpopulation.	Die	Rolle	der	ASXL	Proteine	 in	der	humanen	Embryonalentwicklung	und	
der	Pathogenese	der	verbundenen	Geburtsdefekte	ist	bis	jetzt	ungeklärt.	
Um	zu	untersuchen,	welche	molekularen	Mechanismen	zur	Entstehung	von	BOS	beitragen,	habe	
ich	humane	BOS-Modelle	entwickelt,	basierend	auf	induziert	pluripotenten	Stammzellen,	die	aus	
BOS-Patientenzellen	 generiert	 wurden	 (BOS-iPSZ),	 sowie	 genetisch	 modifizierten	 humanen	
embryonalen	 Stammzellen,	 die	 BOS-relevante	Mutationen	 im	ASXL1-Gen	 tragen	 (ASXL1PSC/PSC).	
Ich	konnte	zeigen,	dass	diese	BOS-Modelle	verkürzte	Versionen	des	ASXL1-Proteins	exprimieren,	
was	den	pluripotenten	Status	der	undifferenzierten	Zellen	nicht	drastisch	beeinflusste.	Ich	fand	
jedoch	 in	 Differenzierungsexperimenten	 in	 vitro,	 dass	 die	 Präsenz	 des	 verkürzten	 ASXL1-
Proteins	 die	 Auswanderung	 von	 NLZ	 aus	 Neuroepithelstrukturen	 verminderte,	 was	 ich	 in	
Transplantationsexperimenten	 in	 Hühnerembryonen	 bestätigte.	 Der	 Effekt	 der	 mutanten	
Proteinform	war	dominant	und	störte	auch	die	Migration	von	hühnereigenen	embryonalen	NLZ	
in	vivo.	Das	regulatorische	Netzwerk	an	Genen,	das	die	Entwicklung	von	NLZ	steuert,	wurde	in		
ASXL1PSC/PSC	 -Neuroepithelstrukturen	 unzureichend	 aktiviert.	 Dabei	 schien	 die	 drastische	
Verminderung	des	ZIC1-Genes	eine	entscheidende	Rolle	zu	spielen,	da	die	Überaktivierung	von	
ZIC1	 in	 ASXL1PSC/PSC	 	Neuroepithelstrukturen	 den	 NLZ-Entwicklungsdefekt	 rückgängig	 machen	
konnte.	 Die	 negative	 Regulierung	 von	 für	 die	 Neural-/NLZ-Entwicklung	 wichtigen	 Faktoren	
wurde	 begleitet	 von	 einer	 lokal	 verstärkten	 Markierung	 dieser	 Gene	 mit	 H3K27me3-
Modifizierungen,	 während	 auf	 globaler	 Ebene	 sowohl	 H3K27me3-	 als	 auch	 H2AK119-Level	
reduziert	 waren.	 Ich	 konnte	 zudem	 die	 Expression	 von	 	 asxl1	 und	 asxl2	 in	 Zebrafisch-
Embryonen	bestätigen	und	habe	eine	asxl1-Zebrafischmutante	entwickelt.	
Zusammenfassend	 stellt	 meine	 Arbeit	 die	 erste	 Studie	 zur	 Expression	 und	 Funktion	 von	
Proteinen	 der	 ASXL-Familie	während	 der	 Differenzierung	 von	 humanen	 Stammzellen	 dar.	 Ich	
konnte	 einen	 neuen,	 dominanten	 Mechanismus	 aufzeigen,	 demzufolge	 BOS-assoziierte	
Mutationen	 zur	 Expression	 von	 verkürzten	 ASXL1-Proteinformen	 führen.	 Diese	 hemmen	 die	
Entwicklung	zu	neuroektodermalen	Vorläufern	und	NLZ,	was	die	kraniofaziellen	und	kognitiven	
Defizite	von	BOS	erklären	kann.	Ich	habe	eine	entscheidende	Rolle	für	ZIC1	 in	der	Entwicklung	
der	 humanen	 NLZ	 in	 vitro	 identifiziert,	 und	 stelle	 die	 	 Hypothese	 auf,	 dass	 mutante	
Proteinformen	 von	 ASXL1	 zur	 aberranten	 Rekrutierung	 des	 PRC2	 und	 damit	 zu	 der	 von	 mir	
beobachteten	 Herunterregulierung	 von	 wichtigen	 Faktoren	 für	 die	 neurale	 und	 NLZ-
Entwicklung	 führen	 könnten.	 Meine	 Ergebnisse	 zur	 globalen	 Verminderung	 der	
H2AK119Ub/H3K27me3-Level	 bestätigen	 die	 bereits	 beschriebene	Überaktivierung	 von	BAP1	
durch	mutante	ASXL1-Formen	in	Tumorzellen,	und	erweitern	sie	um	den	Kontext	der	humanen	
Stammzelldifferenzierung.	Die	Ergebnisse	der	von	mir	angewandten	Modelle	ordnen	BOS,	und	
potenziell	weitere	ASXL-assoziierte	 Syndrome,	 als	Defekte	der	 neuralen	und	NLZ-Entwicklung	
ein,	 und	 können	 zukünftige	 Studien	 und	 Therapien	 in	 diesen	 und	 verwandten	 Syndromen	
unterstützen.	
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Abstract	
During	 embryonic	development,	 chromatin	 landscapes	play	 a	 central	 role	 in	orchestrating	 the	
transcriptional	networks	that	steer	cellular	identities.	De	novo	mutations	in	proteins	that	modify	
chromatin	 can	 severely	 compromise	 developmental	 gene	 networks,	 leading	 to	 defects	 in	 the	
formation	of	 fetal	organs.	The	Additional	sex	combs-like	(ASXL1/ASXL2/ASXL3)	proteins	are	a	
family	of	highly	conserved	transcriptional	regulators	that	act	as	epigenetic	scaffolds,	assembling	
chromatin	 modifiers	 and	 transcription	 factors	 at	 genomic	 targets.	 Via	 recruitment	 of	 the	
Polycomb	 repressive	 complex	 2	 (PRC2),	 ASXL	 proteins	 promote	 Histone	 3	 Lysine	 27	
trimethylation	 (H3K27me3)	 and	 repression	 of	 target	 genes,	 while	 their	 cooperation	 with	
BRCA1-associated	 protein-1	 (BAP1)	 effects	 Histone	 2A	 Lysine	 119	 (H2AK119)	 de-
ubiquitination.	 De	 novo	 truncating	 mutations	 in	 ASXL1	 are	 linked	 to	 the	 severe	 birth	 defect	
Bohring-Opitz	 Syndrome	 (BOS),	which	 is	 characterized	 by	 intellectual	 disabilities,	 craniofacial	
dysmorphisms	and	musculoskeletal	 defects,	 among	other	 symptoms.	A	 subset	 of	BOS	 features	
suggests	 perturbation	 of	 the	 neural	 crest	 (NC),	 a	 multipotent,	 migratory	 embryonic	 cell	
population.	 To	 date,	 the	 functions	 of	 ASXL	 genes	 in	 human	 embryonic	 development	 and	 the	
pathogenesis	of	related	birth	defects	remain	elusive.			
To	decipher	the	developmental	and	molecular	mechanisms	underlying	BOS,	I	generated	a	panel	
of	 human	 pluripotent	 stem	 cell	 lines,	 including	 BOS	 patient-derived	 induced	 pluripotent	 stem	
cells	 (BOS-iPSC)	 and	 genetically	 engineered	 human	 embryonic	 stem	 cell	 lines	 bearing	 BOS-
associated	mutations	(ASXL1PSC/PSC	hESC).	I	could	show	that	BOS	mutations	lead	to	expression	of	
truncated	 ASXL1	 proteins	 (aa	1-900),	 which	 did	 not	 affect	 the	 overall	 pluripotent	 state	 of	
undifferentiated	cells.	However	during	NC	differentiation	 in	vitro,	 expression	of	mutant	ASXL1	
impaired	the	emigration	of	NC	cells	from	neuroepithelial	structures,	which	was	confirmed	upon	
xenotransplantation	 into	 developing	 chicken	 embryos.	 This	 was	 a	 dominant	 effect,	 as	
overexpression	of	 truncated	ASXL1	variants	 in	 chicken	NC	progenitors	 in	vivo	 perturbed	 their	
emigration.	 I	 demonstrated	 that	 the	 characteristic	 gene	 regulatory	 network	 controlling	 NC	
development	was	negatively	regulated	in	ASXL1PSC/PSC	neuroepithelial	cultures,	including	a	panel	
of	neuroectoderm	determinants	and	of	ASXL1	and	ASXL3.	Drastically	 impaired	induction	of	the	
neural	 plate	 border	 specifier	 ZIC1	 was	 central	 to	 the	 NC	 developmental	 defect,	 as	 the	 re-
establishment	 of	 ZIC1	 expression	 in	 mutant	 NC	 cultures	 rescued	 the	 emigration	 phenotype.	
Negative	 regulation	 of	 neural/NC	 specifiers	 and	 ASXL1/ASXL3	 in	 ASXL1PSC/PSC	NC	 progenitor	
cultures	was	associated	with	 target-specific	 local	 increase	of	H3K27me3,	while	global	 levels	of	
H3K27me3	 and	 H2AK119Ub	 were	 reduced.	 I	 furthermore	 confirmed	 expression	 of	 asxl1	 and	
asxl2	in	zebrafish	embryos	and	developed	a	CRISPR-based	model	for	truncated	asxl1	function	in	
this	model.		
In	 summary,	my	 study	 for	 the	 first	 time	 examined	 expression	 and	 functions	 of	 ASXL	paralogs	
during	 commitment	 of	 human	 developmental	 progenitors.	 I	 discovered	 a	 novel	 dominant	
mechanism	of	BOS-associated	mutations	 in	ASXL1,	 leading	 to	 expression	of	 truncated	variants	
that	 perturb	 neuroectoderm	 and	 NC	 progenitor	 development,	 which	 could	 explain	 the	
craniofacial	and	possibly	the	cognitive	symptoms	of	BOS.	I	furthermore	demonstrated	a	crucial	
role	of	ZIC1	during	human	NC	differentiation,	and	showed	that	its	induction	is	perturbed	in	the	
BOS	model.	My	study	provides	initial	results	indicating	that	truncated	ASXL1	aberrantly	recruits	
or	retains	PRC2	at	negatively	regulated	neural/NC	specifiers;	on	the	other	side,	global	reduction	
in	 H2AK119Ub/H3K27me3	 in	 BOS	NC	models	 is	 in	 line	with	 studies	 on	 the	 overactivation	 of	
BAP1	 by	 truncated	 ASXL1	 in	 somatic	 cells,	 and	 implies	 this	 scenario	 in	 differentiation	 and	
development.	 Taken	 together,	 this	 study	 should	 stand	 as	 a	 paradigmatic	 case	 for	 pathological	
development	arising	from	ASXL	mutations,	and	furthermore	suggests	that	BOS	joins	a	group	of	
neuronal	and	NC-related	disorders	arising	from	chromatin-based	transcriptional	misregulations.	
The	 established	 models	 should	 thus	 be	 an	 important	 foundation	 for	 future	 research	 on	
therapeutic	intervention	in	related	disorders.		
	
	 	
	 	 	
1. Introduction 
9	
1.	Introduction	
1.1	Developmental	modeling	systems	
Our	 development	 from	 a	 small	 group	 of	 uncommitted	 pluripotent	 cells	 in	 the	 pre-
implantation	 embryo	 is	 a	 fascinating	 biological	 process.	 While	 sharing	 identical	
genomes,	 embryonic	 cells	 phenotypically	 diversify,	 a	 process	 named	 differentiation,	
through	mechanisms	 that	modulate	 the	expression	of	 the	genome2.	This	 results	 in	 the	
emergence	of	 germ	 layer	progenitors	 that	 further	become	committed	 to	precursors	of	
fetal	 tissues.	 Advancements	 in	 molecular	 biology	 have	 demonstrated	 that	 intricate	
molecular	 networks	 control	 these	 differentiation	 processes	 to	 ensure	 lineage	 fidelity	
and	stability.	However,	understanding	the	details	of	these	regulatory	circuits	is	still	in	its	
infancy,	 and	 while	 the	 investigation	 of	 developmental	 mechanisms	 in	 animal	 models	
provides	the	crucial	 framework	to	comprehend	embryogenesis,	 they	can	only	partially	
explain	human	development	because	of	evolutionary	divergence	in	regulation	3-6.	
This	is	why	the	derivations	of	human	pluripotent	stem	cells	–	of	human	embryonic	stem	
cells	 (hESCs)	 initially,	 and	 of	 induced	 pluripotent	 stem	 cells	 (hiPSCs)	 later	 –	 are	
considered	breakthroughs	in	the	study	of	human	embryonic	regulation7,8.	Indeed,	by	the	
collective	 investment	 of	 efforts,	 it	 has	 been	 clarified	 that	 differentiation	 of	 human	
pluripotent	stem	cells	in	vitro	mimics	embryonic	processes	as	shown	by	 the	 transition	
from	pluripotency	 to	 fetal	and	 tissue	progenitors	and	 further	 to	 specialized	 tissues9,10.	
Accordingly,	human	pluripotent	stem	cells	are	fundamentally	important	for	elucidating	
pathogenic	 mechanisms	 of	 congenital	 disorders	 that	 arise	 from	 perturbations	 in	
embryonic	regulation.	The	latter	paradigm	has	been	exemplified	extensively11,12,	and	is	
the	cornerstone	of	my	PhD	thesis.	Finally,	the	potency	of	human	pluripotent	stem	cells	
represents	 an	 additional	 breakthrough	 in	 medicine	 as	 they	 could	 serve	 as	 unlimited	
source	for	generating	transplantable	differentiated	cells	for	the	treatment	of	numerous	
diseases	and	injuries13,14.		
	
1.1.1	Human	pluripotent	stem	cells		
Pluripotent	human	embryonic	stem	cells	(hESCs)	are	derived	from	the	inner	cell	mass	of	
the	blastocyst,	 representing	a	 cell	population	 that	 in	vivo	 gives	 rise	 to	all	 fetal	organs7	
(Fig.	 1).	 Although	 pluripotent	 cells	 are	 transient	 in	 the	 early	 embryo,	 application	 of	
specific	 pathway	modulators	 promotes	 their	 indefinite	 renewal	 as	 stem	 cells	 in	 vitro,	
while	 maintaining	 their	 potential	 to	 differentiate15.	 This	 knowledge,	 and	
characterization	of	the	gene	regulatory	network	governing	pluripotency	in	mouse	ESCs,	
has	led	to	the	derivation	of	mouse	and	human	iPSCs	by	the	process	of	reprogramming,	
which	relies	on	the	so	called	four	Yamanaka	factors	Oct4,	Sox2,	Klf4	and	c-Myc8	(Fig.	1).	
The	 reprogramming	 process	 has	 since	 been	 refined	 and	 improved	 in	 many	 studies,	
including	the	transient	ectopic	expression	of	factors	via	transfection	of	reprogramming	
factors	as	modified	mRNA16,	episomal	plasmids17	or	proteins18.	These	delivery	methods	
in	conjunction	to	optimized	protocols	and	reagents	produce	hiPSC	lines	that	display	the	
capacities	of	hESC,	including	self-renewal	and	differentiation	into	progenitors	of	all	germ	
layers19.		
The	possibility	of	generating	hiPSCs	on	a	personalized	basis	opens	up	the	possibility	to	
produce	autologous	tissues	and	organs	for	cell	replacement	therapies14.	Moreover,	and	
as	discussed	herein,	patient	derived	hiPSCs	could	serve	as	a	platform	to	model	genetic	
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and	 environmental	 diseases11,12,	 in	 particular	 those	 with	 congenital	 presentation	
according	 to	 the	 logic	 that	 differentiation	 in	 vitro	 mimics	 embryonic	 and	 fetal	
development10.	
	
1.1.2	Genetic	engineering	of	human	pluripotent	stem	cells	
Genome-editing	techniques	that	allow	for	targeted	modification	of	single	nucleotides	or	
larger	genomic	regions	have	opened	up	new	avenues	for	disease	research	using	human	
pluripotent	stem	cells20.	The	most	recent	development	exploits	the	prokaryotic	defense	
mechanism	 CRISPR/Cas	 (Clustered	 Regularly	 Interspaced	 Short	 Palindromic	
Repeats/CRISPR-Associated)21.	 In	 an	adaptation	of	 this	 system	 to	 cultured	pluripotent	
stem	 cells,	 Caspase	 9	 (Cas9)	 nucleases	 can	 be	 recruited	 to	 specific	 genomic	 sites	 via	
short	guide	RNAs	(gRNAs)	for	introducing	point	mutations,	deleting	genomic	regions	or	
for	 integrating	 reporter	 genes22.	 Further	 improvement	 of	 the	method	 has	 led	 to	 high	
editing	efficiencies	and	low	off-target	effects	in	diverse	applications23.	
These	techniques	become	highly	relevant	for	disease	modeling	using	human	pluripotent	
stem	 cells,	 primarily	 for	 the	 introduction	 of	 disease-relevant	 mutations	 into	 human	
pluripotent	 stem	 cell	 lines	 for	 direct	 comparison	 to	 the	 parental	 lines	 as	 isogenic	
controls,	and	by	correcting	mutations	in	patient	derived	iPSCs	as	a	basis	for	comparison.	
These	steps	are	performed	when	the	cells	are	in	the	undifferentiated	state,	so	that	any	
desired	differentiated	progeny	type	can	be	generated	and	studied	directly	in	comparison	
to	the	isogenic	control	cells	(Fig.	1).	It	has	been	further	shown	that	this	modality	can	be	
used	for	tailoring	individualized	treatments	and	identifying	drug	candidates	in	screening	
settings24,25.		
	
1.1.3	Differentiation	of	human	pluripotent	stem	cells	
During	 embryogenesis,	 signaling	 pathways	 as	 a	 means	 of	 cell-to-cell	 communication	
guide	 the	 patterning	 of	 the	 embryo,	 the	 establishment	 of	 cell	 type	 diversity,	 and	 the	
formation	 of	 tissues	 and	 organs.	 Gene-targeting	 studies	 and	 expression	 analyses	 have	
identified	 several	 pathways,	 including	 Wnt,	 Nodal	 and	 bone	 morphogenetic	 protein	
(BMP)	 signaling,	which	 in	a	 coordinated	manner	 control	 early	 steps	of	 embryogenesis	
and	progressively	dictate	cell	 fates,	 from	gastrulation	and	germ	 layer	 formation	 to	 the	
differentiation	and	specialization	of	tissues26.		
These	 key	 events	 can	 be	 recapitulated	 using	 hESCs	 in	 vitro,	 which	 requires	 the	
cooperative	 action	 of	 the	 same	 signaling	 pathways	 that	 govern	 embryogenesis.	
Accordingly,	 differentiation	 protocols	 using	 pluripotent	 stem	 cells	 progress	 through	 a	
primitive	 streak-like	 phase,	 followed	 by	 germ	 layer	 formation	 and	 tissue	
specification10,27.	 Resulting	 differentiated	 cell	 populations	 are	 validated	 based	 on	 the	
expression	of	marker	genes	and	physiological	characteristics	that	identify	fetal	or	adult	
cell	 populations	 in	 vivo27.	 Furthermore,	 in	 defined	 protocols	 exploiting	 embryonic	
signaling	pathways,	pluripotent	stem	cells	give	rise	to	specialized	cells	that	functionally	
integrate	into	host	tissue	upon	transplantation27.	These	studies	show	that	differentiation	
of	pluripotent	stem	cells	mirrors	the	key	events	taking	place	during	embryogenesis,	and	
thus	serves	as	a	relevant	model	to	study	human	embryonic	development.	
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1.1.4	Modeling	developmental	syndromes	using	pluripotent	stem	cells	
Congenital	 defects	 arise	 as	 a	 consequence	 of	 perturbed	 formation	 of	 fetal	 tissues28;	
accordingly,	 the	 elucidation	 of	 disease	 mechanisms	 requires	 investigation	 of	
developmental	 systems.	 Differentiation	 of	 pluripotent	 stem	 cells	 recapitulates	 human	
embryogenesis,	hence	providing	a	suitable	model	 for	developmental	 syndromes	 in	 the	
dish12.	Human	iPSCs	reprogrammed	from	patient-derived	somatic	tissue,	or	genetically	
modified	 hESC	 expressing	 disease-relevant	mutations,	 help	 to	 decipher	 the	molecular	
mechanisms	that	are	involved	in	congenital	syndromes	and	to	establish	screens	for	drug	
discovery25,29,30.	 These	 approaches	 have	 also	 served	 the	 elucidation	 of	 aberrant	
regulation	in	neurocristopathies,	a	group	of	congenital	anomalies	resulting	from	defects	
in	a	distinct	progenitor	cell	population,	the	neural	crest31-34	(see	also	chapter	1.4.3).	As	
this	 embryonic	 lineage	 contributes	 to	hundreds	of	derivatives	 in	 the	body35,	modeling	
neural	crest	development	with	pluripotent	stem	cells	is	a	prerequisite	to	understanding	
many	human	birth	defects	on	a	cellular	and	molecular	level.		
	
	
Figure	1.	Generation,	manipulation	and	application	of	human	embryonic	stem	cells	(hESCs)	and	induced	
pluripotent	stem	cells	(hiPSCs).	
hESCs	 are	 derived	 from	 the	 inner	 cell	 mass	 of	 surplus	 embryos	 obtained	 through	 in	 vitro	 fertilization	
techniques.	 iPSC	 with	 virtually	 equal	 developmental	 properties	 can	 be	 generated	 by	 introduction	 of	
pluripotency	 factors	 into	 adult,	 somatic	 cells,	 which	 induces	 reprogramming,	 resulting	 in	 a	 pluripotent	
state.	 Genetic	manipulation	 via	 techniques	 like	 the	 CRISPR/Cas	 system	 allow	 for	 correction	 of	 disease-
associated	 genes	 in	 patient-derived	 iPSC	 cells,	 or	 introduction	 of	mutations	 into	 healthy	 donor-derived	
hESCs.	Differentiation	of	genetically	manipulated	and	control	hESC	and	hiPSC	lines	can	be	applied	to	study	
(pathological)	embryonic	processes,	perform	drug	screens	and	for	cell-based	therapies.	
	
1.2	Epigenetic	regulation	in	embryonic	development	
It	has	been	thoroughly	demonstrated	that	the	regulation	of	human	pluripotent	stem	cell	
differentiation	 involves	 changes	 of	 transcriptional	 programs;	 the	 regulatory	 network	
that	 regulates	 pluripotency	 diminishes	 during	 exit	 from	 this	 state	 while	 germ	 layer-
specific	 regulators	 become	 activated.	 In	 multipotent	 precursors,	 which	 are	 able	 to	
commit	to	various	terminal	fates,	transcriptional	landscapes	still	harbor	a	certain	degree	
of	 flexibility	 so	 they	 are	 to	 respond	 to	 specific	 guiding	 signals.	 However,	 genetic	
programs	need	to	be	consolidated,	as	cells	have	to	remember	past	fate	choices	even	after	
the	signals	that	initiated	them	are	gone.	These	processes	finally	result	in	tissue-specific	
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gene	 regulatory	 networks,	 in	 which	 pluripotency	 genes	 and	 factors	 associated	 with	
alternative	lineages	are	consistently	turned	off.	
An	 important	 question	 therefore	 is	which	 and	how	 regulatory	 factors	manipulate	 and	
maintain	 transcriptional	programs.	The	best	understood	modality	 is	via	 the	binding	of	
transcription	 factors	 (TFs)	 to	 regulatory	 elements	 of	 genes,	 which	 leads	 to	 their	
activation	 or	 repression	 through	 interactions	 with	 the	 transcriptional	 machinery.	
Nevertheless,	epigenetic	mechanisms	are	also	fundamentally	important	by	shaping	and	
stabilizing	expression	programs,	resulting	in	poising,	long-term	activation	or	silencing	of	
genes.	 These	 processes	 involve	 modifications	 of	 the	 chromatin,	 the	 complex	 of	 DNA,	
proteins	 and	 RNAs	 (Fig.	 2).	Methylation	 of	 the	 DNA,	 covalent	modification	 of	 histone	
tails,	 the	 conformational	 status	 of	 chromatin,	 and	 small	 interfering	 RNAs	 are	 primary	
epigenetic	mechanisms	 that	modulate	gene	expression36-38.	Certain	groups	of	proteins,	
named	 epigenetic	 factors,	 mediate	 these	 processes	 by	 remodeling	 chromatin,	 reading	
and	 interpreting	 epigenetic	 marks	 and	 catalyzing	 nascent	 or	 removing	 existing	
modifications39	(Fig.	2).	In	accordance	with	their	functions,	epigenetic	factors	have	been	
shown	 to	 re-arrange	 chromatin	 landscapes	 and	 thereby	 to	 regulate	 cellular	 identities	
and	to	ensure	lineage	fidelity.	These	activities	present	so-called	‘epigenetic	barriers’	that	
have	to	be	surmounted	in	order	to	switch	cellular	fates40.		
	
	
			 	
Figure	2.	Examples	of	epigenetic	mechanisms	that	regulate	chromatin	structure.	
Methylation	of	DNA	mediated	by	methyltransferases,	modification	of	histone	tails	including	methylation,	
acetylation	 and	 ubiqutination	 catalyzed	 by	 different	 sets	 of	 histone-modifying	 enzymes,	 remodeling	 of	
chromatin	by	specific	remodeling	complexes,	and	non-coding	RNAs	are	involved	in	establishing	chromatin	
landscapes	that	regulate	transcription.	Modified	from36.	
	
1.2.1	Epigenetic	regulation	in	embryonic	syndromes	
Many	 congenital	 disorders	 are	 associated	 with	 mutations	 in	 chromatin	 writers	 and	
remodeling	complexes	(selected	examples	in	Table	1).	For	instance,	haploinsufficiency	
of	 the	 chromatin	 remodeler	 CHD7	 leads	 to	 CHARGE	 syndrome33,34,41,	 and	 dominant	
mutations	of	the	transcriptional	co-activator	CREB-binding	protein	CBP	are	manifested	
in	 Rubinstein-Taybi-Syndrome42.	 Interestingly,	 in	many	 cases,	mutations	 in	 epigenetic	
factors	that	lead	to	congenital	disorders	can	also	promote	tumor	formation	if	they	occur	
in	 somatic	 tissues,	 which	 is	 thought	 to	 involve	 misregulation	 of	 transcriptional	
networks,	resulting	in	overactivation	of	proliferative	programs43	(Table	1).	The	group	of	
genes	that	exhibit	this	dual	functionality	includes	an	important	set	of	epigenetic	factors,	
the	Polycomb	proteins,	which	are	essential	for	embryonic	development	and	pluripotent	
stem	cell	differentiation44-46.	This	underscores	the	importance	of	epigenetic	processes	in	
the	regulation	of	development.	
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Table	 1.	 Examples	 of	 chromatin	 modifiers	 implicated	 in	 congenital	 syndromes	 and	 tumorigenesis.	
MRS,	 mental	 retardation	 syndrome;	 HAT,	 histone	 acteyltransferase;	 HDAC,	 histone	 deacetylase;	 HMT,	
histone	 methyltransferase;	 HDMT,	 histone	 demethylase;	 STAGA,	 SPT3/TAF9/GCN5	 transcription	
coactivator	 complex,	 SWI/SNF,	 SWItch/Sucrose	Non	Fermentable	 chromatin	 remodeling	 complex;	 CHD,	
chromodomain	 helicase	 DNA-binding	 protein	 complex,	 GOF,	 gain-of-function;	 LOF,	 loss-of-function.	
From47,48.	
Gene	 Class	 Function/	Complex	
Germline/	
de	novo	mutations	 Somatic	mutations	
CREBBP/P300	
H
is
to
ne
	m
od
ifi
er
s	
HAT	 Rubinstein-Taybi	 Syndrome	1/2	
B	 cell/follicular	 lymphoma,	
bladder	cancer,	...	
HDAC4	 HDAC	 Brachydactyly-MRS	 Breast	adenocarcinoma	
MLL2	 HMT	 Kabuki	syndrome	1	 Non-Hodgkin	lymphoma	
EZH2	 HMT	 Weaver	syndrome	2	(WVS2)		
GOF:	 Solid	 tumors	 and	 Non-
Hodgkin	 lymphoma;	LOF:	myeloid	
malignancies,	...		
NSD1	 HDMT	
Beckwith–Wiedemann	
syndrome/	 Sotos	 syndrome/	
Weaver	syndrome	1		
Acute	 myeloid	 leukemia,	
endometrial	 carcinoma,	
melanoma,	myeloma,	...	
ATXN7		
Ch
ro
m
at
in
	
re
m
od
el
er
	 STAGA-HAT	 Spinocerebellar	ataxia	7	 Breast	cancer	
ATRX	 SWI/SNF	 Alpha-thalassemia	 X-linked	MRS	
pediatric	 glioblastoma,	 pancreatic	
neuroendocrine	tumours	
CHD7	 CHD	 CHARGE-syndrome	 gastric,	colorectal,	prostate,	breast,	bladder	cancers	
	
	
1.2.2	Keeping	genes	in	check:	Polycomb	group	proteins	
Mutations	 in	 Polycomb	 group	 (PcG)	 genes	 were	 first	 described	 in	 the	 fruit	 fly	
(Drosophila),	 where	 they	 alter	 body	 segmentation,	 a	 phenomenon	 called	 homeotic	
transformations49.	This	phenotype	is	caused	by	de-repression	of	Homeobox	(Hox)	genes,	
factors	 that	 are	 important	 for	 anterior-posterior	 body	 patterning,	 and	 which	 are	
normally	 under	 tight	 spatiotemporal	 control	 by	 the	 PcG	 proteins.	 The	 connection	 to	
different	regulatory	mechanisms,	including	modification	of	local	chromatin	structure	up	
to	global	genome	architecture,	have	shown	that	PcG	factors	are	evolutionary	conserved	
regulators	in	gene	silencing	involved	in	X	chromosome	inactivation,	genomic	imprinting,	
pluripotency,	cell	cycle	control	and	cancer46,50.	
Mammalian	 PcG	 proteins	 assemble	 in	 two	 major	 complexes.	 Polycomb	 repressive	
complex	 2	 (PRC2)	 is	 responsible	 for	 mono-,	 di-	 and	 tri-methylation	 of	 Lysine	 27	 in	
Histone	 351,52.	 The	mammalian	 complex	 consists	 of	 three	 core	members:	 enhancer	 of	
zeste	(EZH1	or	EZH2),	which	catalyzes	methylation,	embryonic	ectoderm	development	
(EED)	 and	 suppressor	 of	 zeste	 (SUZ12),	 both	 of	 which	 are	 essential	 co-factors	 to	 the	
methylation	 reaction50.	 Various	 accessory	 subunits	 further	 regulate	 PRC2	 activity50.	
H3K27me3	 at	 gene	 bodies	 and	 regulatory	 regions	 is	 associated	 with	 compaction	 of	
chromatin	and	reduced	RNA	Polymerase	II	binding,	leading	to	stable	silencing	of	marked	
genes53.		
While	 PRC2	 is	 highly	 conserved	 from	 the	 fruit	 fly	 to	 mammals,	 the	 other	 repressive	
complex,	 PRC1,	 has	 undergone	 immense	 diversification	 during	 evolution54.	 Six	 human	
	 	
	 	 	
1. Introduction 
14	
PRC1	complexes	have	been	described55,	which	assemble	around	the	core	members	Ring	
finger	protein	1	A/B	(RING1A	or	B)	and	one	of	six	Polycomb	group	ring	finger	(PCGF1-6)	
proteins.	They	are	classified	into	canonical	PRC1,	characterized	by	the	presence	of	one	
chromobox	protein	CBX,	and	non-canonical	complexes56.	The	catalytically	active	RING1	
is	a	E3	ubiquitin	ligase	of	Histone	2A	at	Lysine	119	(H2AK119),	a	mark	that	is	thought	to	
induce	chromatin	compaction	and	gene	repression50,56.		
CBX	proteins	 interact	with	H3K27me3	and	 recruit	 canonical	PRC1	complexes,	 thereby	
‘reading’	 the	 epigenome	 and	 instructing	 ubiquitination	 of	 H2AK119	 in	 a	 PRC2-
dependent	manner57	(Fig.	3A).	This	hierarchical	model	–	first	PRC2	and	then	PRC1	–	has	
been	 challenged	 by	 the	 finding	 of	 non-canonical	 PRC1	 complexes	 that	 do	 not	 require	
PRC2	 activity	 to	 mediate	 H2AK119	 ubiquitination57,58.	 Quite	 the	 contrary,	 PRC1.1,	
PRC1.3	 and	 PRC1.5	 can	 recruit	 PRC2	 subunits	 and	 promote	 trimethylation	 of	
H3K27me359,60(Fig.	3A).	Moreover,	several	studies	have	shown	that	both	complexes	can	
engage	each	other	in	a	context-dependent	manner,	and	PRC	complexes	act	cooperatively	
as	well	as	independently50.		
	
1.2.3	Trithorax	proteins	antagonize	Polycomb	function	
While	 PcG	 factors	 function	 as	main	 epigenetic	 repressors,	 the	 Trithorax	 group	 (TrxG)	
proteins	are	their	positive	counterparts.	In	the	fruit	fly,	TrxG	complexes	bind	to	a	set	of	
DNA	elements	that	also	recruit	PcG	complexes,	and	antagonize	PcG	activity	to	maintain	
active	transcriptional	states51.		
Comparable	 to	 the	 PcG,	 TrxG	 factors	 assemble	 in	 multiprotein	 complexes	 of	 various	
flavors.	The	most	 important	players	 in	 transcriptional	 activation	and	maintenance	are	
the	‘switch/sucrose	non-fermentable’	(SWI/SNF)	and	the	‘Complex	proteins	Associated	
with	 Set	 1’	 (COMPASS)	 complexes50.	 The	 human	 analogs	 to	 SWI/SNF,	 the	 ‘BRG1-or	
HBRM-associated	factors’	(BAF)	and	the	‘polybromo-associated	BAF’	(PBAF)	complexes,	
are	nucleosome	remodeling	factors	that	regulate	the	chromatin	structures	of	their	target	
genes61.		
The	initial	COMPASS	complex,	which	diverged	to	several	non-redundant	COMPASS-like	
complexes	in	mammals,	counteracts	PcG	activity	by	mediating	H3K4	methylation.	SET1-
COMPASS	 catalyzes	 bulk	 trimethylation	 at	 active	 promoters	 (Fig.	 3B).	 H3K4me3	
however	can	also	be	catalyzed	independently	of	transcription	and	may	not	be	crucial	for	
initial	 activation,	 but	 rather	 supports	 the	 memory	 of	 active	 states51.	 Different	
mammalian	 ‘mixed	 lineage	 leukemia’	 (MLL)	proteins,	of	which	MLL1	 is	orthologous	 to	
Drosophila’s	 Trx,	 confer	 diverse	 functions	 to	 the	 COMPASS-like	 complexes50.	 MLL1-
COMPASS-like	 methylates	 only	 specific	 loci	 including	 the	 Hox	 genes,	 and	 MLL2-
COMPASS-like	 complexes	 are	 associated	 with	 H3K4	 trimethylation	 of	 ‘bivalent’	 genes		
(Fig.	3B,	see	also	next	chapter).	MLL3/4-COMPASS-like	are	monomethyltransferases	for	
H3K4	 at	 enhancers,	 short	 DNA	 sequences	 that	 serve	 as	 binding	 platform	 for	
transcription	 factors	and	other	 regulatory	proteins	 to	enhance	 transcription	of	nearby	
genes62	(Fig.	3B).		
Of	 note,	 histone	 methylases	 and	 demethylases	 that	 associate	 with	 PcG	 or	 TrxG	
complexes	 respectively	 antagonize	 each	 other63,64.	 Similarly,	 PcG-mediated	 chromatin	
compaction	 hinders	 SWI/SNF-mediated	 chromatin	 remodeling65.	 These	 opposing	
functions	result	in	a	balanced	system	that	can	react	to	new	transcriptional	stimuli,	and	
coordinate	systems	like	the	rapidly	changing	expression	networks	in	embryogenesis.		
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Figure	3:	Recruitment	and	opposing	functions	of	PcG	and	TrxG	complexes.	
	(A)	 Mutual	 targeting	 of	 Polycomb	 repressive	 complexes	 (PRCs)	 to	 chromatin	 results	 in	 chromatin	
condensation	 and	 transcriptional	 repression.	 Recruitment	 can	 occur	 via	 PRC2-mediated	 H3K27me3	
modifications	that	recruit	CBX	of	canonical	PRC1	(cPRC1)	complexes	(“classical	model”),	or	via	interaction	
of	 PRC2-complexes	 with	 H2AK119Ub	 that	 is	 placed	 by	 the	 RING1	 enzyme	 in	 noncanonical	 PRC1	
(ncPRC1)-complexes	 (“alternative	 model”).	 SUZ12,	 EED	 and	 EZH2	 (catalytical	 subunit)	 are	 PRC2	 core	
members.	(B)	Different	TrxG	complexes	methylate	H3K4	at	regulatory	regions.	Methylation	of	promoter	
regions	is	catalyzed	by	SET1-COMPASS,	which	effects	all	degrees	of	H3K4	methylation	and	contributes	to	
active	 transcription,	 and	 by	 MLL2-COMPASS,	 which	 is	 involved	 in	 bivalent	 states.	 MLL3/4-	 COMPASS	
complexes	monomethylate	H3K4	at	enhancers,	which	facilitates	their	activation.	After50.	
	
1.2.4	Polycomb	and	Trithorax	coordinate	developmental	gene	control	
During	embryonic	development,	 the	antagonistic	 functions	of	PcG	and	TrxG	complexes	
stabilize	 the	 cascades	 of	 transcription	 programs,	 and	 loss	 of	 PRC1	 or	 PRC2	 factors	
results	 in	 precocious,	 impaired	 or	 biased	 differentiation	 of	 pluripotent	 stem	 cells66,67.	
The	 majority	 of	 developmental	 regulators	 and	 enhancers	 exhibit	 a	 ‘bivalent’	 state	 in	
pluripotent	 stem	 cells,	 characterized	 by	 the	 presence	 of	 both	 repressive	 (H3K27me3)	
and	 permissive	 (H3K4me3,	 or	 H3K4me1	 in	 the	 case	 of	 enhancers)	 histone	 marking,	
which	is	mediated	by	PcG	and	MLL2	complexes62	(Fig.	4).	This	results	in	a	‘steady-state’	
that	allows	for	immediate	activation	upon	beginning	of	differentiation68.	Ubiquitination	
by	RING1B	also	seems	to	be	involved	in	setting	up	bivalent	chromatin	states,	and	both	
PRC1	and	PRC2	cooperate	in	silencing	developmental	regulators	like	the	Hox	genes	and	
other	 transcription	 factors	 families	 including	 the	 Pax,	 Six,	 Fox	 and	 Sox	 genes	 in	
pluripotent	stem	cells37,66,69,70.	Factors	that	are	needed	to	maintain	the	undifferentiated	
state	 of	 the	 cell	 are	 expressed	 and	 embedded	 in	 an	 active	 chromatin	 structure,	
characterized	 by	 occupation	 of	 promoters	 by	 H3K4me3	 and	 a	 relaxed	 chromatin	
conformation	(Fig.	4).		
After	 induction	of	differentiation	and	upon	lineage	commitment,	repression	of	 lineage-
specific	 regulators	 is	 released,	 and	 pluripotency	 genes	 and	 loci	 associated	 with	
alternative	 fates	 are	 silenced	 (Fig.	 4).	 How	 the	 necessary	 re-arrangement	 of	 PcG	 and	
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TrxG	 complexes	 is	 regulated	 still	 remains	 largely	 elusive,	 but	 variation	 in	 complex	
assembly	 is	known	to	 take	part	 in	 this	well-orchestrated	process.	The	CBX7	subunit	 is	
expressed	in	pluripotent	stem	cells,	and	paralogs	CBX8/2/4	replace	it	within	the	PRC1	
complex	 in	 differentiated	 cells71,72.	 Similar	 mechanisms	 are	 pertinent	 for	 the	 PCGF	
proteins,	as	well	as	the	switch	from	EZH2	to	EZH1	during	differentiation50.	Importantly,	
also	accessory	proteins	and	co-factors	facilitate	specific	targeting	of	the	PcG	complexes	
and	contribute	to	differential	regulation	of	transcription	during	lineage	commitment.	
	
	
		 	
	
Figure	 4.	 TrxG	 and	 PcG	 complexes	 control	 chromatin	 structures	 in	 pluripotent	 stem	 cells	 and	 upon	
lineage	committment.	
	In	 the	undifferentiated	 stage,	pluripotency	genes	are	actively	 transcribed	by	association	with	TrxG	and	
relaxed	histone	 states	 (H3K4me3,	H3	 acetylation),	whereas	 lineage-regulatory	 genes	 are	 in	 a	 poised	 or	
bivalent	 mode,	 marked	 by	 transcription-permissive	 (H3K4me3)	 and	 repressive	 histone	 marks	
(H3K27me3)	and	by	co-localization	of	PcG	and	TrxG	complexes.	This	state	is	resolved	to	either	repression	
or	 activation	 depending	 on	 the	 lineage	 choice,	 paralleled	 by	 repression	 of	 pluripotency.	 Upon	
transcription	factor-mediated	induction	of	expression,	TrxG	complexes	in	cooperation	with	accessory	co-
factors	 maintain	 the	 active	 transcription	 by	 establishing	 a	 permisse	 histone	 landscape	 (H3K4me3,	 H3	
acetylation,	 relaxed	 chromatin	 conformation).	 The	 absence	 of	 inductive	 signals	 results	 in	 occupation	 of	
genes	with	PcG	complexes	and	co-factors	that	generate	repressive	histone	structures	(H3K27me3,	histone	
deacetylation,	chromatin	compaction).		
	
	
Taken	 together,	 the	 TrxG	 and	 PcG	 proteins	 form	 a	 regulatory	 nexus	 that	 memorizes	
transcriptional	changes,	turning	TF-induced	regulations	into	epigenetic	landscapes	that	
last	 beyond	mitosis	 and	 ensure	 lineage	 fidelity	 during	 embryonic	 differentiation.	 The	
discovery	 of	 additional	 co-factors	 that	 interact	 with	 both	 groups	 and	 balance	 their	
functions	 should	provide	 further	 explanations	on	how	 their	 antagonistic	 functions	 are	
integrated.	
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1.3	Mediators	between	repression	and	activation:	Additional	sex	combs	
genes	
	The	Additional	sex	combs	(Asx)	gene	was	classified	in	Drosophila	as	dual	co-factor	of	PcG	
and	TrxG	proteins,	since	mutations	in	Asx	induce	anterior	and	posterior	transformations	
in	 the	 same	 embryo73,74.	 Indeed,	 Li	 et	 al.	 reported	 transient	 interaction	 of	 a	 bipartite	
motif	of	Asx	with	both	 the	SET	domains	of	Trx	and	 the	PcG	 factor	E(z),	which	enables	
target-specific	 regulation	 of	 H3K4me3	 and	 H3K27me3	 by	 Asx75,76.	 Asx	 shares	 several	
characteristics	with	PcG	proteins,	namely	a	subset	of	genomic	targets,	a	similar	protein	
structure	and	a	ubiquitous	developmental	expression	pattern;	however,	Asx	target	gene	
regulation	 is	 tissue-specific,	which	 is	unusual	 for	PcG	 factors77,78.	Hence,	Asx	 seems	 to	
play	context-dependent	roles	 in	 the	 integration	of	activating	and	repressive	epigenetic	
mechanisms.	 The	 important	 regulatory	 functions	 of	 Asx	 are	 highlighted	 by	 its	
evolutionary	 conservation	 and	 diversification	 to	 several	 paralogs	 with	 different	
structures,	expression	patterns	and	functions.	
	
1.3.1	Structural	properties	of	the	Additional	sex	combs-like	family	
Three	 genes	 constitute	 the	 human	 ASXL	 family:	 ASXL1	 and	 ASXL2,	 which	 are	 located	
within	 syntenic	 genomic	 regions	 (DNMT3B-ASXL1-KIF3B	 and	DNMT3A-ASXL2-KIF3C)79		
and	 are	 transcribed	 to	 similarly	 sized	 proteins	 (1541	 and	 1435	 amino	 acids,	
respectively),	and	ASXL3,	which	encodes	for	a	protein	of	2248	amino	acids	(Fig.	5).		
The	 ASXL	 genes	 share	 similar	 transcript	 architectures	 of	 13	 (ASXL1,	 ASXL2)	 or	 12	
(ASXL3)	exons,	respectively,	and	encode	for	 isoforms	through	alternative	splicing.	This	
includes	 not	 yet	 annotated	 exons1,	 which	 can	 result	 in	 the	 production	 of	 conserved	
circular	 isoforms	 in	 the	 case	 of	 ASXL180.	 Usage	 of	 alternative	 polyadenylation	 sites	
predicts	expression	of	 three	ASXL1	 transcripts	of	4925,	5976	and	6864	bp,	however,	a	
highly	 expressed	8	kb	 isoform	was	detected	 in	human	adult	 tissues,	 as	well	 as	 a	6	 kb	
form	and	a	5	kb	transcript,	which	was	detected	only	in	the	testis81.		ASXL	proteins	show	
a	high	degree	of	conservation	of	several	structural	and	functional	domains,	namely	the	
N-terminal	 ASXN	 domain,	 the	 ASXH	 and	 ASXM	 domains	 and	 the	 C-terminal	 plant	
homeodomain	(PHD,	Fig.	5).	The	ASXH	domain	and	the	plant	homeodomain	(PHD)	are	
conserved	in	the	Drosophila	Asx	protein79,	while	its	‘AT	hook’	DNA	binding	motif	was	not	
passed	on	to	mammalian	ASXLs78,81	(Fig.	5).		
In	 silico	 analysis	 of	 the	 ASXL	 proteins	 predicts	 N-terminal	 globular	 domains	 coined	
HARE-HTH,	which	contain	forkhead	domains	that	were	suggested	to	bind	DNA	similarly	
to	 the	FOXO1	protein82,83,	however,	 they	have	not	been	 functionally	validated	yet.	The	
ASXH	region	harbors	two	potential	nuclear	receptor	(NR)	binding	motifs	(LXXLL)	which	
are	presumptively	inactive84,	a	DEUBAD	domain	that	enables	binding	of	ASXL	members	
to	 the	 BRCA1-associated	 protein	 1	 (BAP1)82,85,	 and	 overlaps	 with	 binding	 regions	 of	
several	other	epigenetic	regulators	(HP1,	NCOA1,	LSD1,	the	Cohesin	Core	complex,	Fig.	
5).	Notably,	the	HP1	binding	motif	 is	absent	in	ASXL2.	A	further	NR	binding	motif	that	
mediates	 interaction	 with	 several	 NRs	 in	 complex	 with	 their	 respective	 ligands	 is	
situated	towards	the	C-terminus	of	the	ASXL	proteins	within	the	ASXM2	domain79.	The	
PHD	finger	at	the	very	C-terminus	of	all	ASXL	proteins	is	highly	conserved.	PHD	domains	
are	 typically	 found	 in	 chromatin-associated	 proteins,	 where	 they	 interact	 with	
methylated	 or	 acetylated	 H3	 histones86.	 The	 conformation	 of	 the	 ASXL	 PHD	 finger	
theoretically	 allows	 binding	 of	 internal	 histone	 tails	 such	 as	 K2783,	 although	 exact	
targeting	sites	and	mechanisms	have	yet	to	be	investigated.		
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Proteolytic	degradation	of	ASXL1	is	promoted	through	several	PEST	sequences81,87	and	
via	ubiquitination	of	K351,	which	has	to	be	erased	by	the	de-ubquitinating	enzyme	USP7	
to	 enhance	 ASXL1	 protein	 levels88.	 Several	 conserved	 putative	 nuclear	 localization	
signals	(NLS)	provide	a	mechanism	for	the	transportation	of	ASXLs	to	the	nucleus81.		
Given	 their	 diverse	 interaction	 capacities,	 mammalian	 ASXL	 proteins	 are	 considered	
epigenetic	 scaffolds	 that	 recruit	 other	 enzymes	 to	 target	 sites	 and	 transduce	 signals	
mediated	 by	 nuclear	 hormone	 receptors,	 integrating	 them	 with	 the	 epigenetic	 and	
transcriptional	landscape.	
	
	
	
Figure	5.	Asx	and	the	ASXL	proteins.		
Structure	of	Drosophila	Asx	(A)	and	human	ASXL1	gene	and	protein	(B)	and	ASXL2/3	proteins	(C)	with	
annotated	domains.	White	boxes	in	Asx	indicated	domains	that	are	conserved	in	mammalian	ASXLs,	and	
white	 domains	 in	 ASXL1	 are	 shared	 with	 ASXL2	 and	 ASXL3	 proteins.	 Known	 interaction	 partners	 are	
shown	in	blue	at	the	respective	binding	sites	in	Asx/ASXL1.	The	large	terminal	exon	of	the	human	ASXL1	
transcript	includes	a	mutation	‘hotspot’	(pale	red	box),	in	which	the	majority	of	mutations	that	have	been	
associated	 with	 leukemia	 and	 developmental	 syndromes	 are	 found.	 ASXN	 contains	 a	 HARE-HTH	motif	
proposed	to	 function	 in	DNA	binding.	The	ASXH	domain	harbors	a	DEUBAD	domain	present	 in	all	ASXL	
proteins.	 Histone	 binding	 of	 the	 PHD	 finger	 was	 not	 directly	 shown	 but	 inferred	 from	 sequence	
comparisons.	NLS	and	PEST	sequences	of	ASXL2	and	ASXL3	were	not	determined.	From78,79,81,83-85,88-90.	
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1.3.2	ASXL	proteins	recruit	binding	partners	and	regulate	transcription	
1.3.2.1	Nuclear	hormone	receptors	and	Cohesin	
NRs	 are	 a	 family	 of	 transcription	 factors	 that	 complex	 with	 small	 molecule	 ligands	
including	 steroid	 hormones	 and	 retinoids,	 bind	 to	 responsive	 DNA	 elements	 and	
regulate	 transcription	 of	 their	 target	 genes.	 Thereby,	 they	 are	 involved	 in	 different	
processes	 of	 embryonic	 vertebrae	development,	 cellular	metabolism	and	homeostasis,	
and	cancer91-93.		
Studies	reporting	on	the	interaction	of	ASXL	proteins	with	several	types	of	ligand-bound	
NRs	though	specific	motifs	in	the	ASXM2	domain,	which	is	not	present	in	Drosophila	Asx,	
offered	new	insights	on	how	NR-initiated	transcriptional	regulation	can	be	sustained	by	
chromatin	modifications84.	 	 ASXLs	 seem	 to	 act	 as	 regulatory	 switches	 that	 specifically	
assemble	 transcription	 factors	and	repressive	or	activating	histone	modifiers	at	 target	
promoter	regions	in	a	context-dependent	manner.			
In	 cell	 lines,	 ASXL1	was	 shown	 to	 enhance	 the	 transcriptional	 activity	 of	 the	 Retinoic	
Acid	Receptor	(RAR)	–	Retinoic	X	Receptor	(RXR)	complex,	supposedly	via	binding	and	
recruitment	of	the	histone	acetyltransferase	NCOA1	to	target	promoters84		(Fig.	6A).		By	
contrast,	the	transcriptional	activity	of	a	different	NR,	peroxisome	proliferater-activated	
receptor	 γ	 (PPARγ),	 is	 repressed	 in	 association	 with	 ASXL1.	 This	 occurs	 via	 ASXL1-
mediated	 recruitment	 of	 Heterochromatin	 protein	 1	 (HP1),	 a	 factor	 shown	 to	 lock	
condensed	 chromatin94,	 and	 is	 accompanied	 by	 an	 increase	 in	 H3K9	 trimethylation95		
(Fig.	 6A).	 Interestingly,	 ASXL2,	 which	 lacks	 the	 HP1	 binding	 motif,	 increases	 the	
transcriptional	 activity	 of	 the	 NRs	 PPARγ,	 RAR	 and	 also	 the	 estrogen	 receptor95,96,	
whereas	ASXL3	with	a	retained	HP1	binding	box	was	found	to	repress	the	activities	of	
RARα,	 the	 liver	X	receptor	α	and	the	thyroid	receptor	α95,97.	 	PPARγ	 is	associated	with	
ASXL2	 at	 selected	 promoter	 regions	 together	 with	 the	 TrxG	 protein	 MLL1,	 which	 is	
accompanied	 by	 locally	 increased	 levels	 of	 H3K9ac	 and	 H3K4me3.	 These	 reports	
demonstrate	the	opposing	functions	of	ASXL1/ASXL3	and	ASXL2	at	a	specific	subset	of	
shared	target	genes95.			
A	recent	study	further	extended	the	list	of	ASXL1-binding	proteins	by	core	members	of	
the	Cohesin	complex,	which	function	in	separation	of	sister	chromatids	during	mitosis98,	
and	 it	 was	 suggested	 that	 via	 recruitment	 of	 Cohesin	 members,	 ASXL1	 plays	 an	
important	role	in	this	process90.	
	
1.3.2.2	Interaction	with	Polycomb	repressive	complex	2	
Despite	 the	 multitude	 of	 regulatory	 functions,	 members	 of	 the	 ASXL	 family	 are	
generally	considered	PcG	co-factors.	In	fact,	several	reports	have	confirmed	the	integral	
function	of	ASXL1,	and	partially	also	of	ASXL2,	 in	recruitment	of	the	PRC2	complex	to	
promote	 global	 or	 local	 deposition	 of	 repressive	 H3K27me3	 marks	 and	 gene	
silencing99-103	(Fig.	6B).	
In	human	 leukemia	 cells,	ASXL1	 loss	 or	 knockdown	 leads	 to	 reduction	 in	H3K27me3	
levels	at	transcriptional	start	sites	(TSSs)	of	predominantly	bivalent	genes,	gene	bodies	
and	large	H3K27me3	regions,	and	to	de-repression	of	HOXA	genes99.	This	effect	is	more	
pronounced	upon	complete	knockout	of	Asxl1	 in	hematopoietic	 lineages	 in	mice100,104.	
Shown	not	to	be	mediated	by	transcriptional	repression	of	the	PRC2	complex,	binding	
of	 EZH2	 to	HOXA	 genes	 is	 dramatically	 decreased	 when	 ASXL1	 is	 downregulated	 or	
absent.	The	HOX	loci,	as	well	as	other	CpG-rich	TSSs	of	PcG	target	genes,	are	co-bound	
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by	ASXL1.	Together	with	the	observation	that	re-introduction	of	ASXL1	in	knockdown	
cells	or	 enhanced	endogenous	ASXL1	 levels	 lead	 to	 an	 increase	 in	H3K27me3	marks,	
these	 findings	confirm	a	role	of	ASXL1	 in	 the	recruitment	of	EZH2	 to	 target	sites	and	
promoting	H3K27	trimethylation88,99.	Of	note,	AsxNull	Drosophila	embryos	do	not	exhibit	
reduction	 in	 bulk	 H3K27me3	 levels105,	 although	 Asx	 has	 been	 shown	 to	 regulate	
H3K27me3	at	target	genes75.	 It	 is	 therefore	suggested	that	Asx/ASXLs	are	 involved	in	
PcG	recruitment	in	distinct	cell	types	and/or	at	specific	loci.	Direct	binding	of	ASXL1	to	
core	 PRC2	 members	 EZH2	 and	 SUZ12,	 but	 not	 to	 PRC1	 members,	 was	 detected	 in	
hematopoietic	and	HEK293T	cells99.			
ASXL2	 loss	 also	 results	 in	 slight	 reductions	 of	 H3K27me3	 levels,	 decreased	 PRC2	
binding	 and	 de-repression	 of	 selected	 genes103,	 which	 do	 however	 not	 include	 Hox	
genes	 in	 Asxl2-Null	 mouse	 hearts102.	 Interestingly,	 these	 effects	 are	 accompanied	 by	
increased	deposition	of	H3K27me2,	which	supports	a	model	of	unspecific	PRC2	binding	
and	 mono-	 and	 di-methylation	 of	 H3K27	 by	 Ezh2,	 while	 efficient	 trimethylation	
requires	 tethering	of	 the	PRC2	complex	 through	Asxl250,102.	This	 interaction	however	
seems	to	be	indirect	or	transient103,106.		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	 6.	 The	 diverse	 functionality	 of	 ASXL1	 in	
transcriptional	 regulation	 relies	 on	 its	 association	 with	
nuclear	receptors	and	enzymes.	
(A)	ASXL1	can	bind	several	nuclear	hormone	receptors	via	its	
ASXM2	 domain.	 In	 HEK293	 and	 mouse	 preadipocyte	
fibroblasts,	 the	 association	 of	 ASXL1	 with	 the	 peroxisome	
proliferator-activated	receptor	γ	(PPAR)	-	retinoic	x	receptor	
(RXR)-	 complex	 in	 the	 presence	 of	 rosiglitazone	 (Rosi)	
inhibits	 the	 activation	 of	 adipogenic	 target	 genes	 through	
recruitment	 of	 heterochromatin	 protein-1	 (HP1),	 which	
trimethylates	H3K9.		
Conversely,	binding	of	ASXL1	to	the	retinoic	acid	receptor	(RAR)-RXR	complex	in	the	presence	of	retinoic	
acid	(RA)	results	in	activation	of	RA-target	genes	in	HeLa	cells,	as	ASXL1	additionally	recruits	the	histone	
acteyltransferase	NCOA1. (B)	 ASXL1	 can	 recruit	 Polycomb-repressive	 complex	2	 (PRC2)	 subunits	EZH2	
and	 SUZ12,	 which	 is	 important	 for	 H3K27me3	 placement	 and	 silencing	 of	 bound	 targets.	 (C)	 The	
Polycomb	 repressive	 de-ubiqutination	 complex	 (PR-DUB),	 composed	 of	 ASXL1	 and	 the	 de-ubiqutinase	
BAP1,	 is	 involved	 in	 PcG-mediated	 transcriptional	 regulation	 through	 removal	 of	 ubiquitin	 marks	 at	
H2AK119.	Truncated	variants	of	ASXL1	(ASXL1PSC),	which	can	be	the	result	of	mutations	in	leukemia	cells,	
enhance	the	de-ubiqutinating	activity	of	PR-DUB,	resulting	in	loss	of	H2AK119	and	H3K27me3,	and	gene	
de-repression.	(A-C):	from69,84,95,99,100,107.		
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1.3.2.3	Formation	of	the	PR-DUB	complex	
ASXL	proteins	act	as	regulatory	switches	also	by	regulating	the	Polycomb	repressive	de-
ubiquitinating	 complex	 (PR-DUB).	 Scheuermann	 and	 colleagues	 coined	 this	 name	 in	
2010,	 when	 they	 discovered	 the	 interaction	 between	Drosophila’s	 Asx	 and	 calypso,	 a	
histone	de-ubiquitinating	 enzyme,	which	 is	 conserved	 in	 the	mammalian	ASXL1-BAP1	
complex105.	BAP1	is	a	member	of	a	family	of	ubiquitin	carboxy-terminal	hydrolases	that	
act	as	ubiquitin	proteases	on	diverse	substrates	in	different	cellular	processes108,	and	it	
is	essential	for	mouse	embryonic	development109.		
By	 specifically	 erasing	H2AK119Ub	marks	 (Fig.	 6C),	 the	PR-DUB	 complex	 counteracts	
ubiquitination	 catalyzed	 by	 the	 RING1	 enzyme	 in	 PRC1,	 a	 mark	 that	 is	 involved	 in	
chromatin	compaction,	gene	silencing	and	recruitment	of	PRC2	complexes	as	mentioned	
earlier.	 Surprisingly,	 PR-DUB	 activity	 is	 nevertheless	 required	 for	 PcG-mediated	
silencing	 of	 Hox	 genes,	 as	 well	 as	 for	 their	 activation,	 and	 the	 complex	 is	 bound	 at	
regulatory	 regions	 of	 many	 PcG	 targets	 irrespective	 of	 their	 transcriptional	 status105.	
These	 seemingly	 contradictory	 observations	 imply	 an	 intricate	 balancing	 mechanism,	
which	requires	both	ubiquitination	and	de-ubiquitination	at	 least	 in	the	context	of	Hox	
gene	regulation105,110.		
Knockout	and	Knockdown	studies	indicate	that	the	roles	of	Asx/ASXLs	in	the	PR-DUB	
complexes	 reside	 in	 the	 stabilization	 of	 calypso/BAP1	 protein	 levels105,111,	 and	 in	
facilitating	the	interaction	of	the	catalytically	active	center	of	BAP1	with	its	substrate,	
thus	enhancing	the	reaction85.	All	human	ASXL	paralogs	can	associate	with	BAP1,	and	
their	 DEUBAD	 domains	 (Fig.	 5)	 activate	 the	 de-ubiqutinating	 reaction	 85,106,109,112,113.	
ASXL1	and	ASXL2	form	mutually	exclusive	PR-DUB	complexes	that	might	be	redundant,	
since	 in	 HeLa	 cells,	 only	 knockdown	 of	 both	 ASXL1	 and	 ASXL2	 leads	 to	 significant	
increase	in	H2AK119Ub	levels,	and	not	all	Asxl1	Knockout	studies	report	alterations	in	
H2AK119Ub	 levels104,111.	BAP1	also	positively	affects	expression	and	protein	 levels	of	
ASXL1	and	ASXL288,111,	and	although	it	was	suggested	that	this	does	not	occur	through	
de-ubiqutination	of	the	proteins	themselves,	this	point	might	require	further	analysis88.	
BAP1	 assembles	 additional	 proteins	 including	 HCF1,	 a	 transcriptional	 co-regulator,	
OGT,	KDM1B,	FOXK1/2	and	YY1109,114,	and	may	thus	 form	a	platform	for	different	co-
factors	with	diverging	functions.		
Interestingly,	 mutant	 variants	 of	 the	 ASXL1	 protein	 can	 arise	 as	 a	 consequence	 of	
leukemia-promoting	 mutations,	 which	 generate	 premature	 stop	 codons	 (PSC)	 in	 the	
ASXL1	transcript69,88.	These	truncated	forms	(ASXL1PSC)	can	bind	to	BAP1	and	strongly	
stimulate	 the	 catalytical	 function,	 resulting	 in	 massive	 de-ubiquitination	 and	
concomitant	 reduction	 in	H3K27me3	 levels	 (Fig.	 6C).	These	 findings	provide	 a	novel	
mechanism	for	transcriptional	dysregulation	in	myeloid	malignancies69.	
	
1.3.3	ASXLs	in	embryonic	development		
Regulation	of	Hox	genes	is	an	important	task	of	Asx	during	Drosophila	embryogenesis78,	
and	 an	 evolutionary	 conserved	 developmental	 function	 that	 expanded	 to	 other	 genes	
and	organs	with	the	diversification	of	the	ASXL	family	in	mammals.		
This	 is	 evident	 by	 the	 expression	 of	 all	 Asxl	 paralogs	 during	 mouse	 embryonic	
development115.	Specifically,	Asxl1	and	Asxl2	transcripts	are	expressed	in	the	egg	and	in	
the	 pre-	 and	 the	 postimplantation	 embryo,	 and	 are	 presumably	 regulated	 in	 a	
coordinated	manner,	whereas	the	expression	of	Asxl3	is	restricted	to	mid-gestation	and	
to	 post-natal	 pups	 at	 low	 levels115.	 Expression	 of	 Asxl1	 and	 Asxl3,	 albeit	 the	 latter	 in	
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lower	 levels,	 in	neuroectodermal	 tissues	suggest	a	 role	 in	brain	and/or	eye	 formation,	
which	 is	 supported	 by	 the	 complete	 absence	 or	 reduced	 size	 of	 eyes	 in	 Asxl1	 null	
mice100,116.	 These	 mutants	 exhibit	 embryonic	 lethality	 on	 a	 pure	 inbred	 background,	
with	 resorbed	 embryos	 found	 as	 early	 as	 day	 12.5	 of	 gestation,	whereas	 homozygous	
progeny	 of	mixed	 background	 die	 postnatally	 at	 day	 3.	 They	 show	 reduction	 in	 body	
size,	decreased	kidney	size,	reduced	thymus	and	testis	weight,	splenomegaly,	defects	in	
lung	maturation,	cleft	palate,	skeletal	transformations	and	reduced	skull	size100,107,116-118.	
Heterozygous	animals	displayed	craniofacial	features	in	35	%	of	cases	in	one	study100.	In	
accordance	with	positive	and	negative	misregulation	of	Hox	genes,	both	Asxl1	and	Asxl2	
null	 embryos	 exhibit	 mild	 anterior	 and	 posterior	 transformations,	 visible	 in	 skeletal	
abnormalities100,116,119.	 Notably,	 also	 ASXL3	 seems	 to	 be	 involved	 in	 the	 regulation	 of	
HOX	genes,	as	seen	in	ASXL3-deficient	human	fibroblasts112.		
Asxl1	 seems	 to	 be	 important	 for	 self-renewal	 of	 hematopoietic	 stem	 cells	 as	 well	 as	
erythroid	 development	 and	 terminal	 maturation,	 presumably	 via	 regulating	 PcG-
mediated	histone	modifications100,104.	Asxl2	 takes	over	non-redundant	 functions	 in	 the	
maintenance	 of	 hematopoietic	 stem	 and	 progenitor	 cells103,	 whereas	 Asxl3	 is	 not	
expressed	during	hematopoiesis120.	Apart	 from	the	hematopoietic	 lineage,	Asxl1	 seems	
to	 regulate	 the	 self-renewal	 of	 skeletal	 stem	 cells,	 and	 Asxl1	 ablation	 skews	 their	
differentiation	 from	osteoblasts	 to	 adipocytes118.	This	 contrasts	 in	vitro	 studies,	which	
reported	repression	of	adipocyte	fate	by	Asxl1,	and	activation	of	adipogenesis	by	Asxl2	in	
pre-adipocyte	murine	cell	lines95.		
Furthermore,	 both	 Asxl1	 and	 Asxl2	 are	 important	 for	 different	 aspects	 of	 heart	
development.	Depletion	of	Asxl2	or	Asxl1	 leads	to	heart	defects	of	different	penetrance	
and	 pathologies,	 and	 each	 gene	 cannot	 compensate	 for	 mutations	 in	 the	 other	
paralog107,119.	 Asxl2-mediated	 recruitment	 of	 PRC2	 to	 promoters	 of	 specific	 cardiac	
genes	and	their	repression	via	maintenance	of	H3K27me3	marks	seems	to	be	involved	
both	 in	 embryonic	 heart	 formation	 and	 adult	 heart	 function102,106,119.	 In	 general,	Asxl2	
null	mice	exhibit	less	severe	phenotypes	compared	to	Asxl1	null	mutants,	with	reduced	
body	size	and	perinatal	death102,107,119.	Some	features	in	Asxl2	null	mice	were	attributed	
to	 regulation	 of	 skeletal	 homeostastis,	 as	 it	 was	 proposed	 that	 Axl2	 regulates	
osteoclastogenesis96,121,	 which	 is	 the	 generation	 of	 bone-absorbing	 cells	 from	
hematopoietic	progenitor	cells122.	
Taken	together,	animal	models	revealed	roles	of	Asxls	in	regulation	of	fetal	development,	
specifically	 Hox	 genes,	 craniofacial	 development,	 proliferation	 and	 differentiation	 of	
progenitor	 and	 stem	 cells	 in	 the	 hematopoieitic	 system	 and	 in	 the	 lung,	 kidney	
development,	heart	and	bone	formation,	adipogenesis	and	lipid	and	insulin	homeostasis.	
These	 findings	 mainly	 stem	 from	 analyses	 in	 mouse	 models.	 The	 functions	 of	 ASXL	
proteins	 in	 human	 cell	 systems	 have	 not	 been	 investigated	 thus	 far,	 although	 the	
involvement	 of	 ASXL	 genes	 in	 human	 diseases	 suggests	 important	 functions	 in	
development	and	tissue	homeostasis.	
	
1.3.4	Mutations	in	ASXL	genes	cause	human	diseases	
1.3.4.1	ASXL	genes	and	cancer	
The	contribution	of	ASXL	 genes	 to	 the	control	of	proliferative	processes100,103,113,118	 is	
evident	from	their	involvement	in	tumorigenesis79.		
ASXL1	 is	 among	 the	most	 frequently	mutated	 genes	 in	 all	 types	 of	malignant	myloid	
diseases123,124.	Strikingly,	the	exclusively	heterozygous	mutations	predominantly	reside	
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in	the	last	exon	of	ASXL1,	indicating	a	‘mutation	hotspot’	(see	highlighted	region	in	Fig.	
5A).	 They	 are	 predominantly	 frameshift	 or	 nonsense	 and	 thus	 generate	 PSCs,	 which	
implies	production	of	a	truncated	protein,	excluding	the	functional	NR	binding	motif	as	
well	 as	 the	 putative	 histone-interacting	 PHD	 domain79.	 Nevertheless,	 the	 exact	
pathogenic	 mechanism	 has	 not	 yet	 been	 clarified.	 It	 was	 suggested	 that	 rapid	
degradation	of	mutant	ASXL1	 isoforms	results	in	loss	of	ASXL1	expression	in	cell	 lines	
derived	from	myeloid	leukemia	patients99,125.	However,	new	data	links	putative	ASXL1	
truncating	mutations	 to	PcG	misregulation.	One	 study	 reported	 that	 truncated	ASXL1	
variants	are	not	degraded	but	are	in	fact	as	stable	as	the	long,	native	ASXL1	transcript	in	
leukemia	cell	lines126.	When	ectopically	expressed,	ASXL1	variants	encompassing	the	N-
terminal	635	or	646	amino	acids	inhibit	hematopoietic	differentiation	in	precursor	cells	
and	act	as	drivers	of	myelodysplastic	syndrome	in	mice101.	On	the	molecular	level,	the	
truncated	 isoform	leads	 to	 global	 reduction	 in	 H3K27me3	 levels	 and	 upregulation	 of	
PRC2	target	genes,	including	the	posterior	HOXA	genes,	which	supports	the	hypothesis	
that	truncated	ASXL1	proteins	are	dominantly	acting	and	hamper	EZH2	recruitment	or	
function.		
A	 different	 hypothesis	was	 brought	 forward	 by	 Balasubramani	 et	al,	 who	 noted	 that	
exogenous	 truncated	 ASXL1	 expression	 promotes	 global	 reduction	 of	 H2AK119Ub,	
which	is	indicative	of	increased	activation	of	the	PR-DUB	complex.	This	was	followed	by	
a	reduction	in	H3K27me3	levels	and	skewed	differentiation	in	hematopoietic	precursor	
cells69.	 The	 temporal	 order	 of	 histone	 modification	 events	 suggests	 that	 the	 loss	 of	
H2AK119Ub	signals	might	hinder	recruitment	of	PRC2	complexes.	Recent	studies	that	
expressed	 truncated	Asxl1	 in	mouse	models	have	 confirmed	a	dominant	 effect	of	 the	
mutant	 protein	 in	 the	 progression	 to	 myeloid	 malignancies	 in	 cooperation	 with	
additional	factors127,128.		
Regarding	mutations	in	the	other	ASXL	paralogs	that	were	linked	to	tumorigenesis,	no	
studies	 exist	 on	 their	 molecular	 mechanisms.	 Mutations	 in	 ASXL2	 were	 identified	 in	
myelodysplastic	syndrome	and	acute	leukemia	as	the	second	most	frequent	hit	after	the	
KIT	 gene,	 both	 in	 pediatric	 and	 adult	 cases129.	 ASXL3	 mutations	 were	 described	 in	
various	malignancies,	but	rarely	in	myeloid	disorders129,130.		
In	conclusion,	perturbation	of	ASXL	function	in	somatic	tissues	can	contribute	to	cancer	
progression,	potentially	via	the	production	of	dominant	protein	isoforms.		
	
1.3.4.2	Bohring-Opitz	syndrome	
	In	 2011	 and	2012,	 two	 exome-sequencing	 studies	 identified	 heterozygous,	 truncating	
mutations	 in	 the	ASXL1	 gene	 as	 a	 cause	 for	 Bohring-Opitz-Syndrome	 (BOS),	 a	 human	
congenital	 defect	 described	 initially	 in	 1975131-135.	 The	 characteristic	 symptoms	 that	
clinically	 define	 BOS	 include	 microcephaly	 and	 trigonocephaly,	 severe	 feeding	
difficulties,	 craniofacial	 dysmorphisms,	 intrauterine	 growth	 restriction,	 severe	
developmental	 delay,	 intellectual	 disabilities,	 and	 a	 specific	 limb	 posture	 with	
contractures	of	the	upper	limbs131,132,136	(BOS	posture;	Fig.	7	A-C,	Table	2).	Craniofacial	
features	 comprise	 prominent	 eyes,	 an	 abnormal,	 and	 less	 commonly	 cleft	 palate,	
retrognathia	 (overbite),	 anteverted	 nares,	 nevus	 flammeus	 (port-wine-stain)	 on	 the	
forehead,	upslanted	palpebral	fissures	(upslanted	eyes)	and	rarely	ocular	hypertelorism	
(wide-set	eyes)	(Fig.	7	A-B,	Table	2).			Further	symptoms	found	at	varying	penetrance	
in	 the	 patients	 are	 vision	 impairment	 and	 ophthalmic	 features,	 seizures,	 episodes	 of	
sleep	apnea,	brain	malformations	including	Dandy-Walker	malformation	and	agenesis	of	
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the	corpus	callosum,	cyclic	vomiting,	genital	abnormalities	and	heart	defects131,132,136,137.	
Thus,	 neonatal	 presentation	 is	 variable,	 which	 renders	 initial	 diagnosis	 challenging.	
Interestingly,	BOS	cases	show	comparable	frequencies	of	symptoms	irrespective	of	the	
presence	of	absence	of	ASXL1	mutations,	which	implies	a	commonality	of	the	underlying	
molecular	pathways.	However,	hypertrichosis/hirsutism,	i.e.	abnormal	hair	growth,	and	
myopia	 are	 strongly	 correlated	 with	 perturbation	 of	 the	 ASXL1	 locus,	 suggesting	 an	
exclusive	link134,137.		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	 7.	 Mutations	 in	 human	 ASXL	 genes	
are	 associated	 with	 similar	 developmental	
syndromes.
	(A-C)	 Patients	 diagnosed	 with	 Bohring-
Opitz	 syndrome	 (BOS).	 Characteristic	
features	 are	 port-wine	 stains	 (nevus	
flammeus)	on	 the	 forehead,	upslanting	eyes	
and	 cleft	 lip	 (A),	 narrow	 palate	 (B)	 and	 a	
flexed	 posture	 (C).	 Images	 from132,135.	 (D)	
Truncating	 mutations	 in	 the	 middle	 region	
of	 the	ASXL1	 gene	 are	 associated	with	 BOS	
development.	 From133,134,137.	 (E-F)	 Facial	
appearance	 of	 patients	 diagnosed	 with	
Bainbridge	 Ropers	 syndrome	 (BRS)	 caused	
by	truncating	ASXL3	mutations	(E;	 from138),	
and	 with	 a	 novel	 neurodevelopmental	
syndrome	 associated	 with	 mutations	 in	
ASXL2	(F;	from139).		
	
	
BOS	patients	are	at	high	risk	of	death	during	early	infancy,	which	 is	mainly	caused	by	
recurrent	respiratory	 infections137.	These,	 together	with	persistent	 feeding	difficulties	
observed	 in	 all	 patients,	 require	 repeated	 hospitalizations137.	While	 these	 symptoms	
generally	improve	with	age,	the	specific	BOS	posture	impedes	or	entirely	prevents	for	
patients	to	sit	or	walk	on	their	own,	and	severe	intellectual	disabilities	contribute	to	the	
lack	of	speech	and	reduction	in	purposeful	movements132,137.	
To	date,	there	are	51	BOS	cases	documented	in	the	literature,	of	which	17	were	tested	
positive	on	ASXL1	mutations133,134,137.	Strikingly,	similar	to	the	myeloid	diseases,	all	of	
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these	mutations	are	 frameshift	 or	PSC-gain	and	 lie	 in	 the	penultimate	or	 last	 exon	of	
ASXL1	(Fig.	 	7D),	suggesting	similar	mechanisms.	Although	leukemia	was	not	reported	
in	any	of	the	BOS	patients	with	ASXL1	mutations	so	far,	Wilms	tumor	developed	in	the	
kidneys	 of	 two	patients137.	 This	 is	 noteworthy	 since	murine	Asxl1	 binds	 to	Wtip,	 the	
Wilms	tumor	1-interacting	protein117.	As	described	above,	Asxl1	null	mice	show	partial	
phenotypic	overlap	with	human	BOS	symptoms,	including	low	birth	weight,	craniofacial	
features	 and	 heart	 defects100,107,118.	However,	 it	 is	 not	 yet	 clear	whether	BOS-causing	
mutations	result	in	ASXL1	loss	of	function	or	a	dominant	functionality	of	the	truncated	
protein.	 The	pending	 clarification	of	 a	molecular	 etiology	 is	 of	 special	 importance,	 as	
the	other	ASXL	family	members	are	likewise	implicated	in	congenital	malformations.						
	
1.3.4.3	ASXL2-	and	ASXL3-associated	human	disorders	
Two	 human	 syndromes	 with	 manifestations	 resembling	 those	 of	 BOS	 have	 been	
attributed	to	mutations	in	ASXL2	and	ASXL3139,140.	
Bainbridge-Ropers	 syndrome	 (BRS)	 is	 clinically	 defined	 by	 the	 presence	 of	 mild	
craniofacial	dysmorphisms,	absence	of	speech,	hypotonia,	developmental	delay,	failure	
to	 thrive	 and	 severe	 feeding	 difficulties,	 intrauterine	 growth	 restriction,	 and	
gastrointestinal	symptoms,	and	has	been	linked	to	exclusively	truncating	mutations	in	
the	 penultimate	 or	 last	 exon	 of	 ASXL3112,138,140	 (Fig.	 7E,	 Table	 2).	 In	 total,	 29	 BRS	
patients	have	been	described	to	date	with	mutations	in	the	ASXL3	locus,	and	they	show	
variable	 degrees	 of	 symptomatic	 severity,	 also	 including	 less	 prominent	 features	 as	
slender	habitus,	little	facial	expression,	mild	autism,	sleeping	disorders	and	very	rarely	
trigonocephaly112,138,140-143.	 Arguing	 for	 a	 role	 in	 neuronal	 development,	 missense	
mutation	 in	 ASXL3	 have	 also	 been	 described	 in	 individuals	 with	 autism	 spectrum	
disorders144.			
Most	 recently,	 a	 novel	 neurodevelopmental	 syndrome,	 hereafter	 termed	 NDS,	 was	
defined	by	a	distinct	set	of	symptoms	and	presence	of	heterozygous	truncating	variants	
in	 the	 penultimate	 or	 last	 exon	 of	 ASXL2139.	 The	 six	 patients	 presented	 variable	
developmental	 and	 intellectual	 impairments,	 macrocephaly,	 specific	 facial	 features,	
congenital	heart	disease,	feeding	difficulties	and	hypotonia	(Fig.	7F,	Table	2).		
It	 is	 striking	 that	 all	 known	 ASXL-related	 congenital	 disorders	 are	 associated	 with	
mutations	 in	 analogous	 regions,	 which	 suggests	 a	 common	 pathological	 mechanism.	
One	 group	 reported	 reduced	 ASXL3	 expression	 in	 BRS	 patient-derived	 fibroblasts,	
coupled	 to	 increased	 H2AK119Ub	 levels	 due	 to	 impaired	 PR-DUB	 activity112.	 On	 the	
other	hand,	both	the	wildtype	and	mutant	alleles	of	ASXL2	and	ASXL3	were	reported	to	
be	 expressed	 at	 equal	 levels	 in	 NDS-	 and	 BRS	 patient-derived	 cells,	 respectively,	 in	
other	studies139,140.	This	argues	against	loss-of-function	variants	and	suggests	common	
pathogenic	mechanisms.		
The	 intricate	 chromatin-related	 molecular	 coupling	 behavior	 of	 ASXLs	 likely	
contributes	 to	 the	 broad	 spectrum	of	 symptoms	 and	 affected	 tissues	 in	 these	 human	
disorders.	 Conceivably,	 ASXL	 mutations	 might	 also	 perturb	 the	 development	 of	
embryonic	cell	types	that	contribute	to	a	broad	variety	of	adult	tissues.	The	neural	crest	
constitutes	a	candidate	cell	population	in	this	context,	as	it	is	multipotent	and	involved	
in	many	common	birth	defects	including	craniofacial	dysmorphisms.	
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Table	 2.	 Main	 clinical	 features	 of	 human	 diseases	 associated	 with	 mutations	 in	 ASXL	 genes.
	NA,	not	available/unknown.	From137,139.	
	 Bohring-Opitz	Syndrome	(BOS)	
Bainbridge-Ropers	
Syndrome	(BRS)	
ASXL2-associated	
syndrome	
Gene	
mutation	 Truncating	mutation	in	ASXL1	 Truncating	mutation	in	ASXL3	
Truncating	mutation	in	
ASXL2	
Prenatal	 IUGR	 IUGR	 no	findings	
Growth	
parameters	
Severe	growth	retardation,	
microcephaly	
Severe	growth	retardation,	
microcephaly	 Variable,	macrocephaly	
Nutrition	 Severe	feeding	difficulties	 Severe	feeding	difficulties	 Only	neonatal	problems	
Hypotonia	 Present	 Present	 Present	
Intellectual	
disabilities	 Severe	 Severe	
Variable,	from	moderate	to	
severe	
	Seizures	 Present	 NA	 Variable	
Brain	MRI	
Brain	abnormalities	(Dandy	
Walker	malformation,	
agenesis	of	corpus	callosum)	
Brain	abnormalities	(Dandy	
Walker	malformation,	white	
matter	volume	loss)	
Brain	abnormalities	(white	
matter	volume	loss)	
Craniofacial	
features	
Trigonocephaly,	prominent	
eyes,	ocular	hypertelorism,	
retrognathia,	low-set	
posteriorly	rotated	ears,	high	
narrow	palate,	cleft	palate,	
upslanting	palpebral	fissures,	
prominent	forehead	
Prominent	eyes,	ocular	
hypertelorism,	arched	
eyebrows,	anteverted	nares,	
low-set	posteriorly	rotated	
ears,	high	narrow	palate,	high	
and	broad	forehead	
Prominent	eyes,	ocular	
hypertelorism,	low-set	
posteriorly	rotated	ears,	
broad	nasal	tip,	ptosis	of	
eyelids,	arched	eyebrows,	
epicanthal	folds	
Hair/Skin	 Nevus	flammeus,	hypertrichosis	
deep	palm	creases,	
hypertrichosis	
Deep	palm	creases,	nevus	
flammeus	
Skeleton	
Scoliosis,	ulnar	deviation	of	
hands,	flexed	wrists	and	
elbows	
Ulnar	deviation	of	hands	 Variable	(advances	bone	age,	fractures,	fusions,	scoliosis)	
Heart	 Atrial	and	ventricular	septal	defects	 Patent	ductus	arteriosus	 Atrial	septal	defects	
Eyes	 Myopia,	retinal/optic-nerve	abnormalities,	strabismus	 -	 -	
Infections	 Recurrent	infections	 -	 -	
	
	
1.4	The	neural	crest:	A	versatile	embryonic	cell	population	
The	 neural	 crest	 (NC)	 is	 a	multipotent,	 transient	 embryonic	 cell	 population	 that	 only	
exists	in	vertebrates145.	After	establishment	of	their	NC	identity,	cells	migrate	over	long	
distances	 in	the	embryo,	 invading	various	organs	and	differentiating	 into	a	plethora	of	
cell	 types,	 including	 striated	 muscle,	 dermis,	 cartilage	 and	 bone	 of	 the	 skull,	
odontoblasts	that	contribute	to	the	teeth,	all	pigment	cells	except	those	arising	from	the	
retina,	 sensory	neurons	and	enteric	 ganglia	 in	 the	peripheral	nervous	 system,	 adrenal	
and	other	endocrine	cells,	smooth	muscles,	adipocytes	and	connective	tissue	supporting	
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the	 function	 of	 thymus,	 the	 thyroid	 glands,	 the	 outflow	 tract	 of	 the	 heart	 and	 the	
branchial	vascular	sector35,146,147.	No	other	embryonic	 lineage	generates	such	a	diverse	
spectrum	 of	 derivatives35.	 This	 enormous	 developmental	 potential	 demands	 tight	
control	of	NC	induction,	proliferation,	migration	and	terminal	differentiation;	otherwise,	
perturbations	 of	 NC	 development	 lead	 to	 congenital	 defects146.	 Studies	 in	 Xenopus,	
chicken,	 qail,	 zebrafish	 and	 mouse	 embryos	 have	 provided	 initial	 insights	 into	 a	
generally	 conserved	 transcriptional	 network	 regulating	 the	 different	 steps	 of	 NC	
development.	
	
1.4.1	The	transcriptional	network	directing	neural	crest	identity	
NC	progenitors	arise	in	an	area	between	the	neural	plate,	which	is	the	precursor	of	the	
central	 nervous	 system,	 and	 the	 adjacent	 ectoderm	 during	 early	 gastrulation148.	 This	
region,	 termed	 the	 neural	 plate	 border	 (NPB),	 is	 formed	 by	 a	 combination	 of	 signals	
derived	 from	 interactions	 between	 the	 neural	 plate,	 the	 non-neural	 ectoderm	and	 the	
underlying	 paraxial	 mesoderm,	 and	 include	 intermediate	 levels	 of	 BMP	 signaling	
together	 with	 high	 levels	 of	 Fibroblast	 Growth	 Factors	 (FGF),	 Wnt,	 RA	 and	 Notch	
signaling149	(Fig.	8A).	 Interestingly,	binding	sites	for	WNT	and	BMP-signaling	effectors	
were	 identified	 at	 human	 NC	 cell	 enhancers,	 suggesting	 conservation	 of	 instructive	
mechanisms	during	NC	fate	decisions150.		
Integration	 of	 these	 different	 signals	 induces	 the	 expression	 of	 the	 so-called	 NPB	
specifiers,	which	 include	Tfap2,	Msx1,	Zic1,	Gbx2,	Pax3/7,	Dlx5/6,	Gata2/3,	Foxi1/2	and	
Hairy2151.	 They	 form	 a	 self-maintaining	 regulatory	 network	 that	 confers	NPB	 identity,	
separating	future	NC	from	the	neighboring	central	nervous	system.	The	NPB	specifiers,	
most	 importantly	 Pax3/7,	 Msx1	 and	 Zic1,	 in	 concert	 with	 reiterated	 signaling	 by	 the	
above-mentioned	 pathways	 activate	 the	 next	 set	 of	 regulatory	 factors,	 the	 NC	
specifiers151	(Fig.	8A).		
The	NC	 specification	module	 includes	 c-Myc,	Ets1,	FoxD3,	Tfap2a,	Snail1/2,	 Id,	 and	 the	
SoxE	family	members	(mainly	Sox9	and	Sox10);	importantly,	the	majority	of	NPB	and	NC	
specifiers	 were	 confirmed	 to	 be	 important	 for	 human	 NC	 formation	 in	 vitro	 as	
well150,152,153.	Thus,	 at	 the	 time	 the	neural	 tube	closes,	nascent	NC	cells	 situated	at	 the	
dorsal	 neural	 folds	 are	 identified	 by	 robust	 expression	 of	 an	 autoregulatory	 and	
interconnected	 combination	 of	 factors	 centered	 around	 FoxD3,	 Snail1/2	 and	
Sox8/9/10151.	 Of	 note,	 expression	of	 several	NPB	 specifier	 genes	 can	be	maintained	 at	
this	 stage,	 e.g.	 Zic1,	 Tfap2a	 and	 Msx1151.	 The	 NC	 specifying	 network	 has	 two	 main	
functions:	maintaining	the	developmental	plasticity	of	the	NC	population,	and	initiating	
the	next	step	of	NC	development,	their	emigration149	(Fig.	8A).	
Delamination	of	NC	 cells	 from	 the	neuroepithelium	requires	 enormous	 transcriptional	
and	 structural	 changes	 that	 start	 the	 migratory	 program	 via	 an	 epithelial-to-
mesenchymal	 transition	 (EMT).	 The	 global	 E-Cadherin	 to	 N-Cadherin	 switch	 in	 pre-
migratory	cells154,	mediated	by	the	combinatorial	action	of	NC	specifiers	in	combination	
with	Wnt	signaling,	is	one	of	the	main	drivers	of	EMT,	delamination	and	dispersion	of	NC	
cells151,155,156.	Among	the	few	studies	on	epigenetic	regulation	of	NC	development150,157-
159,	 it	 was	 shown	 that	 the	 PRC2	 complex	 is	 recruited	 by	 Snail2	 and	 important	 for	 E-
Cadherin	 downregulation	 in	 Xenopus160,	 while	 the	 PBAF	 remodeling	 complex	 in	
cooperation	with	 CHD7	 promotes	 transcription	 of	 important	 TFs,	 including	 SOX9	 and	
TWIST1,	to	activate	the	migratory	program	in	human	NC	cells33.		Essentially,	interactions	
within	 the	 migratory	 module	 of	 the	 NC	 regulatory	 network	 equip	 NC	 cells	 with	 the	
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molecular	 machinery	 needed	 for	 migration,	 invasion,	 remodeling	 of	 the	 extracellular	
matrix	and	activation	of	distinct	differentiation	programs161	(Fig.	8A).		
	
	
	
Figure	 8.	 Neural	 crest	 (NC)	 development	 and	 contribution	 to	 craniofacial	 tissues.
	(A)	NC	development	occurs	in	several	steps,	which	are	characterized	by	expression	of	different	modules	
of	a	gene	regulatory	network	in	Xenopus,	zebrafish	and	chicken.	Signaling	pathways,	including	WNT,	BMP,	
Notch	 and	 FGF,	 induce	 the	 formation	 of	 the	 neural	 plate	 border	 (NPB),	 which	 is	 characterized	 by	 the	
expression	of	NPB	specifiers.	This	set	of	genes,	together	with	reiterated	WNT	and	FGF	signaling	pathways,	
activates	 the	 NC	 specifier	 module,	 which	 is	 responsible	 for	 equipping	 premigratory	 NC	 cells	 with	 a	
molecular	 toolset	 for	 their	 delamination	 from	 the	 dorsal	 neural	 tube.	 This	 includes	 an	 epithelial-to-
mesenchymal	 transition	 (EMT)	 and	 activation	 of	 the	 NC	migratory	 expression	module.	 After	migration	
and	invasion	of	target	organs,	post-migratory	NC	cells	differentiate	into	a	variety	of	derivatives,	depending	
on	 external	 stimuli	 that	 modulate	 internal	 differentiation	 programs.	 From158.	 (B)	 Different	 NC	
subpopulations	(highlighted	by	different	colors),	reflecting	regionalization	of	the	body	axis,	emigrate	from	
their	position	of	birth	at	the	neural	folds.	Cranial	NC	cells	migrate	into	the	head	region	and	organize	the	
formation	of	craniofacial	structures,	which	are	colored	depending	on	the	NC	population	that	contributed	
to	their	development.	From162.	
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1.4.2	The	fate	of	neural	crest	cells	
Even	 after	 delamination,	 the	 majority	 of	 NC	 cells	 maintain	 multipotency163.	 While	
migrating,	 NC	 cells	 encounter	 environmental	 cues	 presented	 by	 surrounding	 tissues,	
which	 cooperatively	 with	 cell-intrinsic	 properties	 dictate	 their	 terminal	 identity	 by	
activation	of	tissue-specific	regulatory	networks164.	The	diversification	of	NC	cells	is	also	
guided	by	already	active	transcription	and	signaling	networks,	including	Sox10	and	Wnt	
signaling,	 which	 promote	 the	 derivation	 of	 neurons,	 glia	 and	 melanocytes	 from	 NC	
cells165,	while	BMP	signaling	is	 involved	in	their	differentiation	to	smooth	muscle	cells,	
and	also	in	the	formation	of	the	autonomous	nervous	system166.	
Two	major	 subpopulations,	 cranial	 and	 trunk	NC	 cells,	 emigrate	 from	 the	 neural	 tube	
and	 contribute	 to	 overlapping,	 but	 also	 distinct	 sets	 of	 derivatives.	 Trunk	 NC	 cells	
colonize	 the	 entire	 gut	 wall,	 forming	 all	 neurons	 of	 the	 enteric	 system166,	 and	 also	
contribute	 to	 the	 sympathetic	 ganglia	 and	 the	 dorsal	 root	 of	 the	 peripheral	 nervous	
system167.	
The	 cranial	 NC	 populates	 the	 developing	 pharyngeal	 arches	 and	 the	 head	 region,	
contributing	 to	 formation	 of	 heart	 (vagal	 NC	 subpopulation),	 thymus	 and	 craniofacial	
structures158.	 NC-derived	 ectomesenchyme	 forms	 the	 future	 face	 and	 head	 in	 an	
intricate	 process	 of	 continuous	 interactions	 between	 multiple	 other	 ectodermal,	
mesodermal	and	endodermal	cell	populations162,168,169	(Fig.	8B).	Frontal	bone	formation	
from	 the	 cranial	 NC	 is	 driven	 by	 FGF,	 canonical	 WNT	 and	 sonic	 hedghehog	 (SHH)	
signaling	and	other	molecules,	as	well	as	Msx2,	Tfap2a	and	Sox10	expression170-172.	The	
NC	also	contributes	to	smooth	muscles,	cartilage,	pigment	cells	and	blood	vessels	of	the	
face,	 strongly	 influencing	 the	 facial	 appearance173.	 In	 accordance,	 mutations	 in	 genes	
that	 are	 important	 for	 NC	 development	 result	 in	 congenital	 birth	 defects	 including	
craniofacial	abnormalities172.		
	
1.4.3	Neurocristopathies	
Abnormal	 development	 of	 the	 NC	 in	 response	 to	 genetic	 mutations	 that	 affect	 NC	
proliferation,	migration,	survival	or	differentiation	leads	to	organ	and	tissue	defects	that	
are	collectively	termed	neurocristopathies35,146.	Among	the	most	frequent	pathologies	in	
this	group	are	DiGeorge’s	syndrome,	Goldenhar’s	syndrome,	Waardenburg’s	syndrome,	
CHARGE	 syndrome	 and	 Treacher	 Collins	 syndrome35,146.	 Mutations	 in	 known	 NC	
specifier	genes	are	often	observed	in	these	disorders,	and	correspondingly	to	the	diverse	
array	 of	 NC	 derivatives,	 common	 symptoms	 include	 lack	 of	 outflow	 tract	 septation,	
partial	lack	of	enteric	ganglia	(aganglionosis),	hearing	loss,	mandible	defects,	cleft	palate	
and	pigmentation	defects35.		
CHARGE,	which	is	an	acronym	for	the	characteristic	symptoms	(colonoma	of	iridis,	heart	
defects,	atresia	choanae,	 retarded	growth,	genital	hypoplasia,	ear	anomalies)	observed	
in	 this	 syndrome,	 is	 attributed	 to	 mutations	 in	 CHD741,174.	 This	 chromatin	 modulator	
cooperates	with	SOX2,	SOX9	and	SOX10	in	regulating	NC	specification33,175,	and	 loss	of	
CHD7	 in	 human	 pluripotent	 stem	 cells	 leads	 to	 defective	 delamination	 and	migration,	
and	 reduced	motility	of	derived	 cranial	NC	 cells33,41.	 Impaired	migration	of	NC	 cells	 is	
also	implicated	in	Hirschsprungs	disease,	where	a	lack	of	enteric	NC	results	in	reduced	
innervation	 of	 the	 intestine35.	 Furthermore,	 neurocristopathy-related	mutations	 often	
manifest	 in	 abnormalities	 of	 the	 craniofacial	 skeleton	 through	 defective	 patterning	 of	
cranial	NC	cells,	as	seen	in	Treacher	Collings	syndrome172.	
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It	 was	 estimated	 that	 over	 500	 mendelian	 congenital	 disorders	 likely	 involve	 NC	
perturbation150,	which	makes	the	case	 for	 the	 importance	of	understanding	human	NC	
development.		
	
1.4.4	In	vitro	generation	and	maintenance	of	human	NC	cells	
The	vast	majority	of	knowledge	on	the	factors	that	drive	and	regulate	NC	development	is	
extrapoplated	 from	 animal	 models	 to	 the	 human	 case.	 While	 many	 interactions	 and	
instructive	signals	are	conserved,	mammalian	evolution	is	undoubtedly	accompanied	by	
shuffling	of	regulatory	networks176.	Hence,	to	better	understand	human	NC	specification,	
differentiation	 and	 related	 pathologies,	 NC	 developmental	 processes	 have	 to	 be	
investigated	in	cell	culture	experiments.		
Differentiation	 of	 hESC	 or	 hiPSC	 to	migratory	 NC	 cells	 in	 vitro	 follows	 the	 same	 gene	
cascades	that	also	regulate	embryonic	NC	development,	confirming	the	conservation	of	
master	 regulators	 including	 PAX3,	 TFAP2A,	 ZIC1,	 TWIST1,	 SNA1,	 SLUG,	 MSX1/2	 and	
SOX10150,152,153,177,178.	Approaches	are	generally	based	on	defined	culture	conditions,	and	
initial	protocols	made	use	of	unspecific	instructive	signals	by	stromal	feeder	cells179,180.	
Several	feeder-free	systems	rely	on	variations	of	N2	(/B27)	medium	complemented	with	
BMP	 and	 Transforming	 Growth	 Factor	 β	 (TGFβ)	 inhibitors,	 WNT	 activation	 and/or	
addition	 of	 FGF	 and	 Epithelial	 Growth	 Factor	 (EGF),	 some	 of	 these	 via	 formation	 of	
neural	 rosettes	 or	 neurospheres	 that	 resemble	 neural	 tube	 structures33,34,181-183.	
Isolation	of	pure	NC	populations	from	heterogeneous	neural	precursor	cultures	is	based	
on	 the	 expression	 of	 conserved	 markers	 including	 TFAP2A,	 POU4F1,	 SOX10,	 p75	 and	
HNK1,	although	 it	was	reported	that	HNK1	does	not	 label	all	migratory	cells	 in	human	
embryos184.	 The	 identity	 of	 in	 vitro	 generated	 NC	 cells	 is	 furthermore	 confirmed	 via	
terminal	 differentiation	 into	 their	 derivatives,	 as	 well	 as	 in	 grafting	 experiments	 that	
confirm	in	vivo	migration	capabilities179,185.	
Generation	of	human	NC	cells	in	vitro	has	been	proven	to	be	a	very	useful	tool	to	model	
neurocristopathies	 like	 CHARGE	 syndrome,	 understanding	 molecular	 etiologies	 and	
identifying	 new	 targets	 for	 therapeutic	 intervention33,34.	 Furthermore,	 the	
differentiation	 of	 patient-derived	 iPSC,	 corrected	 for	 their	 disease-specific	 mutations,	
offers	 the	 possibility	 to	 modulate	 or	 restore	 diseased	 tissues	 through	 autologous	
transplantation172,186,187.	 Just	recently,	 tissue-engineered	human	small	 intestine	models	
were	 repopulated	 with	 enteric	 NC	 cells	 derived	 from	 human	 pluripotent	 stem	 cells,	
resulting	 in	 functional	 innervation,	which	 demonstrates	 the	 feasibility	 of	 regenerative	
therapies	in	disorders	like	Hirschsprung’s	disease188.	
In	 all,	 future	 work	 on	 human	 NC	 derivation	 in	 vitro	 will	 likely	 give	 new	 insights	 in	
normal	 and	 pathological	 NC	 development,	 and	 should	 meet	 the	 challenges	 of	 safe	
derivation	and	efficient	homing	and	function	of	NC	cells	in	target	tissues	to	enable	their	
use	in	human	therapies.		 	
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1.5	Aim	and	impact	of	this	work	
During	 the	 last	 years,	 an	 increasing	 list	 of	 human	 congenital	 syndromes	 has	 been	
attributed	to	perturbations	in	ASXL	genes.	While	this	indicates	consistency	with	findings	
on	Asx(l)	functions	during	mouse	and	fly	development,	there	is	a	lack	of	corresponding	
studies	elaborating	on	possible	developmental	roles	of	the	human	counterparts.		
Based	 on	 the	 symptoms	 linked	 to	 heterozygous	 mutations	 in	 ASXL	 genes	 and	 their	
embryonic	origin	and	impact	on	prenatal	growth	and	morphogenesis,	I	hypothesize	that	
ASXL	 proteins	 occupy	 fundamental	 positions	 in	 the	 orchestration	 of	 early	 human	
developmental	 programs.	 Therefore,	 I	 seek	 to	 identify	 how	 ASXL1	 contributes	 to	 the	
commitment	and	maturation	of	embryonic	lineages	on	the	cellular	and	molecular	level.	
My	focus	is	set	on	ASXL1	firstly	because	BOS	is	relatively	severe,	and	secondly	due	to	its	
manifold	 functions	 in	 transcriptional	 regulation.	 How	 these	 are	 involved	 in	 the	
pathogenesis	 of	 BOS	 is	 currently	 not	 known,	 and	 I	 want	 to	 clarify	 whether	 and	 how	
reduction	in	ASXL1	 levels	or	dominant	mutant	variants	contribute	to	the	emergence	of	
BOS	symptoms.	
Findings	 from	 this	 work	might	 likewise	 be	 relevant	 to	 hematological	 disorders,	 since	
truncating	mutations	in	ASXL1	are	causative	to	BOS	as	well	as	human	leukemias.	Some	
advances	were	already	made	in	the	context	of	tumorigenesis,	suggesting	that	malignant	
processes	 might	 arise	 from	 perturbed	 regulation	 of	 ASXL1	 with	 PRC2	 and	 PR-DUB.	
Developmental	 tasks	 of	 these	 complexes	 have	 been	 predicted	 before105,	 and	 can	 be	
inferred	 from	 embryonic	 defects	 in	 Polycomb	 mutants189.	 This	 motivates	 my	
investigations	on	PRC2-	and	BAP1-associated	functions	of	ASXL1	during	differentiation	
of	embryonic	lineages.		
Prior	to	this	undertaking	however	stands	the	identification	of	embryonic	tissues	that	are	
influenced	by	ASXL1	 regulation.	 Craniofacial	 features	 in	BOS	 conceivably	 argue	 for	 an	
involvement	 of	 the	 NC,	 and	 this	 hypothesis	 is	 compliant	 with	 published	 expression	
patterns	of	Asxl1	in	murine	NC-associated	tissues115.	I	want	to	scrutinize	an	involvement	
of	 ASXL1	 and	 BOS-associated	 ASXL1	 mutations	 in	 NC	 development	 as	 a	 conceivable	
mechanism	underlying	 the	 congenital	 birth	 defects	 in	 BOS	 patients.	 Potential	 findings	
might	 furthermore	 expand	 the	 still	 very	 limited	 knowledge	 of	 epigenetic	 regulation	
during	NC	specification	and	differentiation157.		
In	 summary,	 I	 define	 the	 purpose	 of	 the	 following	 work	 as	 an	 attempt	 to	 advance	
insights	 into	 ASXL1	 regulation	 of	 differentiation:	 in	 i)	 normal	 and	 ii)	 BOS-associated	
pathological	development	of	embryonic	lineages,	specifically	the	NC,	and	iii)	Polycomb-
mediated	 epigenetic	 regulations	 involved	 therein.	 	 Thus,	 this	 study	 should	 stand	 as	 a	
paradigmatic	 case	 for	 pathological	 development	 arising	 from	ASXL	mutations,	 and	my	
endeavors	 should	 be	 an	 important	 foundation	 for	 future	 research	 on	 therapeutic	
intervention	 in	 related	 disorders.	 On	 a	 more	 basic	 level,	 ASXLs	 might	 be	 important	
regulatory	 factors	 that	 integrate	 positive	 and	 negative	 signals	 during	 lineage	
commitment	and	confer	specificity	to	PcG-associated	regulations.	Novel	findings	should	
thus	 add	 to	 the	 understanding	 of	 the	 mechanisms	 that	 control	 human	 embryonic	
development	 and	 NC	 development,	 which	 is	 fundamental	 to	 the	 development	 of	 safe	
cell-based	therapies	in	the	culture	dish.	
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2.	Materials	and	methods	
2.1	Materials	
2.1.1	Cell	culture	media,	supplements	and	small	molecule	inhibitors	
Reagents	are	further	specified	in	the	respective	sections	of	the	experimental	procedures	
where	they	were	applied.	Reagents	and	supplies	routinely	used	in	cell	culture	are	listed	
in	Table	M1	below.	
		
Table	M1.	Media,	supplements	and	equipment	used	in	cell	culture	experiments.	cat.	#,	catalogue	number.	
Reagent	 cat.	#	 Supplier	
2-Mercaptoethanol	 31350-010	 Life	Technologies	
Accutase	 A6964-100ML	 Sigma-Aldrich	
B27	Supplement	 17504044	 Life	Technologies	
BMP-2	(recombinant)	 0120-02-10	 PeproTech	
Bovine	Serum	Albumin	(BSA),	Cell	Culture	Grade	 10773877	 Thermo	Fisher	Scientific	
Cell	scraper	 sc-213230	 Santa	Cruz	
CHIR99021	 4953/50	 R&D	Systems	
Collagenase,	type	IV	 17104019	 Life	Technologies	
Cryotubes		 10577391	 Thermo	Fisher	Scientific	
DMEM	 21969035	 Life	Technologies	
DMEM/F12	 11320074	 Life	Technologies	
DMSO	 D5879-100ml	 Sigma-Aldrich	
Dorsomorphin	 3093	 Tocris	
Doxycycline	hydrochloride		 D9891-1G	 Sigma-Aldrich	
EGF	 E9644-.2MG	 Sigma-Aldrich	
Fibronectin	from	human	plasma	 F1056-1MG	 Sigma-Aldrich	
Gelatin,	powdered,	pure	Ph.	Eur.,	NF	 A1693.0500	 AppliChem	
Geltrex	Basement	Membrane	Matrix	 A1413302	 Life	Technologies	
Gentle	Cell	Dissociation	Reagent	 7174	 STEMCELL	technologies	
GlutaMAX,	100X	 35050038	 Life	Technologies	
HyClone™	Fetal	Bovine	Serum	(South	America),	Research	
Grade	
SV30160.03		
LOT	#RZB35918	 GE	Healthcare	
Insulin	 12585014	 Life	Technologies	
Knockout-Serum	Replacement	(KSR)	 10828028	 Thermo	Fisher	Scientific	
Matrigel-Matrix	 354230	 Corning	
MEM	Non-Essential	Amino	Acids	Solution	(NEAA,	100X)	 11140050	 Thermo	Fisher	Scientific	
mFreSR™	 5855	 STEMCELL	technologies	
Millex-GP	Syringe	Filter	Unit,	0.22	µm,	polyethersulfone,		
33	mm,	gamma	sterilized	 SLGP033RS	 Merck	Millipore	
mTeSR1	medium	 5850	 STEMCELL	technologies	
N2	Supplement	 17502048	 Life	Technologies	
Neurobasal	Medium	 21103049	 Life	Technologies	
Phosphate-buffered	Saline	(PBS),	1x	 14190094	 Life	Technologies	
Penicillin-Streptomycin		 15070063	 Life	Technologies	
Recombinant	Human	FGF-basic	(154	a.a.;	bFGF/FGF-2)	 100-18B	 Peprotech	
StemMACS	iPS-Brew	XF		 130-104-368	 Miltenyi	Biotec	
StemMACS	SB431542	in	Solution	 130-106-543	 Miltenyi	Biotec	
Trypsin-EDTA	(0.25%),	phenol	red	 25200056	 Thermo	Fisher	Scientific	
Y-27632	dihydrochloride	(ROCKi)	 1254/10	 R&D	Systems	
µ-Slide	8	Well,	ibidi-treat	 80826	 Ibidi	
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2.1.2	Cell	lines	
Two	different	human	embryonic	stem	cell	 lines,	H9	(WA09)	and	HUES9	iCas9190	 	were	
used	in	this	work	as	control	lines	and	for	genetic	engineering	purposes	as	outlined	in	the	
respective	methods	 sections	 below.	 The	 iCas9	 line	 bears	 a	 genomic	 integration	 of	 the	
endonuclease	Caspase	9	(Cas9),	expression	of	which	can	be	induced	by	administration	of	
doxycycline	(DOX)	to	the	culture	medium190	.		
For	comparison	to	the	BOS	patient-derived	iPSC	that	were	generated	during	this	study	
(see	 section	2.2.2),	 two	 control	hiPSC	 lines	were	 applied.	These	were	generated	by	E.	
Rusha	 and	 Dr.	 Pertek	 at	 the	 hiPSC	 Core	 Facility	 of	 the	 Helmholtz	 Center	 Munich,	
Germany	 via	 reprogramming	 of	 fibroblasts	 from	 a	 healthy	 2-year-old	 donor	 using	
modified	 mRNA	 (for	 details	 on	 the	 reprogramming	 method,	 see191),	 and	 via	
reprogramming	of	B-lymphocytes	derived	from	a	healthy	12-year-old	donor	via	4-in-1-
mini-intronic	plasmids17.	
	
	2.1.3	Chemicals	
All	chemicals	were	of	reagent	grade;	routinely	used	reagents	are	denoted	in	Table	M2	
below.	
	
Table	M2.	Chemicals,	reagents	and	solutions	routinely	used	in	this	study.	
Reagent	 cat.	#	 Supplier	
16%	Formaldehyde	(w/v),	Methanol-free		 10321714	 Thermo	Fisher	Scientific	
2-Mercaptoethanol	 M3148	 Sigma-Aldrich	
Albumin	from	bovine	serum	(BSA)	 A9647-10G	 Sigma-Aldrich	
Ampicillin	sodium	salt	 A-166	 Sigma-Aldrich	
Biozym	LE	Agarose	 840004	 Biozym	
Boric	acid,	electrophoresis	grade	 15166.02	 Serva	Electrophoresis	
DAPI	Nuclear	Staining	Dye		 1351303	 Bio-Rad	Laboratories	
DNA	Gel	loading	dye,	6x	 R0611	 Thermo	Fisher	Scientific	
Dynabeads(R)	Protein	A	for	Immunoprecipitation	 10001D	 Life	Technologies	
EDTA	Dinatriumsalz	Dihydrat	>99%	 X986.1	 Carl	Roth	
EGTA	 3054.1	 Carl	Roth	
Ethanol,	99.8%	 9065.2	 Carl	Roth	
Ultra	pure	glycerol	 15514011	 Thermo	Fisher	Scientific	
Glycine	 23391.02	 Serva	Electrophoresis	
HEPES,	1M	Buffer	Solution		 15630122	 Life	Technologies	
Isopropanol	 6752.2	 Carl	Roth	
Potassium	hydroxide	(KOH)	 6751	 Carl	Roth	
Lithium	chloride	(LiCl)	 62480-500G-F	 Sigma	
Lithium	Acetate	dihydrate,	98%	 15157442	 Thermo	Fisher	Scientific	
Methanol	 45631.02	 Serva	Electrophoresis	
Magenesium		chloride	(MgCl2)	 KK36	 Carl	Roth	
Na-deoxycholate	 D6750-10G	 Sigma-Aldrich	
NaHCO3	 S5761	 Sigma-Aldrich	
Tergitol	type	NP-40	70%	solution	 NP40S	 Sigma-Aldrich	
Nuclease-free	water	(H2O)	 AM9932	 Life	Technologies	
Phenylmethylsulfonylfluorid	(PMSF)	 6367,1	 Carl	Roth	
Powder	Milk,	blotting	grade	 T145.1	 Carl	Roth	
Protease	Inhibitor	Cocktail	Set	III,	EDTA-Free	 539134	 Merk	Millipore	
Ribonucleic	acid,	transfer	from	bakers	yeast	(tRNA)	 R5636-1ML	 Sigma-Aldrich	
SDS	Solution,	20	%	 20768.02	 Serva	Electrophoresis	
Sodium	Chloride	(NaCl)	 P029.2	 Carl	Roth	
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SYBR®	Safe	DNA	Gel	Stain	 5001208	 Life	Technologies	
TE	buffer,	pH	7.4,	RNAse	free	 93302	 Sigma-Aldrich	
TRIS	PUFFERAN®	 5429.3	 Carl	Roth	
Triton™	X-100	 X100-500ML	 Sigma-Aldrich	
Tween(R)-20	 P9416	 Sigma-Aldrich	
	
2.1.4	Kits	
Kits	that	were	routinely	used	in	this	study	are	listed	in	Table	M3	below.	
	
Table	M3.	Kits	routinely	used	in	this	study.	
Kit	 cat.	#	 Supplier	
GeneJET	Plasmid	Miniprep	Kit	 K0502	 Fermentas	
P3	Primary	Cell	4D-Nucleofector®	X	Kit		 V4XP-3024	 Lonza	
PureLink	HiPure	Plasmid	Filter	Maxiprep	Kit	 K210017	 Life	Technologies	
QIAprep	Spin	Miniprep	Kit	 27104	 Qiagen	
QIAquick	PCR	Purification	Kit		 28104	 Qiagen	
QIAquick	Gel	Extraction	Kit	 28704	 Qiagen	
RNA	6000	Pico	kit	 5067-1513	 Agilent	
RNeasy	MinElute	cleanup	kit	 74204	 Qiagen	
RNeasy	Mini	Kit	 4104	 Qiagen	
	
2.1.5	Enzymes	
Unless	 otherwise	 noted,	 enzymes	 were	 used	 in	 the	 provided	 buffers,	 and	 are	 either	
denoted	in	Table	M4	below	or	in	the	respective	sections	of	the	experimental	procedures	
where	they	were	applied.	
	
Table	M4.	Enzymes	or	enzyme	master-mixes	routinely	used	in	this	study.	NEB,	New	England	Biolabs	
Enzyme/	Enzyme	Mix	 cat.	#	 Supplier	
BsaI	 R0535	S	 NEB	
EcoRI-HF	 R3101	 NEB	
Gibson	Assembly	Master-Mix	 E2611	L	 NEB	
Pfu	DNA	Polymerase,	recombinant	 EP0501	 Thermo	Fisher	Scientific	
Power	SYBR®	Green	PCR	Master	Mix	 4367659	 Thermo	Fisher	Scientific	
Proteinase	K	Solution	20	mg/ml		 AM2546	 Life	Technologies	
Q5®	High-Fidelity	2X	Master	Mix	 M0492	 NEB	
Quick	Ligation™	Kit	 M2200	L	 NEB	
RNase	A	(20	mg/ml)	 12091021	 Life	Technologies	
SuperScript®	III	First-Strand	Synthesis	System	for	RT-PCR		 18080051	 Life	Technologies	
T4	DNA	Polymerase	(T4)	 M0203	 NEB	
Taq	PCR	Master	Mix	Kit		 201445	 Qiagen	
TaqMan®	Gene	Expression	Master	Mix	 4369016	 Thermo	Fisher	Scientific	
TopTaq	Master	Mix	Kit	 200403	 Qiagen	
TURBO	DNase	2U/µl		 am2238	 Life	Technologies	
XhoI	(NEB)	 R0146S	 NEB	
	
2.1.6	Oligonucleotides	
Oligonucleotides	used	for	cloning,	CRISPR/Cas	experiments,	quantitative	real-time	PCR	
(qPCR)	 and	 reverse	 transcription	 PCR	 (RT-PCR)	 were	 purchased	 from	 Sigma-
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Aldrich/Merck	(St.	Louis,	USA),	and	sequences	are	listed	in	the	respective	sections	of	the	
experimental	 procedures.	 Primers	 were	 designed	 using	 the	 Primer3web	 software	
version	4.1.0192.	
	
2.1.7	Antibodies	
Table	M5.	Antibodies	used	in	thus	study.	ICC,	Immunocytochemistry;	WB,	Western	Blot;	ChIP,	Chromatin	
immunoprecipitation;	Co-IP,	Co-immunoprecipitation.	
Target/Clone	 Application	 Dilution	 cat.	#	 Supplier	
Oct4	 ICC	 1:400	 2840	(C30A3)	 Cell	Signaling	
Sox2	 ICC	 1:200	 2748	 Cell	signaling	
Nanog	 ICC	 1:200	 ab21603	 Abcam	
Lin28a	 ICC	 1:200	 3978	(a177)	 Cell	Signaling	
TFAP2A	 ICC	 1:200	 sc-184X	 Santa	Cruz	
Sox9	 ICC	 1:100	 -	 obtained	from	Prof.	Dr.	Götz	
SOX10	MAb	(Cl	20B7)	 ICC	 1:100	 MAB2864	 R&D	
Ki67		 ICC	 1:500	 -	 obtained	from	Prof.	Dr.	Götz	
Anti-human	CD57/HNK-1,	Cl.	VC1.1	 ICC	 1:1000	 C6680-50TST	 Sigma	
hNGF	R/p75	NTR	MAb	(Cl	74902)	 ICC	 1:100	 MAB367	 R&D	
Alexa	Fluor	594	anti-rat	IgG	 ICC	 1:1000	 A-11007	 Invitrogen	
Alexa	Fluor	488	anti-rabbit	IgG	 ICC	 1:1000	 A-21206	 Invitrogen	
Alexa	Fluor	488	anti-mouse	IgG	 ICC	 1:1000	 A-21202	 Invitrogen	
Alexa	Fluor	647	anti-mouse	IgG	 ICC	 1:1000	 A-21235	 Invitrogen	
Alexa	Fluor	594	anti-rabbit	IgG	 ICC	 1:1000	 A-21207	 Invitrogen	
ASXL1	(clone	12F9)	 ICC	 1:2	 -	 this	study/E.	Kremmer	
ASXL1	(clone	4F6)	 WB	 1:10	 -	 this	study/E.	Kremmer	
ZIC1	 WB	 1:400	 AF4978-SP	 R&D	
H2A	 WB	 1:5000	 GTX129418	 GeneTex	
Ubiquityl-Histone	H2A	(Lys119)		 WB	 1:2000	 8240	 New	England	Biolabs	
H3K27me3	 ChIP	and	WB	 1:750	 C15410069	 Diagenode	
ACTIN	 WB	 1:1000	 3700	 Cell	Signaling	
mouse	anti-rat	IgG	(isotype	IgG2a),	
HRP-conjugated	 WB	 1:1000	 -	 Dr.	Kremmer	
Goat	anti-mouse	IgG	HRP-
conjugated	 WB	 1:30,000	 115-035-003	 Dianova/Jackson	
Goat	anti-rabbit	antibody,	HRP-
conjugated	 WB	 1:30,000	 111-035-045	 Dianova/Jackson	
rabbit	IgG	isotype	control	 ChIP,	Co-IP	 5	µl/IP	 GTX35035	 GeneTex	
EZH2	 Co-IP	 10	µl/IP	 39934	 Active	Motif	
	
2.1.8	Software	
Table	M6.	Software	routinely	used	for	analyses	or	visualization	of	results	in	this	study.	
Software	 Supplier	
ApE	-	A	plasmid	Editor	v2.0.46	 M.	Wayne	Davis	
Genomatix	Software	Suite	v3.10	 Genomatix	AG	
R	v3.3.2	 The	R	foundation	for	Statistical	Computing	(R	Core	team	2014)	
Image	Lab	v5.2.1	 Bio-Rad	Laboratories	
Fiji/ImageJ	v2.0.0	 National	Institutes	of	Health	NIH,	USA	
Excel	(for	mac	2011)	v14.0.0	 Microsoft	Corporation	
Integrative	Genomics	Viewer	v2.3.98	 Broad	Institute,	USA	
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2.2	Experimental	procedures	
	
2.2.1	Maintenance	of	pluripotent	stem	cell	lines	
Routine	passaging	and	maintenance	of	pluripotent	stem	cells	was	performed	essentially	
as	described	before193,	for	details	and	modifications	see	below.	
2.2.1.1	Cultivation		
All	iPSC	and	hESC	lines	were	cultivated	in	mTeSR1	medium	(STEMCELL	technologies)	or	
StemMACS	 iPS-Brew	 XF	 (Miltenyi	 Biotec),	 each	 prepared	 according	 to	 the	
manufacturer’s	 specifications	 with	 addition	 of	 1%	 Penicillin-Streptomycin	 (Pen-Strep,	
Life	Technologies).	Cells	were	maintained	as	 feeder-free	cultures	on	6-well	and	10	cm	
cell	cultures	plates	that	had	been	coated	for	>15	min	with	Matrigel	(Corning)	or	Geltrex	
(Life	 Technologies),	 respectively,	 according	 to	 the	manufacturer’s	 specifications.	 Cells	
were	maintained	in	a	HERAcell	240i	incubator	at	37	°C	and	5	%	CO2.		
	
2.2.1.2	Passaging	
Routine	 passaging	was	 performed	 by	washing	 of	 cells	with	 phosphate-buffered	 saline	
(PBS;	Life	Technologies),	 followed	by	harvesting	of	cells	after	40-60	min	 incubation	at	
37	 °C	 with	 a	 filtered	 2	mg/ml	 Collagenase	 Type	 IV	 (Life	 Technologies)	 solution	 in	
DMEM/F12	 (Life	 Technologies).	 The	 collagenase	 solution	 was	 quenched	 with	 fresh	
medium	 and	 detached	 colonies	 were	 collected	 by	 precipitation,	 resuspended	 in	 fresh	
culture	 medium,	 broken	 to	 smaller	 pieces	 by	 pipetting	 with	 a	 1	 ml	 pipette	 and	
transferred	to	plates	at	roughly	1:5-1:10	dilution.	
	
2.2.1.3	Freezing	and	thawing	of	pluripotent	stem	cells		
All	centrifugation	steps	were	performed	at	room	temperature	(RT)	for	3	min	and	200xg	
on	a	Megafuge	40R	centrifuge	(Thermo	Fisher	Scientific).	
Freezing	of	cells	was	performed	by	washing	one	confluent	6-well	with	PBS	followed	by	
10	min	incubation	with	1	ml	Accutase	(Sigma-Aldrich),	which	was	then	quenched	with	
3	ml	of	fresh	medium	and	detached	cells	were	harvested	via	centrifugation.	Cell	pellets	
were	 resuspended	 in	 mFreSR	 (STEMCELL	 technologies),	 transferred	 to	 cryotubes	
(Thermo	 Fisher	 Scientific,	 cat.	 #375418)	 and	 cooled	 to	 -80°C	 in	 freezing	 containers	
(Thermo	 Fisher	 Scientific,	 cat.	 #5100-0001).	 After	 24	 hours	 cells	 were	 transferred	 to	
liquid	nitrogen.	
For	thawing,	cells	were	taken	from	liquid	nitrogen,	quickly	thawn	in	a	water	bath	at	37	
°C,	 resuspended	 in	 fresh	 culture	 medium,	 centrifuged	 and	 the	 supernatant	 was	
discarded.	Cells	were	taken	up	in	medium	and	plated	as	described	before.	
	
2.2.2	Generation	of	induced	pluripotent	stem	cell	(iPSC)	lines	
2.2.2.1	Isolation	of	patient-derived	fibroblasts	(BOS	fibroblasts)	
Informed	 consent	 on	 the	 donation	 of	 patient	 specimens	 was	 given	 in	 the	 study	 that	
initially	described	the	two	patients	#1	(female,	6	years)	and	#2	(male,	10	years),	which	
harbor	heterozygous	mutations	in	the	ASXL1	locus,	c2407_2411del5	(#1)	and	c2893C>T	
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(#2),	 respectively134.	 Patient	 material	 was	 obtained	 in	 collaboration	 with	
Prof.	Giovannucci	 Uzielli	 (University	 of	 Florence,	 Italy)	 and	 Dr.	 Magini	 (S.	 Orsola-
Malpighi	University	Hospital,	Bologna,	Italy).	The	skin	biopsies	were	dissociated	using	a	
scalpel,	 and	 plated	 in	 fibroblast	medium	 (Table	 M11)	 on	 cell	 culture	 plates	 that	 had	
been	coated	with	a	0.1	%	gelatine	solution	(AppliChem).	After	approximately	2	weeks,	
fibroblasts	began	to	grow	out	of	specimens,	and	the	biopsy	tissue	was	removed	from	the	
well	upon	confluency.	Fibroblasts	 cultures	were	passaged	by	 treatment	with	0.5	ml	of	
0.25	 %	 Trypsin-EDTA	 (Life	 Technologies)	 for	 up	 to	 5	 minutes	 at	 37	 °C,	 followed	 by	
collection	 of	 detached	 cells	 in	 fresh	 medium,	 centrifugation	 for	 3	 min	 at	 300xg	 and	
transfer	onto	0.1	%	gelatine-coated	plates	in	fresh	medium.	Fibroblast	lines	#1	and	#2	
were	expanded	and	after	images	were	captured,	the	cultures	were	either	stored	frozen	
in	liquid	nitrogen,	as	described	above,	in	fibroblast	freezing	medium	[90%	fetal	bovine	
serum	(FBS,	HyClone,	GE	Healthcare)	and	10	%	DMSO	(Sigma-Aldrich)],	or	subjected	to	
reprogramming	via	modified	mRNA	or	episomal	plasmids.		
	
2.2.2.2	Modified	mRNA-mediated	reprogramming	
Reprogramming	of	BOS	fibroblast	lines,	using	a	cocktail	of	modified	mRNAs	(OCT4,	SOX2,	
LIN28A,	CMYC	and	KLF4	mmRNAs),	was	performed	to	generate	BOS-iPSC	lines	#1-0	and	
#2-0,	 respectively,	 by	 E.	 Rusha	 and	 Dr.	 Pertek	 at	 the	 hiPSC	 Core	 Facility,	 Helmholtz	
Center	Munich,	Germanys	as	described	 in191.	The	mmRNAs	were	provided	by	 the	RNA	
CORE	unit	of	the	Houston	Methodist	Hospital	and	contained	the	following	modifications:	
5-Methyl	CTP,	a	150	nt	poly-A	tail,	ARCA	cap	and	Pseudo-UTP.	
	
2.2.2.3	Episomal-based	reprogramming	
Episomal-mediated	reprogramming	was	performed	on	BOS	fibroblast	 lines	to	generate	
BOS-iPSC	lines	#1-1	and	#2-1,	respectively,	by	E.	Rusha	and	Dr.	Pertek	at	the	hiPSC	Core	
Facility	of	the	Helmholtz	Center	Munich,	using	a	protocol	based	with	slight	modifications	
on17.	
	
2.2.3	Generation	of	ASXL1PSC/PSC	hESC	lines	via	CRISPR/Cas	
The	ASXL1	 locus	was	modified	 in	 iCas9	hESC,	as	 the	DOX-inducible	Cas9	expression	 in	
combination	 with	 introduction	 of	 gRNAs	 allows	 for	 simple	 genetic	 engineering	
according	to	the	CRISPR/Cas	system.	Deletions	of	around	500	bp	were	introduced	that	
should	i)	be	detectable	via	PCR	and	ii)	result	in	truncating	mutations	corresponding	to	
ASXL1	mutations	reported	in	BOS	patients134.		
2.2.3.1	gRNA	design	and	vector	construction	
A	pair	of	gRNAs	flanking	the	region	bp	2436-2877	of	the	human	ASXL1	transcript,	thus	
located	within	the	BOS	‘mutation	hotspot’	(Fig.	7D),	was	selected	using	the	MIT	CRISPR	
design	 webpage	 (http://crispr.mit.edu),	 and	 sense/antisense	 oligonucleotides	 were	
designed	according	to	published	instructions194:	
gRNA	1:	CCATTGTCTGCAGGAACGGT	(target	locus:	chr20:32435128)	
gRNA	1-sense:	CACCGCCATTGTCTGCAGGAACGGT	
gRNA	1-antisense:	AAACACCGTTCCTGCAGACAATGGC	
	
gRNA	2:	AGTGAAGTAAGGCTGTCAAG	(target	locus:	chr20:32435569)	
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gRNA	2-sense:	CACCGTGGACTGTGCCATCTCGAGG	
gRNA	2-antisense:	AAACCCTCGAGATGGCACAGTCCAC	
	
The	sense	and	antisense	strand	were	annealed	for	integration	into	expression	vectors	as	
follows:	 gRNA	 oligonucleotides	 were	 resuspended	 in	 TE	 to	 a	 final	 concentration	 of	
1	µg/µl,	and	1	µl	of	each	gRNA	and	reverse	compliment	fragment	were	combined	in	100	
µl	TE.	The	mixtures	were	denatured	 in	a	Mastercycler	nexus	(Eppendorf)	 for	5	min	at	
100°C,	with	 subsequent	 temperature	 decline	 of	 5	 °C/minute	 to	 allow	 for	 annealing	 of	
complementary	 gRNA	 fragments.	 The	 resulting	 doublestrand	 gRNAs	were	 ligated	 into	
the	pBS/U6	Vector	(obtained	from	Dr.	Modic,	Helmholtz	Center	Munich)	using	the	Quick	
Ligation™	Kit	(NEB)	according	to	the	manufacturer’s	instructions.	1	µl	of	the	ligation	mix	
was	 transformed	 into	competent	E.	coli,	 followed	by	plasmid	 isolation,	confirmation	of	
correct	 integration	 via	 Sanger	 sequencing	 using	 the	 ‘U6	 forward’	 primer	 (5’-3’:	
GAGGGCCTATTTCCCATGATTCC)	 and	 plasmid	 purification,	 all	 as	 described	 in	 sections	
2.2.6.3	and	2.2.8.4.	
2.2.3.2	Manipulation	of	the	ASXL1	locus	in	iCas9	and	isolation	of	clones	
iCas9	hESC	were	electroporated	with	3	µg	of	each	purified	gRNA	expression	plasmid	as	
described	 in	 the	 next	 section.	 Cas9	 expression	 was	 induced	 after	 nucleofection	 by	
addition	 of	 1	µg/ml	 DOX	 (Sigma-Aldrich)	 for	 48h.	 To	 allow	 for	 isolation	 of	 clones,	
electroporated	cells	were	detached	and	harvested	by	Accutase	 treatment	as	described	
before	 and	 the	 resulting	 single	 cell	 suspension	was	plated	at	 low	density	on	Matrigel-
coated	15	cm	plates	in	mTeSR1	medium,	adding	10	µM	ROCKi	(Y-27632;	R&D	Systems)	
for	48	h.	A	subset	of	the	culture	was	subjected	to	bulk	genomic	DNA	isolation	and	PCR	
for	 detection	 of	 deletions	 as	 described	 below.	 After	 approximately	 10	 days,	 single	
colonies	were	 isolated	via	picking	 into	Matrigel-/Geltrex-coated	96	well	plates	using	a	
200	µl-pipette.	Clones	in	96-well	plates	were	passaged	via	treatment	with	50	µl	Gentle	
Cell	Dissociation	Reagent	(STEMCELL	Technologies)	per	well,	followed	by	disruption	of	
colonies	through	vigorous	pipetting,	and	transfer	of	cell	suspensions	to	new	plates	at	1:3	
dilution	 in	medium	 containing	 10	µM	ROCKi.	 To	 detect	 genetic	manipulation	 of	 single	
clones	 in	 96-well	 plates,	 cells	were	washed	with	 PBS,	 and	 subjected	 to	 genomic	 DNA	
isolation,	 followed	 by	 PCR	 using	 ‘ASXL1-GT’	 primers	 (5’-3’;	 forward:	
GAGCACCCCTGGAAAGTGTA;	 reverse:	 TGCTTCAGAGTCTCCGTTGA)	 and	 analysis	 of	 PCR	
products	via	agarose	gel	electrophoresis,	all	as	described	in	sections	2.2.9	and	2.2.8.1.	
Upon	confirmation	of	excision	of	approximately	500	bp	within	the	genomic	ASXL1	locus,	
PCR	fragments	were	isolated	as	described	in	section	2.2.8.2.	Deletion	was	confirmed	via	
Sanger	 sequencing	 (see	 section	 2.2.8.4)	 using	 the	 ‘ASXL1-GT’	 forward	 primer	 and	
correct	homozygous	clones	were	maintained	as	individual	ASXL1PSC/PSC	hESC	lines	on	6-
well	plates.		
2.2.3.3	Nucleofection		
Cultures	 of	 approximately	 80	 %	 confluency	 were	 dissociated	 and	 harvested	 using	
Accutase	 as	 described	 above,	 and	 cell	 numbers	 were	 counted	 using	 a	 Neubauer	
Chamber.	 1	 x	 106	 cells	 were	 nucleofected	 with	 6	 µg	 of	 DNA	 in	 total	 on	 a	 4D	
NucleofectorTM	System	(Lonza)	using	the	CB-156	program	and	the	P3	Primary	Cell	4D-
Nucleofector	X	Kit	(Lonza)	according	to	the	manufacturer’s	specifications.	Cells	were	re-
plated	on	a	Matrigel/Geltrex-coated	well	of	a	6	well	plate	 in	pre-warmed	mTeSR1	and	
10	µM	ROCKi	(only	added	for	the	first	24	hours).	Subsequently,	cells	were	subjected	to	
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selection	 or	 single	 cell	 dissociation	 depending	 on	 the	 application	 as	 described	 in	
respective	sections.		
	
2.2.4	 Generation	 of	 PB-ASXL1PSC,	 PB-ASXL1FL	 and	 PB-ZIC1	 hESC	 overexpression	
lines		
2.2.4.1	Construction	of	vectors	
For	 the	 construction	 of	 overexpression	 vectors,	 several	 fragments	 per	 vector	 were	
amplified	via	PCR	and	isolated	as	described	in	sections	2.2.8.1	and	2.2.8.2.	The	primers	
and	 templates	 used	 for	 amplification	 are	 listed	 in	Table	 M7.	 The	 PiggyBac	 backbone	
(SRF-PB#9)	 was	 obtained	 from	 Dr.	 Shaposhnikov	 (Helmholtz	 Center	 Munich),	 and	
harbors	 an	 eGFP	 coding	 sequence	 followed	 by	 a	 P2A	 cleavage	 signal	 upstream	 of	 the	
inserted	 sequence,	 which	 allows	 for	 cleaving	 of	 translated	 GFP	 and	 ASXL1/ZIC1	
peptides.	The	backbone	furthermore	contains	a	tetracycline-inducible	promoter	system,	
a	 Hygromycin	 resistance	 gene	 and	 a	 transposon,	 which	 enables	 genomic	 integration	
upon	co-transfection	with	a	transposase	plasmid.		
Purified	 fragments	were	 ligated	 to	 final	constructs	using	 the	Gibson	Assembly	Master-
Mix	 (NEB)	 according	 to	 the	 manufacturer’s	 instructions;	 amounts	 used	 for	 each	
fragment	 are	 given	 in	Table	 M7.	 3	 µl	 of	 each	 ligation	mixture	were	 transformed	 into	
competent	 bacteria;	 plasmids	 were	 isolated,	 analyzed	 for	 correct	 construction	 via	
sequencing	and	purified,	all	as	described	in	sections	2.2.8.3	and	2.2.8.4.		
	
Table	M7.	Primers	and	fragments	used	to	construct	overexpression	vectors.		
G.A.,	Gibson	Assembly;	SRF-PB#9	from	Dr.	Shaposhnikov.	*	cat.	#BC104848-seq-TCHS1003-GVO-TRI.	
Vec
tor	
Fragments	(length);	
pmol	used	in	G.A.	
Primers	used	for	amplification	of	fragments	(5′-3′);		
	
Template	
PB
-A
SX
L1
PS
C 	
Fragment	1	
(3669	bp);	
0.2	pmol	used	
Forward	(for):		
cttacttcactctggactgtgccatcttaactgcagcgcggggatctcatgctgg	
reverse	(rev):	‘PB-rev’	
tggagctcccgtgaggcgtgcttgtcaatgcggtaagtgt		
Touchdown-PCR	from	72	°C	to	60	°C	(1	°C/cycle)	
SRF-PB#9		
Fragment	2	
(4486	bp);	
0.	2	pmol	used		
for:	
acacttaccgcattgacaagcacgcctcacgggagctcca		
rev:	
ggtgaacagctcctcgcccttgctcaccatggatccgagctcggtaccaagctta		
Touchdown-PCR	from	72	°C	to	60	°C	(1	°C/cycle)	
SRF-PB#9	
Fragment	3	
(747	bp);	
0.2	pmol	used	
for:	‘eGFP-for’	
aaacttaagcttggtaccgagctcggatccatggtgagcaagggcgaggagctgt		
rev:	gcgctccttcttcttcttctgtttgtccttcttgtcgtcatcgtctttgtagtc	
Touchdown-PCR	from	72	°C	to	60	°C	(1	°C/cycle)	
SRF-PB#9	
Fragment	4	=	ASXL1	
transcript,	N-terminal	
2892	bp);	
0.2	pmol	used	
for:	‘ASXL1-for’	
cccatggactacaaagacgatgacgacaagaaggacaaacagaagaagaagaag	
rev:		
gaactccagcatgagatccccgcgctgcagttaagatggcacagtccagagtga	
H9	hESC-
derived	
cDNA	
PB
-A
SX
L1
FL
	
Fragment	5(3669	bp);	
0.05	pmol	used	
for:	ctctgtgtattgtgccttgtggtgagataactgcagcgcggggatctcatgctgg	
rev:	‘PB-rev’	
SRF-PB#9	
Fragment	6	 See	Fragment	2	 SRF-PB#9	
Fragment	7	 See	fragment	3	 SRF-PB#9	
Fragment	8=	
ASXL1	transcript,	4656	
bp)	
for:	‘ASXL1-for’	
rev:		
gaactccagcatgagatccccgcgctgcagttatctcaccacaaggcacaatac	
H9	hESC-
derived	
cDNA	
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PB
-Z
IC
1	
Fragment	9	
(3669	bp);	
0.05	pmol	used	
for:	ttaacgaatggtacgtttaactgcagcgcggggatctcatgctgg	
rev:	‘PB-rev’	
Tm	:	Touchdown-PCR	from	72	°C	to	60	°C	(1	°C/cycle)	
SRF-PB#9		
Fragment	10		 See	Fragment	2	 SRF-PB#9	
Fragment	11		
(747	bp);	
0.02	pmol	used	
for:‘eGFP-for’	
rev:	gggccggcgtccaggagcatcttgtcgtcatcgtctttgtagtc	
Tm	:	Touchdown-PCR	from	72	°C	to	60	°C	(1	°C/cycle)	
SRF-PB#9	
Fragment	12	=	ZIC1	
transcript	(1344	bp);	
0.05	pmol	used	
for:	cccatggactacaaagacgatgacgacaagatgctcctggacgccgg	
rev:	
gaactccagcatgagatccccgcgctgcagttaaacgtaccattcgttaaaattggaa
g;	Tm=65	°C	
ZIC1	
cDNA,	
Biocat*	
	
Sequencing	of	constructs	was	performed	using	following	primers	(5’-3’):	
ASXL1PSC	construct	
1:	gtcagcccacttaccagatatgc	
2:	ggcttcattagacccacagc	
3:	ctgctgctggaagtgtgatg	
4:	gaggaggagaggggttgttt	
ASXL1FL	construct	
1:	tctatggcagtggtgacctc	
2:	tccacacctgaatcctcacc	
3:	tcgcagacattaaagcccgt	
4:	ccagtgacaaatcccattacatcc	
ZIC1	construct	
1:	aacgtggtcaacgggcag	
2:	gcagcatagtgctccgaacg	
	
2.2.4.2	Generation	of	stable	overexpression	lines	
The	PB-	ASXL1PSC	construct	was	introduced	into	iCas9	(=control)	hESC,	the	PB-	ASXL1FL	
construct	was	introduced	into	H9	hESC,	and	PB-	ZIC1	was	introduced	into	control	hESC	
and	 ASXL1PSC/PSC	 hESC,	 all	 via	 nucleofection	 as	 described	 in	 section	 2.2.3.3.	 For	 each	
nucleofection,	 3	 µg	 of	 a	 plasmid	 expressing	 the	 PiggyBac	 transposase	 (obtained	 from	
Dr.	Shaposhnikov)	 was	 co-transfected.	 Stably	 integrated	 clones	 were	 selected	 by	 2	
weeks’	 treatment	 with	 50	µg/ml	 Hygromycin	 B	 (Thermo	 Fisher	 Scientific,	 cat.	 #	
10687010).	 To	 initially	 test	 for	 successful	 integration,	 overexpression	was	 induced	 in	
PB-ASXL1PSC,	PB-ASXL1FL	and	PB-ZIC1	hESC	via	treatment	with	1	µg/ml	DOX	for	24h,	and	
eGFP	expression	was	assessed	via	fluorescence	microscopy.	Expression	of	truncated	or	
endogenous	 ASXL1	 or	 ZIC1	 was	 tested	 by	 qPCR	 and	 RT-PCR	 using	 ASXL1	
primers/taqman	probes	and	ZIC1	primers,	respectively	(Table	M10),	Western	blotting	
and	 immunocytochemistry	 (for	 antibodies	 see	Table	M5),	 all	 as	 described	 in	 sections	
2.2.10,	2.2.12	and	2.2.13.		
	
2.2.5	Generation	of	hESC	reporter	lines	GFP-ASXL1PSC/PSC	and	GFP-control	
ASXL1PSC/PSC	and	control	hESC	lines	were	transfected	as	described	above	with	3	µg	of	the	
plasmid	expressing	the	Piggybac	transposase	together	with	a	PiggyBac	vector	harboring	
an	 eGFP	 expression	 cassette	 under	 the	 constitutively	 active	 CAG	 promoter	 (vector	
obtained	 from	 D.	 Shaposhnikov).	 4	days	 after	 transfection,	 homogenous	 cultures	 of	
eGFP-expressing	 cells	 were	 obtained	 by	 fluorescence-activated	 cell	 sorting	 (FACS)	 as	
described	in	the	next	section.		
	
2.2.5.1	Flourescence	activated	cell	sorting	(FACS)	
Each	one	well	of	transfected	and	untransfected	cells	were	dissociated	with	1	ml	0.25	%	
trypsin	 and	 harvested	 by	 centrifugation	 as	 described	 above.	 Cells	 were	 then	
resuspended	 in	 1	 ml	 PBS	 containing	 4	 %	 FBS	 and	 5	 mM	 EDTA	 (Carl	 Roth),	 filtered	
through	a	35	µm	cell	strainer	(Corning,	cat.	#352235)	and	analyzed	on	a	FACS	ARIA	III	
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(BD	 Biosciences).	 For	 sorting,	 cells	 were	 first	 gated	 using	 SSC-A	 (side	 scatter-area)	
against	 FSC-A	 (forward	 scatter-area)	 according	 to	morphology	 of	 the	 population,	 and	
doublets	 were	 exluded	 according	 to	 FSC-W	 (forward	 scatter-width)	 against	 FSC-A	
(forward	scatter-area).	Gating	of	positive	cells	was	performed	with	non-transfected	cells	
serving	 as	 a	 negative	 control.	 eGFP-positive	 cells	 were	 sorted	 into	 fresh	 mTeSR1	
medium	containing	10	µM	ROCKi,	2	%	Pen-Strep	and	1:100	Fungizone	®	Antimycotic	
(Thermo	Fisher	Scientific,	cat.#	15290-018),	plated	and	maintained	as	described	earlier.	
	
2.2.6	Differentiation	of	human	pluripotent	stem	cells	
2.2.6.1.	Short-term	differentiation	
For	 short-term	 undirected	 differentiation	 or	 germ	 layer	 induction,	 hESC	 lines	 were	
dissociated	using	Accutase	 and	plated	 at	 250,000	 cells	 per	well	 of	 a	 6-well	 plate	with	
10	µM	ROCKi	in	mTeSR1medium,	which	was	replaced	24	h	later	with	FBS-Diff,	KSR-Diff,	
2SMADi,	CHIR	or	ACTIVIN	A	medium	(see	Table	M11).	Cells	were	harvested	after	24	h	
or	5	days	and	subjected	to	RNA	isolation,	reverse	transcription	and	qPCR	as	described	in	
section	2.2.10,	for	primers	see	Table	M10.	
	
2.2.6.2	Neural	crest	(NC)	differentiation		
Cells	were	 subjected	 to	NC	differentiation	5-7	days	after	passaging	and	differentiation	
was	performed	according	to	Bajpai	et	al.33.		
On	 day	 0,	 cells	 of	 one	 well	 (6-well	 plate)	 or	 one	 10	 cm-plate	 were	 treated	 with	
Collagenase	solution	as	described	before,	and	fully	detached	colonies	were	harvested	in	
2-4	ml	 of	 PBS,	 followed	 by	 an	 additional	 washing	 step	 in	 PBS.	 Pellets	 were	 carefully	
resuspended	twice	in	1	ml	of	prewarmed	NC-induction	medium	(Table	M11)	using	a	1	
ml	pipette	to	generate	spheres	of	medium	size,	which	were	transferred	to	one	well	of	a	
uncoated	6-well	plate	containing	3	ml	of	prewarmed	NC	induction	medium,	and	cultures	
were	 kept	 at	 37	 °C.	 This	 basic	 protocol	 was	 modified	 according	 to	 experimental	
conditions:	 for	 ChIP-qPCR	 and	 RNA-seq,	 spheres	 were	 generated	 and	 maintained	 on	
uncoated	10	cm	plates.	For	overexpression	studies,	NC	differentiation	was	performed	in	
uncoated	24-well	plates	to	allow	for	easier	quantification	of	spheres.	Overexpression	of	
PB-ASXL1PSC	 and	 PB-ZIC1	 constructs	 in	 stable	 cell	 lines	 was	 induced	 via	 addition	 of	
1	µg/ml	DOX	from	day	1-7	(PB-ASXL1PSC)	or	day	3/4-7	(PB-ZIC1).	
From	day	1-4,	medium	was	changed	daily	to	remove	apoptotic	cells	and	debris.	For	this,	
spheres	 were	 collected	 via	 precipitation,	 medium	 was	 aspirated	 and	 spheres	 were	
carefully	 resuspended	 in	 fresh	 NC	 induction	medium	 and	 transferred	 back	 to	 culture	
plates.	Differentiation	cultures	were	not	examined	or	handled	on	days	5	and	6	(except	
for	 transplantation	experiments,	see	section	2.2.16.1)	 to	ensure	undisturbed	adhesion	
of	 neuroepithelial	 structures	 (neurospheres)	 to	 the	 plates.	 On	 day	 7,	 attachment	 of	
neurospheres	was	assessed	in	brightfield	microscopy	(see	section	2.2.7.7).	From	day	7	
onward,	 medium	 was	 changed	 every	 other	 day	 until	 plates	 were	 confluent	 (usually	
around	 day	 11-15).	 Residual	 neurospheres	 were	 removed	 via	 aspiration,	 cells	 were	
washed	with	 PBS	 and	 treated	with	 0.5	ml	 Accutase	 for	 5	minutes	 at	 37	 °C.	 2-4	ml	 of	
prewarmed	NC-Maintenance	medium	 (Table	M11)	were	 added	 to	 the	well	 to	 quench	
the	Accutase	solution,	 followed	by	pipetting	 to	dissociate	NC	cells,	 and	0.5-1	ml	of	 the	
cell	dispersion	were	added	onto	a	well	that	had	been	coated	with	a	5	µg/ml	fibronectin	
(Sigma-Aldrich)	solution	in	PBS	and	contained	prewarmed	NC-Maintenance	medium.	NC	
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cultures	 were	 passaged	 and	 maintained	 in	 this	 way	 in	 NC-Maintenance	 medium	 on	
fibronectin-coated	 plates	 for	 2-4	 passages,	 when	 the	 medium	 was	 replaced	 by	 NC-
Maintenance	+	BC	(Table	M11).	Thus,	NC	cultures	could	be	maintained	for	around	10-
15	passages,	before	they	ceased	to	proliferate.		
To	determine	expression	of	NC	markers	and	ASXL1-3,	NC	differentiation	cultures	were	
harvested	at	different	timepoints	during	differentiation	and	subjected	to	further	
analyses	as	described	in	chapter	2.2.7.6.	
	
Table	M11.	Cell	culture	media	used	in	differentiation	experiments	and	for	fibroblast	lines.	
Name	 Base	 Supplements	
Fibroblast	medium	 DMEM	 10	%	fetal	bovine	serum,	1	%	NEAA,	1	%	GlutaMAX,	1	%	Pen-Strep	
FBS-Diff	 DMEM/F12	
10	%	fetal	bovine	serum,	1	%	NEAA,	1	%	GlutaMAX,	0.2	
%	2-mercaptoethanol	(Life	Technologies),	1	%	Pen-
Strep	
KSR-Diff	 DMEM/F12	 20	%	Knockout	Serum	Replacement,	1	%	NEAA,	1	%	GlutaMAX,	0.2	%	2-mercaptoethanol,	1	%	Pen-Strep	
2SMADi	 50	%	DMEM/F12,	50	%	Neurobasal	medium	
0.5	x	N2,	0.5	x	B27,	10	µM	SB431542,	5	µM	
Dorsomorphin	
CHIR	 DMEM/F12	 1	%	B27,	5	µM	CHIR99021	
ACTIVIN	A	 DMEM/F12	 1.5	%	FBS,	100	ng/ml	Activin	A	
NC-Induction	 50	%	DMEM/F1,	50	%	Neurobasal	medium	
0.5	%	N2,	0.5	%	B27,	0.5	%	GlutaMAX,	1	%	Pen-Strep,	
20	ng/ml	bFGF,	20	ng/ml	EGF,	5	µg/ml	insulin	
NC-Maintenance	 as	above	
0.5	%	N2,	0.5	%	B27,	0.5	%	GlutaMAX,	1	%	Pen-Strep,	
20	ng/ml	bFGF,	20	ng/ml	EGF,	1	mg/ml	BSA	(Thermo	
Fisher)	
NC-Maintenace	+BC	 as	above	 as	above,	+	50	pg/ml	BMP-2	and	3	µM	CHIR99021	
	
2.2.6.3	Differentiation	of	NC	cells	to	mesenchymal	stem	cells	(MSCs)	and	derivatives	
NC	 cells	 of	 passage	 2-6	were	 treated	with	 Accutase	 as	 described	 above,	 diluted	 using	
StemMACS	MSC	Expansion	Medium	 (human,	Miltenyi,	 cat.	#130-091-680),	 transferred	
to	 uncoated	 wells	 of	 a	 6-well	 plate	 and	 kept	 in	 StemMACS	 MSC	 Expansion	 Medium.	
Change	 in	 morphology	 was	 visible	 directly	 after	 passaging,	 and	 after	 7	 days,	 cells	
displayed	a	homogenous,	 spindle-shaped	morphology.	NC-derived	MSC	were	passaged	
using	0.05	%	Trypsin-EDTA	(Thermo	Fisher	Scientific,	cat.	#25300054).	At	passage	2-3,	
the	 cells	 were	 subjected	 to	 flow	 cytometry	 analysis	 or	 osteoblast/adipocyte	
differentiation	on	24-well	plates	via	treatment	with	StemMACS	MSC	Expansion	Medium	
(=	negative	control),	StemMACS	OsteoDiff	Media	(human,	Miltenyi,	cat.	#	130-091-678)	
or	StemMACS	AdipoDiff	Media	(human,	Miltenyi,	cat.	#	130-091-677)	for	21-26	days.		
	
2.2.7	Analysis	of	undifferentiated	and	differentiated	cell	lines	
2.2.7.1	Assessment	of	morphology	and	eGFP	expression	
Image	 capture	 and	 visual	 examination	 of	 cultures	 in	 brightfield	 and	 fluorescence	
microscopy	was	performed	on	a	Leica	DMIL	LED	microscope	using	the	ICC50	HD	or	DFC	
450C	camera.	
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2.2.7.2	Analysis	of	nonsense-mediated	decay	in	BOS-iPSC	
Undifferentiated	 iCas9	 hESC	 (=Control	 hESC)	 and	 BOS-iPSC	 were	 treated	 with	
100	µg/ml	 cycloheximide	 (Sigma-Aldrich,	 cat.	 #C7698)	 for	 6	 h,	 and	 then	 subjected	 to	
RNA	 isolation,	 reverse	 transcription,	qPCR	and	RT-PCR	as	described	 in	section	2.2.10,	
using	primers	listed	in	Table	M8:	
	
Table	M8.	Primers	used	for	RT-PCR	nonsense-mediated	decay	experiments	(5’-3’).	
Target	 forward	primer	 reverse	primer	
Caspase-2	 gttacctgcacaccgagtcacg	 gcgtggttctttccatcttgttggtca	
B2M	(β-Globulin)	 ctcacgtcatccagcagaga	 tctttttcagtgggggtgaa	
ASXL1-Exon	1	 ggacaaacagaagaagaagaagga	 tgcctctatgacctgcagaa	
ASXL1-Exon	12-A	 tcgcagacattaaagcccgt	 agctctggacatggcagttc	
ASXL1-Exon	12-B	 agttgggaccaagcacaaac	 aagtgacccaccagttccag	
	
2.2.7.3	Sequencing	of	ASXL1	transcripts	in	BOS-iPSC	
To	 determine	 whether	 mutant	 alleles	 were	 transcribed	 to	 stable	 mRNA	 in	
undifferentiated	BOS-iPSC	#1-0	and	#2-0,	 these	 lines	were	subjected	 to	RNA	 isolation,	
reverse	 transcription	 and	 RT-PCR	 as	 described	 in	 chapter	 2.2.10.	 Following	 primers	
were	used	to	amplify	target	regions	from	cDNA	(5’-3’):	
For:	TCGCAGACATTAAAGCCCGT	
Rev:	CAGAGGCTGTATCCGTGGA	
PCR	products	were	isolated	using	the	QIAquick	PCR	Purification	Kit	(Qiagen)	according	
to	the	manufacturer’s	specifications	and	subjected	to	Sanger	sequencing	(using	primer	
GAGCACCCCTGGAAAGTGTA)	 and	 analyzed	 on	 the	 presence	 of	 patient-specific	mutations	
(see	chapter	2.2.8.4).		
	
2.2.7.4	Analysis	of	HOX	gene	induction	
H9	hESC,	control	hiPSC	and	BOS-iPSC	were	kept	in	mTeSR1	in	6-well	plates,	and	retinoic	
acid	 (Sigma-Aldrich,	 cat.	 #R2625)	 in	 DMSO	 was	 added	 to	 the	 cultures	 to	 final	
concentrations	of	0.5,	1,	2.5	and	5	µM,	using	DMSO-treated	cultures	as	negative	control.	
Cells	were	 imaged	 and	harvested	 after	 24	h	 and	 subjected	 to	RNA	 isolation	 and	qPCR	
(see	section	2.2.10)	using	primers	stated	in	Table	M9	below.	
	
Table	M9.	Primers	used	for	HOX	gene	detection	(5’-3’).	
Target	 forward	primer	 reverse	primer	
HOXA1	 cccaaaacagggaaagttggagag	 cgcgcgtcaggtacttgttgaag	
HOXA2	 cctcagccacaaagaatccctg	 ctccacccttcggggtctg	
HOXA3	 cagctcatgaaacggtctgcg	 cgcacactctgacaggggtttg	
HOXA4	 catgtcagcgccgttaaccc	 cgccgggtcaggtatcgattg	
HOXA5	 ctgcacataagtcatgacaacataggc	 ctgcgggtcaggtaacggttg	
HOXB1	 caagacagcgaaggtgtcagag	 ggcccggctcaggtacttg	
HOXB2	 ctgcagatggcctgggactg	 ccttctccagttccagcagc	
HOXB4	 gagcacggtaaaccccaattacg	 gccgtgtcaggtagcggttg	
HOXB5	 cacatcagccatgatatgaccgg	 gtgggcgatctcgatgcg	
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2.2.7.5	Cell	density	assays	
Control	hiPSC,	control	hESC	or	BOS-iPSC	were	dissociated	using	Accutase	as	described	
before,	 counted	using	a	Neubauer	Chamber	and	seeded	at	different	densities	as	 single	
cells	 in	 fresh	 medium	 containing	 10	µM	 ROCKi.	 After	 24	 h,	 48	 h	 or	 96	 h,	 cells	 were	
subjected	to	expression	analysis	as	described	in	the	next	section.	
	
2.2.7.6	Transcript	and	protein	analysis	in	control	and	mutant	cell	lines	
Expression	of	pluripotency	factors,	germ	layer	markers,	NC	markers	or	ASXL	genes	was	
detected	via	transcriptional	and/or	protein	expression	analysis	in	undifferentiated	lines	
and	NC	cultures	derived	thereof.	For	stable	overexpression	lines,	induction	of	constructs	
via	1	µg/ml	DOX	 treatment	was	usually	performed	 for	24	h	prior	 to	 sample	 collection	
and	analysis,	unless	stated	otherwise.	
For	 transcriptional	 analyses,	 cell	 cultures	 were	 subjected	 to	 RNA	 isolation	 and	
qPCR/RT-PCR/microarray/RNA-seq,	as	described	in	section	2.2.10,	primers	and	probes	
are	listed	in	Table	M10.	For	Western	Blot,	adherent	cells	were	washed	once	with	PBS,	
harvested	 in	PBS	using	a	cell	scraper	(Santa	Cruz)	 to	 lift	off	colonies,	and	collected	via	
centrifugation	 at	 500xg	 for	 5	min	 at	 4	°C.	 Neurospheres	 in	NC	 differentiation	 cultures	
were	 collected	 directly	 via	 centrifugation,	 and	 washed	 once	 in	 PBS.	 Cell	 pellets	 were	
stored	at	-80	°C	and	then	subjected	to	protein	extraction	and	Western	Blot	as	described	
in	 chapter	 2.2.13;	 antibodies	 used	 for	 detection	 are	 listed	 in	 Table	 M5.	 For	
immunocytochemistry,	 cells	were	plated	 as	 single	 cells,	 using	Accutase,	 onto	µ-Slide	8	
Well	 chambers	 (Ibidi).	After	2-4	days,	 cultures	were	 fixed	and	 stained	as	described	 in	
section	2.2.12,	using	antibodies	listed	in	Table	M5.	
	
2.2.7.7	Analysis	of	neurosphere	attachment	
Assessment	of	NC	differentiation	via	quantification	of	neurospheres	was	performed	at	
day	 7	 or	 at	 day	 8	 of	 the	 protocol	 via	 brightfield	 microscopy.	 Neurospheres	 were	
classified	 into	 three	 categories:	 attached	 neurospheres	 that	 showed	 delamination	 of	
prospective	 NC	 cells	 (=delaminating	 neurospheres),	 attached	 neurospheres	 without	
outgrowth,	 and	 floating	neurospheres.	 If	 feasible,	 neurospheres	 of	 all	 three	 categories	
were	counted	per	cell	line,	and	the	number	of	delaminating	neurospheres	in	percent	of	
the	total	number	of	neurospheres	derived	from	the	respective	cell	line	was	determined.	
Otherwise,	 the	 number	 of	 delaminating	 neurospheres	 derived	 from	 BOS-iPSC	 or	
ASXL1PSC/PSC	hESC	was	directly	compared	to	 the	number	of	delaminating	neurospheres	
in	 control	 hiPSC	or	 control	 hESC-derived	NC	 cultures,	 respectively.	 Furthermore,	 total	
number	of	neurospheres	derived	from	ASXL1PSC/PSC	and	control	hESC	were	determined.	
	
2.2.7.8	Flow	cytometry	analysis	of	MSC	cultures	
Flow	cytometry	analysis	of	MSC	cultures	was	performed	by	V.	Rishko	(Helmholtz	Center	
Munich)	 using	 the	MSC	 phenotyping	 kit	 (Miltenyj	 Biotec,	 #130-095-198)	 according	 to	
the	manufacturer’s	specifications	on	a	FACS	ARIA	III	(BD	Biosciences),	with	subsequent	
analysis	 using	 the	 FlowJo	 X	 10.0.7r2	 software.	 For	 controls,	 MSC	 cultures	 were	
incubated	with	isotype	control	cocktail	from	the	kit.	
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Table	M10.	Primers	and	probes	used	for	analysis	of	cell	lines	on	pluripotency	markers,	germ	layer	and	NC	
specifiers,	and	ASXL	genes	(5’-3’).	*	detection	of	full-length	ASXL1	in	BOS-iPSC	
Name	 application	 forward	primer	 reverse	primer	
ASXL1-
Taqman	 qPCR	 TaqMan	Gene	Expression	Assay	ID:	Hs00392415_m1,	LT	
ASXL1-FL	 RT-PCR*	 aaggacaaacagaagaagaagaag	 ttatctcaccacaaggcacaatac	
ASXL1	 qPCR	 gccacaggtcaaatgaagc	 ggtccgagagttgatcagg	
ASXL2	 qPCR	 ctaaagcaggcgctaaagc	 gctttgacagtctttagtgag	
ASXL2-
Taqman	 qPCR	 TaqMan	Gene	Expression	Assay	ID:	Hs00827052_m1,	LT		
ASXL3	 qPCR	 catacgtttgcttccttacct	 acttcccatctgcctatcc	
ASXL3-
Taqman	 qPCR	 TaqMan	Gene	Expression	Assay	ID:	Hs00296943_m1,	LT		
CER1	 qPCR	 caggacagtgcccttcagcca	 acagtgagagcaggaggtatgg	
E-CAD	 qPCR	 gcctcctgaaaagagagtggaag	 tggcagtgtctctccaaatccg	
FOXA2	 qPCR	 gggagcggtgaagatgga	 tcatgttgctcacggaggagta	
GAPDH	 qPCR	 TaqMan	Gene	Expression	Assay	ID:	Hs02758991_g1,	LT	
GAPDH	 qPCR	 tgcaccaccaactgcttagc	 ggcatggactgtggtcatgag	
GBX2	 qPCR	 gcggaggacggcaaaggcttc	 gtcgtcttccacctttgactcg	
GDF3	 qPCR	 gtctcccgagacttatgctacg	 agtagaggagcttctgcaggca	
HNK1	 qPCR	 gaaagcagcctccttcgagaac	 cctcattcaccagcactggctt	
MESP1	 qPCR	 ctgcctgaggagcccaagt	 gcagtctgccaaggaacca	
N-CAD	 qPCR	 cccacaccctggagacattg	 gccgctttaaggccctca	
NANOG	 qPCR	 TaqMan	Gene	Expression	Assay	ID:Hs04260366_g1,	LT		
Nestin	 qPCR	 gtctcaggacagtgctgagccttc	 tcccctgaggaccaggagtctc	
OCT4	 qPCR	 TaqMan	Gene	Expression	Assay	ID:Hs00999632_g1,	LT		
p75	 qPCR	 cctcatccctgtctattgctcc	 gttggctccttgcttgttctgc	
PAX3	 qPCR	 ggctttcaaccatctcattcccg	 gttgaggtctgtgaacggtgct	
PAX6	 qPCR	 gcggagttatgatacctacacc	 gaaatgagtcctgttgaagtgg	
SNAI2	 qPCR	 atctgcggcaaggcgttttcca	 gagccctcagatttgacctgtc	
SOX10	 qPCR	 atgaacgccttcatggtgtggg	 cgcttgtcactttcgttcagcag	
SOX17	 qPCR	 ggcgcagcagaatccaga	 ccacgacttgcccagcat	
SOX2	 qPCR	 TaqMan	Gene	Expression	Assay	ID:Hs01053049_s1,	LT		
SOX9	 qPCR	 aggaagctcgcggaccagtac	 ggtggtccttcttgtgctgcac	
T	 qPCR	 caacctcactgacggtgaaaaa	 acaaattctggtgtgccaaagtt	
TFAP2A	 qPCR	 gacctctcgatccactccttac	 gagacggcattgctgttggact	
ZIC1	 qPCR	 gatgtgcgacaagtcctacacg	 tggaggattcgtagccagagct	
	
	
2.2.7.9	Oilred	O/Alizarin	Red	staining	of	adipocytes	and	osteoblasts	
For	 detection	 of	 calcium-containing	 osteoblast	 cells	 derived	 from	 MSCs,	 Alizarin	 Red	
staining	was	perfomed	as	follows:	Cells	were	washed	twice	in	2	ml	of	PBS	and	then	fixed	
for	30	min	at	RT	 in	10	%	Formalin	 (neutral	buffered,	 Sigma-Aldrich	 cat.	#HT501128),	
followed	by	 two	washing	steps	 in	2	ml	de-ionized	water	each.	Cells	were	stained	with	
1	ml	of	a	filtrated	Alizarin	red	staining	solution	[20mg/mL	Alizarin	red	S	(Carl	Roth,	cat.	
#0348.1)	in	de-ionized	water]	for	45	min	at	RT,	washed	four	times	with	1	ml	de-ionized	
water	and	imaged	in	1	ml	PBS.		
For	evaluation	of	adipogenic	differentiation	of	MSCs,	Oil	Red	O	staining	was	performed	
as	follows:	Cells	were	washed	twice	in	2	ml	PBS	and	fixed	for	30	min	in	10	%	Formalin	
as	before.	Subsequently,	 cells	were	washed	 twice	with	2	ml	of	 tap	water	and	 fixed	 for	
5	min	with	1	ml	of	60	%	2-propanol	at	RT,	which	was	then	replaced	by	1	ml	of	a	filtrated	
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Oil	 Red	 O	working	 solution	 [1.8	mg/ml	 Oil	 Red	 O	 (Sigma-Aldrich	 cat.	 #O0625)	 in	 de-
ionized	water,	diluted	from	a	stock	solution	in	2-propanol].	After	10	min	incubation	at	
RT,	 cells	 were	 washed	 twice	 with	 2	ml	 of	 PBS,	 and	 afterwards	 stained	 with	 1	 ml	 of	
filtrated	Mayer’s	Hematoxylin	solution	(Sigma,	cat.	#MHS1)	for	5	min	at	RT.	Cells	were	
then	washed	twice	with	2	ml	of	tap	water	and	imaged	in	1	ml	PBS.	
	
2.2.8	Molecular	cloning	procedures	
2.2.8.1	PCR	and	agarose	gel	electrophoresis	
Amplification	 of	 DNA	 fragments	 for	 construction	 of	 vectors	 was	 performed	 using	 the	
Q5®	High-Fidelity	2X	Master	Mix	(NEB)	according	to	the	manufacturer’s	specifications,	
either	in	a	final	volume	of	25	µl	for	detection	on	agarose	gels,	or	in	a	final	volume	of	50	µl	
for	 subsequent	 isolation	 of	 PCR	 fragments.	 Annealing	 temperatures,	 primers	 and	
templates	are	given	in	the	respective	sections.			
Amplification	of	genomic	target	regions	in	samples	derived	from	CRISPR-targeted	hESC	
clones,	 mouse	 or	 zebrafish	 for	 genotyping	 purposes,	 or	 from	 bacterial	 colonies	 to	
confirm	successful	transformation	of	plasmids,	was	performed	using	the	TopTaq	Master	
Mix	 Kit	 (Qiagen)	 according	 to	 the	 manufacturer’s	 specifications	 at	 an	 annealing	
temperature	of	60	°C.	1	µl	of	genomic	DNA	was	added	to	the	PCR	reaction	mixture	in	a	
final	volume	of	20	µl;	alternatively	for	bacteria	colony	PCR,	material	of	one	colony	was	
transferred	 into	 the	well	of	a	96-well	PCR	plate	containing	20	µl	of	 the	pre-made	PCR	
reaction	mixture	using	a	200	µl	pipette	tip.	
DNA	Gel	loading	dye	(Thermo	Fisher	Scientific)	was	added	to	PCR	products,	which	were	
separated	 on	 1%	 agarose	 gels	 containing	 SYBR®	 Safe	 DNA	 Gel	 Stain	 (1:20,000;	 Life	
Technologies)	in	LAB	buffer	(10	mM	lithium	acetate,	10	mM	boric	acid	in	dH2O)	at	200	V	
and	visualized	on	the	ChemiDoc™	MP	System	(Bio-Rad	Laboratories).		
	
2.2.8.2	Isolation	of	PCR	products	
PCR	fragments	were	isolated	via	two	different	methods.	If	gel	electrophoresis	confirmed	
amplification	 of	 one	 specific	 product,	 PCR	 products	were	 isolated	 using	 the	 QIAquick	
PCR	Purification	Kit	(Qiagen).	If	PCR	resulted	in	detection	of	several	products,	the	band	
of	expected	size	was	excised	from	the	agarose	gel	and	subjected	to	DNA	isolation	using	
the	QIAquick	Gel	Extraction	Kit	(Qiagen).	Isolated	PCR	products	were	stored	at	-20°C.		
	
2.2.8.3	Transformation	and	plasmid	isolation	
NEB®	5-alpha	Competent	E.	coli	(High	Efficiency,	NEB,	cat.	#C2987)	where	transformed	
with	 DNA/ligation	 mixture	 (see	 respective	 sections)	 according	 to	 the	 manufacturer’s	
specifications.	50	µl	of	transformed	bacteria	were	plated	on	a	pre-warmed	Luria	Bertani	
(LB)	 agar	 plate	 containing	 50	 µg/ml	 ampicillin	 and	 incubated	 at	 37	 °C	 overnight.	
Colonies	were	 picked	 into	 3	ml	 LB	medium	 containing	 50	 µg/ml	 ampicillin	 and	 again	
incubated	 at	 37	 °C	 overnight.	 Plasmid	 DNA	 was	 isolated	 using	 either	 the	 GeneJET	
Plasmid	Miniprep	Kit	(Fermentas)	or	the	QIAprep	Spin	Miniprep	Kit	(Qiagen)	according	
to	the	manufacturers’	instructions.	Plasmids	were	then	subjected	to	Sanger	sequencing	
(chapter	2.2.8.4)	to	confirm	correct	integration/construction.	Upon	validation,	cultures	
were	used	to	inoculate	100	ml	LB	medium	containing	50	µg/ml	ampicillin,	incubated	at	
37	 °C	 overnight,	 and	 plasmids	 were	 isolated	 using	 the	 PureLink	 HiPure	 Plasmid	 FP	
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Maxiprep	 Kit	 (Life	 Technologies)	 according	 to	 the	 manufacturer’s	 instructions.	
Subsequent	 to	 the	 last	ethanol	purification	step,	plasmids	were	 resuspended	 in	 sterile	
dH2O,	concentration	was	measured	using	the	Nanodrop	ND-1000	system,	and	plasmids	
were	stored	at	-20°C.	
LB	medium:	16	g/l	Trypon/Pepton	from	Casein	(Roth	cat.	#	8952.2),	5	g/l	yeast	extract	
(Roth,	cat.	#	2363.2)	and	10	g/l	NaCl	(Roth,	cat.	#	P029.2)	
LB	agar	plate:	LB	medium	+	15	g/l	agar	(Agar-Agar,	Carl	Roth	cat.	#	5210.2)	
	
2.2.8.4	Sanger	sequencing	
Isolated	 PCR	 fragments	 or	 plasmids	 were	 subjected	 to	 Sanger	 Sequencing	 at	 GATC	
Biotech	 (Konstanz,	 Germany),	 and	 analysis	 of	 sequences	 to	 validate	 correct	
construction/integration	 was	 performed	 using	 the	 ApE	 (A	 plasmid	 Editor,	 v2.0.46)	
software.	
	
2.2.9	Genomic	DNA	isolation	
Genomic	DNA	isolation	was	performed	using	the	QuickExtract	DNA	Extraction	Solution	
1.0	(Biozym,	cat.	#101098)	according	to	manufacturer’s	instructions,	and	extracted	DNA	
was	stored	at	-20°C.	Below,	the	specification	for	different	applications	are	given:	
96-well	plates:	10	µl	of	DNA	Extraction	Solution/well	
Bulk	cell	pellets:	50-200	µl	of	DNA	Extraction	Solution/pellet	
Zebrafish	fin	tips/mouse	tail	tips:	30	µl	of	DNA	Extraction	Solution/sample	
		
2.2.10	Transcription	analyses	
2.2.10.1	Isolation	of	RNA		
Lysis	of	samples	was	performed	in	350	or	600	µl	RLT	buffer	(supplied	with	the	RNeasy	
Mini	Kit,	Qiagen)	that	was	either	i)	added	directly	onto	adherent	cells	grown	in	24-	or	6-
well	cell	culture	plates,	ii)	added	to	cell	pellets	that	had	been	harvested	via	Accutase	or	
Trypsin	 treatment	 as	 described	 before,	 iii)	 added	 to	 neurospheres	 collected	 via	
centrifugation,	 or	 iv)	 added	 to	 zebrafish	 samples.	 In	 all	 cases,	 homogenization	 was	
performed	 via	 pipetting	 or	 forcing	 of	 lysed	 samples	 through	 a	 0.50	 x	 16	 mm	 needle	
(Omnifix®-F	fine	dosage	syringe	Omnilab	cat.	#5421735).	Homogenized	samples	in	RLT	
buffer	were	 either	 stored	 at	 -80°C,	 or	 directly	 subjected	 to	 RNA	 isolation,	 which	was	
performed	 using	 the	 RNeasy	 Mini	 Kit	 (Qiagen)	 according	 to	 the	 manufacturer’s	
instructions.	Isolated	RNA	was	stored	at	-80°C.		
	
2.2.10.2	Reverse	transcription	
RNA	concentration	was	measured	using	the	Nanodrop	ND-1000	system.	For	all	samples	
of	one	experiment,	similar	RNA	concentrations	(100-800	ng)	were	reverse	transcribed	
using	the	SuperScript®	III	First-Strand	Synthesis	System	(Life	Technologies)	with	oligo	
dT	primers	according	to	manufacturer’s	instructions.	
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2.2.10.3	RT-PCR		
The	 Taq	 PCR	 Master	 Mix	 Kit	 (Qiagen)	 was	 used	 according	 to	 the	 manufacturer’s	
instructions	to	amplify	target	regions	from	1	µl	oligodT-amplified	cDNA.	Products	were	
visualized	via	agarose	gel	electrophoresis	as	described	for	PCR	products.		
	
2.2.10.4	qPCR	
Power	SYBR®	Green	PCR	Master	Mix	(Life	Technologies)	or	TaqMan®	Gene	Expression	
Master	 Mix	 (Life	 Technologies)	 were	 used	 for	 qPCR	 on	 a	 QuantStudio	 12k	 Flex	 (Life	
Technologies)	according	to	the	recommended	cycling	conditions.	Reaction	mixtures	per	
sample	were:		 	
	
	 	 	 					SYBR®	Green	qPCR																		TaqMan®	qPCR	
Master	Mix	 	 	 					4.5	µl	 	 	 			5	µl	
Primer	mix	(5µM)/probe		 								1	µl	 	 	 0.5	µl	
cDNA	 	 	 	 				0.5	µl	 	 	 0.5	µl	
H2O	 	 	 	 				3.5	µl	 	 	 			4	µl	
	
Primers	are	indicated	in	the	respective	sections	and	in	Table	M10.	Relative	expression	
level	 was	 calculated	 as	 follows:	 Ct	 values	 were	 first	 normalized	 to	 the	 respective	 Ct	
values	of	housekeeping	gene	GAPDH,	 then,	 resulting	delta	Ct	 values	of	 treated	 cells	 or	
BOS	lines	were	compared	to	control	cells	or	untreated	cells,	as	denoted	in	the	respective	
charts,	according	to	the	following	formula:	
	
Relative	expression	level	(mutant	compared	to	control)	=	2-(delta	Ct(mutant)	–	delta	Ct(control))	
	
2.2.10.5	Microarray	in	iPSC	lines	
For	microarray	 analysis,	 RNA	was	 isolated	 from	BOS-iPSC	 lines	 #1-0	 and	#2-0	 (three	
passages	 per	 line),	 H9	 hESC	 (three	 passages),	 mmRNA-derived	 control	 hiPSC	 (two	
passages)	 and	 fibroblasts	 #1	 and	 #2	 (three	 wells	 per	 line)	 as	 described	 in	 chapter	
2.2.10.1.	RNA	quality	was	assessed	with	the	RNA	6000	Pico	Kit	(Agilent)	on	an	Agilent	
2100	 Bioanalyzer	 and	 subjected	 to	 cDNA	 preparation	 with	 the	 Ovation®	 Pico	 WTA	
System	V2	(NuGEN,	cat.	#3302-60)	and	the	Encore™	Biotin	Module	(NuGEN,	cat.	#4200-
60)	 according	 to	 the	 manufacturer’s	 specifications.	 Hybridization	 onto	 GeneChip®	
Human	 Gene	 2.0	 ST	 Arrays	 (Affymetrix,	 cat.	 #902113)	 and	 subsequent	 scanning	 was	
performed	 with	 the	 GeneChip®	 Hybridization,	 Wash,	 and	 Stain	 Kit	 (Affymetrix,	 cat.	
#900720)	according	to	the	supplied	protocol.	
For	data	analysis,	CEL	files	were	processed,	normalized	and	run	quality	assessed	using	
the	Expression	Console	 software	 (Build	1.3.1.187,	Affymetrix),	which	was	also	used	 to	
build	Principal	Component	Analysis	 (PCA)	plots.	Annotated	expression	 files	were	 then	
analysed	using	the	CARMAweb	software	(v1.5,	Medical	University	Innsbruck),	available	
under	https://carmaweb.genome.tugraz.at/carma/.	Differentially	expressed	genes	were	
determined	using	moderated	 t-statistics	 (limma	package),	with	correction	 for	multiple	
testing	 according	 to	 the	 Benjamini	&	Hochberg	method.	 A	 gene	was	 considered	 to	 be	
differentially	expressed	 if	 its	corrected	p-value	BH	was	below	a	 threshold	of	0.1	 (false	
discovery	rate	<10%),	with	a	linear	fold-change	>2.	Resulting	gene	sets	were	subjected	
to	 literature-based	 tissue	 enrichment	 analysis	 using	 the	 GeneRanker	 tool	 within	 the	
Genomatix	Software	Suite	v3.10.		
	 	
	 	 	
2. Materials and methods 
49	
2.2.10.6	Sequencing	of	total	RNA	in	NC	cultures		
A	subset	of	material	collected	from	day	7	NC	cultures	in	section	2.2.14	(ChIP-qPCR)	was	
used	for	RNA	extration	using	the	RNeasy	Mini	Kit	as	described	above.	RNA	quality	was	
assessed	 using	 the	 RNA	 6000	 Pico	 Kit	 (Agilent)	 on	 an	 Agilent	 2100	 Bioanalyzer.	 Per	
RNA-seq	library,	1	µg	of	RNA	was	treated	with	RiboZero	Gold	(Human/Mouse/Rat)	kit	
(Illumina,	cat.	#RS-122-2301)	to	remove	ribosomal	RNA,	followed	by	RNA	cleanup	using	
the	 RNeasy	 Minelute	 RNA	 cleanup	 kit	 (Qiagen).	 Sequencing	 libraries	 were	 prepared	
using	the	TruSeq	Stranded	total	RNA	LT	kit	(Illumina,	cat.	#RS-122-2301)	according	to	
the	 supplied	 protocol,	 including	 11	 cycles	 of	 PCR	 followed	 by	 purification	 with	
Agencourt	 Ampure	 XP	 beads	 (Beckman-Coulter,	 cat.	 #A63881).	 Libraries	 were	 again	
evaluated	on	 the	Bioanalyzer	using	 the	DNA	1000	kit	 (Agilent,	 cat.	#5067-1504).	DNA	
concentration	was	measured	using	a	Qubit	dsDNA	HS	Assay	Kit	(Life	Technologies,	cat.	
#Q32854),	 libraries	 were	 pooled	 and	 diluted	 stepwise	 to	2	 nM	 according	 to	 the	
manufacturer’s	 instructions	and	 subjected	 to	 single-end	 sequencing	 for	75	 cycles	on	a	
NextSeq	with	the	NextSeq	500/550	v2	reagent	cartridge	(Illumina,	cat.	#FC-404-2005).	
Quality	of	the	sequencing	run	was	confirmed	via	QC	reports	on	the	Illumina	BaseSpace	
platform	and	the	FastQ	tool	provided	on	the	Galaxy	platform195.		Reads	were	mapped	to	
the	hg19	genome	using	TopHat	and	read	count	was	performed	by	Dr.	Simon	(Helmholtz	
Center	 Munich,	 Germany)	 using	 the	 featureCounts	 (v1.5.0)	 function	 of	 the	 Subread	
package196	and	the	hg19	human	gene	annotation.	Differential	gene	expression	analysis	
was	 performed	with	 the	 DESeq2	 package197	 in	 R	 v3.3.2;	 genes	with	 a	maximum	 read	
count	 of	 zero	 were	 considered	 to	 be	 non-expressed	 and	 thus	 removed	 from	 further	
analysis.	 PCA	Plots	 and	Volcano	 Plots	were	 built	 using	 the	 ggplot2,	 dplyr	 and	 ggrepel	
packages	 in	 R,	 respectively.	 To	 characterize	 misregulated	 gene	 sets,	 the	 list	 of	
significantly	 downregulated	 transcripts	 (padj<0.05)	 was	 submitted	 to	 the	 Genomatix	
Software	Suite	GeneRanker	Analysis	as	described	above.		
	
2.2.11	Generation	of	monoclonal	antibodies	
2.2.11.1	Cloning	of	expression	constructs	
To	construct	vectors	expressing	N-terminal	ASXL1	 or	ASXL2	 fragments	 that	were	used	
for	immunization	or	validation	of	specific	antibodies,	respectively,	a	ligase-independent	
cloning	 (LIC)-approach	 was	 followed	 based	 on	 a	 protocol	 supplied	 by	 Dr.	Geerlof	
(Helmholtz	 Center	 Munich).	 Reaction	 mixtures	 prepared	 at	 different	 steps	 of	 the	 LIC	
protocol	are	denoted	in	Table	M12.	
First,	 the	pETM13/LIC	plasmid,	which	contains	a	C-teminal	His6-tag	 (Dr.	Geerlof),	was	
linearized	via	BsaI	(NEB)	treatment	for	1	h	at	50	°C	(Step	1).	The	linearized	plasmid	was	
isolated	 via	 gel	 purification	 as	 described	 in	 chapter	2.2.8.2,	 and	 treated	with	T4	DNA	
Polymerase	(T4;	NEB)	for	30	min	at	RT	(Step	2).	The	Polymerase	was	afterwards	heat-
inactivated	at	75°C	for	20	min.		
The	 ASXL1	 (bp	 1-1854	 =	 aa	 1-618)	 and	 ASXL2	 (bp	 1-1983	 =	 aa	 1-661)	 inserts	 were	
amplified	from	H9	hESC-derived	cDNA	via	PCR	(Step	3)	using	following	primers	(5′-3):	
	
ASXL1-AB-for:	AAGAAGGAGAACAACCATGAAGGACAAACAGAAGAAGAAGAAG	
ASXL1-AB-rev:	GACCCGACGCGGTTTTAATGTCTGCGAGGGTCC	
ASXL2-AB-for:	AAGAAGGAGAACAACCATGAGGGAAAAGGGACGTAG	
ASXL2-AB-rev:	GACCCGACGCGGTTTTGATGTCTGCAAGAGTTCTG	
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Cycling	conditions	were	as	follows:	
	
					Step		 	 Time		 	 		Temperature			 Cycles	
Denaturation		 	 2	min		 	 						95°C		 					 					1	
Denaturation		 	 30	sec		 	 						95°C	 					
Annealing		 	 30	sec		 	 						60°C																		 			30	
Extension		 	 4	min	 	 						72°C	
Extension		 	 10	min							 						72°C		 					 					1	
	
PCR	products	were	analyzed	on	agarose	gels,	extracted	and	purified	as	described	before.	
The	inserts	were	then	treated	with	T4	(Step	4)	under	the	same	conditions	as	in	Step	2.	
Ligation	of	T4-treated	inserts	and	plasmid	(Step	5)	were	performed	for	5	min	at	22	°C	
and	terminated	via	addition	of	addition	of	1	μl	EDTA	(25	mM)	for	5	min	at	22	°C.			
	
Table	 M12.	 Reaction	 mixtures	 applied	 at	 different	 steps	 1-	 5	 of	 the	 LIC	 procedure.	 *	 supplied	 with	
enzymes;	**Thermo	Fisher	Scientific	cat.	#R0181,	***	Life	technologies,		cat.	#18080051	
1.	Linearization	of	
pETM-13/LIC	
2.	T4	treatment	of	
linearized	pETM-
13/LIC	
3.	PCR	
amplification	of	the	
insert	
4.	T4	treatment	of	
insert	
5.	Annealing	of	
insert	and	
pETM-13/LIC	
5	μl		
10X	NEB	buffer	3*	
2	μl		
10X	NEB	buffer	2*	
5	μl		
10X	Pfu	polymerase	
buffer	
2	μl		
10X	NEB	buffer	2*	
1	μl		
T4-treated	
vector	DNA	
5	μg		
pETM-13/LIC	
vector	DNA	
600	ng		
BsaI-digested	
pETM-13/LIC	
0.5	μl	forward	and	
reverse		primer	(100	
pmol/μl)*	
0.2	pmol		
PCR	product	
2	μl		
T4-treated	
insert	DNA	
2.5	μl		
BsaI	(10	units/μl)	
0.5	μl		
dTTP	(100	mM)**	
100	ng		
dNTPs	(10	mM	each)	
1	μl		
DTT	(100	mM)	 	
ad	50	μl	with	dH2O	 1	μl		DTT	(100	mM)***	
2	μl		
cDNA	
0.5	μl		
dATP	(100	mM)**	 	
	 0.2	μl	100x	BSA	
1	μl		
Pfu	DNA	polymerase	
(2.5	units/μl)	
0.2	μl		
100X	BSA	 	
	
0.4	μl	T4	DNA	
polymerase	
(3	units/μl)	
ad	50	μl	with	dH2O	
0.4	μl	T4	DNA	
polymerase	
(3	units/μl)	
	
	 ad	20	μl	with	dH2O	 	 ad	20	μl	with	dH2O	 	
	
1	 μl	 of	 ligation	 mixture	 per	 construct	 were	 used	 for	 transformation	 into	 competent	
bacteria,	and	colony-PCR	was	performed	using	‘ASXL1-AB’	and	‘ASXL2-AB’	primer	pairs	
to	 determine	 successfully	 transformed	 bacteria	 clones,	 which	 were	 used	 for	 plasmid	
isolation,	all	as	described	in	sections	2.2.8.1	and	2.2.8.3,	and	three	purified	plasmids	per	
clone	were	subjected	to	Sanger	sequencing	(see	2.2.8.4)	to	confirm	correct	integration	
of	the	ASXL1/ASXL2	inserts	and	presence	of	the	His6-tag	using	following	primers	(5′-3′):	
	
T7	primer	(provided	by	GATC	Biotech):	TAATACGACTCACTATAGGG	
pETM13-rev:	TTGTTAGCAGCCGGATCTC	
Sequencing	of	ASXL1	(central	part):	CTGCATCAGGGTTCTCGG	
Sequencing	of	ASXL1	(3’	end):	GCCCACTAAAGAGGAGCC	
Sequencing	of	ASXL2	(central	part):	GATGGACAGACAGGCAGC	
Sequencing	of	ASXL2	(3’	end):	CCAGCAGCCATTTCAGGT	
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2.2.11.2	Protein	expression	and	purification		
Correct	 pETM-13/LIC-ASXL1	 and	 pETM-13/LIC-ASXL2	 constructs	 were	 used	 for	
expression	and	purification	of	N-terminal	ASXL1	and	ASXL2	fragments	by	Dr.	Geerlof	in	
the	Protein	Expression	and	Purification	Core	Facility	at	the	Helmholtz	Center	Munich.	
	
2.2.11.3	Antibody	production		
50	 µg	 purified	His-tagged	 human	ASXL1	 protein	was	 used	 by	Dr.	 Elisabeth	 Kremmer,	
Dr.	Regina	Feederle	and	Andrew	Flatley	in	the	Monoclonal	Antibody	Core	Facility	of	the	
Helmholtz	Center	Munich	to	generate	monoclonal	antibodies	in	rat	hybridoma	cultures,	
according	 to	 their	 published	 method198,	 providing	 clones	 that	 detected	 the	 ASXL1	
fragment,	but	not	the	ASXL2	fragment	in	enzyme-linked	immunosorbent	assays	(ELISA).	
I	 validated	 these	 clones	 further	 by	Western	 blot	 analysis	 (see	 chapter	2.2.13)	 on	 H9	
hESC	 and	 induced	 PB-ASXL1PSC	 and	 PB-ASXL1FL	 hESC.	 Experiments	 in	 this	 study	were	
performed	 with	 hybridoma	 culture	 supernatants	 of	 clones	 12F9	 and	 4F6	 (both	 rat	
IgG2a/k).			
	
2.2.12	Immunocytochemistry	
Cells	were	fixed	with	4%	formaldehyde/PBS	for	10-15	min	at	RT	and	permeabilized	and	
blocked	 using	 0.1	%	 Triton	 X-100	 (Sigma-Aldrich),	 3	%	 donkey	 serum	 (Biowest,	
cat.	#S2170-500)	 and	 0.1	%	 bovine	 serum	 albumine	 (BSA;	 Sigma-Aldrich)	 in	 PBS	 for	
25	min	at	RT.	Primary	and	secondary	antibodies	were	diluted	to	working	concentrations	
in	1%	BSA/0.1	%	Triton	X-100/PBS.	Primary	antibody	was	incubated	overnight	at	4	°C,	
secondary	for	1	hour	at	RT	(for	antibodies,	see	Table	M5).	Specimens	were	washed	with	
PBS	 containing	 DAPI	 (Bio-Rad	 Laboratories)	 before	 mounting	 in	 Aqua-Poly/Mount	
(Polysciences,	 cat.	 #18606-20).	 Images	 were	 obtained	 using	 a	 Zeiss	 Axiovert	 200M	
epifluorescent	microscope.		
	
2.2.13	Western	Blotting	
Total	 protein	 lysates	 were	 prepared	 via	 lysis	 of	 cell	 pellets	 in	 RIPA	 buffer	 (50	 mM	
TrisHCl,	 pH8.0;	 150	mM	NaCl;	 1	%	Triton	X-100;	 0.5	%	Na-Deoxycholate;	 0.1	%	 SDS)	
containing	 Protease	 Inhibitor	 Cocktail	 Set	 III	 (Merck	 Millipore).	 After	 addition	 of	 2x	
Laemmli	 Sample	 Buffer	 (Bio-Rad	 Laboratories,	 cat.	 #161-0737)	 supplemented	 with	
10	%	2-mercaptoethanol	 (Sigma-Aldrich),	 samples	were	heated	 to	95°C	 for	5	min	and	
subsequently	 separated	 via	 SDS	 PAGE	 on	Mini-PROTEAN	 TGX	 Stain	 Free	 Gels,	 4-15%	
gels	 (Bio-Rad	 Laboratories,	 cat.	#	456-8086)	 using	 SDS	 running	 buffer	 (25	 mM	 Tris,	
192	mM	glycine,	0.1	%	SDS)	in	a	Mini	Trans-Blot	Cell	(Bio-Rad	Laboratories).	The	Trans-
Blot	Cell	was	also	used	for	subsequent	wet	blotting	on	nitrocellulose	membranes	(Bio-
Rad	Laboratories,	cat.	#162-0115)	in	blotting	buffer	(25	mM	Tris,	92	mM	glycine,	20	%	
methanol,	0.1	%	SDS).	Following	3x	5	min	washing	steps	in	TBS-T	(20	mM	Tris,	150	mM	
NaCl,	 0.1	%	 Tween-20),	 membranes	 were	 blocked	 for	 1	 h	 in	 5	%	milk	 powder	 (Carl	
Roth)	 in	 TBS-T	 and	 afterwards	 incubated	 with	 primary	 antibodies	 (see	 Table	 M5)	
diluted	to	working	concentrations	in	5%	milk	powder	in	TBS-T	at	4	°C	overnight.	After	
3x	5	min	TBS-T	washing	steps,	membranes	were	incubated	with	HRP-coupled	secondary	
antibodies	(see	Table	M5)	in	5	%	milk	powder	in	TBS-T,	washed	four	times	in	TBS-T	for	
15	 min	 each	 and	 activated	 for	 1	 min	 using	 Clarity	 Western	 ECL	 Substrate	 (Bio-Rad	
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Laboratories,	 cat.	 #170-5060)	 on	 the	 ChemiDoc™	MP	 System	 (Bio-Rad	 Laboratories).	
Intensities	 of	 analyzed	 proteins	 were	 normalized	 to	 respective	 Actin	 band	 intensities	
using	Image	Lab	v5.2.1	to	determine	relative	protein	levels.		
	
2.2.14	Chromatin	immunoprecipitation	followed	by	qPCR	(ChIP-qPCR)	
ChIP-qPCR	was	performed	essentially	as	described	by	Krendl	et	al.199;	details	and	slight	
modifications	are	outlined	below.	The	compositions	of	buffers	and	solutions	are	listed	in	
Table	M14.	All	steps	were	performed	on	ice	unless	otherwise	noted.		
2.2.14.1	Preparation	of	chromatin	
NC	 cultures	 for	 ChIP	 analysis	 were	 derived	 from	 control	 hESC	 and	ASXL1PSC/PSC	 hESC	
(clones	 A,	 C,	 and	D)	 at	 day	 7	 of	 three	 independent	 differentiation	 experiments	 (three	
10	cm-plates	 per	 replicate).	 For	 harvesting	 of	 the	 cultures,	 which	 contained	 both	
neurospheres	 and	 adherent	 cells,	 neurospheres	 were	 first	 collected	 from	 the	 culture	
plates,	and	both	neurospheres	and	adherent	cells	were	washed	with	PBS.	Subsequently,	
neurospheres	 were	 transferred	 back	 to	 the	 plates	 and	 cells	 were	 dissociated	 with	
0.25	%	Trypsin-EDTA	and	harvested	via	centrifugation	as	described	before.	
Pellets	were	 resuspended	 in	 a	 solution	of	 10	ml	 cold	DMEM/F12	with	1	ml	of	 freshly	
prepared	crosslinking	solution.	Crosslinking	was	performed	for	10	min	 in	at	RT	under	
constant	 shaking	 (30	 rpm	 on	 a	 Polymax	 1040,	 Heidolph)	 and	 stopped	 by	 addition	 of	
glycine	at	a	final	concentration	of	0.125	M.	Fixed	cells	were	harvested	via	centrifugation	
at	 2000xg	 for	 5	 min	 at	 4	 °C,	 and	 each	 pellet	 was	 resuspended	 in	 5	 ml	 ice	 cold	 PBS	
containing	50	µl	100	mM	PMSF	and	collected	as	before.	This	washing	step	was	repeated	
once,	 and	 pellets	 were	 flash	 frozen	 in	 liquid	 nitrogen	 and	 stored	 at	 -80	 °C	 until	
proceeded	further.	
For	 lysis,	cell	pellets	were	thawn	on	ice	for	1	h	and	resuspended	in	500	µl	LB1	freshly	
supplemented	with	protease	inhibitor	(1X),	followed	by	incubation	on	a	rotating	wheel	
for	10	min	at	4	°C.	Cells	were	collected	via	centrifugation	at	2000xg	for	5	min	at	4	°C,	and	
each	 pellet	 was	 resuspended	 in	 500	 µl	 LB	 2	 freshly	 supplemented	 with	 protease	
inhibitor	 (1X),	 followed	 by	 incubation	 and	 collection	 as	 before.	 Pellets	 were	 then	
resuspended	in	120	µl	LB3	and	transferred	into	Bioruptor®	Microtubes	(Diagenode,	cat.	
#C30010016)	 and	 sonicated	 in	 200	 µl	 LB3	 for	 10	 min	 on	 the	 Bioruptor®	 Pico	
(Diagenode).	
2.2.14.2	Pre-treatment	of	magnetic	beads	
For	 10	 pre-clearing	 reactions,	 1	 ml	 TE	 buffer	 (Sigma-Aldrich)	 supplied	 with	 1	mg	
denaturated	tRNA	(Sigma-Aldrich)	and	20	µg	of	rabbit	 IgG	isotype	control	(Table	M5)	
was	 used	 to	 resuspend	200	 µl	Dynabeads(R)	 Protein	A	 for	 Immunoprecipitation	 (Life	
Technologies)	 after	 bead	 storage	 solution	 had	 been	 discarded	 on	 a	 MagnaRack™	
Magnetic	 Separation	 Rack	 (Thermo	 Fisher	 Scientific).	 The	 pre-clearing-bead	mixtures	
were	 incubated	 on	 a	 rotating	wheel	 at	 4	 °C	 overnight	 and	 subsequently,	 pre-clearing	
beads	were	washed	three	times	with	each	1	ml	WB1	for	5	min	on	a	rotating	wheel	at	4	
°C.	Afterwards,	pre-clearing	beads	were	resuspended	in	200µl	TE	buffer.	
For	each	ChIP	reaction,	20	µl	Dynabeads	were	 incubated	with	100	µg	BSA	and	200	µg	
denaturated	 tRNA	 in	 1	ml	 TE	 on	 a	 rotating	wheel	 overnight	 at	 4	 °C.	 On	 the	 next	 day,	
blocked	beads	were	washed	three	times	with	WB1	as	described	before	and	resuspended	
in	20	µl	TE	per	ChIP.	
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2.2.14.3	Chromatin	immunoprecipitation	
Per	sample,	10	µl	(5	%)	of	sheared	chromatin	was	stored	as	input	sample	at	-80	°C,	and	
the	remaining	chromatin	was	diluted	to	2	ml	in	ChIP	dilution	buffer.	100	µl	pre-clearing	
beads	(see	above	section)	were	added	and	the	mixtures	were	incubated	for	2	hours	at	4	
°C	on	a	rotating	wheel.	 	Thus	pre-cleared	chomatin	was	collected	and	divided	into	two	
aliquots	 per	 sample,	 to	 which	 2	 µl	 rabbit	 IgG	 control	 antibody	 or	 1.4	 µl	 H3K27me3	
antibody	 (Table	 M5)	were	 added,	 respectively,	 and	 incubated	 on	 a	 rotating	wheel	 at	
4	°C	overnight.	Then,	each	ChIP	 reaction	was	 incubated	with	20	µl	blocked	beads	 (see	
above	 section)	 for	 3	 hours	 at	 4	 °C	 on	 a	 rotating	wheel.	 Chromatin-bound	 beads	were	
washed	according	to	the	following	steps,	each	performed	for	5	min	at	4	°C	on	a	rotating	
wheel:		
2	x	WB1		
1x	WB2	
1x	WB3	
2x	WB4	
Antibody-bound	 chromatin	was	 then	 eluted	 twice	 from	 the	 beads	 via	 incubation	with	
first	130	µl,	then	100	µl	Elution	buffer/sample	under	constant	shaking	at	1,400	rpm	(on	
a	Thermomixer	Comfort,	Eppendorf)	 for	15	min	at	65	°C,	and	supernatants	of	 the	 two	
elution	 rounds	 were	 combined.	 	 Input	 samples	 were	 thawn,	 filled	 up	 to	 230	 µl	 with	
Elution	buffer	and	treated	along	with	the	ChIP	samples.	All	samples	were	filled	up	with	
TE	to	a	volume	of	300	µl	and	incubated	with	200	µg/ml	RNase	A	(Life	Technologies)	for	
45	min	at	37	°C.	Then,	sodium	chloride	and	3	µl	Proteinase	K	(Life	Technologies)	were	
added	to	final	concentrations	of	150	µM	and	260	µg/ml,	respectively,	and	samples	were	
de-crosslinked	 under	 occasional	 shaking	 (15	 min	 per	 hour)	 at	 600	 rpm	 and	 65	°C	
overnight.	ChIPed	DNA	was	purified	with	the	QIAquick	PCR	Purification	Kit	according	to	
the	manufacturer’s	specification	and	used	to	quantify	the	enrichment	of	H3K27me3	over	
input	samples	as	described	below.		
	
Table	M14.	Buffers	used	for	ChIP.	WB,	Wash	buffer;	LB,	Lysis	buffer.	
Name	 Composition	
Crosslinking	solution	 50	mM	Hepes/KOH,	100	mM	NaCl,	1	mM	EDTA,	0.5	mM	EGTA,	11%	Formaldehyde	
WB	1	 50	mM	Tris.HCl	pH	8.8,	0.1%	SDS,	0.1%	Na-Deoxycholate,	1%	Triton	X-100,	150	mM	NaCl,	1	mM	EDTA,	0.5	mM	EGTA	
WB	2	 WB2,	50	mM	Tris.HCl	pH	8.0,	0.1%	SDS,	0.1%	Na-Deoxycholate,	1%,	Triton	X-100,	500	mM	NaCl,	1	mM	EDTA	and	0.5	mM	EGTA	
WB	3	 50	mM	Tris.HCl	pH	8.0,	250	mM	LiCl,	0.5%	Na-Deoxycholate,	0.5%	NP-40,	1	mM	EDTA	and	0.5	mM	EGTA	
WB	4	 50	mM	Tris.HCl	pH	8.0,	10	mM	EDTA	and	5	mM	EGTA	
LB	1	 50	mM	Hepes/KOH,	140	mM	NaCl,	1	mM	EDTA,	10%	glycerol,	0.5%	NP-40,	0.25%	Triton	X-100	
LB	2	 10	mM	Tris.HCl,	200	mM	NaCl,	1	mM	EDTA,		0.5	mM	EGTA	
LB	3	 10	mM	Tris.HCl,	100	mM	NaCl,	1	mM	EDTA,	0.5	mM	EGTA,	0.1%	Na-Deoxycholate,	0.5%	N-lauroylsarcosine,	0.1%	SDS	
ChIP	dilution	buffer	 50	mM	Tris.HCl	pH	8.0,	167	mM	NaCl,	1.1%	Triton	X-100	and	0.11%	Na-Deoxycholate	
Elution	buffer	 1%	SDS,	0.1	M	NaHCO3		
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2.2.14.4	Primer	design,	qPCR	and	enrichment	analysis	
Primers	for	the	ASXL1,	ASXL3,	ZIC1/ZIC4,	FOXP2	and	HOXB2	 loci	were	designed	to	span	
80-150	bp	regions	that	showed	an	enrichment	for	H3K27me3	in	H1	hESC	according	to	
ENCODE	 data200,	 using	 Primer3Plus	 (http://primer3plus.com/cgi-
bin/dev/primer3plus.cgi).	Quantitative	detection	of	 target	 loci	by	 selected	primers	was	
tested	in	SYBR®	Green	qPCR	(see	chapter	2.2.10.4)	on	gDNA	at	concentrations	of	0.6,	3,	
15,	75,	150	and	300	ng/µl.	Primer	pairs	that	were	used	in	SYBR®	Green	qPCR	on	input	
samples	and	IgG	control/H3K27me3	ChIP	samples	are	shown	in	Table	M13.	Primers	for	
the	 detection	 of	 the	 ACTIN	 (ACTB)	 locus	 (negative	 control)	 were	 obtained	 from	 and	
validated	by	Dr.	Krendl199.		
	
Table	M13.	Primers	used	for	detection	of	H3K27me3	enrichment	in	ChIP	samples	(5′-3′).	*from199		
Name	 forward	sequence	 reverse	sequence	 genomic	location	
ZIC1-ChIP-Ex1	 aacgtggtcaacgggcag	 gcagcatagtgctccgaacg	 chr3:147128490+147128671	
ZIC4-ChIP-Ex3	 gggaaaggacaagggaaggg	 aacaggccaaccacatttgc	 chr3:147113701+147113827	
FOXP2-ChIP-Promoter	 cgactgagatgtcctttcgc	 cgttttggtgaaattcgcagc	 chr7:113723769+113723850	
FOXP2-ChIP-Intron	 taaccgtgcacagggatgac	 gcgacctctctaaagcggaa	 chr7:113727353+113727474	
ACTB-ChIP*	 aacggcagaagagagaacca	 aagatgacccaggtgagtgg	 chr7:5568699+5568803	
HOXB2-Intron-ChIP	 tctctagtctacagccccgg	 ggatctgaggttccggcg	 chr17:48543918+48544024	
ASXL1-ChIP-Intron1	 tctaacggttctgcacctgg	 cccagggtcataaacacccg	 chr20:32360403+32360545	
ASXL3-ChIP-Intron1	 gttcggcgtttgtgagttcaa	 cacagacacgcaaccaccta	 chr18:33579112+33579216	
	
For	 enrichment	 analysis,	 first,	 input	Ct	 values	were	 adjusted	 according	 to	 the	dilution	
factor	 (20x),	 then,	 the	 mean	 Ct	 of	 2	 technical	 replicates	 per	 sample	 and	 primer	 was	
compared	to	the	adjusted	input	value	using	the	following	formula:	
	
Enrichment	(in	%	input)	=	100	x	2-(Ct	(IP	sample)-	Ct	(adjusted	input))	
	
H3K27me3	antibody	specificity	was	validated	via	high	enrichment	in	repressed	HOXB2	
locus,	and	low	enrichment	for	H3K27me3	at	the	ACTINB	locus.		
	
2.2.15	Co-Immunoprecipitation	
Nuclear	 lysates	of	 neurospheres	derived	 at	NC	differentiation	day	3	 from	PB-ASXL1PSC	
with	or	without	DOX	treatment	were	prepared	and	subjected	to	co-immunoprecipitation	
using	EZH2	and	IgG	control	antibodies	(Table	M5)	with	the	Nuclear	Complex	Co-IP	Kit	
(Active	Motif,	cat.	#	54001)	according	to	the	manufacturer’s	instructions,	and	detection	
was	 performed	 via	 Western	 Blot,	 using	 ASXL1	 and	 EZH2	 antibodies	 (Table	 M5),	 as	
described	in	section	2.2.13.	
	
2.	2.16	Chicken	experiments	
Experiments	 were	 carried	 out	 in	 collaboration	 with	 Dr.	 Rada-Iglesias	 at	 the	 CMMC	
(Cologne,	 Germany).	 According	 to	 German	 animal	 care	 guidelines,	 no	 IACUC	
(Institutional	 Animal	 Care	 and	 Use	 Committee)	 approval	 was	 necessary	 to	 perform	
chicken	 embryo	 experiments.	 White	 fertilized	 chicken	 eggs	 (Gallus	 gallus	 domesticus)	
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were	obtained	from	a	 local	breeder	(LSL	Rhein-Main)	and	incubated	at	37	°C	and	80%	
humidity	 until	 reaching	 desired	 stages	 as	 determined	 according	 to	 Hamburger	 and	
Hamilton	(HH)201.	
2.2.16.1	In	ovo	transplantation	of	neurospheres	and	analysis	of	emigration	
Neurospheres,	which	I	derived	from	GFP-ASXL1PSC/PSC	and	GFP-control	lines	at	day	5	of	
NC	 differentiation,	 were	 inserted	 in	 the	 developing	 anterior	 neural	 region	 (i.e.	
hindbrain)	of	chicken	embryos	at	 the	8-10	somite	stage	(HH10)	by	Dr.	Rehimi	(CMMC	
Cologne).	 The	 operated	 eggs	 were	 re-incubated	 until	 stage	 HH22,	 when	 the	 embryos	
were	isolated	and	analyzed	under	a	fluorescence	stereo	microscope	(Olympus	SZX	16).	
The	 distance	 between	 transplanted	 neurospheres	 and	 furthest	 migrated	 cells,	 the	
diameter	 of	 transplanted	 neurospheres	 and	 the	 total	 number	 of	 emigrated	 cells	were	
determined	using	the	Fiji/ImageJ	software202.	
2.2.16.2	In	ovo	electroporation	of	truncated	ASXL1	overexpression	constructs	
For	 overexpression	 experiments	 in	 chicken	 embryos,	 the	 truncated	 chicken	 (Gallus	
gallus)	 ASXL1	 cDNA	 sequence	 (Gg-ASXL1PSC;	 N-terminal	 2445	 bp)	 and	 the	 truncated	
human	ASXL1	 cDNA	sequence	 (hASXL1PSC;	N-terminal	2892	bp)	were	each	 cloned	 into	
the	 pCIG	 vector	 harboring	 a	GFP	 coding	 sequence	 coupled	 to	 the	 T2A	 cleavage	 signal	
(obtained	from	Dr.	Rehimi).		
5	 µg	 of	 the	 pCIG	 vector	 were	 linearized	 using	 20	 Units	 of	 EcoRI-HF	 and	 XhoI	 (NEB)	
according	 to	 the	 supplier’s	 specifications,	 and	 purified	 with	 the	 QIAquick	 PCR	
Purification	Kit.	Gg-ASXL1	and	hASXL1	fragments	were	amplified	from	chicken	(obtained	
from	 Dr.	Rehimi)	 or	 human	 cDNA	 (control	 hESC-derived)	 via	 RT-PCR	 as	 described	 in	
section	2.2.10.3,	using	following	primers	(5’-3’):	
	
Gg-ASXL1PSC	-pCIG-for	
TCTCATCATTTTGGCAAAGAATTGCTCGAGGCCACCATGAGGGAGATGAAGCAGC	
Gg-ASXL1PSC	-pCIG-rev	
AGGGGCGGATCCCCCGGGCTGCAGGAATTCTTAGAGTTCTGACACAACCCTGC	
	
hASXL1PSC	-pCIG-for	
TCTCATCATTTTGGCAAAGAATTGCTCGAGGCCACCATGAAGGACAAACAGAAGAAGAAGAAG	
hASXL1PSC	-pCIG_EX-rev	
AGGGGCGGATCCCCCGGGCTGCAGGAATTCTTAAGATGGCACAGTCCAGAGTGA	
	
PCR	products	were	purified	using	the	QIAquick	PCR	Purification	Kit.	100	ng	 linearized	
pCIG	vector	(0.024	pmol)	were	mixed	with	either	78	ng	Gg-ASXL1PSC	or	94	ng	hASXL1PSC	
fragment	(0.048	pmol	each),	and	ligated	using	the	Gibson	Assembly	Master	Mix	(NEB).	
Transformation	into	competent	bacteria	and	colony-PCRs	were	performed	as	described	
in	chapters	2.2.8.1	and	2.2.8.3,	using	following	primer	combinations	(5’-3’):	
	
pCIG-	Gg-ASXL1PSC	construct:	Gg-ASXL1PSC	-pCIG-for	+	ATCCTCACCCCTGTTTCGTT		
	
pCIG-	hASXL1PSC	construct:	hASXL1PSC	-pCIG-for	+		CTGCTGCTGGAAGTGTGATG	
	
Positive	 bacteria	 clones	 were	 subjected	 to	 plasmid	 preparation	 and	 confirmation	 of	
constructs	by	Sanger	sequencing,	all	as	described	in	sections	2.2.8.3	and	2.2.8.4,	using	
following	primers	(5’-3’):	
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pCIG-	Gg-ASXL1PSC	construct	
1:	ATCCTCACCCCTGTTTCGTT		
2:	CCAGATATGCCCCAGGATCA	
pCIG-	hASXL1PSC	construct	
1:	CTGCTGCTGGAAGTGTGATG	
2:	GTCAGCCCACTTACCAGATATGC	
3:	GAGGAGGAGAGGGGTTGTTT	
4:	GGCTTCATTAGACCCACAGC	
	
Injections	 of	 correct	 pCIG-	 Gg-ASXL1PSC	 and	 pCIG-hASXL1PSC	 constructs	 into	 the	 target	
site	 of	 the	 developing	 brain	 and	 neural	tube	 of	HH9-10	 chicken	 embryos,	 followed	 by	
electroporation	and	imaging	at	developmental	stages	HH19	and	HH24,	were	carried	out	
by	 Dr.	 Rehimi.	 For	 control	 experiments,	 the	 pCIG	 vector	 expressing	 only	 GFP	 was	
electroporated.		
	
2.2.17	Mouse	experiments	
The	 Asxl1tm1a(EUCOMM)Wtsi	mouse	 strain	 (Mus	musculus),	 described	 by	 McGinley	 et	 al.107,	
was	maintained	on	a	C57BL/6NCrl	background.	Evaluation	of	this	genetically	modified	
line	 (Abschlussbeurteilung	 genetisch	 veraenderter	 Zuchtlinien)	 did	 not	 indicate	 a	
burden	 according	 to	 the	 German	 legal	 guidelines.	 Mouse	 husbandry	 and	 experiments	
were	 performed	 at	 the	 Helmholtz	 Center	 Munich	 respecting	 animal	 welfare	 in	
accordance	to	European	Directive	2010/63/EU.	
2.2.17.1	Breeding,	genotyping	and	phenotypes	
Breeding	 of	 heterozygous	 carrier	 mice,	 as	 determined	 by	 genotyping	 for	 each	
generation,	 to	C57BL/6NCrl	wildtype	 (wt)	mice	was	performed	 for	 ten	generations	 to	
ensure	generation	of	congenic	animals203.		
Genotyping	 was	 performed	 on	 animals	 at	 postnatal	 day	 P20-22.	 Genomic	 DNA	 was	
extracted	from	ear	punch	biopsies	and	the	Asxl1	target	region	was	amplified	by	PCR,	all	
as	 described	 in	 sections	 2.2.9	 and	 2.2.8.1,	 via	 combination	 of	 following	 primers	
(strategy	and	primers	supplied	by	the	EuMMCR	at	the	Helmholtz	Center	Munich):	
	
Detection	of	reporter	construct	knockin:	CAACGGGTTCTTCTGTTAGTCC	
Asxl1-for:	ATATACTTGGTTACACTCGGAGGC	
Asxl1-rev:	CTCCTCTAATTCATTTCCAAACCAGG	
	
The	presence	of	two	bands	in	agarose	gel	electrophoresis	allowed	for	the	identification	
of	heterozygous	animals,	as	opposed	to	the	generation	of	one	PCR	product	in	wt	animals.	
Occasionally	 (<1	 pup	 per	 litter),	 one	 of	 the	 following	 phenotypes	 was	 observed	 in	
heterozygous	 animals:	 unilateral	 microphthalmia,	 anaphthalmia	 or	 cataracts	 and	
reduced	birth	weight,	and	phenotypic	mice	and	wt	littermates	were	imaged.	
	
2.2.17.2	LacZ	staining	of	whole-mount	mouse	embryos	
As	 the	Asxl1tm1a(EUCOMM)Wtsi	mouse	 strain	 carries	 a	 lacZ	 reporter	within	 the	 endogenous	
Asxl1	 locus,	 X-Gal	 stainings	were	 performed	on	whole-mount	 embryos	 to	 assess	Asxl1	
expression	 patterns	 in	 vivo.	 Composition	 of	 used	 buffers	 and	 solutions	 are	 listed	 in	
Table	M15.		
One	 timed	 pregnancy	 (heterozygous	 x	 wt	 mating)	 was	 terminated	 via	 cervical	
dislocation	11	days	after	a	mating	plug	was	observed	(corresponding	to	embryonic	day	
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E11.5),	and	embryos	were	prepared	in	cold	PBS.	Tail	tips	were	separated	and	subjected	
to	genotyping	as	described	above,	and	embryos	were	fixed	in	LacZ	Fix	at	RT	for	30	min.	
Followed	by	3x	5	min	of	washing	in	LacZ	Wash	buffer,	embryos	were	stained	for	3	h	in	
LacZ	Stain	at	37	°C	 in	darkness.	Subsequently,	embryos	were	washed	 for	3x	15	min	 in	
LacZ	Wash	buffer	and	fixed	overnight	at	4	°C	(in	darkness)	using	lacZ	Fix.	Embryos	were	
then	transferred	to	4	%	PFA	and	imaged	on	a	Zeiss	Stereo	Lumar.V12	microscope.		
	
Table	M15.	Buffers	and	solutions	used	for	X-Gal	stainings.	
Name	 Composition	
LacZ	Fix	 4	%	Paraformaldehyd,	5	mM	EGTA	(pH	7.4),	2	mM	MgCl2	in	PBS	(pH	7.4)	
LacZ	Wash	 2	mM	MgCl2,	0.02	%	NP-40	in	PBS	(pH	7.4)	
LacZ	Stain	 1	mM	Ferrocyanide	(Sigma-Aldrich,	cat.	#P9387),	1	mM	Ferricyanide	(VWR	International,	cat.	#0713),	1	mg/ml	X-β-Gal	(Carl	Roth,	cat.	#2315.2)	in	LacZ	Wash	
	
2.2.18	Zebrafish	experiments	
Zebrafish	experiments	were	carried	out	 in	collaboration	with	Dr.	Hernan	Lopez-Schier	
(Helmholtz	Center	Munich).	
All	 experiments	 were	 approved	 by	 the	 government	 of	 Upper	 Bavaria	 (Regierung	 von	
Oberbayern,	Munich,	Germany;	Tierversuchsvorhaben	Gz.:	55.2-1-154-2532-202-2014)	
and	 were	 performed	 in	 accordance	 with	 animal	 protection	 standards.	 The	 zebrafish	
(Danio	rerio)	wt	 line	AB	was	used.	Zebrafish	embryos	and	 larvae	were	kept	at	28.5	 °C	
and	were	staged	according	to	Kimmel	et	al.204.		
2.2.18.1	Transcription	analysis	in	zebrafish	embryos	and	larvae	
Zebrafish	 wt	 embryos	 were	 collected	 at	 different	 developmental	 stages	 and	 2-10	
embryos	 per	 stage	 and	 replicate	 were	 euthanized	 via	 transfer	 to	 liquid	 nitrogen.	
Subsequently,	RNA	extraction	was	performed	using	 the	RNeasy	Micro	Kit	 (Qiagen,	cat.	
#74004)	according	to	the	manufacturer’s	specifications.	Isolated	RNA	was	subjected	to	
reverse	 transcription	 and	qPCR/RT-PCR	as	described	 in	 section	2.2.10,	 using	primers	
denoted	below:	
	
RT-PCR	
asxl1	(Exon	5-10)-forward:	AACAGCATCCACCACATCAA			-reverse:	ACATCTCCAGCTTCGCTCAT	
asxl2	(Exon	5-9)-for:	GCAGCAAACTCATGTCTCCA						-rev:	CCTTCAAGGCTCCATCCATA	
gapdh	for:		GTGTAGGCGTGGACTGTGGT															-rev:	TGGGAGTCAACCAGGACAAATA	
	
Power	SYBR®	Green	qPCR:	
asxl1-for:		AACAGCATCCACCACATCAA									-rev:	AGGCACTGGAGGAAGTCTCA	
asxl2-for:	TGAGGGAACGACAGAAGAAGA						-rev:	CATGGGTGTGTTGGGGTACT	
elfa*-for:		CTTCTCAGGCTGACTGTGC																		–rev:	CCGCTAGCATTACCCTCC	
	
*elfa	 was	 selected	 as	 housekeeping	 gene	 as	 gapdh	 is	 not	 stably	 expressed	 in	 zebrafish	
embryos205.		
2.2.18.2	RNA	in	situ	hybridization	
To	 detect	 expression	 of	 asxl1	 and	 asxl2	 in	 zebrafish	 embryos,	 antisense	 RNA	 probes	
complimentary	 to	 the	 endogenous	 transcripts	 were	 generated	 and	 used	 for	 in	 situ	
hybridizations,	alongside	with	sense	probes	as	negative	controls.	
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2.2.18.2.1	Generation	of	probes	
Following	primers	were	used	to	amplify	each	two	fragments	of	zebrafish	asxl1	and	asxl2	
transcripts	 in	 RT-PCR	 (see	 chapter	2.2.10.3)	 from	 zebrafish	 cDNA	 (isolated	 at	 6	 hpf,	
1	dpf,	2	dpf	and	3	dpf):		
	
asxl1	(Exon	5-10):	see	above*	
asxl1	(Exon	1-2)-for:	GGCTGTAGGAGCGACTGAAG			-rev:	TTGGGGCATCAGAAAAGTTC	
asxl2	(Exon	5-9):	see	above	
asxl2	(Exon	3-7):	TGGCACTTCTCCTCTTGCTT			-rev:	GGCAGCGTTCACTCTTTTTC	
	
*As	this	primer	set	amplifies	two	alternative	asxl1	transcripts,	the	larger	fragment	including	the	
alternatively	spliced	exon	was	isolated.	
	
PCR	 products	 were	 purified	 from	 agarose	 gels	 using	 the	 QIAquick	 Gel	 Extraction	 Kit.	
50	ng	of	each	fragment	were	treated	with	one	unit	of	Taq	Polymerase,	according	to	the	
supplied	protocol	(Qiagen,	cat.	#201205),	for	25	min	at	72	°C	to	create	3’adenylation	for	
cloning	into	the	pCR™II-TOPO™	Vector	with	the	TOPO™	TA	Cloning™	Kit	(Dual	Promoter,	
Life	 Technologies,	 cat.	 #K461020)	 according	 to	 the	 manufacturer’s	 specifications.	
Transformation,	 plasmid	 isolation	 and	 Sanger	 sequencing	 (using	 primers	 M13-FP:	
TGTAAAACGACGGCCAGT	 and	 M13-RP:	 CAGGAAACAGCTATGACC;	 GATC	 Biotech),	 were	
performed	as	described	in	sections	2.2.8.3	and	2.2.8.4.		
Correct	 clones	 were	 linearized	 using	 either	HindIII	 or	 EcoRV	 (NEB,	 cat.	 #R0104	 and	
R0195,	 respectively)	 according	 to	 the	 orientation	 of	 inserts,	 to	 allow	 for	 in	 vitro	
transcription	of	antisense	and	sense	transcripts	from	the	SP6	or	T7	promoter	present	in	
the	 pCR™II-TOPO™	 Vector.	 In	 vitro	 transcription	 was	 performed	 using	 the	 DIG	 RNA	
labeling	 Kit	 SP6/T7	 (Roche/Sigma-Aldrich,	 cat.	 #11175025910)	 according	 to	 the	
manufacturer’s	instructions,	followed	by	DNase	I	(Life	Technologies)	treatment	at	37	°C	
for	 30	min.	 RNA	 probes	 were	 purified	 LiCl/Ethanol	 precipitation	 as	 follows:	 To	 each	
transcription	 reaction,	 80	 µl	 TE,	 10	 µl	 of	 4	M	 LiCl	 (Sigma)	 and	 200	 µl	 100	%	Ethanol	
(Carl	Roth)	were	added,	and	precipitation	was	performed	at	-20	°C	overnight.	RNA	was	
collected	via	centrifugation	at	4	°C	and	13,000	rpm	in	a	tabletop	centrifuge	(Fresco	21,	
Thermo	 Fisher	 Scientific)	 for	 20	 min,	 pellets	 were	 washed	 once	 with	 75	 %	 Ethanol,	
centrifuged	as	before	 for	15	min	and,	 after	 removal	 of	 ethanol,	 dried	 for	5	min	 at	RT.	
Each	pellet	was	resuspended	in	12	µl	RNase	free	TE	buffer,	and	1	µl	was	mixed	with	9	µl	
RNAse-free	water	and	2	µl	Ambion	loading	dye	(Thermo	Fisher	Scientific,	cat.	#AM8546)	
and	 analyzed	 via	 gel	 electrophoresis	 for	 5	min	 at	 120	 V.	 RNA	 probes	 were	 stored	 at										
-80	°C.		
2.2.18.2.2	Hybridization	and	staining	
All	solutions	and	buffers	are	listed	in	Table	M16.		
Embryos	 of	 wt	 zebrafish	 were	 incubated	 in	 Petri	 dishes	 containing	 fish	 water	 and	
collected	 at	 6	 hpf,	 36	 hpf	 and	 48	 hpf.	 For	 latter	 stages,	 fish	water	was	 replaced	with	
0.0045	%	1-Phenyl-2-Thiourea	(PTU)	solution	in	1x	Danieau	medium	starting	from	the	
end	of	gastrulation	in	order	to	prevent	pigmentation206.	Embryos	at	6	hpf	were	manually	
dechorionated	 using	 forceps.	 All	 embryos	were	 fixed	 overnight	 in	 a	 freshly	made	 4%	
formaldehyde/PBS	solution	at	4	°C.	
The	next	day,	embryos	were	transferred	to	methanol	(MeOH)	in	following	steps	(all	RT	
incubation	steps	under	constant	shaking):	
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PBS-T		 	 	 	 	 	 	 10	min	
25%	MeOH/75%	PBS-T	 	 	 	 5	min	
50%	MeOH/50%	PBS-T		 	 	 	 5	min	
75%	MeOH/25%	PBS-T		 	 	 	 5	min	
100%	MeOH	 	 	 	 	 	 1	h	at	-20	°C		
	
Subsequently,	embryos	were	re-hydrated	in	following	steps:	
	
75%	MeOH/25%	PBS-T		 	 	 	 5	min	RT	
50%	MeOH/50%	PBS-T		 	 	 	 5	min	RT	
25%	MeOH/75%	PBS-T		 	 	 	 5	min	RT	
100%	PBS-T	 	 	 	 	 	 3x	5	min	RT	
	
Proteinase	 K	 digestion	 (10	 µg/ml	 in	 PBS)	 was	 performed	 at	 RT	 for	 2	 min	 (6	 hpf	
embryos),	10	min	(36	hpf)	or	15	min	(48	hpf).	Embryos	were	washed	twice	in	PBS-T	for	
5	min,	re-fixed	in	1	ml	4	%	formaldehyde/PBS	for	20	min	at	RT,	and	washed	five	times	
for	5	min	 in	PBS-T.	Embryos	were	 then	transferred	to	HM+	for	5	min	at	RT,	 then	pre-
hybridized	in	HM+	for	2	h	at	67	°C.	Per	probe	and	stage,	500	µl	HM+	plus	500	ng	probe	
(asxl1/asxl2,	 antisense/sense)	 were	 combined	 and	 heated	 to	 67	 deg	 for	 10	 min.	 The	
HM+/probe	mix	was	then	added	to	embryos	and	hybridized	overnight	at	67	°C.		
The	 following	day,	hybridized	embryos	were	washed	according	 to	 the	 following	steps,	
for	each	probe/stage	in	500	µl	of	the	respective	solutions:	
	
100	%	HM-	 67	°C	 5	min	
75%	HM-/25%	2xSSC	 67	°C	 15	min	
50%	HM-/50%	2xSSC	 67	°C	 15	min	
25%	HM-/75%	2xSSC	 67	°C	 15	min	
2x	SSC	 67	°C	 15	min	
0.1x	SSC	 67	°C	 2	x	30	min	
75%	0.1x	SSC/25%	PBS-T	 RT	+	shaking	 10	min	
50%	0.1x	SSC/50%	PBS-T	 RT	+	shaking	 10	min	
25%	0.1x	SSC/75%	PBS-T	 RT	+	shaking	 10	min	
PBS-T	 RT	+	shaking	 10	min	
	
Washed	embryos	were	transferred	to	400	µl	Blocking	buffer	for	2	h	shaking	at	RT	and	
afterwards	 incubated	 with	 500	 µl	 DIG	 antibody	 (supplied	 by	 Dr.	 Lopez-Schier)	 in	
Blocking	buffer	(1:2000)	shaking	at	4	°C	overnight	in	darkness.	
The	following	day,	washes	were	performed	as	follows:	
	
PBS-T	 RT	+	shaking	+	darkness	 3	x	10	min	
PBS-T	 RT	+	shaking	+	darkness	 4	x	30	min	
PBS-T	 RT	+	shaking	+	darkness	 4	x15	min	
PBS-T	 4	°C	+	shaking	+	darkness	 overnight	in	1500	µl	
	
The	 following	 day,	 all	 washing	 and	 incubation	 steps	 were	 performed	 in	 darkness.	
Embryos	were	first	incubated	in	500	µl	AP-	buffer	for	5	min	at	RT,	then	twice	for	5	min	
in	 500	 µl	 AP+	 buffer,	 and	 subsequently	 transferred	 to	 12-well	 plates.	 2	 ml	 staining	
solution	[1	ml	AP+	plus	4.5	µl	NBT	(Sigma-Aldrich,	cat.	#N6876)	and	3.5	µl	BCIP	(Sigma-
Aldrich,	 cat.	 #B6149)]	 were	 added	 per	 well	 and	 incubated	 while	 shaking	 at	 RT.	 The	
reaction	was	monitored	until	 the	desired	staining	 intensity	was	reached,	and	embryos	
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were	 washed	 3x	 5	 min	 with	 PBS-T	 at	 4	°C	 while	 shaking.	 The	 staining	 reaction	 was	
stopped	by	washing	twice	in	PBS-T	plus	1	mM	EDTA	at	4	°C.		Embryos	were	imaged	and	
stored	in	stop	solution	or	glycerol.	
	
Table	M16.	Buffers	and	solutions	used	for	RNA	in	situ	hybriziation	in	zebrafish	embryos.	Chemicals	and	
reagents	were	obtained	from	Dr.	Lopez-Schier,	Helmholtz	Center	Munich.	
Name	 Composition	
PBS-T	 PBS	+	0.2	%	Tween-20	
HM-	 60	%	formamide,	5	x	SSC,	0.1	%	Tween-20,	0.0092	M	citric	acid	in	H2O	
HM+	 HM-	plus	50	µg/ml	Heparin	and	500	µg/ml	tRNA	(yeast)	
Blocking	buffer	 2	mg/ml	BSA	and	1	%	lamb	serum	in	PBS-T	
AP-	 100	mM	Tris.Hcl	(pH	9.5),	100	mM	NaCl,	0.1	%	Tween-20	in	H2O	
AP+	 AP-	plus	50	mM	MgCl2	
20	x	SSC	 3	M	NaCl,	300	mM	Na3Citrate	x2	H2O;	pH	7.0	
	
2.2.18.3	Generation	of	zebrafish	mutant	via	CRISPR/Cas		
To	 generate	 truncating	 asxl1	 mutations	 in	 the	 zebrafish,	 insertions/deletions	 (indels)	
were	generated	 in	 the	center	region	of	 the	zebrafish	asxl1	 locus	using	 the	CRISPR/Cas	
technology.	To	optimize	the	injection	procedure,	first	the	slc452	gene,	which	is	disrupted	
in	 albino	 mutants,	 was	 targeted	 as	 pigmentation	 presented	 an	 efficient	 readout	 for	
successful	CRISPR	targeting.	
2.2.18.3.1	Generation	of	gRNAs	
gRNAs	were	 designed	 using	 the	MIT	 CRISPR	 design	 webpage	 as	 described	 in	 section	
2.2.3.1.	Two	gRNA	sequences	targeting	exon	6	of	 the	slc45a2	 locus	were	selected,	and	
one	 gRNA	 targeting	 exon	 12	 of	 asxl1.	 Oligonucleotides	 were	 designed	 to	 contain	 the	
gRNA	 sequence	 flanked	 by	 a	 T7	 promoter	 and	 the	 gRNA	 scaffold,	 according	 to	 a	
published	 method207,	 resulting	 in	 following	 antisense	 oligonucleotides	 (5′-3′,	 gRNA	
indicated	in	lower	case):				
	
slc45a2	(A)		
AAAAGCACCGACTCGGTGCCACTTTTTCAAGTTGATAACGGACTAGCCTTATTTTAACTTGCTATTTCT
AGCTCTAAAACatatatggcagaagcagcctCTATAGTGAGTCGTATTACGC	
slc45a2	(B)		
AAAAGCACCGACTCGGTGCCACTTTTTCAAGTTGATAACGGACTAGCCTTATTTTAACTTGCTATTTCT
AGCTCTAAAACatcagaccggttcccaaaccCTATAGTGAGTCGTATTACGC	
	
asxl1	
AAAAGCACCGACTCGGTGCCACTTTTTCAAGTTGATAACGGACTAGCCTTATTTTAACTTGCTATTTCT
AGCTCTAAAACctgggcacgggcttgctgtgCTATAGTGAGTCGTATTACGC	
	
The	 gRNA	 antisense	 oligonucleotides	 were	 annealed	 to	 the	 T7	 primer	
(TAATACGACTCACTATAG)	 in	 TE	 buffer	 at	 a	 final	 concentration	 of	 50	 µM	 each	 for	
5	minutes	at	95	°C,	then	cooled	to	RT	for	5	hours	and	diluted	to	3	µM	in	TE	buffer.	1	µl	of	
the	annealed	mix	was	subjected	to	in	vitro	transcription	with	the	MEGAshortscript™	T7	
Transcription	 Kit	 (Thermo	 Fisher,	 cat.	 #AM1354)	 according	 to	 the	 supplied	 protocol	
(4	h	 incubation	at	37	°C).	gRNAs	were	treated	for	15	min	with	TURBO	DNase	supplied	
with	 the	 kit,	 and	 extracted	 with	 phenol:chloroform	 (Roti®-
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Phenol/Chloroform/Isoamylalkohol,	 Carl	 Roth,	 cat.	 #A156.3)	 followed	 by	 2-propanol	
precipitation	 overnight	 at	 -20	 °C	 according	 to	 the	 supplied	 protocol.	 The	 pellet	 was	
resuspended	 in	 20	µl	 RNase-free	 H2O,	 aliquoted	 and	 stored	 at	 -80	°C.	 1	 µl	 per	 gRNA	
were	analyzed	via	gel	electrophoresis	to	exclude	degradation.	
2.2.18.3.2	Generation	of	Cas9	mRNA		
The	 pCS2-Cas9-NLS	 plasmid207,	 harboring	 a	 Cas9	 sequence	 fused	 to	 a	 nuclear	
localization	signal	(NLS)	was	obtained	from	Dr.	Chapouton	(Helmholtz	Center	Munich),	
with	consent	from	Dr.	Schmid,	DZNE	Munich,	Germany.		
According	to	the	following	reaction	mixture,	the	pCS2-Cas9-NLS	plasmid	was	linearized	
for	2	hours	at	37	°C:	
	
5	µl	Buffer	B	(Supplied	with	ApaI	enzyme)	
12.5	µl	pCS2-Cas9-NLS	plasmid	(=	5	µg)	
5	µl	ApaI	(=50	units,	Thermo	Fisher,	cat.	#ER1411)	
27.5	µl	dH2O	
	
Linearization	was	confirmed	on	a	0.8	%	agarose	gel,	and	the	linearized	plasmid	was	in	
vitro	 transcribed	 using	 the	 SP6	 mESSAGE	 machine	 Kit	 (Thermo	 Fisher	 #AM1340)	
followed	by	LiCl	precipiation	of	the	Cas9	mRNA	overnight	at	-20	°C,	all	according	to	the	
supplied	protocols.	The	pellet	was	resuspended	in	20	µl	RNase-free	H2O,	of	which	1	µl	
were	analyzed	via	gel	electrophoresis	to	exclude	degradation.	
2.2.18.3.3	Microinjection	and	analysis	of	targeted	fish	and	mutants	
gRNA	 and	Cas9	mRNA	were	 co-injected	 into	 one-cell	 stage	 zebrafish	 embryos	 using	 a	
Femtojet	 (Eppendorf).	 For	 each	 slc45a2	 gRNA,	 microinjections	 were	 performed	
according	to	two	published	methods:	
	
	 HW208		 HR207		
Cas9-NLS	mRNA	 300	ng/ul	 0.5	µg/ul	
gRNA	 12.5	ng/ul	 2.4	µg/ul	
Injection	volume	 2	nl	 2	nl	
Embryos	were	assessed	daily	on	a	stereoscope,	with	uninjected	siblings	as	controls,	 to	
identify	perturbed	pigmentation,	indicating	successful	targeting	of	the	slc45a2	locus.		
According	 to	 these	 test	 experiments,	asxl1	 gRNA	was	 injected	 together	with	Cas9-NLS	
mRNA	 into	 zebrafish	 embryos	 using	 method	 ‘HW’.	 Several	 injected	 founder	 embryos	
(1	dpf,	with	uninjected	embryos	as	control)	were	subjected	to	genotyping	as	described	
below	 to	 confirm	 targeting	 of	 the	 asxl1	 locus,	 and	 the	 remaining	 injected	 fish	 were	
maintained.	Adult	 founder	 fish	were	bred	 to	wt	 fish,	 and	 the	 adult	 F1	 generation	was	
genotyped	 to	 detect	 heterozygous	 asxl1	 mutants.	 Heterozygous	 matings	 were	 then	
performed	to	generate	heterozygous	and	homozygous	F2	offspring,	which	was	assessed	
for	 phenotypes	 and	 imaged	 on	 the	 Leica	 DMIL	 LED	 microscope.	 Phenotypes	 of	 F2	
embryos	and	 larvae	were	classified	as	normal,	mild	phenotype	(slightly	shorter	 tail	or	
mild	edema),	pericardial	edema,	shortened/no	tail	 (caudal	 truncations),	and	combined	
edema/no	 tail.	 Several	 embryos	 of	 each	 phenotype	 were	 subjected	 to	 genotyping	 as	
described	below.		
2.2.18.3.4	Genotyping	of	founder,	F1	and	F2	fish	
Genomic	DNA	isolation	was	performed	on	single	embryos	that	had	been	euthanized	via	
freezing	 as	 described	 before,	 or	 on	 fin	 biopsies	 derived	 from	 adult	 fish	 anesthetized	
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using	a	0.004	%	MS-222	solution	(Sigma-Aldrich,	cat.	#E10521),	for	the	DNA	extraction	
protocol	see	section	2.2.9.	The	target	region	in	asxl1	was	amplified	via	PCR	as	described	
in	chapter	2.2.8.1	using	following	primers	(5’-3’):	
	
ZF-asxl1-GT-for:	CTTCCTCTTCCTCCTCCAC	
ZF-asxl1-GT-rev:	CTGTAGTTGTGCTCCCGAC	
	
PCR	 products	were	 isolated	 using	 the	 QIAquick	 PCR	 Purification	 Kit	 and	 subjected	 to	
Sanger	 sequencing	 using	 primer	 ‘ZF-asxl1-GT-for’	 (see	 chapter	2.2.8.4).	 Results	 were	
analyzed	for	indel	mutations	and	mutant	sequences	were	transcribed	in	silico	using	the	
Ape	software	(see	Table	M6)	to	determine	the	putative	effects	of	introduced	mutations	
on	expression	of	theoretical	truncated	asxl1	proteins.	
	
2.2.19	Statistical	analysis	
Sample	 sizes	 are	 indicated	 in	 the	 respective	 figures	 and	 figure	 captions;	 values	 are	
expressed	as	mean	+/-	standard	error	of	the	mean	as	calculated	with	the	Excel	software	
(version	 14.0.0	 for	 Mac).	 For	 pairwise	 comparison	 of	 means,	 Shapiro-Wilk	 test	 was	
applied	in	R	studio	version	3.3.2	to	evaluate	normal	distribution	of	samples,	and	if	given,	
Welch’s	 t-test	 was	 applied.	 Otherwise,	 Wilcox	 test	 was	 used	 to	 test	 for	 statistical	
significance.	
	
2.2.20	Generation	of	charts	and	visualization	of	data	from	public	databases	
Boxplots,	PCA	plots	and	volcano	plots	were	generated	in	R	studio	v3.3.2,	all	other	charts	
were	generated	using	the	Excel	software	(version	14.0.0	for	Mac).	
ENCODE	data200	on	H3K4me3-,	H3K27me3-	and	EZH2-ChIP,	 as	well	 as	RNA-seq	 in	H1	
hESC,	HSMM	and	NHEK	cell	lines	were	visualized	on	the	IGV	genome	browser	2.3	or	the	
WashU	 epigenome	 browser	 under	 http://epigenomegateway.wustl.edu/browser/,	
respectively.		
Heatmaps	 displaying	 transcriptional	 data	 of	 the	 developing	 human	 brain	 were	 from:	
©2010	 Allen	 Institute	 for	 Brain	 Science.	 BrainSpan	 Atlas	 of	 the	 Developing	 Human	
Brain,	available	under:	http://www.brainspan.org/.	
The	ASXL	gene	tree	was	generated	with	the	Comparative	Genomics	tool	of	the	Ensembl	
genome	browser	91	under	https://www.ensembl.org/index.html.	
Annotation	of	functional	protein	domains	in	chicken	and	zebrafish	ASXL	proteins	was	
extracted	from	data	on	the	Uniprot	database209	under	https://www.uniprot.org/.	
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3.	Results	
3.1.	Expression	of	ASXL	genes	in	pluripotency,	differentiation	and	brain	
development	
Despite	 mutations	 being	 involved	 in	 developmental	 syndromes,	 no	 studies	
examined	 the	 contribution	 of	 ASXLs	 to	 human	 embryonic	 development	 thus	 far.	
Focusing	 first	 on	potential	 roles	during	progenitor	 commitment	 at	 the	 germ	 layer	
level,	 I	 evaluated	 transcriptional	 levels	 and	 histone	 marks	 of	 human	 ASXL	 genes	
during	early	differentiation	of	human	pluripotent	stem	cells	and	analyzed	datasets	
of	human	embryonic	development	in	parallel.	
As	shown	in	Fig.	9A,	transcripts	of	all	three	human	paralogs	ASXL1,	2	and	3	could	be	
detected	 by	 RNA-seq	 in	 hESCs	 of	 the	 H9	 line;	 while	 ASXL1	 and	 ASXL2	 were	
expressed	at	 similar	 levels,	ASXL3	was	detected	at	 lower	 transcript	numbers.	This	
corresponded	to	RNA-seq	data	based	on	the	H1	 line	(ENCODE	project200;	Fig.	 9B).	
Interestingly,	 reviewing	 the	 ENCODE	 epigenome	 dataset	 revealed	 that	 the	
transcriptional	start	sites	(TSSs)	of	both	ASXL1	and	ASXL3	exhibit	H3K27m3	as	well	
as	 H3K4me3	 in	 H1	 cells	 (Fig.	 9B),	 reflecting	 a	 bivalent	 state	 characteristic	 of	
developmental	 regulators.	 The	 bivalent	 chromatin	 state	 of	 ASXL1	 is	 resolved	 to	
H3K4	trimethylation	in	two	adult	cell	lines	representing	human	skeletal	muscle	and	
epidermal	 keratinocytes,	 indicating	 that	 it	 is	 actively	 transcribed.	 Conversely,	 the	
TSS	of	ASXL3	retains	a	bivalent	status	and	ASXL3	 is	not	expressed	in	these	somatic	
cell	 lines.	 The	 TSS	 of	 ASXL2	 is	 found	 in	 an	 H3K4	 trimethylated	 state	 in	
undifferentiated	 cells	 as	 well	 as	 in	 selected	 somatic	 cell	 lines,	 and	 ASXL2	 is	
expressed	in	all	these	lines	(Fig.	9B).		
To	analyze	transcriptional	dynamics	during	commitment	to	progenitors	equivalent	
to	 the	 germ	 layer	 stage	 of	 development,	 I	 used	 diverse	 differentiation	 protocols.	
ASXL1	 and	 ASXL2	 levels	 increased	 after	 three	 days	 of	 growth	 in	 a	 medium	 that	
promotes	spontaneous	differentiation	 induced	by	withdrawal	of	basic	FGF	(bFGF),	
which	was	accompanied	by	a	 slight	decline	of	OCT4/POU5F1	expression	 (Fig.	 9C).	
Induction	 of	 specific	 germ	 layer	 programs	 via	 BMP4	 (mesoderm	 induction210),	
retinoic	 acid	 (RA;	 neural	 induction211)	 and	 Activin	 A	 (endoderm	 induction212)	
treatment,	likewise	induced	upregulation	of	ASXL1	and	ASXL2	(Fig.	9C).	Murine	Asxl	
genes	 are	 expressed	 in	 the	 embryonic	 brain115,	 and	 intellectual	 deficits	 and	
microcephaly	 are	 observed	 in	 all	 BOS	 patients89.	 I	 therefore	 investigated	 the	
involvement	of	ASXLs	in	neuronal	differentiation.	Indeed,	I	noted	strong	induction	of	
ASXL1	in	human	neural	stem	cell	cultures	compared	to	undifferentiated	cells,	while	
the	induction	of	ASXL2	and	ASXL3	was	considerably	lower	(Fig.	9D,	RNA	provided	
by	Dr.	Klaus,	Helmholtz	Center	Munich).	It	should	be	mentioned	that	given	the	initial	
level	of	ASXL1	 in	undifferentiated	cells	 (Fig.	 9A),	 these	data	 indicate	 that	ASXL1	 is	
highly	expressed	 in	neural	stem	cells.	Analysis	of	published	RNA-seq	data	that	has	
been	 based	 on	 samples	 collected	 at	 different	 timepoints	 during	 neuronal	
differentiation213	 gave	 similar	 results:	ASXL1	 was	 strongly	 upregulated	 already	 at	
day	11	of	neuronal	differentiation,	prior	to	PAX6,	the	neuronal	master	regulator,	and	
its	levels	were	also	maintained	longer	compared	to	PAX6	upon	passaging	(Fig.	9E).	
ASXL2	levels	declined	slightly	during	differentiation,	while	the	ASXL3	transcript	was	
only	detected	at	very	low	levels	(Fig.	9E).	
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Figure	9.	Regulation	of	ASXL	paralogs	during	progenitor	commitment	from	hESCs	and	human	brain	
development.		
(A)	 Transcript	 levels	 of	 ASXL	 genes	 and	 pluripotency	 factor	OCT4	 in	 undifferentiated	 hESC;	 cpm,	
counts	 per	 million	 (n=8;	 RNA-seq	 data	 from199)	 (B)	 Transcript	 levels	 and	 histone	 modifications	
H3K4me3	 and	 H3K27me3	 at	 ASXL	 loci	 in	 H1	 hESC	 and	 human	 cell	 lines	 HSMM	 (Human	 Skeletal	
Muscle	and	Myoblast)	and	NHEK	(Normal	Human	Epidermal	Keratinocytes).	Data	from	the	ENCODE	
project200.	 (C)	 qPCR	 analysis	 of	ASXL	 genes	 and	OCT4	 in	 H9	 hESC	 samples	 treated	with	 50	 ng/ml	
BMP4,	0.5	µM	retinoic	acid	(RA),	5	ng/ml	ACTIVIN	A	or	solely	FBS-containing	differentiation	medium	
(DM)	for	72h.	(D)	Expression	analysis	of	ASXL	genes	and	PAX6	in	neuronal	stem	cell	cultures	derived	
from	 SH	 hiPSC	 (RNA	 provided	 by	 Dr.	 Klaus,	 Helmholtz	 Center	 Munich).	 (E)	 Transcription	 level	
dynamics	 during	 different	 steps	 of	 neuronal	 differentiation	 from	 H1	 hESCs.	 [Raw	 data	 from213.	
Neuronal	 progenitor	 cells	 were	 obtained/maintained	 in	 N2B27	 +	 Noggin	 (day	 11)	 or	 N2B27	 +	
20	ng/ml	 bFGF	 and	 EGF	 (P9	 and	 P22)].	 (F)	 Spatiotemporal	 expression	 pattern	 of	ASXL	 genes	 and	
Doublecortin	(DCX),	a	regulator	of	neuronal	progenitor	migration,	in	human	brain	development;	pcw,	
post-conceptional	week.	Image	modified	from	human.brain-map.org.	
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A	 review	 of	 in	 vivo	 transcriptomics	 data	 from	 human	 brain	 tissues,	 sampled	 at	
different	 developmental	 stages	 from	 embryonic	 week	 8	 to	 40	 years	 of	 age,	
corroborated	these	findings	(Fig.	9F,	human.brain-map.org).	ASXL1,	and	to	a	lesser	
extent	 ASXL3,	 are	 expressed	 during	 fetal	 brain	 development	 and	 display	 a	
spatiotemporal	 expression	 pattern	 resembling	 that	 of	 Doublecortin	 (DCX),	 a	
microtubule-associated	gene	 found	 in	migrating	neuronal	progenitors214	 (Fig.	 9F).	
In	accordance	with	transcriptional	analyses	in	vitro,	ASXL2	is	expressed	at	relatively	
low	levels	in	the	developing	and	adult	human	brain	(Fig.	9F).			
Taken	 together,	 these	 data	 imply	 a	 role	 for	 ASXLs	 as	 developmental	 regulators,	
particularly	 of	 ASXL1	 (and	 ASXL3)	 in	 the	 formation	 and	 maturation	 of	 neuronal	
lineages.	
	
3.2.	Generation	of	human	pluripotent	stem	cell-based	models	for	BOS	
According	 to	 the	 expression	 and	 upregulation	 of	 ASXL	 paralogs	 during	 hESC	
differentiation,	 which	 suggests	 an	 involvement	 during	 the	 specification	 and	
maturation	 of	 embryonic	 progenitors,	 mutations	 in	 ASXL	 genes	 might	 thereby	
negatively	 affect	 formation	 of	 fetal	 tissues.	 This	 could	 result	 in	 the	 congenital	
dysmorphisms	that	are	observed	in	BOS,	BRS,	and	the	neurodevelopmental	disorder	
associated	with	mutations	 in	ASXL2.	 In	 order	 to	 investigate	 the	 pathogenesis	 and	
mechanisms	 pertinent	 to	 perturbation	 of	 developmental	 programs,	 I	 generated	
several	human	pluripotent	stem	cell-based	models	harboring	ASXL1	mutations.	
	
3.2.1	BOS	patient-derived	human	induced	pluripotent	stem	cell	lines	(BOS-
iPSC)	
In	 collaboration	 with	 Prof.	 Giovannucci	 Uzielli	 (University	 of	 Florence,	 Italy)	 and	
Dr.	Magini	 (S.	 Orsola-Malpighi	 University	 Hospital,	 Bologna,	 Italy),	 I	 obtained	 skin	
biopsies	 from	 two	 BOS	 patients,	 5	 and	 7	 years	 old,	 which	 harbor	 heterozygous	
mutations	 in	 ASXL1.	 Both	 mutations,	 p.Q803TfsX17	 in	 the	 female	 patient	 #1	 and	
p.R965X	in	the	male	patient	#2,	are	 located	 in	the	 ‘mutation	hotspot’	of	 the	ASXL1	
coding	region	(Fig.	7D)		and	result	in	premature	STOP	codons134	(PSCs;	Fig.	10A).	I	
derived	 fibroblasts	 from	the	patient	skin	explants	(Fig.	 10B),	and	with	the	help	of	
Dr.	 Pertek	 and	 E.	 Rusha	 (Helmholtz	 Center	 Munich),	 I	 generated	 patient-specific	
human	induced	pluripotent	stem	cell	lines	(BOS-iPSC).	Each	line	was	reprogrammed	
separately	by	two	different,	 integration-free	methods:	via	 introduction	of	modified	
mRNA191	or	4-in-1	mini-intronic	plasmids17,	resulting	in	four	BOS-iPSC	lines	[female	
lines	#1-0	(mmRNA)	and	#1-1	(4-in-1)	and	male	lines	#2-0	(mmRNA)	and	#2-1	(4-
in-1),	Fig.	10B	and	Table	3].	In	comparison	to	control	hiPSC	lines,	all	four	BOS-iPSC	
lines	did	not	exhibit	any	apparent	defect	in	self-renewal,	morphology	(Fig.	10B),	or	
expression	of	 pluripotency	markers	 according	 to	 qPCR	 and	 immunocytochemistry	
with	the	exception	of	a	slight	upregulation	of	the	NANOG	transcript	in	BOS	line	#2-0	
(Fig.	10C	and	D).		
	
	
	
	
	 	
	 	 	
3. Results 
66	
	
ASXL1 
                       
200 1541 aa 400 600 800 1000 1200 
BOS patient #1: p.Q803TfsX17 
BOS patient #2: p.R965X  0
1
2
3
4
5
OCT4 NANOG
	
	
Control iPSCs 
iPSC clone  #2-0/#2-1 
	
iPSC clone #1-0/#1-1 
	
	
Ex
pr
es
si
on
 le
ve
l 
re
la
tiv
e 
to
 c
on
tro
l l
in
e 
 
A 
B 
C 
D 
 c
on
tr
ol
 iP
SC
 
#2
-0
 
#1
-0
 
NANOG/DAPI OCT4/DAPI SOX2/DAPI LIN28/DAPI 
fibroblasts iPSC clones 
#1-0 
#2-0 
#1-1 
#2-1 
B
O
S patient-derived  
BOS patient #1 
BOS patient #2 
Control 
Control 
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	 10.	 Generation	 of	 BOS-patient	 derived	 human	
induced	stem	cells.		
(A)	 Scheme	 of	ASXL1	 gene	with	mutations	 reported	 in	
BOS	 patients	 #1	 and	 #2134,	 of	 whom	 fibroblasts	 were	
obtained	in	this	study.	The	red	box	indicates	location	of	
mutations	 reported	 in	 other	 BOS	 patients133,137.	 (B)	
Bright-field	 images	 of	 control	 and	 BOS-patient-derived	
iPSCs	 and	 parental	 fibroblasts.	 (C,	 D)	 Analysis	 of	 core	
pluripotency	 transcription	 factors	 in	 undifferentiated	
BOS	 iPSC	 lines	#1-0	and	#2-0	 compared	 to	 the	 control	
iPSC	 line	 via	 qPCR	 (n=2;	 C)	 and	 immunocytochemical	
staining	(D).		
	
3.2.2	Introduction	of	BOS-like	ASXL1	mutations	to	human	embryonic	stem	
cells	
In	order	 to	generate	 isogenic	human	pluripotent	stem	cell	models	 for	BOS,	 I	made	
use	 of	 a	 genetically	 modified	 HUES9	 hESC	 line,	 which	 harbors	 an	 integrated	 tet-
inducible	Caspase	9	enzyme190	(iCas9).	To	target	ASXL1	in	this	line,	I	electroporated	
two	gRNAs	and	treated	the	cells	with	doxycycline	(DOX)	for	24	h.	By	subsequently	
raising	clones,	 I	was	able	 to	propagate	a	clone	(clone	A)	with	an	excised	region	of	
476	bp	within	the	‘mutation	hotspot’	of	ASXL1	(Fig.	11A).	I	confirmed	the	deletion	
via	amplification	of	the	targeted	area	by	PCR	and	subsequent	sequencing	(Fig.	11B	
and	 C;	 c.2419_2894del476).	 I	 expanded	 three	 additional	 clones	 of	 which	 two	
exhibited	 identical	 deletions	 on	 both	ASXL1	 alleles	 	 (c.2419_2894del476,	 clones	 B	
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and	C),	 and	one	 compound	heterozygous	 clone	with	a	475	bp	deletion	present	on	
one	 copy,	 and	 an	 inversion	 of	 476	 bp	 on	 the	 other	 allele	
(c.2419_2893inv//c.2419_2893del475,	 clone	D)	 (Table	 3;	no	heterozygous	 clones	
were	identified).	Molecularly,	these	mutations	corresponded	to	the	genotype	of	BOS	
patient	 #1.	 The	 ASXL1PSC/PSC	 hESC	 clones	 did	 not	 show	 obvious	 defects	 in	
morphology	 (Fig.	 11D),	 self-renewal	 or	 expression	 of	 pluripotency	 markers,	 as	
judged	by	immunocytochemistry	and	qPCR	(Fig.	11	E,	F).		
	
	
Figure	11.	Generation	of	ASXL1PSC/PSC	hESC	lines	carrying	BOS-like	truncating	mutations	in	ASXL1.		
(A)	 Scheme	 of	 ASXL1	 locus,	 indicated	 is	 the	 CRISPR-mediated	 deletion	 introduced	 in	 ASXL1PSC/PSC	
hESC.	 (B)	 Amplification	 of	 the	 ASXL1	 locus	 via	 PCR	 confirms	 homozygous	 476	 bp	 deletion	 in	
ASXL1PSC/PSC	hESC	 clone	 A	 (third	 lane	 showing	 a	molecular	marker).	 (C)	 Sanger	 sequencing	 of	 the	
ASXL1	locus	in	ASXL1PSC/PSC	hESC	clone	A	and	in	control	cells;	the	deletion	start	site	is	indicated.	(D)	
Bright-field	 images	 of	 control	 hESC	 and	 ASXL1PSC/PSC	 hESC	 colonies.	 (E,	 F)	 Immunocytochemical	
staining	 (E)	 and	 qPCR	 analysis	 (F)	 of	 core	 pluripotency	 transcription	 factors	 in	 undifferentiated	
ASXL1PSC/PSC.	
	
3.2.3	Detection	of	overexpressed	ASXL1	variants	by	a	novel	antibody	
The	investigation	of	potential	ASXL1	pathogenic	isoforms	required	the	generation	of	
antibody	tools	to	recognize	full-length	and	N-terminal	mutant	ASXL1	variants.	Using	
cDNA	isolated	from	hESC	as	a	template,	I	amplified	both	the	full-length	transcript	of	
ASXL1	 (ASXL1FL)	 and	 an	 N-terminal	 fragment	 encompassing	 bp	 1-2892,	 and	
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introduced	an	artificial	STOP	codon	at	its	3’	end	to	generate	a	transcript	that	equals	
the	putative	ASXL1	mRNA	variant	expressed	in	BOS	patient	#2	(ASXL1PSC,	Fig.	12A).		
	
	
	
Figure	 12.	 Generation	 of	ASXL1	overexpression	 lines	 and	 detection	 of	 ASXL1	 variants	 by	 a	 novel	
monoclonal	antibody.		
(A,	 B)	 Scheme	of	 full-length	 and	 truncated	ASXL1	 transcripts	 (ASXL1FL	 and	ASXL1PSC,	 A)	 that	were	
cloned	 into	 DOX-inducible	 PiggyBac	 overexpression	 plasmids	 harboring	 an	 eGFP	 coding	 sequence	
(B).	 These	 constructs	 were	 stably	 introduced	 into	 control	 hESC	 to	 generate	 PB-ASXL1FL	and	PB-
ASXL1PSC	cell	 lines	analyzed	in	(C-G).	(C)	Confirmation	of	PiggBac	gene	cassette	via	detection	of	 live	
eGFP	 expression	 in	 PB-ASXL1PSC	 and	 PB-ASXL1FL	 hESC	 lines	 after	 24	 h	 of	 DOX	 treatment.	 (D)	
Detection	 of	ASXL1	 expression	 in	 PB-ASXL1FL	and	PB-ASXL1PSC	lines	 after	 48	h	 of	DOX	 induction	 via	
qPCR	 (n=2).	 (E)	 OCT4	 expression	 analyzed	 via	 qPCR	 in	 control,	 PB-ASXL1FL	and	PB-ASXL1PSC	 hESC	
with	or	without	DOX	treatment	 for	48	h	(n=2).	 (F,	 G)	Detection	of	ASXL1	expression	 in	PB-ASXL1FL	
and	PB-ASXL1PSC	lines	 after	 48	h	 of	DOX	 induction	using	novel	monoclonal	 antibody	 clone	12F6	on	
Western	Blots	from	whole	cell	extracts	(F),	and	in	immunocytochemistry	using	clone	12F9	(G).	
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The	 sequences	 were	 cloned	 into	 a	 PiggyBac	 plasmid,	 in	 an	 open	 reading	 frame	
downstream	 of	 the	 coding	 sequence	 for	 the	 enhanced	 green	 fluorescent	 protein	
(eGFP)	 and	 the	 viral	 P2A	 sequence	 that	 mediates	 cleavage	 of	 eGFP	 from	 the	
downstream	peptide	 (plasmid	 backbone	 provided	 by	Dr.	 Shaposhnikov,	 Helmholz	
Center	 Munich;	 Fig.	 12B).	 Assembled	 PB-ASXL1FL	 and	 PB-ASXL1PSC	vectors	 were	
stably	introduced	into	the	cell	lines	mentioned	above,	namely	H9	and	the	iCas9	line	
(Table	 3).	 Integration	 of	 the	 plasmids	was	 confirmed	 by	 induction	 of	 eGFP	 upon	
administration	of	DOX	(Fig.	 12C).	 Importantly,	PB-ASXL1FL	 and	 to	a	higher	degree	
the	PB-ASXL1PSC	cells	exhibited	strong	induction	of	ASXL1	expression	within	24	h	of	
DOX	 treatment	 (Fig.	 12D).	 This	 did	 not	 cause	 an	 overt	 effect	 on	 the	 pluripotency	
factor	OCT4,	which	exhibited	slight	reduction	upon	DOX-treatment	of	control	cells,	
and	 minor	 increase	 upon	 induction	 of	 either	 the	 full-length	 or	 the	 truncated	
constructs	PB-ASXL1PSC	and	PB-ASXL1FL	(Fig.	12E).	
I	 used	 these	 cell	 lines	 to	 test	 the	 specificity	 of	 two	 novel	 monoclonal	 antibodies	
directed	 against	 the	 N-terminal	 part	 of	 ASXL1,	 which	 were	 produced	 in	 rat	
hybridoma	cultures	 in	collaboration	with	Dr.	Kremmer	and	Dr.	Geerlof	(Helmholtz	
Center	Munich).	Western	Blot	analysis	of	DOX	treated	PB-ASXL1FL	and	PB-ASXL1PSC	
lines	validated	antibody	clones	4F6	and	12F9	by	detection	of	the	truncated	ASXL1PSC	
variant	at	approximately	80-90	kDa	alongside	the	full	length	protein	at	around	170	
kDa	 (predicted	 165	 kDa;	 Fig.	 12F).	 The	 ASXL1FL	 construct	 produced	 a	 250	 kDa	
signal	 (Fig.	 12F),	 and	 the	 increased	 size	 could	 be	 explained	 by	 post-translational	
modifications	 of	 the	 ectopic	 protein,	 or	 alternatively	 by	 inefficient	 cleavage	 of	 the	
P2A	peptide;	however,	 I	did	not	test	 these	possibilities	 in	detail.	DOX-treated	GFP-
positive	cells	from	the	PB-ASXL1PSC	and	PB-ASXL1FL	clones	exhibited	ASXL1	signal	in	
immunocytochemistry	 using	 antibody	 clone	 12F9,	 which	 produced	 better	 results	
than	clone	4F6	(not	shown),	confirming	antibody	recognition	of	the	overexpressed	
protein	isoforms	(Fig.	12G).	Notably,	overlapping	DAPI	and	ASXL1	signals	indicate	
the	 correct	 nuclear	 localization	 of	 the	 full-length	 and	 truncated	 ASXL1	 variants.	
Since	 the	 iCas9	 line	 carries	 a	 FLAG-tagged	 Cas9	 enzyme,	 I	 could	 not	 use	 the	
overexpression	 plasmid-based	 N-terminal	 FLAG-tag	 (Fig.	 12B)	 to	 detect	 the	
truncated	 ASXL1	 construct.	 However,	 according	 to	 the	 successful	 detection	 of	 a	
truncated,	BOS-like	ASXL1	variant	using	the	novel	monoclonal	antibodies,	I	applied	
clones	 4F6	 and	 12F9	 in	 further	 Western	 Blots	 and	 immunocytochemistry,	
respectively.		
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Table	3.	Human	pluripotent	stem	cell	lines	generate	and/or	analyzed	in	this	study.		
BOS,	Bohring-Opitz	syndrome;	aa,	amino	acids	
Name	 Line	 Generation	
(see	Methods	for	details)	
genomic	 ASXL1	
background	
ASXL1	 variants	
expressed	
BOS-iPSC	
#1-0	
#1-1																						
#2-0	
#2-1	
iPSC	
(#1=f,	
#2=m)	
Reprogramming	 of	 BOS	
patient	 fibroblasts	 via	
mmRNA(-0)	 and	 4-in-1-
mini-intronic	plasmids(-1)	
heterozygous	
mutation	in	ASXL1	
(#1:	c.2407_2411del5,		
#2:	c.2893C>T)	
putative	 truncated	
ASXL1	 (818	 aa	 in	
#1,	 964	 aa	 in	 #2)	
and	 wildtype	
ASXL1		
(1542	aa)	
Control	iPSC	 iPSC	 reprogramming	 of	 control	
fibroblasts	 (2	 year	 old	
donor)	 via	 mmRNA	 and	
control	B-lymphocytes	(12	
year	old	donor)	via	4-in-1-
mini-intronic	plasmids17		
wildtype:	ASXL1+/+		 wildtype	ASXL1	
Control	
hESC	
iCas9	
hESC	
(HUES9)	
HUES9	 harbouring	
integration	 of	 a	
tetracycline-inducible	
Caspase9190	
wildtype:	ASXL1+/+		 wildtype	ASXL1	
ASXL1PSC/PSC	 iCas9	
hESC	
CRISPR/Cas	 mediated	
deletion	 and	 inversion	 of	
475-476	 bp	 in	 ASXL1,	
leading	 to	 premature	
STOP	codons	(PSC)	
clones	A,	B,	C:	
c.2419_2894del476			
clone	D:	
c.2419_2893inv//	
c.2419_2893del475			
putative	 truncated	
ASXL1		
(809	aa/824	aa)	
PB-ASXL1FL	
	
PB-ASXL1PSC	
H9	hESC/	
iCas9	
hESC	
Stable	 integration	of	a	 tet-
inducible	 Piggybac	
construct	bearing	GFP	and	
full	 length	 (4626	 bp)	 or	
truncated	 (N-terminal	
2892	bp)	ASXL1	 transcript	
into	H9	hESC	 (FL)	or	 iCas9	
(PSC)	
ASXL1+/+	 	 ;	 random	
integration	 of	 PB-
ASXL1FL		
or	PB-ASXL1PSC	
Overexpression	 of	
full-length	 (1541	
aa)	 or	 truncated	
ASXL1	construct	
(964	 aa)	 and	
endogenous	
expression	 of		
wildtype	ASXL1	
GFP-Control	
	
GFP-	
ASXL1PSC/PSC		
iCas9	
hESC	
stable	 integration	 of	 a	
constitutively	 expressed	
Piggybac-GFP	 cassette	 in	
control	 hESC	 and	
ASXL1PSC/PSC	clones	A	and	D	
see	 clones	 A	 or	 D	 or	
control	hESC	
wildtype	
ASXL1/putative	
truncated	 ASXL1	
(809	aa/824	aa)	
PB-ZIC1-
Control	
	
PB-ZIC1-
ASXL1PSC/PSC	
iCas9	
hESC	
stable	 integration	of	 a	 tet-
inducible	 Piggybac	
construct	bearing	GFP	and	
ZIC1	 in	 control	 hESC	 or	
ASXL1PSC/PSC	clone	A	
see	 clone	 A	 or	 control	
hESC	
wildtype	
ASXL1/putative	
truncated	 ASXL1	
(809	aa)	
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3.3.	Characterization	of	BOS	models	in	the	undifferentiated	state	
Having	 established	 a	 comprehensive	 toolset	 for	 analyzing	 the	 pathological	
mechanisms	 of	 BOS,	 I	 initially	 investigated	 the	 impact	 of	 BOS-associated	 ASXL1	
mutations	on	expression	of	the	protein	itself,	on	auto-	and	paralog	regulation	and	on	
expression	of	developmental	genes	in	pluripotent	cells.	
		
3.3.1	Pluripotent	stem	cell	models	for	BOS	express	truncated	ASXL1	
Based	 on	 the	 locations	 of	 the	 PSCs	 in	 ASXL1	 loci	 of	 BOS	 patients	 #1/#2	 and	
ASXLPSC/PSC	 hESC,	 I	 predicted	 that	 these	 transcripts	 should	 escape	 nonsense-
mediated	 decay	 (NMD)	 and	 could	 produce	 truncated	 protein	 variants	 of	 818	 and	
964	amino	acids,	 respectively,	which	 lack	 the	NR	 interaction	domain	and	 the	PHD	
finger	 (Fig.	 13A).	 Sanger	 sequencing	 of	 reverse	 transcribed	 mRNA	 isolated	 from	
BOS-iPSC	 lines	revealed	that	mutant	ASXL1	 transcripts	bearing	the	patient-specific	
mutations	were	expressed	(Fig.	13B).	Furthermore,	blocking	NMD	by	cycloheximide	
treatment	 did	 not	 elevate	ASXL1	 levels	 in	 BOS-iPSCs	 compared	 to	 control	 hiPSCs,	
implying	that	mutant	transcripts	are	not	depleted	by	NMD	(Fig.	13C).	In	accordance,	
the	novel	antibody	clone	4F6	confirmed	the	expression	of	truncated	ASXL1	protein	
isoforms	 in	 undifferentiated	 BOS-iPSC	 and	ASXLPSC/PSC	 hESC,	 but	 not	 in	 respective	
control	lines,	identified	by	weak	bands	at	~90-100	kDa	(Fig.	13D,	E).	The	170	kDa	
band,	 supposedly	 representing	 the	 full-length	ASXL1	protein,	was	 still	 detected	 in	
ASXL1PSC/PSC	 cell	 extracts.	This	 indicated	 that	 the	monoclonal	antibody	 (clones	4F6	
and	12F9)	recognized	ASXL1	and	ASXL2	proteins,	which	are	of	similar	size	(165	kDa	
and	153	kDa),	owing	to	their	high	homology81.	Although	I	could	not	prove	or	reject	
the	 cross	 specificity,	 as	 it	 proved	difficult	 to	 knock	down	or	 knockout	ASXL2	 on	 a	
homozygous	 ASXLPSC/PSC	 background,	 my	 working	 hypothesis	 remains	 that	 the	
~170	kDa	band	represents	endogenous	ASXL1	protein.	 Intriguingly,	both	 the	BOS-
iPSC	line	#1-0	and	the	ASXL1PSC/PSC	cell	clones,	which	express	similar	mutant	ASXL1	
forms,	 displayed	 also	 an	 additional	 band	 at	 around	 130	kDa,	 which	 was	 barely	
detectable	 in	 control	 hESCs/hiPSCs	 (Fig.	 13D,	 E).	 I	 furthermore	 noticed	 two	
additional	bands	 in	Western	Blots	of	all	 analyzed	 lines,	one	at	around	70	kDa	and	
one	 clearly	 above	 250	 kDa	 (Supplementary	 Fig.	 S1).	 Finally,	 ASXL1	 protein	
localization	was	not	altered	in	BOS-iPSC	in	comparison	to	control	iPSC,	as	shown	in	
immunocytochemistry	(Fig.	13F).	I	also	observed	exclusion	of	ASXL1	staining	from	
mitotic	nuclei	(Fig.	13F,	red	arrows).	
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Figure	13.	Human	pluripotent	stem	cell	models	for	BOS	express	truncated	ASXL1.		
(A)	 Schematics	 of	 wildtype	 (wt)	 and	 putative	 truncated	 ASXL1	 proteins	 expressed	 in	 BOS-iPSC,	
ASXL1PSC/PSC	hESC	and	PB-ASXL1PSC.	(B)	Sequencing	of	reverse	transcribed	ASXL1	transcripts	isolated	
from	 BOS	 patient-derived	 iPSC	 lines	 #1-0	 and	 #2-0.	 (C)	 Cycloheximide	 (CHX)	 treatment	 does	 not	
enhance	ASXL1	mRNA	expression	in	BOS-iPSC	lines	compared	to	control	iPSC	as	detected	by	RT-PCR	
(left)	 and	 qPCR	 (right),	 using	 primers	 directed	 against	 Exon	 1	 (1)	 or	 Exon	 12	 (12-A	 and	 12-B)	 of	
ASXL1.	 Detection	 of	 Caspase	 2	 splice	 isoforms	 confirmed	 inhibition	 of	 nonsense-mediated	 decay	
(NMD)	by	CHX	treatment,	β-Gobulin	served	as	negative	control.	(D-E)	Detection	of	truncated	ASXL1	
variants	in	patient-derived	BOS-iPSC	(D)	and	ASXL1PSC/PSC	hESC	(E),	but	not	in	respective	control	lines	
in	Western	 Blot	 using	 monoclonal	 antibody	 clone	 4F6.	 (F)	 BOS-iPSC	 show	 nuclear	 localization	 of	
ASXL1,	comparable	to	control	iPSC,	as	detected	with	the	monoclonal	antibody	clone	12F9	and	DAPI	
in	immunocytologial	stainings.	Note	exclusion	of	ASXL1	staining	from	mitotic	nuclei	(red	arrows).	
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3.3.2	Transcriptome	analysis	of	BOS-iPSCs	
As	 described	 above,	 BOS-iPSC	 lines	 did	 not	 exhibit	 overt	 dysregulation	 of	 the	
pluripotent	 state.	 However,	 according	 to	 the	 assumption	 that	mutations	 in	ASXL1	
might	 still	 lead	 to	 perturbations	 that	 could	 alter	 commitment	 towards	 specific	
lineages,	 I	 performed	microarray-based	 transriptome	 profiling	 of	 undifferentiated	
H9	hESCs,	a	control	hiPSC	line	and	the	#1-0	and	#2-0	BOS-iPSC	lines,	as	well	as	the	
original	patient	fibroblasts.	
Principal	 component	 analysis	 revealed	 clustering	 of	 transcriptional	 profiles,	 and	
expectedly,	 the	 largest	 difference	 noted	 was	 between	 fibroblasts	 and	 pluripotent	
stem	 cell	 samples	 (Fig.	 14A).	 Furthermore,	 BOS-iPSC	 #1-0	 clustered	 loosely	with	
the	control	hESC	and	 iPSC	 lines,	while	BOS-iPSC	#2-0	exhibited	a	notable	distance	
from	 controls	 lines	 or	 the	 BOS-iPSC	 #1-0	 cells	 (Fig.	 14A).	 Despite	 transcriptional	
differences	observed	between	the	BOS-iPSC	lines,	I	intended	to	determine	whether	
they	 exhibit	 misregulation	 of	 common	 signaling	 pathways.	 Comparing	 BOS-iPSC	
transcriptomes	 to	 control	 samples,	 I	 found	 that	 163	 and	 200	 genes	 were	
significantly	and	more	than	twofold	up-	or	downregulated,	respectively	(Fig.	14B).	
Among	 the	 most	 upregulated	 genes	 in	 the	 BOS-iPSC	 lines	 were	 several	
uncharacterized	 loci	 and	 long	 non-coding	 RNAs,	 the	 neuronal	 lineage	 inducing	
factor	Neuronatin	1215	(NNAT	1),	and	three	genes	involved	in	TGFβ	signaling,	NODAL,	
CER1	 and	GDF3216-218	 (Fig.	 14B).	 These	 factors	 and	 additional	 upregulated	 genes	
were	 classified	 with	 the	 tissue	 category	 ‘germ	 layer’	 by	 the	 Genomatix	 Pathway	
System,	 indicating	 a	 transcriptional	 profile	 in	 BOS-iPSC	 that	 is	 concordant	 with	
pluripotency,	 stem	 cell	 differentiation	 and	 enhanced	 TGFβ	 signaling	 (Fig.	 14C,	
Table	4).	I	was	able	to	confirm	increased	levels	of	GDF3	and	CER1	 in	BOS-iPSC	via	
qPCR	 analysis	 	 (Fig.	 14D,	 E).	 Further	 upregulated	 gene	 sets	 in	 BOS-iPSCs	 were	
linked	to	transcription-related	processes,	teratoma	and	liver	cancer	(Table	4).	Gene	
sets	 with	 decreased	 expression	 in	 BOS-iPSC	 compared	 to	 control	 cells	 were	
associated	 with	 muscular	 processes	 and	 protein	 stability,	 neuronal	 and	 heart	
tissues,	 seizures,	 fetal	 growth	 retardation,	 and	hematological	 disorders	 (Table	 4).	
Expression	of	the	pluripotency	markers	OCT4,	SOX2	and	REX1	did	not	differ	between	
BOS-iPSC	and	control	hiPSC/hESC,	corroborating	my	earlier	qPCR	results,	however	I	
noted	a	slight	increase	in	expression	of	NANOG	in	BOS-iPSC	(Fig.	14F).	
I	 also	 sought	 to	 identify	 possible	 effects	 of	 truncating	 ASXL1	 mutations	 on	 the	
activation	of	anterior	HOXA	and	HOXB	genes	according	to	the	known	involvement	of	
ASXL	genes	in	Hox	gene	regulation	 in	vivo	and	 in	vitro99,116.	The	Hox	gene	cluster	is	
activated	 in	 response	 to	 RA	 treatment	 in	 murine	 ESC	 in	 vitro,	 mimicking	 the	
induction	of	Hox	genes	via	RA-bound	RAR	during	embryogenesis219-221.	 I	 therefore	
examined	 the	 response	of	 anterior	HOXA	 and	HOXB	 loci	 to	 increasing	doses	of	RA	
(0.5-5	μM)	in	control	and	BOS-iPSCs	(Fig.	15A).	I	noted	morphological	responses	in	
the	 treated	 cell	 cultures	 even	 at	 the	 lowest	 RA	 concentration,	 as	 shown	 by	 a	
representative	image	in	Fig.	15B.	While	selected	HOX	genes	displayed	distinct	dose-
response	 trends	 and	 activation	 levels,	 I	 could	 not	 detect	 significant	 differences	
between	 induction	 in	 BOS-iPSC	 and	 control	 iPSC	 lines	 for	 genes	 HOXA1,	 HOXA3,	
HOXA5,	HOXB2,	HOXB5.	 However,	 I	 noted	 a	 negative	 effect	 on	HOXA2	 and	HOXB1	
induction	 in	 the	 BOS-iPSC	 lines,	 suggesting	 a	 link	 to	ASXL1	mutations	 (Fig.	 15A).	
Furthermore,	 a	 pattern	 emerged,	 where	 BOS-iPSC	 #2	 consistently	 expressed	 the	
highest	HOX	levels	in	all	doses	(shown	for	HOXA4	or	HOXB4;	Fig.	15A).	
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Figure	14.	Global	transcriptome	analysis	and	validation	of	candidate	genes	in	undifferentiated	BOS-
iPSC.		
(A-F)	 Analysis	 of	 global	 transcriptome	 data	 obtained	 from	 microarray	 analysis	 of	 samples	 from	
undifferentiated	BOS-iPSC#1-0	and	#2-0	(3	clones	per	line)	and	parental	fibroblasts	(3	passages	per	
patient),	undifferentiated	control	hESC	(3	passages)	and	control	hiPSC	(2	passages,	mRNA-derived).		
(A)	PCA	plot	of	global	transcriptomes.	(B)	Most	upregulated	genes	in	BOS-iPSC	compared	to	control	
hiPSC/hESC	(Benjamini	&	Hochberg	adjusted	p-values	BH	<	0.1).	(C)	Upregulated	genes	in	BOS-iPSC	
compared	to	control	hiPSC/hESC	(BH<0.1,	linear	change	>2)	are	associated	with	germ	layers	(p-value	
1.57E-12)	 by	 the	 Genomatix	 Pathway	 System.	 Dotted	 lines	 indicated	 co-citations,	 solid	 lines	
represent	curated	 interactions.	(D,	 E)	Transcriptional	analysis	of	 candidate	genes	 from	microarray	
analyses.	 	Expression	of	GDF3	(D)	and	CER1	(E)	 in	hiPSC	lines	quantified	via	microarray	analysis	or	
SybrGreen	 qPCR	 (n=2,	 not	 determined	 in	 hiPSC).	 (F)	 Main	 pluripotency	 genes	 are	 expressed	 at	
comparable	levels	in	BOS-iPSC	and	control	hiPSC/hESC.	
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Table	 4.	 Association	 of	 misregulated	 gene	 sets	 in	 BOS-iPSC	 lines	 with	 molecular	 functions	 and	
diseases.		
Analysis	of	global	 transcriptome	data	 in	control	and	BOS-iPSC	(related	to	Figure	14);	differentially	
regulated	 genes	 (Benjamini	 &	 Hochberg	 adjusted	 p-values	 BH	 <	 0.1;	 linear	 change	 >	 2)	 were	
subjected	to	GeneRanker	analysis	with	the	Genomatix	Software.	The	maximum	five	most	significant	
results	of	every	category	with	p-values	calculated	by	the	Genomatix	Software	are	given.	
	
Upregulated	in	BOS-iPSC	
		p-value	
Downregulated	in	BOS-iPSC	
p-value	
GO-term/	
Biological	
Process	
Regulation	Of	Transcription,	DNA-
dependent	 1.44e-08	
Regulation	Of	Muscle	System	
Process	 2.94e-04	
Regulation	Of	RNA	Biosynthetic	
Process	 1.77e-08	 Regulation	Of	Protein	Stability	 6.46e-04	
Regulation	Of	RNA	Metabolic	
Process	 3.46e-08	 Striated	Muscle	Contraction	 6.99e-04	
Transcription,	DNA-dependent	 3.69e-08	 Protein	Stabilization	 9.38e-04	
Regulation	Of	Macromolecule	
Metabolic	Process	 4.16e-08	
Regulation	Of	Muscle	
Contraction	 1.13e-03	
Pathway	
TGF	β	 1.85e-08	
Cystic	Fibrosis	Transmembrane	
Conductance	Regulator	(Atp	
Binding	Cassette	Sub	Family	C,	
Member	7)	
4.87e-03	
Nodal	 1.56e-06	 Protein	Tyrosine	Phosphatase,	Receptor	Type	 9.03e-03	
Activin	A	Receptor,	Type	Ib	 7.72e-06	 Gonadotropin	Releasing	Hormone	 9.88e-03	
Differentiation	 3.09e-04	 	 	
Hedgehog	 1.69e-03	 	 	
Tissue	
Germ	Layers	 1.57e-12	 Oligodendroglia	 2.85e-05	
Pluripotent	Stem	Cells	 6.87e-10	 Olfactory	Nerve	 1.94e-04	
Primitive	Streak	 7.79e-10	 Heart	 2.47e-04	
Endoderm	 4.16e-09	 Secretory	Vesicles	 3.54e-04	
Embryonic	Stem	Cells	 1.46e-08	 Mesencephalon	 1.30e-03	
Diseases	
Fracture	Adverse	Event	 4.58e-06	 Seizures	 3.26e-05	
Seminoma	 1.65e-05	 Fetal	Growth	Retardation	 6.02e-05	
Teratoma	 2.13e-05	 Sinus	Rhythm	 1.24e-04	
Carcinoma,	Embryonal	 3.15e-05	 Hyperlipoproteinemia	Type	Ii	 3.19e-04	
Non-small	Cell	Carcinoma	 1.19e-04	 Acute	Erythroid	Leukemia	 3.74e-04	
Associated	
Cancer	
Tissues	
Liver	 1.25e-03	
Haematopoietic	and	lymphoid	
tissue	 6.84e-03	Endometrium	 4.01e-03	
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Figure	15.	Undifferentiated	BOS-iPSC	show	reduced	induction	of	HOXA2	and	HOXB1	upon	treatment	
with	retinoic	acid	(RA).		
(A)	 Two	 clones	 of	 control	 hiPSC	 (mRNA-derived)	 and	BOS-iPSC	 lines	 #1-0	 and	#2-0	were	 treated	
with	increasing	doses	of	RA	in	pluripotent	conditions	for	24	h,	and	expression	of	anterior	HOXA	and	
HOXB	 genes	was	determined	via	qPCR.	 (B)	 24	h	 of	 0.5	 µM	RA	 treatment	 in	pluripotent	 conditions	
induces	morphological	changes	in	hESC.	
	
	
Taken	 together,	 I	 noted	 subtle	 changes	 in	 BOS-iPSC	 transcriptomes,	 which	 could	
affect	 differentiation	 pathways	 and	 future	 lineage	 commitment,	 although	 the	
robustness	of	the	pluripotent	state	was	generally	not	affected.	
	
3.3.3	Regulation	of	early	lineage-specific	genes	in	BOS	hESC	models	
As	noted	above,	similar	to	the	BOS-iPSC	lines,	 the	molecular	characteristics	of	BOS	
hESC	 models	 did	 not	 indicate	 overt	 perturbation	 of	 the	 pluripotency	 circuitry.	
Nonetheless,	to	exclude	gross	developmental	perturbation,	I	analyzed	a	small	panel	
of	genes	that	govern	gastrulation	and	are	used	as	markers	for	early	differentiation.	
Representing	different	germ	layers,	I	tested	Nestin	and	PAX6	(ectoderm),	MESP1	and	
T/Brachyury	 (mesoderm),	 and	 FOXA2	 and	 SOX17	 (endoderm).	 Except	 for	 a	 4-fold	
increase	in	SOX17	expression,	I	could	not	detect	misregulation	of	lineage	specifiers	
in	ASXL1PSC/PSC	and	PB-ASXL1PSC	lines	compared	to	control	hESC	(Fig.	16A).		
The	 PB-ASXL1PSC	 line	 represents	 a	 putative	 aggravated	 form	 of	 BOS	 due	 to	
unphysiological	induction	of	truncated	ASXL1	protein	upon	DOX	treatment.	This	led	
to	a	broader,	but	at	maximum	4-fold	increased	expression	of	germ	layer	specifiers,	
including	Nestin,	PAX6,	MESP1	and	T,	but	not	SOX17	(Fig.	16B).		Interestingly,	when	
subjected	 to	 short-term,	 undirected	 differentiation	 via	 bFGF	 removal	 for	 24	 h,	
overexpression	of	truncated	ASXL1	led	to	twofold	upregulation	of	SOX17	and	FOXA2,	
which	was	not	observed	in	the	DOX-treated	control	line	(Fig.	16C).	
Together,	this	suggested	that	truncated	ASXL1	correlates	with	modest	induction	of	
endoderm-related	genes	in	a	context-dependent	manner	
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Figure	 16.	Expression	of	selected	germ	layer	
markers	 in	 cultures	 expressing	 truncated	
ASXL1.		
(A-C)	Expression	of	developmental	regulatory	
genes	 in	 ASXL1PSC/PSC	 lines	 relative	 to	control	
hESC	 (A),	 and	 upon	 overexpression	 of	
truncated	ASXL1	through	48h	of	DOX	addition	
in	 PB-ASXL1PSC	 versus	 control	 hESC	 in	 the	
undifferentiated	state	(n=2;	B)	or	treated	with	
differentiation	 medium	 containing	 knockout	
serum	replacement	for	24	h		(n=2;	C).		
	
3.3.4	Regulation	of	ASXL	transcript	levels		
Because	 cross-regulation	 of	 ASXL	 paralogs	 has	 been	 previously	 reported111,	 I	
decided	to	test	this	possibility	in	the	pluripotent	stem	cell	models	described	herein	
to	 assess	 the	 effect	 of	 mutant	 ASXL1	 alleles.	 By	 analyzing	 levels	 of	 ASXL1-3	 in	
undifferentiated	BOS-iPSC	 and	ASXLPSC/PSC	 hESCs,	 I	 found	 that	 the	BOS-iPSC	 clones	
from	 different	 donors	 or	 reprogrammed	 by	 different	 methods	 varied	 slightly	 in	
expression	of	ASXL	genes	(Fig.	 17A),	but	a	specific	 trend	of	misregulation	was	not	
consistently	detected	in	both	iPSC	lines	(Fig.	17B).	Isogenic	ASXL1PSC/PSC	hESC	lines	
did	 not	 show	 significant	 clone-to-clone	 variability	 (Fig.	 17C),	 and	 comparable	
transcript	 levels	 between	 mutant	 clones	 and	 the	 control	 line	 suggested	 that	 no	
regulation	of	ASXL	genes	by	truncated	ASXL1	took	place	in	the	undifferentiated	cells.	
To	 confirm	 this	 finding,	 I	 used	 the	 PB-ASXL1PSC	 hESC	 line,	 which	 expresses	
exceptionally	high	levels	of	truncated	ASXl1	upon	treatment	by	DOX.	Indeed,	I	noted	
similar	 results	with	only	 slight	 increase	of	ASXL2	 and	ASXL3	 upon	overexpression	
(Fig.	17D).	
However,	 induction	 of	 differentiation	 programs	 for	 5	 days	 seemed	 to	 allow	 or	
promote	autoregulatory	mechanisms:	treatment	of	hESC	lines	with	SMAD	inhibitors	
SB431542	and	Noggin	to	induce	neuroectoderm182,	or	WNT	activation	via	treatment	
with	 the	 glycogen	 synthase	 kinase	 3	 (GSK-3)	 inhibitor	 CHIR99021	 to	 induce	
mesoderm222,	 led	 to	 upregulation	 of	 ASXL3	 in	 PB-ASXL1PSC	 cells	 overexpressing	
truncated	 ASXL1	 (Fig.	 17E).	 This	 effect	 was	 not	 observed	 in	 Activin	 A-treated	
cultures	 induced	 towards	 endoderm,	 although	 ASXL1	 overexpression	 levels	 were	
comparable	 in	 all	 differentiation	 conditions,	 hence,	 transcriptional	 variability	was	
not	likely	to	account	for	differential	ASXL3	regulation	(Fig.	17E).		
I	 observed	 that	 PB-ASXL1PSC	 exhibited	 higher	 induction	 of	ASXL1	 than	 PB-ASXL1FL	
hESC		(Fig.	12D).	To	test	whether	this	was	a	clone	specific	effect	or	due	to	activation	
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of	the	endogenous	ASXL1	locus	by	truncated	ASXL1,	I	designed	primers	to	detect	the	
3’	 end	 of	 the	 ASXL1	 transcript	 in	 RT-PCR	 of	 samples	 isolated	 from	 control,	 PB-
ASXL1PSC	and	PB-ASXL1FL	hESC	line.	This	experiment	did	not	reveal	upregulation	of	
the	 endogenous	 ASXL1	 transcript	 upon	 overexpression	 of	 truncated	 ASXL1	 (Fig.	
17F).		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	17.	Transcriptional	regulation	of	ASXL	genes	in	BOS	models.		
(A-D)	 Expression	 analysis	 of	ASXL	 genes	 in	 BOS-iPSC	 via	 qPCR	 (A;	
n=2)	and	microarray	(B;	n=3),	and	via	qPCR	in	mutant	hESC	lines	(C;	
control:	n=4;	ASXL1PSC/PSC	clones	A,	B,	D:	n=4,	clone	C:	n=2)	and	in	PB-
ASXL1PSC	 hESC	 upon	 DOX	 treatment	 to	 induce	 overexpression	 of	
truncated	ASXL1	(D;	n=2);	all	relative	to	the	respective	control	 lines	
and	 treatments.	 (E)	 Quantification	 of	 ASXL3	 and	 ASXL1	 transcript	
levels	 via	 qPCR	 in	 5-day	 differentiation	 cultures	 of	 DOX-treated	
control-	 and	 PB-ASXL1PSC	 cells	 relative	 to	 untreated	 samples.	
Differentiation	conditions	were	dual	SMAD	inhibiton	(SB431542	and	
Dorsomorphin;	2SMADi),	1	%	B27	and	5	µM	CHIR	 (CHIR)	and	1.5%	
FBS	and	100	ng/ml	Activin	A;	ACTIVIN	A);	n=2.	(F)	RT-PCR	results	for	
the	 detection	 of	 the	 3’	 region	 in	 ASXL1	 transcripts	 isolated	 from	
control,	 PB-ASXL1FL	and	 PB-ASXL1PSC	 hESC,	 untreated	 or	 after	 DOX	
addition	for	24	h.	
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3.3.5	Regulation	of	ASXL	protein	levels	
Despite	the	fact	that	ASXL1	transcript	levels	were	generally	unaffected	by	truncated	
ASXL1,	I	noted	elevated	levels	of	wildtype	ASXL1	protein	in	BOS-iPSC	line	#2-0	(Fig.	
13D).	This	was	not	a	clone/reprogramming	method-specific	effect,	as	I	detected	full-
length	 ASXL1	 protein	 in	 both	 male	 BOS-iPSC	 lines	 #2-0	 and	 #2-1	 that	 were	
reprogrammed	by	different	methods,	using	exposure	where	ASXL1	in	control	hiPSC	
and	female	BOS-iPSC	lines	was	too	low	to	be	detected	(Fig.	18A).		
	
	 					
Figure	18.	ASXL1	expression	is	dynamically	regulated	in	pluripotent	stem	cells.		
(A)	Detection	of	ASXL1	protein	in	cell	extracts	of	control	hiPSC	and	BOS-iPSC.	(B)	Quantification	of	
endogenous	 ASXL1	 levels	 in	 two	 clones	 A	 and	 B	 of	 PB-ASXL1PSC-hiPSC	 that	 ectopically	 express	
truncated	ASXL1	after	48h	of	DOX	treatment	(+DOX),	relative	to	untreated	cells	(-DOX).	(C)	Detection	
of	 ASXL1	 in	 extracts	 isolated	 from	 H9	 hESC	 at	 different	 timepoints	 after	 seeding.	 (D)	 Brightfield	
images	of	control	hiPSC	48h	after	seeding	at	indicated	cell	densities.	(E)	Analysis	of	ASXL1	expression	
via	qPCR	in	uninduced	PB-ASXL1PSC	hESC,	harvested	at	two	timepoints	after	seeding	at	different	cell	
densities	 as	 indicated.	 (F)	 Detection	 of	 ASXL1	 protein	 in	 extracts	 isolated	 from	 control	 hiPSC	 at	
different	timepoints	after	seeding	of	different	cell	densities,	as	 indicated.	(G)	Analysis	of	 full-length	
ASXL1	levels	in	control	hESC	and	BOS-iPSC	that	were	collected	48h	or	72h	after	seeding	at	different	
densities.	 Intensity	of	 full-length	ASXL1	bands	was	determined	 relative	 to	 that	of	 the	 control	hESC	
samples	(48h	and	lowest	seeding	density).	
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An	increase	 in	endogenous	ASXL1	protein	was	also	observed	upon	overexpression	
of	truncated	ASXL1	in	hESCs	(Fig.	12E)	or	in	hiPSCs	(Fig.	18B).	As	I	did	not	notice	
this	 effect	 in	 ASXL1PSC/PSC	hESCs	 (Fig.	 13E)	 or	 upon	 overexpression	 of	 full-length	
ASXL1	 (Fig.	 12E),	 I	propose	 that	 truncated	ASXL1	variants	differentially	affect	 the	
stability	of	the	wildtype	copy	of	ASXL1.	
Dynamic	 regulation	 of	 ASXL1	 was	 further	 indicated	 by	 the	 observation	 that	
prolonged	cultivation	leads	to	reduction	of	ASXL1	levels	in	H9	hESCs	(Fig.	18C).	To	
examine	whether	this	was	due	to	increasing	confluency,	I	seeded	control	hESC	and	
hiPSC	 at	 varying	 densities	 (Fig.	 18D),	 and	 collected	 the	 cultures	 at	 different	 time	
points,	which	revealed	that	both	ASXL1	mRNA	and	protein	were	downregulated	in	a	
time-	 and	 density-dependent	 manner	 (Fig.	 18E,	 F).	 Notably,	 the	 uncharacterized	
band	at	70	kDa	exhibited	a	cultivation	time-dependent	decline	as	well	(Fig.	18B,	F).	
The	inverse	correlation	between	density	and	ASXL1	protein	levels	was	perturbed	in	
the	BOS-iPSC	lines	in	comparison	to	control	hESC	(Fig.	18G).		
I	 surmise	 that	 depending	 on	 the	 type	 of	 mutation	 or	 construct,	 cells	 expressing	
truncated	ASXL1	display	misregulation	of	the	wildtype	ASXL1	protein.	
	
3.3.6	Global	histone	modifications	in	pluripotent	BOS	models	
Truncated	ASXL1	was	proposed	to	enhance	the	de-ubiquitinating	activity	of	BAP1	in	
tumor	 cells,	 which	 results	 in	 decreased	 H2AK119	 levels	 and	 consequently	 in	
reduction	of	H3K27me3,	presumably	via	diminished	recruitment	of	PRC269.	On	the	
other	hand,	ASXL1	is	able	to	directly	bind	the	PRC2	proteins	EZH2	and	SUZ12	and	
promote	 H3K27me3	 placement99.	 Thus,	 I	 sought	 to	 assess	 whether	 expression	 of	
truncated	 ASXL1	 variants	 alters	 the	 global	 chromatin	 landscape	 in	 the	
undifferentiated	state	with	regard	to	the	associated	histone	modifications.	However,	
quantification	 of	 global	 H3K27me3	 and	 H2AK119Ub	 levels	 in	 ASXL1PSC/PSC	hESC,	
induced	PB-ASXL1PSC	and	PB-ASXL1FL	hESC,	BOS-iPSC	and	their	parental	 fibroblasts	
in	 comparison	 to	 respective	 control	 cells	 did	 not	 reveal	 consistent	 or	 strong	 de-
regulation	 of	 these	 chromatin	modifications,	 except	 for	 a	 slight	 increase	 in	 global	
H3K27me3	levels	in	BOS-iPSC	lines	(Fig.	19).	This	was	not	unexpected	in	light	of	the	
merely	mild	transcriptional	alterations	I	observed.		
Hence,	 I	 concluded	 that	 expression	 of	 truncated	 ASXL1	 did	 not	 impact	 viability,	
maintenance,	 transcriptional	 stability	 or	 histone	 modification	 landscapes	 of	
pluripotent	stem	cells	in	my	analyses.	
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Figure	 19.	 Global	 H3K27me3	 and	
H2AK119Ub	 levels	 are	 not	 strongly	
or	 consistently	 affected	 by	 ASXL1	
mutations	 or	 overexpression	 of	
ASXL1	in	undifferentiated	cells.		
(A)	 Quantification	 of	 global	
H2AK119Ub	 levels	 in	 ASXL1PSC/PSC	
hESC	 and	 DOX-treated	 control,	 PB-
ASXL1FL	 and	 PB-ASXL1PSC	 hESC	 to	
induce	overexpression	of	full-length	
or	 truncated	 ASXL1,	 respectively;	
n=4	(n=16	for	ASXL1PSC/PSC	hESC).		
(B,	 C)	 Total	 H2AK119Ub	 levels	 determined	 in	 control	 hiPSC	 and	 BOS-iPSC	 (B)	 and	 parental	
fibroblasts;	n=2	(C).	 (D,	 E)	Quantification	of	global	H3K27me3	 levels	 in	ASXL1PSC/PSC	hESC,	and	DOX	
treated	control	hESC	or	PB-ASXL1PSC	hESC	to	induce	overexpression	of	truncated	ASXL1	(n=11-12;	D),	
and	 in	 control	 hiPSC	 and	 BOS-iPSC	 (E).	 (A-E)	 H2AK119Ub/H3K27me3	 band	 intensities	 were	
normalized	to	ACTIN	band	intensities.	
	
3.4.	Modeling	neural	crest	development	in	BOS		
Based	on	the	expression	of	truncated	ASXL1	protein	in	BOS-iPSC	and	corresponding	
homozygous	 hESC	 models,	 which	 however	 did	 not	 affect	 self-renewal	 and	
maintenance	 of	 pluripotency,	 I	 postulated	 that	 lineage-specific	 effects	 of	 mutant	
ASXL1	 variants	 cause	 developmental	 defects	 in	 BOS.	 All	 patients	 affected	 by	 BOS	
display	craniofacial	dysmorphisms	 to	a	varying	degree,	 including	abnormal	palate,	
small,	 rotated	 ears	 and	protruding	 eyes131.	 Formation	of	 the	head	and	 face	 region	
strongly	 relies	 on	 the	 correct	 emergence,	 migration	 and	 function	 of	 the	 neural	
crest162	 (NC),	 and	 I	 concluded	 that	 BOS-causing	 ASXL1	 mutations	 might	 affect	
development	of	the	NC	lineage,	resulting	in	described	facial	symptoms.	To	confirm	
this	hypothesis,	I	sought	to	examine	involvement	of	ASXL	proteins	in	NC	progenitor	
commitment,	 delineate	 possible	 perturbations	 upon	 expression	 of	 the	 truncated	
ASXL1	variant,	and	to	uncover	potential	molecular	mechanisms	underlying	cellular	
phenotypes.		
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3.4.1	Implementation	of	a	protocol	for	human	neural	crest	differentiation	
In	 order	 to	 analyze	 potential	 disruptive	 effects	 of	 truncated	 ASXL1	 on	 human	NC	
development,	I	implemented	a	NC	differentiation	method	that	relies	on	aggregation	
of	 human	 pluripotent	 stem	 cells	 to	 floating	 neuroepithelial	 structures,	 termed	
neurospheres,	in	the	presence	of	EGF,	bFGF	and	insulin33	(Fig.	20A).		
	
	
	
Figure	20.	Differentiation	of	hESC	to	NC-like	cells.		
(A)	 Timeline	 of	NC	differentiation	protocol	 and	bright-field	 images	 of	 intermediate	 steps	 and	 final	
NC-like	cells	during	in	vitro	differentiation	from	control	hESC.	Neurospheres	were	kept	on	uncoated	
plates	in	induction	medium	(N2/B27	+	bFGF,	EGF	and	insulin).	After	sufficient	outgrowth	of	NC-like	
cells,	 neurospheres	 were	 removed	 and	 NC	 cells	 were	 transferred	 to	 fibronectin-coated	 plates	 in	
maintenance	medium	(*;	like	induction	medium,	replacement	of	insulin	with	bovine	serum	albumin).	
After	2-3	passages,	NC	cells	were	kept	in	maintenance	medium	supplemented	with	BMP2	and	CHIR	
(**).	Protocol	modified	from33.	(B,	C)	Expression	of	NC	specifying	genes	in	control	hESC-derived	NC	
cells	as	determined	by	qPCR	(B)	and	immunocytochemical	staining	(including	Ki67;	day	18	or	later;	
C).	 (D)	Expression	of	early	primitive	streak	markers	was	undetectable	or	very	low	in	hESC-derived	
NC	cells	at	passage	3	(n=5).	
	
	
The	 neurospheres,	 which	 mimic	 neurogenesis	 within	 the	 neural	 tube,	 are	
subsequently	plated	in	uncoated	tissue	culture	plates	and	give	rise	to	delaminating	
and	migrating	neural	crest-like	cells.	 I	observed	this	behavior	 in	NC	differentiation	
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cultures	 from	 control	 hESC	 as	 shown	 in	 representative	 brightfield	 images	 in	 Fig.	
20A,	and	was	able	to	expand	and	cultivate	emigrated,	presumptive	NC	cells	after	the	
removal	 of	 attached	 neurospheres.	 Expected	 NC	 specifying	 genes	 TFAP2A,	 PAX3,	
SNAI2	 (SLUG)	 and	 SOX9	were	 upregulated	 in	 the	 cultures	 at	 day	 11	 and	 day	 18,	
confirming	their	NC	identity	(Fig.	20B).	SOX10,	which	labels	early	NC	cells	at	all	axial	
levels	but	becomes	downregulated	in	cranial	NC	cells	at	later	developmental	stages	
in	vivo223,	followed	a	similar	trend	of	early	induction	and	later	decline,	but	its	levels	
were	generally	low	(Fig.	20B).	Nevertheless,	expression	of	SOX10	was	noted	on	the	
protein	level,	as	well	as	of	SOX9	and	HNK1,	albeit	at	low	levels	(Fig.	20C).	Virtually	
all	 derived	NC	 cells	 expressed	TFAP2A	 and	p75/NGFR	 and	proliferated	 readily	 as	
shown	 by	 positive	 staining	 of	 KI-67	 (Fig.	 20C).	 At	 passage	 3,	 transcript	 levels	 of	
neuronal,	endoderm	and	mesoderm-associated	genes	NESTIN,	PAX6,	FOXA2,	SOX17	
and	T	were	barely	detectable	 (Fig.	 20D).	After	passage	3,	NC	 cells	were	passaged	
roughly	 at	 1:5	 ratio	 every	 4	 days	 in	 a	 medium	 containing	 BSA,	 BMP2	 and	
CHIR99021,	until	around	passage	15,	when	cultures	showed	signs	of	senescence.	
To	 furthermore	 corroborate	 their	 lineage,	 I	 tested	 whether	 the	 putative	 NC	 cells	
could	 give	 rise	 to	mesenchymal	 stem	 cells	 (MSCs;	Fig.	 21),	 which	 are	 among	 the	
expected	progeny	of	NC	cells162.		
	
								 	
	
Figure	 21.	 In	 vitro	generated	NC	 cells	 differentiate	 to	mesenchymal	 stem	 cells	 (MSCs)	
and	terminal	lineages.		
(A-C)	 MSCs	 derived	 from	 NC	 cells	 show	 mesenchymal	 morphology	 in	 brightfield	
microscopy	 (A),	 express	 MSC-surface	 markers	 but	 not	 hematopoietic	 marker	 CD45	 as	
determined	 by	 flow	 cytometry	 (red,	 isotype	 control;	 B),	 and	 can	 be	 terminally	
differentiated	to	osteoblasts	and	adipocytes	as	confirmed	by	positive	Alizarin	Red	and	Oil	
Red	O	staining,	respectively,	after	26	days	of	differentiation	(C).	
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Indeed,	 exposure	 of	 NC	 cultures	 to	 MSC	 maintenance	 medium	 as	 performed	 in	
published	 protocols224	 resulted	 in	 the	 manifestation	 of	 a	 spindle-shaped	
morphology	 characteristic	 of	 MSCs;	 furthermore,	 putative	 NC-derived	 MSCs	
expressed	 consensus	 MSC	 surface	 markers	 CD73,	 CD90	 and	 CD105	 but	 not	 the	
hematopoietic	marker	 CD45225,	 and	 terminally	 differentiated	 into	 osteoblasts	 and	
adipocytes,	 which	 I	 confirmed	 by	 increased	 levels	 of	 mineralization	 as	 shown	 by	
Alizarin	 Red	 staining,	 or	 intracellular	 lipid	 accumulation	 via	 Oil	 Red	 O	 staining,	
respectively226	 (Fig.	 21).	 This	 concludes	 that	 in	 vitro	 generated	 NC	 cells	 were	
capable	of	generating	mesenchymal	derivatives,	which	is	one	of	the	developmental	
functions	of	embryonic	NC	populations	in	vivo.	
The	NC	cells	exhibited	upregulation	of	both	ASXL1	and	ASXL3	transcripts	(Fig.	22A),	
which	 I	 confirmed	 by	 co-localization	 of	 ASXL1	 with	 TFAP2A	 protein	 via	
immunocytochemistry	 (Fig.	 22B).	 This	 supported	 my	 hypothesis	 that	 ASXL1	 is	
specifically	involved	in	NC	development,	as	opposed	to	ASXL2,	which	is	ubiquitously	
expressed	 but	 not	 induced	 in	 this	 population	 (Fig.	 22A).	 Furthermore,	 I	 detected	
full-length	and	truncated	ASXL1	protein	in	ASXL1PSC/PSC	-derived	NC	cultures	at	day	3	
and	day	 5,	 together	with	 the	 band	 at	 130	 kDa	 that	was	 yet	 unaccounted	 for	 (Fig.	
22C).	At	day	7	of	differentiation,	full-length	ASXL1	in	ASXL1PSC/PSC	cultures	amounted	
to	roughly	70	%	of	ASXL1	protein	levels	in	control	cultures	(Fig.	22C),	indicating	a	
potential	 downregulation	 of	 wildtype	 transcripts	 in	 mutant	 cells	 during	 NC	
differentiation.		
	
	
Figure	22.	Expression	of	ASXL	genes	in	NC	cultures.		
(A)	 Relative	 expression	 level	 of	 ASXL1-3	 in	 control	 hESC-derived	 NC	 cells	 (Passage	 2);	 n=3-5;	
*p<0.05,	 ****p<0.0001;	Wilcoxon	 test	 (ASXL1)/Welch’s	 t-test	 (ASXL2/3).	 (B)	 Immunocytochemical	
stainings	 show	 co-localization	 of	 NC	 specifier	 TFAP2A	 and	 ASXL1	 in	 control	 hESC-derived	 NC	
cultures	at	day	18.	(C)	Detection	of	ASXL1	protein	variants	by	Western	blot	 in	NC	cultures	derived	
from	ASXL1PSC/PSC	and	control	hESC	at	day	3,	5	and	7	of	differentiation.	
	
	
Importantly,	 validation	 of	 the	 NC	 differentiation	 protocol	 together	 with	 the	
confirmed	 presence	 of	 the	 putative	 disease-causing	 ASXL1	 variant	 during	 NC	
induction	 enabled	 me	 to	 assess	 a	 potential	 dominant	 perturbation	 of	 NC	
development	in	BOS	model	lines.		
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3.4.2	Truncated	ASXL1	impairs	differentiation	to	migrating	neural	crest	cells		
I	 noticed	 that	 ASXL1PSC/PSC	 mutations	 drastically	 reduced	 the	 attachment	 of	
neurospheres	derived	 from	these	clones	and	diminished	 the	emigration	of	NC-like	
cells	 (Fig.	 23A).	 A	 similar	 effect	 was	 observed	 also,	 albeit	 to	 a	 lesser	 extent,	 in	
neurospheres	 derived	 from	 BOS-iPSCs	 with	 heterozygous	 ASXL1	 mutations	 (Fig.	
23B).	 Co-variations	 in	 patient	 clones	 correlated	 with	 the	 method	 used	 for	
reprogramming	and/or	number	of	passages,	as	mRNA-reprogrammed	clones	(#1-0,	
#2-0)	 were	 cultivated	 for	 around	 15	 more	 passages	 than	 the	 episomally-
reprogrammed	 lines	 (#1-1,	 #2-1)	 and	 showed	 stronger	 reduction	 in	 neurosphere	
attachment	(Fig.	23B).		
	
	
Figure	23.	Differentiation	to	migrating	NC	cells	is	impaired	by	expression	of	truncated	ASXL1.		
(A,B)	Percentage	of	attached	neurospheres	with	emigrating	cells	at	day	7	of	NC	differentiation,	from	
ASXL1PSC/PSC	hESC	clones	related	to	control	hESC	(6	independent	experiments;	A)	and	from	BOS-iPSC	
related	to	control	iPSC	(n=3	independent	experiments;	B).	 (C)	Percentage	of	attached	neurospheres	
derived	 from	 control	 hESC	 and	 PB-ASXL1PSC	 hESC	 without	 (-DOX)	 and	 with	 (+DOX)	 induced	
overexpression	 of	 truncated	 ASXL1,	 in	 relation	 to	 the	 total	 number	 of	 neurospheres	 that	 were	
generated;	n=3.	(D)	Total	number	of	neurospheres	(floating	and	attached)	derived	from	ASXL1PSC/PSC	
hESC	and	control	hESC;	n=10,	 ****p<0.0001;	Welch’s	 t-test.	(E)	Brightfield	 images	of	neurospheres	
with	peripheral	outgrowth	(derived	from	control	hESC)	or	apoptotic	cells	(derived	from	ASXL1PSC/PSC	
hESC)	at	day	7	of	NC	differentiation.	(F)	Percentage	of	attached,	outgrowing	neurospheres	related	to	
the	 total	 number	 of	 generated	 neurospheres	 at	 day	 7	 and	 day	 8	 of	 NC	 differentiation	 from	
ASXL1PSC/PSC	hESC	and	control	hESC;	n=6-12;	***p<0.001;	ns,	not	significant;	Welch’s	t-test.	
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Dramatic	 impairment	 of	 NC	 differentiation	was	 observed	 upon	 overexpression	 of	
truncated	ASXL1,	which	 led	 to	 a	 nearly	 complete	 failure	 of	 neurosphere	 to	 attach	
and	produce	migratory	NC-like	cells	(Fig.	23C),	emphasizing	the	dominant	effect	of	
the	truncating	mutations.	Importantly,	 lower	numbers	of	attached	neurospheres	in	
ASXL1PSC/PSC	 compared	 to	 control	 cultures	 were	 not	 due	 to	 a	 change	 in	 the	 total	
number	 of	 neurospheres	 derived	 from	 ASXL1PSC/PSC	 clones,	 which	 were	 in	 fact	
significantly	higher	(Fig.	 23D).	However,	 the	appearance	of	 floating,	round	cells	 in	
the	 periphery	 of	weakly	 adherent	 neurospheres	 from	ASXL1PSC/PSC	 lines	 suggested	
that	if	cells	were	unable	to	differentiate	and	migrate,	they	underwent	apoptosis	(Fig.	
23E).	The	occurrence	of	weakly	attached	ASXL1PSC/PSC	neurospheres	prompted	me	to	
maintain	 NC	 cultures	 further	 in	 an	 undisturbed	 ‘adhesion	 stage’,	 which	 indeed	
seemed	to	allow	some	of	the	mutant	cells	to	produce	delaminating	NC	cells,	evident	
at	 day	 8	 (Fig.	 23F).	 This	 implied	 that	 NC	 development	 was	 delayed	 in	 cultures	
bearing	 truncated	 ASXL1.	 In	 this	 context	 it	 should	 be	 noted	 that	 successfully	
attaching	neurospheres	in	ASXL1PSC/PSC	and	BOS-iPSC	gave	rise	to	NC	cells	that	were	
indistinguishable	 from	 control	 cells	 as	 based	 on	 morphology	 (Fig.	 24A)	 and	
expression	of	NC	specifying	genes	on	the	mRNA	(Fig.	24B,	C)	and	protein	level		(Fig.	
24D).	 I	however	noted	reduced	expression	 levels	of	p75	 and	SOX10	 in	 the	mutant	
cultures	at	passage	3	(Fig.	24C).		
Taken	together,	 these	findings	supported	the	notion	that	NC	symptoms	in	BOS	are	
caused	 by	 a	 dominant	 negative	 effect	 of	 the	 truncated	 ASXL1	 protein	 on	 NC	
induction,	which	might	impair	and/or	delay	their	emigration.	
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Figure	 24.	 NC	 cells	 derived	 from	 BOS	 lines	 are	
comparable	to	control-derived	NC	cells.		
(A)	 Brightfield	 images	 of	 NC	 cells	 of	 Passage	 1,	
derived	 from	 control	 hESC/hiPSC,	 BOS-iPSC	 and	
ASXL1PSC/PSC	 hESC.	 (B,C)	 Expression	 levels	 of	 NC	
specifying	 genes	 in	 day	 11	 (n=2)	 and	 day	 18	
ASXL1PSC/PSC	 NC	 cultures	 related	 to	 undifferentiated	
ASXL1PSC/PSC	hESC	(B),	and	in	control	and	ASXL1PSC/PSC	
NC	 cultures	 (Passage	 3)	 related	 to	 undifferentiated	
control	hESC	(n=2-5;	C),	as	determined	by	qPCR.	(D)	
Immunocytochemical	 staining	 of	 NC	 markers	
TFAP2A	and	HNK1	 in	day	18	NC	 cells	derived	 from	
ASXL1PSC/PSC	hESC.		
		
	
	
3.4.3	Truncated	ASXL1	impairs	NC	migration	in	vivo		
To	corroborate	these	findings	and	rule	out	potential	artifacts	due	to	attachment	of	
neurospheres	 on	 plastic	 dishes,	 I	 conducted	 functional	 in	 vivo	 assays	 for	 NC	
development	in	collaboration	with	Dr.	Rehimi	and	Dr.	Rada-Iglesias	(CMMC	Cologne,	
Germany).	 I	 integrated	 constitutive	 GFP-expression	 plasmids	 into	 control	 and	
ASXL1PSC/PSC	hESCs	 (clones	 A	 and	 D,	 Table	 3),	 and	 subjected	 the	 cultures	 to	 NC	
differentiation	 for	 5	 days.	 Resulting	 GFP-labeled	 neurospheres	 were	 transplanted	
into	 the	developing	hindbrain	of	 stage	HH9-10201	 chicken	embryos,	and	migratory	
NC	progeny	delaminating	from	the	neurospheres	were	analyzed	48	hours	later	(Fig.	
25A,	 B).	 GFP-ASXL1PSC/PSC	 neurospheres	 showed	 a	 significant	 reduction	 in	 the	
number	of	 emigrating	 cells	 compared	 to	 isogenic	 control	 neurospheres	 (Fig.	 25B,	
C),	despite	being	of	similar	size	(Fig.	25D).	For	the	cells	that	did	emigrate,	a	modest	
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reduction	in	migration	distance	was	observed	in	ASXL1	mutant	neurospheres	(Fig.	
25E).		
	
						 	
		
	
Figure	25.	Transplantation	of	neurospheres	in	ovo	confirms	developmental	defects	of	ASXL1PSC/PSC	NC	
cells.		
(A)	Workflow	of	 neurosphere	 transplantation	 experiments	 and	 representative	 brightfield	 and	GFP	
image	of	a	chicken	embryo	(dorsal	view)	that	was	engrafted	with	day	5	neurospheres	derived	from	
GFP-control	 and	GFP-ASXL1PSC/PSC	hESCs	 (arrows	 indicate	 transplanted	 neurosphere);	 images	 taken	
directly	after	transplantation.	(B)	Exemplary	brightfield	and	GFP	images	of	chicken	embryos	(dorsal	
view,	 anterior	 to	 the	 left)	 48	 h	 after	 transplantation	 of	 GFP-Control	 and	 GFP-ASXL1PSC/PSC	hESC-	
derived	neurospheres	as	outlined	in	(A).	(C-E)	Analysis	of	n=9	and	n=21	embryos	transplanted	with	
GFP-Control	 or	 GFP-ASXL1PSC/PSC	 neurospheres,	 respectively,	 as	 outlined	 in	 (A):	 quantification	 of	
emigrating	 cells	 (p=0.037,	 Wilcoxon	 test;	 C),	 diameter	 of	 transplanted	 neurospheres	 (D),	 and	
distance	between	NS	and	furthest	migrated	cell	(p=0.05,	Welch’s	t-test;	E);	a.u.,	arbitrary	unit.		
	
I	 furthermore	 set	 out	 to	 confirm	 the	 dominant	 effect	 of	 truncated	 ASXL1	 on	 the	
delamination	of	embryonic	NC	cells.	The	chicken	homolog	of	ASXL1	is	highly	similar	
to	human	ASXL1	in	size	and	domain	architecture	as	determined	from	the	annotated	
sequence	 in	 the	UniProt	database209	 (Fig.	 26A),	 and	 I	 constructed	overexpression	
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plasmids	harbouring	GFP	(control)	or	GFP	coupled	to	a	BOS	patient-like,	truncated	
variant	of	the	chicken	ASXL1	transcript	(chicken	ASXL1PSC,	Fig.	26A).	These	plasmids	
were	transfected	into	the	NC	progenitor	zone	of	chicken	embryos	at	stage	HH9-10.	
Analysis	 of	 electroporated	 embryos	 at	 stages	 HH19	 and	 HH24	 revealed	 strongly	
inhibited	 delamination	 and	 reduced	 migration	 of	 the	 GFP-chicken	 ASXL1PSC-
transfected	 cells	 relative	 to	 cells	 expressing	 the	 control	 GFP	 plasmid	 (Fig.	 26B).	
Interestingly,	 also	 cells	 electroporated	 with	 a	 plasmid	 encoding	 for	 the	 human	
truncated	ASXL1PSC	transcript	showed	defective	emigration	(Fig.	26B).	Collectively,	
this	indicates	that	the	truncated	form	of	ASXL1	induces	NC-related	symptoms	in	BOS	
by	 diminishing	 the	 formation	 and	migration	 of	 NC	 progenitors,	 and	 that	 this	 is	 a	
dominant	and	evolutionary	conserved	effect.	
	
	
Figure	26.	Overexpression	of	truncated	chicken	ASXL1	impairs	NC	migration	in	vivo.		
(A)	Predicted	chicken	(Gallus	gallus)	ASXL1	protein	with	annotated	domains	(UniProt	F1P445),	and	
chicken	wildtype	ASXL1	transcript	and	truncated	ASXL1PSC	construct.	(B)	Representative	fluorescence	
images	 of	 chicken	 embryos	 electroporated	 at	 stage	 HH9-10	with	 plasmids	 expressing	GFP	 or	GFP	
coupled	to	truncated	chicken	or	human	ASXL1PSC;	images	taken	at	HH19	and	HH24	(n=10	embryos).	
The	red	rectangle	indicates	orientation	and	region	of	the	embryos	(head/hindbrain)	that	are	shown.	
	
3.4.4	 The	 neural	 crest	 regulatory	 network	 is	misregulated	 in	 ASXL1	mutant	
cells	
To	 delineate	 a	 molecular	 basis	 for	 the	 paucity	 of	 ASXL1PSC/PSC	 -NC	 cells	 and	 their	
migration	 impairment,	 I	 analyzed	 the	 transcriptomes	 of	 cultures	 at	 day	 7	 of	 NC	
differentiation	 by	 total	 RNA	 sequencing.	 Examination	 of	 global	 transcript	 cohorts	
revealed	 mutually	 exclusive	 clustering	 of	 samples	 harboring	 ASXL1PSC/PSC	 and	
wildtype	 alleles	 (Fig.	 27A),	 with	 1202	 genes	 being	 down-,	 and	 1448	 being	
upregulated	(padj<0.05),	 indicating	extensive	changes	 in	expression	programs	(Fig.	
27B).	This	was	to	be	expected	since	at	day	7,	ASXL1PSC/PSC	cultures	consisted	mainly	
of	 floating	 neurospheres,	 whereas	 control	 hESC-derived	 cultures	 displayed	 a	
mixture	of	 floating	and	attached	neurospheres	 together	with	delaminating	NC-like	
cells.	 Strikingly,	 the	 neural	 plate	 border	 specifier	ZIC1	was	most	 significantly	 and	
highly	reduced	in	ASXL1PSC/PSC	cultures	(Fig.	27B).		
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Figure	 27.	 Whole	 transcriptome	 analysis	 in	 NC	
cultures.		
(A)	 Principal	 component	 analysis	 of	 the	 global	
transcriptomes	 of	 ASXL1PSC/PSC	 and	 control	 hESC-
derived	 day	 7	NC	 cultures	 as	 determined	 by	 total	
RNA	sequencing;	control:	n=3;	ASXL1PSC/PSC	clone	A	
and	 C:	 n=2,	 ASXL1PSC/PSC	 clone	 D:	 n=3;	 samples	
derived	 from	 three	 independent	 differentiation	
experiments.	 (B)	 Volcano	 plot	 exhibiting	
differentially	 expressed	 genes	 in	 day	 7	 NC	
progenitor	cultures,	based	on	(A).	
	
	
To	 assess	 how	 the	 observed	 strong	 downregulation	 of	 the	ZIC1	 locus	 affected	 the	
general	NC	identity	of	ASXL1PSC/PSC	cultures,	I	evaluated	the	expression	of	published	
human	NC	markers	in	the	datasets	(Fig.	28A).	In	control	cultures,	early	NC	genes34	
(NGFR,	B3GAT1,	ITGA4),	as	well	as	human	neural	plate	border	and	NC	specifiers	 in	
pre-migratory	and	migratory	stages150,152,153	(GBX2,	PAX3/7,	MSX1/2,	TFAP2A,	ZIC1,	
FOXD3,	 SNAI1/2,	 SOX9,	 SOX10,	 TWIST1)	 and	 the	 nuclear	 receptors	 NR2F1/2	 that	
promote	human	NC	gene	expression150	were	expressed	(Fig.	28A).	NOTCH	signaling	
pathway	members	HES1/5,	NOTCH1	 and	 JAG1,	 which	 are	 important	 regulators	 of	
human	NC	differentiation153,	were	 also	 present	 at	 high	 transcript	 levels	 in	 the	NC	
cultures	(Fig.	 28A).	 I	 furthermore	noted	expression	of	ETS-1,	 a	 factor	 that	confers	
cranial	identity	in	NC	cells227,	whereas	transcript	levels	of	placodal	genes	EYA2,	SIX1	
and	DLX3	 were	 almost	 undetectable,	 excluding	 the	 assumption	 of	 cranial	 sensory	
placode	 identity	 in	 the	 cultures152,228	 (Fig.	 28A).	Most	 importantly,	 several	 of	 the	
human	NC	regulatory	genes	exhibited	mild	to	strong	downregulation	in	ASXL1PSC/PSC	
cultures	 (Fig.	 28A).	 This	was	 in	 line	with	 the	dramatic,	 50-fold	 reduction	 in	ZIC1,	
which	represents	one	of	the	key	regulators	in	the	mutually	supportive	NC	regulatory	
network151.	 Accordingly,	 many	 of	 the	 genes	 assigned	 to	 this	 network	 were	
negatively	 regulated	 in	 ASXL1PSC/PSC	 cultures,	 and	 I	 grouped	 the	 downregulated	
factors	 into	 different	 stages	 of	 NC	 development	 in	 Fig.	 28B,	 reflective	 of	 their	
functional	 characterization	 in	 model	 systems150,158,229.	 The	 deregulated	 cohort	
included	 early	 neural	 plate	 border	 marker	 specifiers	 (GBX2),	 NC	 inducers	 and	
specifiers	 (PAX3,	 ZIC1,	 MSX1,	 NRF2F1/2	 and	 HES5),	 genes	 activating	 the	
delamination	and	migratory	program	(ZEB2,	TWIST1	and	SOX5)	and	several	Ephrins	
and	their	cognate	receptors,	which	serve	as	guidance	cues	during	NC	migration	(Fig.	
28B).	Factors	governing	the	differentiation	to	NC	derivatives	(COL2A1,	DCT,	BRN3A,	
MASH1)	were	similarly	diminished	in	ASXL1PSC/PSC	cultures	(Fig.	28B).	
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Figure	28.	Expression	of	truncated	ASXL1	 leads	to	misregulation	of	gene	networks	associated	with	
NC	development	and	EMT.		
(A-C)	Analysis	of	total	RNA	sequencing	data	derived	at	day	7	of	three	independent	NC	differentiation	
experiments.	 (A)	 Confirmation	 of	NC	 identity	 in	 day	 7	 progenitor	 cultures	 based	 on	 expression	 of	
published	human	NC	markers	and	NOTCH	signaling	pathway	members,	and	low	transcript	levels	of	
placode-associated	 genes.	 ETS1	 is	 a	 cranial	 NC	 cell	 transcription	 factor230.	 ASXL1PSC/PSC-derived	
cultures	showed	reduced	expression	levels	of	several	NC	specifiers	and	NOTCH	factors,	ZIC1	was	the	
most	 significantly	 downregulated	 gene.	 RPKM,	 reads	 per	 kilobase	 per	 million	 mapped	 reads;	
****padj<0.0001,	***padj<0.001,	**padj<0.01,	*padj<0.05;	ns,	not	significant.	(B)	Diagram	of	functionally	
characterized	genes	important	for	different	steps	of	NC	development,	as	determined	in	Xenopus,	fish,	
human	and	chicken	experiments150,151,153,	and	their	 level	of	misregulation	(padj<0.05)	 in	ASXL1PSC/PSC	
compared	to	control	day	7	NC	progenitors.	(C)	Quantification	of	E-Cadherin	(E-CAD)	and	N-Cadherin	
(N-CAD)	 expression	 at	 day	 3	 and	 5	 (qPCR,	 n=2),	 and	 of	 E-CAD,	 N-CAD	 and	 Cadherin-6	 (CDH6)	
expression	at	day	7	(RNA-seq)	of	NC	differentiation	from	ASXL1PSC/PSC	compared	to	control	cells.	
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In	 accordance	 with	 the	 perturbation	 of	 NC	 delamination	 and	 emigration,	 I	
furthermore	 observed	 significant	 misregulation	 of	 Cadherin	 genes	 in	 ASXL1PSC/PSC	
cultures.	This	encompassed	higher	levels	of	the	epithelial	Cadherin	CDH1	and	lower	
levels	of	N-Cadherin/CDH1	and	Cadherin	6/CDH6	in	comparison	to	control,	the	latter	
of	which	are	expressed	in	NC	cells	during	delamination149	(Fig.	28B,	C).	The	inverse	
expression	of	E-Cadherin	 and	N-Cadherin	 in	ASXL1PSC/PSC	 compared	 to	 control	 cells	
was	 already	 observed	 during	 neurosphere	 formation,	 indicating	 an	 early	
deregulation	of	signaling	cascades	in	the	neuroepithelial	structures	(Fig.	28C).	
	
3.4.5	Ectopic	expression	of	ZIC1	rescues	the	NC	differentiation	defect	in	vitro	
In	 line	with	 a	 potential	 perturbation	 of	 the	NC	 regulatory	 network	 already	 at	 the	
NPB	 stage,	 I	 postulated	 that	 insufficiently	 induced	 ZIC1	 levels	 might	 be	 critically	
limiting	 the	 differentiation	 of	 ASXL1PSC/PSC	 cells	 by	 misregulation	 of	 downstream	
effectors	 in	 NC	 differentiation	 and	 specification.	 To	 verify	 this	 hypothesis,	 I	
constructed	 tet-inducible	 ZIC1	 overexpression	 vectors	 and	 integrated	 them	 into	
control	 and	ASXL1PSC/PSC	 hESCs	 (Fig.	 29A,	 Table	 3),	which	 I	 then	 subjected	 to	NC	
differentiation	with	or	without	DOX	treatment	from	day	3	or	day	4	of	the	protocol.	
Strikingly,	 overexpression	 of	 ZIC1	 in	 PB-ZIC-ASXL1PSC/PSC	 neurospheres	 led	 to	 full	
reversion	 of	 the	 attachment	 and	 outgrowth	 phenotype	 (Fig.	 29B).	 While	 ZIC1	
expression	 was	 over	 100-fold	 reduced	 in	 uninduced	 PB-ZIC-ASXL1PSC/PSC	 cultures	
(also	 confirming	 the	RNA-seq	 results),	DOX	 treatment	 equalized	 the	 levels	of	ZIC1	
target	 gene	 SNAI2	 and	 of	 NPB	 co-factor	 GBX2151	 (Fig.	 29C).	 This	 indicated	 that	
diminished	ZIC1	levels	are	(at	least	partly)	responsible	for	NC	differentiation	defects	
in	mutant	ASXL1	cultures	in	vitro.	
	
	
Figure	29.	Rescue	of	the	in	vitro	NC	differentiation	defect	by	ZIC1	overexpression.		
(A)	Western	Blot	showing	the	detection	of	ZIC1	protein	expression	in	undifferentiated	control	hESC	
that	 carry	 stable	 integration	 of	 a	 DOX-inducible	 PB-ZIC1	 overexpression	 plasmid;	 H3K27me3	
detection	served	as	 loading	control.	(B)	Analysis	of	attached	neurospheres	with	emigrating	cells	 in	
PB-ZIC1-Control	 and	 PB-ZIC1-ASXL1PSC/PSC	 lines	 at	 day	 7,	 left	 untreated	 or	 treated	 with	 DOX	 to	
overexpress	ZIC1	 from	day	3	 (n=2-3)	 or	 day	4	 (n=3,	 independent	 experiments);	 *padj<0.05;	 ns,	 not	
significant;	Welch’s	 t-test.	 (C)	 Quantification	 of	ZIC1,	SLUG	and	GBX2	 expression	 in	 lines	 from	 (B),	
with	or	without	DOX	treatment	from	day	4	to	day	7	of	differentiation;	n=3,	**padj<0.01;	Welch’s	t-test.		
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3.4.6	 The	 transcriptional	 signature	 of	 BOS	 NC	 models	 relates	 to	 perturbed	
signalling	cascades	and	BOS	symptoms		
NC	 specification	 relies	 on	WNT	and	BMP	 signals	 that	 activate	 neural	 plate	 border	
genes;	 furthermore,	 reiterated	WNT	 signaling	 acts	 in	 concert	 with	 Pax3	 and	 Zic1	
during	NC	induction151.	Corresponding	to	the	strong	reduction	in	ZIC1	and	other	NC	
specifiers,	 I	 noticed	 that	 several	 canonical	 and	 non-canonical	 WNT	 ligands	 and	
frizzled	receptors	(FZD)	were	expressed	at	significantly	lower	levels	in	ASXL1PSC/PSC	
compared	 to	 control	 cultures	 at	 day	 7	 of	 NC	 differentiation	 (Fig.	 30A).	 These	
included	 factors	 with	 described	 functions	 during	 NC	 development	 in	 Xenopus,	
chicken	 and	mice231-233	 (FZD3,	WNT3A	and	WNT8B)	 but	 also	 additional	 receptors	
and	ligands	that	are	less	well	or	not	characterized	in	NC	development	(FZD7,	FZD2,	
FZD1,	 FZD10,	 WNT7A/B,	 WNT2B,	 WNT4,	 WNT5B).	 With	 regard	 to	 the	 equally	
important	function	of	BMP	signaling	levels	during	NC	induction234,	I	also	examined	
the	 transcript	 levels	 of	 CER1,	 GDF3	 NODAL	 and	 NANOG,	 for	 which	 I	 had	 noted	
upregulation	 in	undifferentiated	BOS-iPSCs	(Fig.	 14).	 Interestingly,	 the	BMP/TGFβ	
factors	were	slightly,	but	with	the	exception	of	NANOG	 (padj=0.04)	not	significantly	
increased	in	ASXL1PSC/PSC	NC	cultures	(Fig.	30B).	
	
	
Figure	 30.	 Downregulated	 genes	 in	 ASXL1PSC/PSC	 NC	 cultures	 are	 associated	 with	 WNT	 signaling,	
disturbed	differentiation	and	BOS-related	symptoms.		
(A-C)	 Analysis	 of	 total	 RNA	 sequencing	 data	 at	 day	 7	 of	 three	 independent	 NC	 differentiation	
experiments.	 Shown	 are	 transcript	 levels	 of	 most	 highly	 expressed	 frizzled	 receptors	 and	 WNT	
ligands	 (A)	 and	of	BMP/TGFβ	pathway	 regulators	CER1,	GDF3	and	NODAL	 and	pluripotency	 factor	
NANOG.	 (B)	 in	 NC	 cultures;	 *padj<0.05,	 **padj<0.01,	 ****padj<0.0001;	 ns,	 not	 significant.	 (C)	 Most	
significant	 Medical	 Subject	 Headings-	 (MeSH-)	 Terms	 associated	 with	 downregulated	 genes	
(padj<0.05)	in	ASXL1PSC/PSC	compared	to	control	NC	cultures.		
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Taken	 together,	 my	 transcriptome	 analyses	 indicate	 that	 truncating	 ASXL1	
mutations	 result	 in	misregulation	of	 crucial	 signaling	pathways	and	regulatory	NC	
transcription	 factors,	 thereby	 impairing	 NC	 development.	 Intriguingly,	 transcripts	
that	 were	 downregulated	 in	 ASXL1PSC/PSC	 cultures	 (padj<0.05)	 were	 highly	 and	
significantly	 associated	 with	 the	 Medical	 Subject	 Headings	 (MeSH)-Term	
‘craniofacial	 abnormalities’,	which	 is	 a	main	 characteristic	 of	BOS	patients132	 (Fig.	
30C).	Additional	conditions	that	are	commonly	diagnosed	in	BOS	were	also	linked	to	
gene	cohorts	with	reduced	transcripts	in	ASXL1PSC/PSC	cultures,	including	‘agenesis	of	
corpus	callosum’,	 ‘nervous	system	malformations’,	 ‘musculoskeletal	abnormalities’,	
‘seizures’	 and	 ‘communication	 disorders’	 (Fig.	 30C).	 Several	 of	 these	 terms	 hint	
towards	 a	 general	 affection	 of	 neural	 tube	 development	 in	 ASXL1	 mutant	 cells,	
which	 was	 supported	 by	 the	 strong	 association	 of	 downregulated	 gene	 sets,	 in	
particular	 the	 highly	 downregulated	 FOXP2,	 with	 the	 GO-Term	 ‘nervous	 system	
development’	(Fig.	27B,	Table	5).	Providing	a	further	link	between	transcriptional	
misregulations	 in	NC	cultures	and	BOS	symptoms,	 I	noticed	the	concordant	strong	
downregulation	 of	 ZIC1	 and	 ZIC4	 (Fig.	 27B),	 which	 are	 an	 immediately	 adjacent	
gene	 pair.	 Deletion	 of	 the	 ZIC1/ZIC4	 locus	 is	 associated	 with	 Dandy-Walker	
malformation,	a	condition	found	in	some	BOS	patients137	(Fig.	30C).	In	general,	the	
strong	 correlation	 between	 BOS	 phenotypes	 and	 gene	 ontology	 of	 misregulated	
transcripts	 in	 ASXL1PSC/PSC	NC	 cultures	 supported	 my	 hypothesis	 that	 truncating	
ASXL1	mutations	are	underlying	a	molecular	mechanism	that	affects	the	developing	
NC	population	in	BOS.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 	
	 	 	
3. Results 
95	
Table	5.	Downregulated	genes	in	ASXL1PSC/PSC	NC	cultures	are	associated	with	the	GO-term	‘Nervous	
system	development’.		
Genomatix	pathway	analysis	of	significantly	(padj<0.05)	downregulated	genes	in	ASXL1PSC/PSC-	versus	
control	 hESC-derived	 NC	 cultures	 (RNA-seq	 at	 day	 7	 of	 differentiation,	 n=3-7).	 GO-term	 ‘nervous	
system	development’	(GO:0007399)	ranked	highest	with	a	p-value	of	1,12E-60.	
ABAT	 DLX1	 GJB1	 NCOA6	 PHOX2A	 SRR	
ADGRB3	 DMRT3	 GLI3	 NDNF	 PLXNA4	 ST8SIA2	
ADGRG1	 DMRTA2	 GLRA2	 NEFM	 PLXNC1	 ST8SIA4	
ADGRL3	 DNER	 GLRB	 NEGR1	 POTEE	 STMN2	
APCDD1	 DN4F6	 GPM6A	 NELL1	 POU3F2/Brn2	 STMN4	
APLP1	 DPYSL4	 GRIK1	 NEUROD1	 POU3F3	 SULF1	
ARNT2	 DPYSL5	 GRIN3A	 NEUROD4	 POU4F1/Brn3a	 TAGLN3	
ARX	 DRGX	 GST4F6	 NEUROG1	 POU4F2	 TAL2	
ASCL1	 DRP2	 HEYL	 NEUROG2	 PRDM16	 TCF12	
ASTN1	 DSCAML1	 HIPK2	 NF1	 PRELP	 TH	
ATOH8	 EFNA5	 HOXB1	 NFASC	 PRRX1	 TLX3	
BCHE	 EFNB2	 HPCAL4	 NHLH1	 PTN	 TNIK	
BCL2	 EFNB3	 INSC	 NKD1	 PTPRO	 TPBG	
BMP5	 EGR3	 ISLR2	 NKX6-1	 RELN	 TWIST1	
BMP6	 ELAVL3	 ITGA8	 NKX6-2	 RFX4	 UNC5C	
BMPR1B	 EMX1	 KCNC1	 NLGN1	 RGS9	 UNCX	
BOC	 EMX2	 KDM6B	 NLGN3	 RNF165	 VAX1	
CBLN2	 EN1	 KIAA2022	 NME5	 ROBO2	 VAX2	
CDH2	 EN2	 KIF26B	 NNAT	 RORB	 VIM	
CDKN2C	 EPHA3	 L1CAM	 NOVA1	 RTN4RL1	 WLS	
CDON	 EPHA4	 LEF1	 NR2E1	 S100B	 WNT2B	
CHD7	 EPHA7	 LHX2	 NR2F2	 S1PR1	 WNT3A	
CHL1	 EPHB1	 LHX9	 NR4A2	 SARM1	 WNT5B	
CLDN11	 F2	 LRP2	 NRCAM	 SCN3A	 WNT7A	
CNTF	 FABP7	 LRRK2	 NRGN	 SCRG1	 WNT8B	
CNTFR	 FAIM2	 LRRTM2	 NRN1	 SDK2	 XK	
CNTN2	 FAM212A	 LSAMP	 OLIG1	 SEMA3A	 ZBTB16	
CNTN3	 FAT4	 LY6H	 OLIG2	 SEMA3C	 ZEB1	
CNTN6	 FEZF2	 MAB21L2	 OLIG3	 SEZ6L	 ZEB2	
COL25A1	 FGF17	 MAP1B	 ONECUT2	 SHANK1	 ZFHX3	
COL2A1	 FGF8	 MAP2	 OTX1	 SHC3	 ZIC1	
COLQ	 FGF9	 MAP6	 PARK2	 SIM2	 ZNF521	
CRB1	 FIGF	 MBD5	 PAX3	 SLC8A3	 ZNF536	
CRB2	 FLRT1	 MDGA1	 PAX5	 SLIT2	 ZSWIM6	
CTNNA2	 FOXG1	 MDGA2	 PAX6	 SLITRK1	 	
CXCR4	 FOXJ1	 MEF2C	 PAX8	 SLITRK5	 	
CYP46A1	 FOXP2	 MEIS1	 PCDH12	 SNAP25	 	
DCC	 FZD1	 METRN	 PCDH19	 SOX1	 	
DCHS1	 FZD10	 MSX1	 PCDH9	 SOX3	 	
DCLK2	 FZD3	 MYO16	 PCDHB11	 SOX5	 	
DCT	 GBX2	 MYT1L	 PCSK2	 SOX6	 	
DCX	 GDF7	 NAV1	 PDGFC	 SPEF2	 	
DKK1	 GFRA1	 NCAM1	 PGAP1	 SPHK1	 	
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3.4.7	Regulation	of	ASXL	expression	in	ASXL1	mutant	NC	cultures	
With	 regard	 to	 potential	 cross-regulatory	 mechanisms	 between	 ASXL	 paralogs	
(Figs.	 17,	 18	 and	22A,C),	 I	 examined	 transcriptional	 regulation	 of	ASXL	 genes	 in	
mutant	 NC	 cultures.	 The	 dominant	 negative	 ASXL1	 alleles	 were	 associated	 with	
reduced	 expression	 of	 both	 ASXL1	 and	 ASXL3,	 but	 unaltered,	 or	 even	 slightly	
increased	ASXL2	transcript	levels	during	day	3-10	of	NC	differentiation	(Fig.	31A-C).	
Interestingly,	 this	was	 in	 line	with	co-induction	of	ASXL1	 and	ASXL3	 in	 control	NC	
cultures	 (Fig.	 22A).	 The	 reduction	 in	ASXL1	 levels	 persisted	 in	 passaged	NC	 cells,	
while	the	downregulation	of	ASXL3	seemed	to	be	reversed	in	passaged	cultures	(Fig.	
31D).	 ASXL1	 was	 also	 reduced	 in	 passaged	 NC	 cells	 derived	 from	 BOS-iPSC,	
suggesting	that	this	was	in	fact	a	disease-relevant	finding	(Fig.	31E).	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	 31.	 Misregulation	 of	 ASXL1	 in	 NC	 cultures	 that	
express	truncated	ASXL1	protein.		
(A)	 Transcript	 levels	 of	ASXL	 genes	 in	 day	 7	 NC	 cultures,	
based	 on	 sequencing	 of	 total	 RNA	 of	 independent	
differentiation	 experiments;	 ****padj<0.0001;	 ns,	 not	
significant.	 (B)	 Alignment	 of	 RNA-seq	 densities	 based	 on	
experiment	outlined	 in	(A)	within	the	 last	exons	of	ASXL1.	
Arrowhead	indicates	CRISPR-mediated	deletion.		
(C,D)	 Quantification	 of	 ASXL1-3	 expression	 levels	 at	 different	 time	 points	 during	 NC	
differentiation	 (qPCR,	n=3-5;	C)	 and	 in	 Passage	 3	 NC	 cultures	 (n=2;	D)	 from	ASXL1PSC/PSC	hESC	
compared	to	control	hESC.	(E)	RT-PCR-based	detection	of	full-length	ASXL1	transcript	in	control	
hESC-	and	BOS-iPSC-derived	NC	cultures	(Passage	2).	GAPDH	Ct	values	are	given	as	normalization	
control.		
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3.4.8	Global	and	local	chromatin	modifications	in	BOS	NC	models	
Transcriptional	 misregulations	 in	 ASXL1PSC/PSC	 NC	 cultures	 raised	 the	 question	 of	
whether	 they	 arise	 from	 altered	 chromatin	 modifications	 that	 are	 mediated	 by	
truncated	ASXL1	variants.	Indeed,	I	observed	a	decrease	in	the	global	levels	of	both	
H2AK119Ub	 and	 H3K27me3	 in	 NC	 cultures	 that	 were	 derived	 from	 ASXL1PSC/PSC	
clones,	 indicating	 that	 overactivation	 of	 the	 PR-DUB	 complex	 and	 subsequent	
reduced	PRC2	recruitment	might	 take	place	 in	 the	mutant	cultures69	 (Fig.	 32A-C).	
Downregulation	 of	 NC	 specifying	 genes,	 however,	 suggested	 aberrant	 repressive	
mechanisms,	and	since	full-length	ASXL1	was	shown	to	promote	the	recruitment	of	
the	PRC2	complex	to	chromatin99,	I	hypothesized	that	enhanced	local	recruitment	of	
PRC2	 by	 the	 truncated	 ASXL1	 protein	 could	 take	 place.	 To	 investigate	 this	
possibility,	I	performed	chromatin	immunoprecipitation	of	H3K27me3	in	day	7	NC	
cultures,	followed	by	qPCR	using	target-specific	primers	(ChIP-qPCR).	This	revealed	
increased	 H3K27me3	 levels	 at	 ZIC1	 and	 ZIC4	 in	 ASXL1PSC/PSC	 clones	 compared	 to	
control	cells,	which	was	also	observed	in	other	negatively	regulated	loci,	including	of	
ASXL1,	ASXL3	and	FOXP2	(Fig.	32D,	E).	ACTIN	and	HOXB2	were	used	as	positive	and	
negative	 controls,	 respectively,	 and	 indeed	 these	 loci	 did	 not	 show	 significant	
differences	 in	 H3K27me3	 levels	 between	 control	 and	 ASXL1PSC/PSC	 cultures	 (Fig.	
32D).	Arguing	in	favor	of	increased	EZH2	recruitment	via	truncated	ASXL1,	analysis	
of	public	epigenome	datasets	revealed	binding	of	EZH2	to	the	ZIC1/ZIC4	locus	in	H1	
hESC	(ENCODE;	Fig.	32E),	and	it	was	reported	that	truncated	ASXL1	interacts	with	
EZH2	 in	 vitro101.	 In	 order	 to	 confirm	 this	 interaction	 in	 NC	 cultures,	 I	 performed	
initial	 co-immunoprecipitation	 experiments,	 which	 however	 require	 further	
optimization	and	did	not	yield	conclusive	results	(Supplementary	Fig.	S3).	
In	 conclusion,	 I	 found	 that	BOS-associated	mutations	give	 rise	 to	 truncated	ASXL1	
variants	 that	 dominantly	 impair	 NC	 induction,	 which	 is	 accompanied	 by	
misregulation	of	 genes	 associated	with	NC	and	nervous	 system	development,	BOS	
symptoms	 and	 reduction	 in	 ASXL1/3	 levels.	 	 Increased	 H3K27me3	 levels	 at	
downregulated	 genes	 suggest	 enhanced	 PRC2	 recruitment,	 presumably	 via	 the	
mutant	 ASXL	 protein.	 Moreover,	 I	 propose	 that	 these	 mechanisms	 underlie	 NC-
related	 BOS	 symptoms	 and	 that	 ASXL1	 (and	 ASXL3)	 are	 critical	 regulators	 of	 NC	
development,	as	elaborated	in	the	Discussion.	
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Figure	 32.	 Expression	 of	 truncated	ASXL1	 is	 associated	with	 global	 reduction	 of	H2AK119Ub	 and	
H3K27me3	but	local	increase	of	H3K27me3	at	repressed	NC	genes.		
(A)	 Representative	 Western	 Blot	 of	 cell	 lysates	 from	 day	 3,	 5	 and	 7	 NC	 cultures	 derived	 from	
ASXL1PSC/PSC	(clones	A	and	B)	relative	to	control	hESC-derived	cultures.	(B-C)	Quantification	of	global	
H2AK119Ub	 (B)	 and	 H3K27me3	 (C)	 levels	 relative	 to	 ACTIN	 during	 NC	 differentiation	 from	
ASXL1PSC/PSC	 clones	 and	 control	 cells	 (n=3).	 (D)	 Chromatin	 Immunoprecipitation	 for	 H3K27me3	
followed	by	quantitative	PCR	(ChIP-qPCR)	in	NC	progenitors	derived	at	day	7	from	ASXL1PSC/PSC	and	
control	lines.	The	ACTB	and	HOXB2	 loci	were	used	as	positive	and	negative	controls	for	H3K27me3,	
respectively	(n=3-7	from	independent	experiments;	*p<0.05,	**p<0.01;	ns,	not	significant;	Welch’s	t-
test/Wilcoxon	test).	(E)	ChIP-qPCR	occupancy	analysis	of	H3K27me3	at	the	FOXP2	gene	in	day	7	NC	
progenitors	of	ASXL1PSC/PSC	and	control	HESCs	(n=3-7	from	independent	experiments,	Welch’s	t-test).	
(F)	ChIP-seq	data	from	the	ENCODE	project200,	showing	binding	of	EZH2	to	the	ZIC1/ZIC4	locus	in	H1	
hESC.	
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3.5	Characterization	of	Asxl	genes	in	two	animal	models	
In	 addition	 to	 characterization	 of	 pathological	 ASXL1	 variants	 in	 human	
differentiation	 systems,	 I	 set	 out	 to	 investigate	 whether	 these	 findings	 have	
relevance	for	tissue	formation	in	vivo.		To	this	end,	I	established	and	analyzed	mouse	
and	 zebrafish	 models	 for	 (truncated)	 Asxl	 function	 in	 embryogenesis	 and	 fetal	
development.		
	
3.5.1	Asxl1	is	involved	in	mouse	neuroectoderm	development	
My	transcriptional	analyses	in	human	developmental	progenitors	implicated	ASXL1	
in	the	formation	of	embryonic	lineages,	in	particular	the	neural	crest	and	neuronal	
lineages.	To	corroborate	these	findings,	I	made	use	of	the	Asxl1tm1a(EUCOMM)Wtsi	mouse	
strain	bearing	a	LacZ-Neomycin	reporter	cassette	in	the	Asxl1	locus,	which	results	in	
functional	 loss	 of	 one	 gene	 copy	 in	 heterozygous	 animals,	 but	 enables	 tracing	 of	
Asxl1	expression235.	This	mouse	 line	has	been	studied	by	McGinley	and	colleagues	
on	a	C57BL/6NTac	background107.		In	my	case,	the	line	was	generated	by	injection	of	
mouse	 ESC	 line	 EPD0080_1_B11	 (obtained	 from	 the	 EuMMCR	 at	 the	 Helmholtz	
Center	Munich)	 into	Balb/c	embryos	(T.-W.	Qiao	and	Dr.	Pertek,	Helmholtz	Center	
Munich),	 followed	 by	 breeding	 of	 F1	 chimeras	 to	 C57BL/6NCrl	 wt	 mice.	 Further	
backbreeding	 of	 heterozygous	 carrier	mice,	 as	 determined	 by	 PCR	 genotyping	 for	
each	 generation,	 to	 C57BL/6NCrl	 wt	 mice	 was	 performed	 for	 ten	 generations	 to	
ensure	generation	of	congenic	animals203.		
Initially	 in	 backcrossing	 generation	 N5	 and	 in	 further	 generations,	 I	 noticed	
phenotypic	changes	at	variable,	but	generally	low	penetrance	in	Asxl1+/-	pups,	which	
occasionally	 presented	 reduced	 birth	 weight	 and	 size	 (Fig.	 33A),	 as	 well	 as	
unilateral	 or	 bilateral	 cataracts,	 microphthalmia	 or	 anaphthalmia	 (Fig.	 33B).	
Reduced	or	missing	eyes	and	growth	defects	have	been	described	in	the	present	and	
other	 Asxl1	 knockout	 lines	 of	 different	 backgrounds,	 but	 commonly	 only	 in	
homozygous	 animals100,107,116.	 Otherwise,	 behavior	 of	 affected	 Asxl1+/-	 pups	 was	
normal,	 they	were	thriving	well	and	around	postnatal	day	P20,	heterozygous	mice	
born	at	half	of	 their	 littermates’	size	became	indistinguishable	 from	their	wildtype	
siblings.		
I	analyzed	Asxl1+/-	embryos	at	embryonic	days	E11.5	and	E14.5	after	X-gal	staining	
to	 determine	 expression	 of	 the	 β-Galactosidase	 gene	 within	 the	 Asxl1	 locus.	 This	
reaffirmed	Asxl1	 expression	 in	 neuroectodermal	 tissues	 including	 brain,	 eyes	 and	
the	 closing	 neural	 tube,	 as	 well	 as	 in	 the	 heart,	 limbs,	 hair	 follicles,	 ears	 and	
pharyngeal	arches	as	reported	before115,116	(Fig.	33C).	Staining	of	the	closing	neural	
tube	and	pharyngeal	arches	indicated	expression	of	Asxl1	in	the	NC	and	NC-derived	
tissues,	 which	 corresponded	 to	 the	 craniofacial	 features	 reported	 in	 homozygous	
Asxl1	null	mice100	(Fig.	33C).		
Overall,	 the	 Asxl1-LacZ	 Knock-in	 mouse	 proved	 useful	 to	 delineate	 presumptive	
functions	 for	Asxl1	 in	 NC	 and	 neuroectoderm	 development,	which	 I	 inferred	 here	
from	embryonic	expression	patterns.	With	regard	to	the	craniofacial	and	ophthalmic	
features	that	are	reported	in	BOS	patients137,	this	should	provide	critical	clues	to	the	
clarification	of	BOS	pathogenesis.	
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Figure	33.	Murine	Asxl1	is	expressed	in	neuro-ectodermal	lineages	and	involved	in	eye	formation	in	
mice.		
(A-C)	Analysis	of	 the	Asxl1tm1a(EUCOMM)Wtsi	mouse	strain	 that	carries	a	 lacZ	reporter	knocked	 into	 the	
Asxl1	 locus.	(A)	Asxl1+/-	and	Asxl1+/+	(wt)	 littermates	 (P15).	(B)	Asxl1+/-	mice	display	 cataracts	 (left)	
and	 unilateral	 and	 bilateral	microphthalmia	 (middle	 and	 right).	 (C)	 LacZ	 staining	 in	whole-mount	
Asxl1+/-	and	wt	embryos	of	embryonic	day	E11.5.	Asxl1	is	highly	expressed	in	the	closing	neural	tube	
and	brain	and	also	detected	in	limb	buds	and	pharyngeal	arches.	
	
	
3.5.2	Identification	and	analysis	of	zebrafish	asxl1	and	asxl2	genes	
Owing	 to	 the	 ease	 of	 manipulation	 and	 analysis	 of	 transparent	 embryos,	 the	
zebrafish	(Danio	rerio)	belongs	to	the	preferred	biomedical	model	organisms,	and	is	
widely	used	to	 investigate	mechanisms	of	embryonic	morphogenesis,	 including	NC	
formation	 and	migration236.	Hence,	 in	 collaboration	with	Dr.	 López-Schier	 and	Dr.	
Viader	 Llargues	 (Helmholtz	 Center	 Munich),	 I	 sought	 to	 identify	 hitherto	
uncharacterized	 Asxl	 homologs	 in	 the	 zebrafish	 and	 establish	 a	 disease-relevant	
system	to	analyze	the	potentially	conserved	function	of	truncated	ASXL	variants.	
	
3.5.2.1	asxl1	and	asxl2	are	expressed	during	zebrafish	larvae	development	
Analysis	 of	 public	 databases	 revealed	 homology-based	 prediction	 of	 two	 ASX	
orthologs	 in	 the	 zebrafish	 genome,	 asxl1	 and	 asxl2	 (Fig.	 34A).	 Interestingly,	 the	
evolutionary	 history	 of	 ASX	 genes	 suggests	 that	 the	 teleost	 fish,	 including	 the	
zebrafish,	 lost	 the	 Asxl3	 paralog	 that	 presumably	 resulted	 from	 speciation	 of	 a	
theoretical	Asxl1/Asxl3	precursor	gene	and	 is	still	 found	 in	 the	spotted	gar,	a	 ray-
finned	fish	that	split	off	from	the	teleost	fish	branch237	(Fig.	34A).		
	
	
Asxl1
+/- 
Asxl1
+/+ 
A 
C 
B 
Asxl1
+/+ Asxl1+/- 
	 	
	 	 	
3. Results 
101	
	
	
Figure	34.	Zebrafish	ASX	homologs	asxl1	and	asxl2	are	expressed	in	embryos	and	larvae.		
(A)	Gene/protein	tree	representing	the	evolutionary	history	of	Asx	and	orthologous	genes.	Predicted	
zebrafish	asxl1	and	asxl2	genes	are	shown	in	red.	Red	nodes	indicate	duplication	events;	blue	nodes	
represent	 speciation	 towards	 paralogs	 and	 orthologs.	 From238.	 (B)	 Predicted	 zebrafish	 asxl1	 and	
asxl2	proteins	(UniProt	Q6P6X8	and	E7FG88)	show	conservation	of	domains	HARE-HTH,	ASXH	and	
PHD.		(C)	Expression	of	asxl1	and	asxl2	in	wildtype	zebrafish	embryos	6	hours	post	fertilization	(hpf)	
and	1-3	days	post	fertilization	(dpf)	as	determined	by	RT-PCR.	Predicted	transcript	sizes	are	given;	
two	transcripts	were	detected	for	asxl1	(arrows).	Gapdh,	normalization	control;	M,	molecular	marker.	
(D)	Identification	of	a	novel,	alternatively	spliced	exon	between	annotated	exons	7	and	8	of	zebrafish	
asxl1	confirmed	by	sequencing	of	asxl1	transcripts	from	(C).	(E)	qPCR	analysis	of	zebrafish	asxl1	and	
asxl2	 during	 embryo	and	 larvae	development;	 normalization	using	elongation	factor	1	alpha	 (elfa);	
n=3.	
	
I	conducted	BLAST	search	of	the	asxl1/2	sequences,	which	indicated	that	despite	the	
genome	duplication	event	in	teleost	fish239,	the	asxl1	and	asxl2	loci	are	not	present	in	
duplicated	 form.	 Predicted	 protein	 sequences	 harbor	 the	 conserved	 HARE-HTH,	
ASXH	and	PHD	sequences	(UniProt	 ID	F1Q5H5	and	E7FG88),	and	the	total	protein	
identity	 between	 human	 and	 zebrafish	 orthologs	 is	 39%	 and	 52%	 for	 asxl1	 and	
asxl2,	 respectively	 (Fig.	 34B).	 I	 furthermore	 identified	putative	NR-binding	motifs	
(LVTQLL)	 in	 translations	 of	 both	 sequences,	 indicating	 that	 the	 ASXM2	 domain	 is	
retained	in	the	zebrafish	homologs	as	well.		
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	To	 identify	 whether	 the	 genes	 are	 transcribed,	 I	 performed	 RT-PCR	 in	 samples	
isolated	at	different	 stages	of	embryonic	 zebrafish,	which	confirmed	expression	of	
asxl1	and	asxl2	from	6	hours	post	fertilization	(hpf)	to	3	days	post	fertilization	(dpf;	
Fig.	 34C).	 I	 detected	 two	 asxl1	 transcripts	 at	 all	 analyzed	 stages,	 and	 sequencing	
confirmed	an	alternatively	spliced,	novel	exon	of	120	bp	between	annotated	exons	7	
and	 8	 (asxl1	 transcript	 XM_001341206.5,	 NCBI	 Reference	 sequence;	Fig.	 34C,	 D).	
Asxl1	and	asxl2	 transcripts	showed	a	highly	similar,	dynamic	expression	pattern	in	
zebrafish	embryos,	with	strong	decline	from	3	hpf	to	1-2	dpf,	 followed	by	a	steady	
increase	in	asxl2	levels	while	asxl1	transcript	levels	remained	constant	(Fig.	34D).		
To	analyze	the	expression	pattern	 in	embryonic	 tissues,	 I	performed	whole-mount	
in	situ	hybridization	using	sense	and	antisense	mRNA	probes	constructed	from	asxl2	
and	 asxl1	 transcripts.	 Asxl1	 mRNA	 was	 detected	 in	 6	 hpf	 embryos,	 in	 brain	
structures	and	pectoral	 fin	buds	of	36	hpf	 embryos,	 and	eyes	and	otic	 capsules	 at	
48	hpf		(Fig.	35A).	Similarly,	I	detected	Asxl2	expression	in	the	otic	capsule	and	the	
eye,	albeit	at	 low	levels,	 in	48	hpf	embryos	(Fig.	 35B).	Notably,	similar	expression	
patterns	were	detected	using	two	different	probes	of	each	asxl1	(one	including	the	
novel	exon)	and	asxl2.	
	
								 	
	
Figure	35.	Expression	patterns	of	asxl1	and	asxl2	in	zebrafish	embryos.		
(A,	 B)	 RNA	 in	 situ	 hybridization	 of	 whole-mount	 zebrafish	 embryos	 at	 different	
developmental	stages	with	asxl1	(A)	and	asxl2	(B)	sense	(negative	control)	and	antisense	
probes	 shows	 labeling	 of	 the	 pectoral	 fin	 buds	 (red	 arrow),	 brain	 structures	 (red	
arrowhead),	the	otic	capsules,	i.e.	the	developing	inner	ear	(black	arrows)	and	the	retina	
(black	arrowhead).		
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3.5.2.2	Manipulation	of	zebrafish	asxl1	
In	 an	 attempt	 to	 generate	 a	 BOS-relevant	 in	 vivo	 disease	 model,	 I	 employed	 the	
CRISPR/Cas	technique	to	induce	mutations	within	the	central	region	of	the	zebrafish	
asxl1	locus,	corresponding	to	the	mutated	alleles	in	BOS	patients.		Genome	editing	in	
zebrafish	 requires	 injection	 of	 the	 Cas9	 mRNA	 and	 the	 targeting	 gRNAs	 into	
embryos	 at	 the	1-cell	 stage	 	 (Fig.	 36A).	 To	 optimize	 editing	 efficiency,	 I	 validated	
two	injection	protocols207,208	by	targeting	the	albino	gene	slc34a2,	and	one	injection	
method	gave	rise	to	embryos	and	larvae	with	disrupted	pigmentation	(Fig.	36B).	I	
followed	 this	method	 for	 injection	of	a	gRNA	against	 the	asxl1	 locus,	 targeting	 the	
region	 around	 bp	 2120	 of	 the	 4980	 bp	 transcript.	 Analysis	 of	 F1	 and	 F2	 progeny	
revealed	at	 least	9	different	 types	of	mutations	 that	had	been	produced,	 including	
deletions,	 insertions	 and	 base	 conversions	 (Fig.	 36A,C).	 All	 of	 the	 mutations	
furthermore	 resulted	 in	 PSCs	 that	 predicted	 expression	 of	 truncated	 protein	 in	
mutated	 fish.	Offspring	of	heterozygous	F1	crossings	showed	variable	phenotypes,	
and	mainly	 comprised	 pericardial	 and	 yolk	 sac	 edemas	 and	 caudal	 truncations	 to	
varying	 degrees,	 from	 slightly	 shortened	 or	 bend	 fish	 to	 runts	 (Fig.	 36D).	 These	
malformations	 were	 also	 observed	 in	 around	 50%	 of	 ‘wildtype’	 fish	 not	 bearing	
targeted	mutations	in	asxl1,	indicating	that	these	might	be	unspecific	developmental	
defects	 (Fig.	 36E);	 however,	 I	 did	 not	 exclude	 off-target	 effects	 in	 the	 phenotypic	
putative	wt	fish.	Moreover,	all	of	the	larvae	bearing	mutations	were	associated	with	
phenotypes	at	80	%	to	100	%	penetrance,	and	the	combined	presence	of	edema	and	
truncated	tail	was	only	found	in	confirmed	mutant	fish	(Fig.	36E).		
Taken	 together,	 I	verified	expression	of	asxl1	 and	asxl2	homologs	 in	 the	zebrafish,	
and	the	establishment	of	mutant	asxl1	lines	can	serve	as	a	tool	fur	future	studies	on	
the	conservation	of	functional	roles	for	BOS-relevant	mutations	in	embryogenesis.	
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Figure	36.	Generation	of	zebrafish	asxl1	mutants	via	CRISPR/Cas	genome	editing.		
(A)	 Scheme	 of	 CRISPR/Cas	 editing	 and	 breeding	 procedure.	 Injection	 of	 Cas9	 mRNA	 and	 asxl1-
targeting	gRNA	 into	1-cell	 stage	embryos	 leads	 to	 the	development	of	chimeric	 founder	 fish.	These	
are	crossed	to	wt	fish	to	generate	heterozygous	F1	progeny,	which	after	genotyping	can	be	inbred	to	
generate	 heterozygous	 and	 homozygous	 F2	 fish	 for	 phenotypic	 analysis.	 (B)	 Validation	 of	 CRISPR	
editing	 protocols	 via	 generation	 of	 albino	 mutants;	 shown	 are	 founder	 fish	 (larval	 stage).	 Two	
different	 protocols	 (HW	 and	 HR)	 were	 followed	 to	 inject	 two	 different	 gRNAs	 (A	 or	 B),	 targeted	
against	 tthe	 slc45a2	 (albino)	 gene240.	 Note	 reduced	 pigmentation	 in	 the	 eye	 (magnified	 image),	
indicating	 successful	 targeting	 of	 the	 slc45a2	 gene.	 	 (C)	 CRISPR-mediated	 target	 mutations	 as	
determined	 by	 sequencing	 of	 the	 asxl1	 locus	 in	 F1/F2	 fish.	 1	 represents	 the	 wildtype	 sequence,	
numbers	 2-10	 label	 different	 mutations	 including	 conversion	 of	 bases	 (red	 bases),	 deletions	 (red	
dashes)	and	 insertions	 (underscored).	The	 targeting	site	of	 the	asxl1	 gRNA	(yellow)	used	 to	 create	
these	mutations	is	indicated,	as	well	as	the	Protospacer	Adjacent	Motif	(PAM,	blue).	(D,	E)	Exemplary	
images	 of	 phenotypes	 observed	 in	 F2	 asxl1	 mutants	 (D)	 and	 their	 quantification	 according	 to	 the	
associated	 mutation	 (E).	 Mutation	 numbers	 refer	 to	 (C);	 numbers	 in	 parentheses	 indicate	 the	
number	of	analyzed	fish.	‘No	target	mutation’	indicates	that	no	mutations	were	found	in	the	analyzed	
region	of	the	asxl1	locus.	Predicted	asxl1	protein	sizes	were	calculated	from	the	location	and	type	of	
mutation	that	was	identified	in	the	respective	fishes.	
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4.	Discussion	
4.1.	 Human	 ASXL	 paralogs	 are	 differentially	 expressed	 during	 hESC	
differentiation	
The	 ASXL	 family	 is	 a	 versatile	 group	 of	 homologous	 proteins	 that	 appear	 to	 serve	 as	
epigenetic	 platforms:	 owing	 to	 a	 multi-domain	 structure,	 they	 associate	 with	
transcription	 factors	 and	 chromatin	 modifiers	 at	 target	 gene	 sites,	 presumably	
conferring	 specificity	 to	 Polycomb-associated	 regulatory	 mechanisms77,241.	
Developmental	roles	of	ASXL	genes	in	spatiotemporal	gene	control,	best	documented	for	
the	Hox	 loci,	were	 reported	 in	 animal	models	 and	 in	 studies	 employing	 cell	 lines	 and	
tissue	 progenitors81,96,99,100,103,106,107,116,242,243.	 This	 work	 is	 to	 my	 knowledge	 the	 first	
study	to	investigate	and	discuss	roles	of	the	ASXL	genes	during	differentiation	of	human	
pluripotent	stem	cells,	in	particular	for	a	pathological	variant	of	ASXL1	that	is	connected	
to	congenital	birth	defects.		
I	initially	found	that	human	ASXL1-3	genes	exhibit	distinct	expression	patterns	in	hESC	
differentiation.	 ASXL1/2	 are	 expressed	 in	 undifferentiated	 cells	 and	 are	 rapidly	
upregulated	 in	 response	 to	 differentiation	 cues	 (Fig.	 9C),	 mirroring	 the	 induction	
pattern	of	Asxl1	during	in	vitro	differentiation	from	mouse	ESC244	and	the	expression	of	
murine	Asxl1/2	 during	 early	 stages	 of	 embryogenesis115,	which	 suggests	 similar	 early	
roles	in	human	development.	Also	corresponding	to	mouse	development115,	ASXL3	is	not	
significantly	expressed	in	undifferentiated	cells	and	becomes	(slightly)	activated	only	at	
late	stages	of	neuronal	differentiation	(Fig.	9E).	The	presence	of	an	alternatively	spliced	
exon	 in	ASXL3,	which	 harbors	 STOP	 codons	 in	 all	 reading	 frames	 and	 is	 degraded	 via	
NMD,	was	reported	recently1.	 I	also	detected	the	presence	of	 the	 ‘NMD-exon’	 in	ASXL3	
transcripts	 isolated	 from	 hESCs	 (Supplementary	 Fig.	 S2),	 indicating	 that	 this	
posttranscriptional	mechanism	is	involved	in	regulating	ASXL3	expression1.	
The	presence	of	both	repressive	and	activating	chromatin	marks	on	ASXL1/ASXL3	TSSs	
suggests	 a	 bivalent	 condition	 in	 the	 pluripotent	 state,	 however	 this	 should	 be	
interpreted	 with	 caution	 because	 ASXL1	 is	 detected	 at	 significant	 levels	 in	
undifferentiated	cells	(Fig.	9A,B).	Therefore,	rather	than	bivalency,	heterogeneity	in	the	
culture	 might	 explain	 the	 co-localization	 of	 H3K4me3	 and	 H3K27me3	 marks	 in	 the	
ASXL1	locus	better.	This	is	supported	by	the	fact	that	in	undifferentiated	cells,	ASXL1	is	
expressed	 at	 different	 levels	 also	 depending	 on	 confluency	 and	 cultivation	 time	 (Figs.	
17,	18).	With	regard	to	ASXL3,	the	hypothesis	of	this	gene	being	poised	is	more	likely,	as	
it	 is	 not	 expressed	 in	 undifferentiated	 cells	 and	 becomes	 activated	 in	 specific	
developmental	 lineages	 (NC	 and	 neuronal	 differentiation).	 Silencing	 in	 other	
developmental	states,	including	hematopoietic	cells120	(H3K27	trimethylation	of	the	TSS	
in	a	lymphoblast	cell	 line200)	also	supports	this	notion.	ASXL2	however	appears	to	be	a	
‘epigenetic	 housekeeping	 factor’	 based	 on	 its	 constant	 expression	 and	 H3K4	
trimethylated	state	in	the	analyzed	lines.	Indeed	it	has	been	postulated	that	Asxl2	might	
be	 more	 important	 for	 the	 maintenance	 of	 histone	 marks	 than	 for	 their	 initial	
placement106.	
The	 diverged	 functions	 of	ASXL1/ASXL3	 and	ASXL2	 is	 also	 supported	 by	 their	 distinct	
expression	patterns;	while	ASXL1/3	 is	upregulated	during	fetal	brain	development	and	
neuronal	differentiation	in	vitro,	ASXL2	is	constantly	expressed	at	low	to	moderate	levels	
in	 the	 CNS	 or	 in	 neuronal	 progenitors	 (Fig.	 9E,	 F).	 Moreover,	 de	 novo	 mutations	 in	
ASXL1/3	 or	 ASXL2	 lead	 to	 distinct	 brain	 abnormalities	 including	 macrocephaly	 or	
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microcephaly,	 respectively137.	 Finally,	 the	 proposed	 evolutionary	 history	 of	ASX	 genes	
involves	early	separation	of	putative	ASXL2	and	ASXL1/ASXL3	precursor	proteins	(Fig.	
34A).	This	is	reflected	for	instance	in	the	shared	HP1	binding	motif	in	ASXL1/3,	which	is	
absent	 in	 ASXL2,	 and	 the	 corresponding	 repressive	 roles	 of	 the	 former	 proteins	 in	
chromatin	 regulation95,97.	 Taken	 together,	 this	 brings	 me	 to	 conclude	 specific	 versus	
redundant	 roles	of	 the	ASXL	 paralogs	 in	maintenance	of	human	pluripotent	 stem	cells	
and	differentiation.	
	
4.2	Generation	of	human	developmental	models	for	BOS		
The	concurrence	of	phenotypically	overlapping	congenital	defects,	caused	by	mutations	
that	 are	 all	 located	 in	 the	 penultimate	 or	 last	 exon	 of	 paralogous	 genes,	 raises	 the	
question	 of	 common	 pathogenic	 mechanisms	 and	 developmental	 pathways	 in	 ASXL-
associated	 disorders.	 The	 elucidation	 of	 molecular	 mechanisms	 underlying	 BOS	 is	 of	
particular	 interest:	 firstly,	 truncating	mutations	 in	ASXL1	 are	very	common	 in	myeloid	
transformations	as	well	(for	instance,	in	50%	of	myelomonocytic	leukemia	cases245),	and	
secondly,	ASXL1	is	involved	in	the	function	of	important	epigenetic	complexes,	including	
PR-DUB	and	PRC279,	and	their	roles	in	human	embryonic	development	are	not	clear	yet.	
To	address	 this	question,	 I	generated	a	 toolset	 that	enabled	me	to	examine	 the	role	of	
BOS	 mutations	 in	 pluripotent	 stem	 cells	 and	 progenitor	 commitment.	 Importantly,	 I	
relied	on	using	iPSCs	derived	by	two	different	integration-free	reprogramming	methods	
per	 line	 to	 obtain	 BOS-iPSC	 clones,	 allowing	 for	 the	 subtraction	 of	 potential	 method-
related	effects.	Moreover,	 this	provided	a	measure	 to	 reduce	artifacts	 that	are	derived	
from	 cell	 line	 variability,	 which	 was	 indeed	 observed	 in	 transcriptional	 analysis	 of	
undifferentiated	BOS-iPSCs	(Figs.	10C,	15,	17A)	and	their	sphere	attachment	properties	
(Fig.	 23B).	 I	 postulate	 that	 several	 factors	 might	 contribute	 to	 these	 inconsistencies,	
including	 i)	 donor-specific	 genetic	 polymorphisms	 that	 are	 unrelated	 to	 the	 disease-
causing	 mutations,	 ii)	 genetic/epigenetic	 aberrations	 that	 can	 be	 introduced	 in	
reprogramming,	and	iii)	unknown	functions	of	ASXL1	during	somatic	reprogramming,	a	
process	relying	on	alteration	of	the	chromatin	landscapes246.	Nevertheless,	phenotypes	
including	 ASXL1	 protein	 regulation	 and	 the	 general	 defect	 in	 NC	 differentiation	were	
consistent	across	the	clones,	showing	that	my	approach	provided	me	a	way	to	subtract	
line-specific	artifacts.	
Due	to	these	issues,	I	have	generated	a	system	of	isogenic	cell	lines,	a	concept	that	was	
shown	 to	 lower	 clone-specific	 confounding	 effects	 in	 studying	 disease-related	
phenotypes	 in	 iPSC	 and	 hESCs247,248.	 In	 accordance,	 isogenic	 ASXL1PSC/PSC	 hESC	 lines	
exhibited	 little	 clonal	 variability	 (Fig.	 17C,	 Fig.	 23A),	 arguing	 for	 their	 application	 to	
study	 the	molecular	 pathogenesis	 of	 BOS.	 Although	 I	 did	 not	 analyze	 the	 CRISPR/Cas	
targeted	hESC	clones	for	potential	off-target	effects,	careful	selection	of	gRNAs	and	most	
importantly	 the	 inclusion	 of	 several	 clones	 in	 the	majority	 of	my	 experiments	 should	
decrease	 the	 influence	of	potential	off-target	effects	 to	a	minimum249,250.	 I	had	 initially	
attempted	to	generate	ASXL1PSC/+	lines	to	faithfully	model	the	situation	in	BOS	patients;	
the	unambiguous	 identification	of	heterozyous	 clones	was	however	not	 feasible,	 and	 I	
therefore	concentrated	my	analyses	on	homozygous	ASXL1PSC/PSC	clones.	The	phenotypes	
uniformly	seen	in	all	of	these	clones	should	thus	exclusively	be	connected	to	the	function	
of	putative	 truncated	ASXL1	protein.	Moreover,	 the	possibility	of	 interactions	between	
truncated	and	full-length	ASXL1	is	eliminated	in	ASXL1PSC/PSC	lines,	meaning	they	cannot	
fully	recapitulate	mechanisms	in	BOS-iPSC.	However,	I	conducted	additional	analyses	in	
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PB-ASXL1PSC	 hESC,	 which	 constitute	 an	 aggravated	 ‘heterozygous’	 BOS	 model	 due	 to	
strong	overexpression	of	a	truncated	ASXL1	variant	on	a	wildtype	background.		
The	 overexpression	 line	 furthermore	 allowed	 to	 validate	 monoclonal	 antibodies	 that	
detect	 the	N-terminus	of	ASXL1.	Despite	 that	 the	novel	 antibody	clones	4F6	and	12F9	
were	 selected	 in	 binding	 assays	 also	 based	 on	 negative	 reaction	 towards	 N-terminal	
ASXL2	peptides,	detection	of	additional	bands	and	most	importantly	the	constant	band	
detected	 at	~170	 kDa	 (also	 in	 the	ASXL1PSC/PSC	 cell	 lines)	 suggests	 that	 the	 antibodies	
recognized	ASXL	isoforms	or	paralogs.	I	attempted	to	examine	the	possibility	of	ASXL2	
recognition	 by	 generating	 a	 double	 ASXL1PSC/PSC/ASXL2PSC/PSC	 line	 or	 alternatively	 via	
knocking	down	ASXL2	 in	ASXL1PSC/PSC,	 but	 these	 attempts	were	not	 yet	 unsuccessful.	 I	
presume	 that	 I	 was	 unable	 to	 derive	 compound	 clones	 because	 of	 crucial	 functional	
redundancy,	as	both	ASXL1	and	ASXL2	are	required	to	maintain	the	PR-DUB	complex111	
and	also	indicated	by	the	number	of	shared	target	genes	in	pre-adipocyte	cells95.	In	line	
with	 this	 rational,	 ASXL1	 and	 ASXL2	 mutations	 never	 coincide	 in	 human	 cancers,	
whereas	ASXL1	and	ASXL3	mutations	are	found	in	combination251.	Hence,	this	suggests	
that	hESCs	might	not	be	able	to	cope	with	concomitant	loss	of	ASXL1	and	ASXL2.	
The	novel	antibody	detected	additional	bands	of	70	kDa,	130	kDa	and	above	300	kDa	at	
different	levels	in	wildtype	and	mutant	cells	(Fig.	13D,	E	and	Supplementary	Fig.	S1).	
Notably,	Inoue	et	al	mentioned	similar	backgrounds	when	using	antibodies	targeting	the	
N-terminus	 of	 ASXL1	 in	 heterozygous	 ASXL1	 mutant	 lines101,126,	 which	 implies	 that	
sequence	 homology	 to	 other	 proteins	 can	 impede	 the	 specific	 detection	 of	N-terminal	
ASXL1	variants.	It	is	unlikely	for	ASXL3	with	its	predicted	molecular	weight	of	240	kDa	
to	 have	 produced	 bands	 at	 300	 kDa,	 considering	 that	 it	 was	 nearly	 undetected	 in	
undifferentiated	 hESCs.	 Nevertheless,	 I	 propose	 that	 the	 70	kDa	 and	 130	 kDa	 bands	
represent	 ASXL	 isoforms	 based	 on	 the	 dynamic	 regulation	 of	 these	 genes	 that	 is	
dependent	on	the	presence	of	specific	ASXL1	mutations	and	cell	density,	and	reports	of	
alternative	splicing	and	usage	of	different	polyadenylation	sites	in	ASXL	transcripts80,81.	
Furthermore,	 when	 I	 performed	 initial	 immunoprecipitation	 experiments	 to	 identify	
interactions	of	overexpressed	ASXL1	constructs	and	EZH2	in	PB-ASXL1PSC	cells,	targeting	
of	 EZH2	 led	 to	 enrichment	 of	 a	 70	 kDa	protein,	 indicating	 an	 interaction	with	 a	 short	
isoform	 of	 ASXL1	 in	 these	 preliminary	 experiments	 (Supplementary	 Fig.	 S3).	
Proteomic	 analysis	 of	 candidate	 isoforms	 could	 clarify	 this	 issue	 and	 provide	 new	
insights	 into	 the	 complex	 regulation	 of	 ASXL	 proteins	 in	 human	 pluripotent	 stem	 cell	
differentiation	 and	 disease.	 Interestingly,	 a	 recent	 study	 predicted	 the	 generation	 of	
conserved	 ASXL1	 and	 ASXL2	 variants	 of	 77	kDa	 and	 89	kDa,	 respectively,	 that	 result	
from	 ribosomal	 frameshifting	 events,	 connecting	 the	 N-terminal	 ASXN	 and	 ASXH	
domains	to	transframe	products252.	However,	ribosomal	frameshifting	is	though	to	occur	
only	in	1-2	%	of	transcripts252,	which	renders	detection	via	Western	Blot	highly	unlikely,	
unless	these	proteins	are	highly	stabile.	
ASXL1	 proteins	 contain	 motifs	 allowing	 for	 nuclear	 transportation,	 and	
immunocytochemical	 analyses	 in	 this	 and	 other	 studies	 suggest	 mainly	 nuclear	
localization	 of	 ASXL1101,111,253,	 but	 also	 faint	 cytoplasmatic	 detection	 (Figs.	 12G	 and	
22B),	 which	 is	 in	 line	 with	 suggested	 functions	 of	 Asxl1	 in	 the	 cytoplasma254	 and	
presence	of	Drosphila	Asx	in	both	nuclei	and	cytoplasm78.	
In	all,	I	have	generated	a	novel	monoclonal	antibody	targeting	the	N-terminus	of	human	
ASXL1,	 and	 a	 set	 of	 BOS	 pluripotent	 stem	 cell	models.	 These	 include	 disease-relevant	
lines	with	presumed	physiological	expression	of	mutant	ASXL1	proteins	(BOS-iPSC),	an	
‘enhanced’	model	for	analyzing	the	dominant	function	of	truncated	ASXL1	(PB-ASXL1PSC)	
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and	 an	 isogenic	model	 system	 that	 focuses	 on	 the	 isolated	 function	 of	BOS-associated	
mutations	(ASXL1PSC/PSC	hESC).		
	
4.3	BOS-associated	mutations	in	ASXL1	lead	to	expression	of	truncated	
protein	
The	 implementation	 of	 BOS	 model	 lines	 in	 combination	 with	 a	 monoclonal	 antibody	
confirmed	 the	 stable	 expression	 of	 truncated	 ASXL1	 variants	 in	 undifferentiated	
ASXL1PSC/PSC	hESC	and	importantly	also	in	BOS-iPSCs	(Fig.	13).	This	was	already	hinted	
by	 the	 detection	 of	 mutant	 ASXL1	 transcripts,	 which	 escaped	 NMD	 as	 I	 predicted	
according	 to	 the	 location	 of	 the	 mutation	 within	 the	 large	 terminal	 exon255.	 Similar	
mechanisms	have	been	proposed	for	ASXL1-associated	mutations	in	leukemias101,126-128,	
and	for	ASXL2	mutations	causing	a	novel	neurodevelopmental	syndrome139.	Decreased	
ASXL3	 transcript	 and	 protein	 levels	 were	 observed	 in	 one	 BRS	 patient;	 however,	
degradation	via	NMD	was	not	assessed	in	the	corresponding	study112.		
Evolutionary	 conserved	 features	 that	 characterize	 ASXL	 proteins	 are	 the	 N-terminal	
HARE-HTH	 motif	 and	 ASX-H	 domain	 and	 the	 C-terminal	 PHD	 finger.	 Comparison	
between	homologs	 indicates	 lower	 conservation	of	 the	 central	part	of	 the	protein	and	
high	conservation	of	the	N-	and	C-terminus,	illustrating	the	functional	importance	of	the	
domains115.	 Since	 the	 ASX-H	 domain	 mediates	 binding	 to	 BAP1/calypso	 and	 is	 also	
present	 in	 Asx,	 it	 appears	 that	 activity	 in	 the	 PR-DUB	 complex	 is	 one	 of	 the	 most	
fundamental	 tasks	 of	 ASX	 orthologs	 besides	 PcG/TrxG	 mediated	 gene	 regulation75,79.	
Concerning	the	PHD	finger,	exact	mechanisms	are	less	well	understood.	It	encompasses	
one	part	of	the	bipartite	SET-domain	binding	motif	in	Drosophila	Asx75,	and	it	would	be	
of	 interest	 to	 determine	whether	 these	 dual	 binding	motifs,	 enabling	 interaction	with	
both	 PcG	 and	 TrxG	 proteins,	 are	 also	 found	 in	 the	 human	 protein.	 However	 arguing	
against	this	possibility,	one	study	showed	that	truncated	ASXL1	can	still	bind	to	EZH2101.	
PHD	domains	confer	the	ability	to	bind	modified	histones83,	thus	serving	as	‘readers’	of	
epigenetic	 states,	 and	 mutations	 within	 PHD	 fingers	 are	 involved	 in	 various	 human	
diseases256.	 Structural	 properties	 of	 ASXL	 PHD	 fingers	 theoretically	 allow	 binding	 of	
internally	 methylated	 histone	 tails	 such	 as	 H3K27me383,	 which	 offers	 an	 attractive	
model	 concerning	 how	ASXLs	 could	 be	 involved	 in	 fine-tuning	H3K27me3	deposition.	
Pathogenic	 truncations	 within	 the	 ASXL1	 protein	 thus	 uncouple	 the	 modules	
responsible	 for	 hypothetical	 DNA	 targeting	 (the	 HARE-HTH	 domain)	 and	 chromatin	
modification	(via	co-factors)	from	the	chromatin	reading	module.	Accordingly,	it	would	
be	 of	 particular	 interest	 to	 compare	 the	 binding	 capacities	 of	wildtype	 and	 truncated	
ASXL1	protein,	for	instance	in	mononucleosome	binding	assays257,258,	to	determine	how	
loss	of	the	PHD	domain	affects	ASXL1	function.		
Interestingly,	Asx	frameshift	mutants	in	the	fruit	fly	also	lead	to	expression	of	truncated	
Asx	 protein	 (aa	 1-432)	 at	 levels	 comparable	 to	 the	 wildtype	 protein	 (1669	 aa)105.	 In	
general,	 truncated	 Asx	 mutants	 had	 a	 stronger	 phenotype	 in	 de-repression	 of	 target	
genes	 than	 deletion	 of	 the	 entire	 Asx	 locus73.	 This	 indicates	 a	 gain-of-function	 of	 the	
truncated	protein,	and	supports	the	notion	of	a	comparable	dominant	ASXL1PSC	function	
in	mammalian	developmental	contexts.		
Truncated	ASXL1	proteins	retain	PEST	sequences	and	the	ubiqutination	site	at	K351,	all	
of	 which	 promote	 proteolytic	 degradation.	 I	 generally	 observed	 lower	 levels	 of	
truncated	 ASXL1	 compared	 to	 wildtype	 protein,	 and	 the	 difficulties	 I	 and	 others	
encountered	 while	 attempting	 to	 detect	 the	 truncated	 variants101	 might	 stem	 from	
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enhanced	 degradation	 of	 the	 mutant	 variant,	 which	 could	 furthermore	 explain	 why	
truncated	ASXL1	variants	were	not	found	in	other	studies99,125.		
Taken	together,	with	increasing	evidence	leading	to	the	general	consensus	on	a	gain-of-
function	 of	 truncated	 ASXL1	 variants	 in	 human	 myeloid	 disorders69,101,126,128,259,	 I	
showed	here	 for	 the	 first	 time	that	a	 truncated	ASXL1	protein	 is	 likewise	expressed	 in	
BOS	patient-derived	 iPSC	 and	 related	hESC	models,	 and	might	 thus	 contribute	 to	BOS	
pathogenesis.		
	
4.4	Cross-regulation	of	ASXL	transcript	and	protein	levels	
My	studies	did	not	reveal	deregulation	of	endogenous	ASXL1,	ASXL2	or	ASXL3	transcripts	
upon	 expression	 of	 truncated	 ASXL1	 in	 undifferentiated	 cells	 (Fig.	 17A-D).	 However,	
concomitant	reduction	of	ASXL1	and	ASXL3,	but	not	of	ASXL2	was	evident	in	NC	cultures	
derived	from	ASXL1PSC/PSC	clones	(Fig.	31).	Moreover,	ASXL3	expression	was	induced	by	
strong	 overexpression	 of	 truncated	 ASXL1	 after	 short-term	 differentiation	 (Fig.	 17E)	
but	 not	 in	 pluripotent	 conditions,	 which	 promotes	 the	 concept	 of	 (truncated)	 ASXL1	
regulating	 gene	 expression	 in	 developmental	 contexts	 rather	 than	 in	 undifferentiated	
pluripotent	 stem	 cells.	 Reduced	 ASXL1	 transcript	 and	 protein	 levels	 in	 established	
ASXL1PSC/PSC	NC	cultures	(Figs.	22C	and	31)	agree	with	studies	in	Drosophila	and	in	the	
mouse,	which	have	suggested	that	the	Asx(l)	protein	binds	and	autoregulates	the	genetic	
locus78,100.	This	observation	 furthermore	reinforces	 the	hypothesis	 that	 transcriptional	
regulation	 by	mutant	 ASXL1	 proteins	 occurs	 in	 developmental	 progenitors	 but	 not	 in	
pluripotent	stem	cells.		
Notwithstanding	 these	 findings,	 I	noted	variable	band	 intensities	of	ASXL1	 in	Western	
blotting	 of	 undifferentiated	BOS	models	 (Figs	 13D,E	 and	 18A,B,G).	 DOX-induced	 PB-
ASXL1PSC	 and	 BOS-iPSC	 lines	 #2-0	 and	 #2-1,	 which	 all	 express	 the	 ASXL1	 variant	 of	
964	aa,	exhibited	increased	levels	of	the	putative	ASXL1/2	band	at	170	kDa,	but	very	low	
levels	of	a	130	kDa	band.	In	contrast,	ASXL1PSC/PSC	hESC	clones	and	BOS-iPSC	lines	#1-0	
and	#1-1,	which	express	ASXL1	variants	of	809-824	aa,	showed	lower	or	equal	levels	of	
the	 170	 kDa	 band	 and	 pronounced	 130	 kDa	 bands	 in	 comparison	 to	 control	 cells.	 Of	
note,	 these	 results	 were	 obtained	 in	 cell	 cultures	 collected	 at	 similar	 densities.	 The	
truncated	 ASXL1	 protein	 did	 not	 alter	 the	 general	 ASXL1	 localization	 as	 detected	 by	
immunocytochemical	staining	in	BOS-iPSC	and	PB-ASXL1PSC	(Figs.	12G	and	13F),	which	
is	in	line	with	other	studies	where	extopically	expressed	truncated	ASXL1	variants	were	
nuclear69,101.	 I	 concluded	 that	 truncated	 ASXL1	 influences	 the	 stability	 of	 ASXL1	
(isoforms)	and/or	paralogs	 in	a	mutation-dependent	manner,	which	might	be	relevant	
for	BOS	pathogenesis.	Future	studies	should	thus	attempt	to	identify	observed	bands	at	
130	 and	 170	 kDa,	 and	 examine	 how	 amino	 acids	 824-964	 of	 mutant	 ASXL1	 proteins	
might	 function	 in	 regulating	 the	 respective	 proteins.	 I	 propose	 that	 analysis	 of	
posttranscriptional	mechanisms141,252	or	ubiquitination	pathways88		could	give	valuable	
insights	in	this	matter.		
On	 another	note,	 I	 noted	 inverse	 correlation	between	ASXL1/2	 levels	 (170	kDa	band)	
and	cellular	density	of	 analyzed	 control	 cultures	 (Fig.	 18C-G).	Both	ASXL1	and	ASXL2	
are	 involved	 in	 the	regulation	of	proliferation111,113,260,	and	correspondingly,	 transcript	
and	protein	levels	might	be	dynamically	adjusted	according	to	the	cell	cycle	stage.		
Taken	 together,	 my	 analyses	 identified	 ASXL	 regulation	 on	 the	 transcript	 level	 in	
developmental	progenitors,	potentially	including	regulation	via	chromatin	modifications	
in	NC	cultures	(Fig.	32D),	and	on	the	protein	level	in	accordance	to	cell	density	and	the	
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presence	of	truncated	ASXL1	variants	(Fig.	37A).	These	regulatory	mechanisms	seem	to	
be	 perturbed	 in	 BOS	models,	 and	might	 contribute	 to	 different	 pathogenic	 outcomes.	
This	adds	 to	 the	knowledge	of	 the	complex	regulation	of	ASXLs	by	splicing80,141,	NMD1	
and	auto-/cross-regulatory	mechanisms100,111,253.	
	
4.5	 Expression	 of	 truncated	 ASXL1	 does	 not	 impair	 maintenance	 of	 the	
pluripotent	state		
In	 line	 with	 a	 proposed	 role	 of	 ASXL1	 in	 progenitor	 specification,	 but	 not	 during	
induction	 or	 maintenance	 of	 pluripotency,	 I	 neither	 observed	 obvious	 defects	 in	
reprogramming	of	BOS	patient	fibroblasts,	nor	did	I	note	significant	deviations	in	rates	
of	spontaneous	differentiation	in	BOS-iPSC	in	comparison	to	control	 lines.	Accordingly,	
ASXL1	 mutations	 did	 not	 dramatically	 affect	 expression	 of	 selected	 pluripotency-
relevant	genes	(Figs.	10C,	14F).	Analysis	of	germ	layer-associated	genes,	HOX	genes	and	
iPSC	transcriptomes	gave	indications	for	subtle	to	modest	changes	in	the	transcriptional	
landscapes	of	cells	expressing	truncated	ASXL1,	which	is	consistent	with	a	minor	role	of	
ASXL1	mutations	in	pluripotency	(Figs.	14,	15	and	Table	4).	
Interestingly,	while	transcriptomes	of	patient	fibroblasts	clustered	together	in	principal	
component	 analysis,	 those	of	 the	derived	BOS-iPSC	 lines	did	not	 (Fig.	 14A).	 BOS-iPSC	
showed	 deviations	 of	 the	 genomewide	 transcriptional	 landscape,	 with	 606	 and	 798	
genes	 being	 up-	 and	 downregulated,	 respectively,	 in	 #2-0	 versus	 control	 lines,	 while	
only	 172	 and	 273	 genes	 were	 up-	 and	 downregulated,	 respectively,	 in	 line	 #1-0	
compared	 to	 control	 lines.	 I	 also	 noted	 slightly	 enhanced	 cell	 size,	 and	 persistently	
enhanced	 HOX	 and	 ASXL	 transcription	 in	 the	 #2-0	 iPSCs.	 These	 findings	 were	 not	
consistent	in	line	#2-1,	which	expressed	ASXL	genes	similar	to	control	levels	and	showed	
normal	morphology,	suggesting	clone-specific	effects.		
In	an	attempt	to	subtract	clone-dependent	variations,	I	conducted	paired	analysis	of	the	
two	BOS-iPSC	lines	relative	to	control	iPSC	and	hESC	lines.	This	crude	approach	masked	
subtle	 transcriptional	changes	due	to	combination	of	different	cell	 lines	 in	each	group,	
but	certainly	resulted	in	a	list	of	robust	and	relevant	transcriptional	changes	with	regard	
to	 ASXL1	 truncations.	 I	 initially	 focused	 on	 developmental	 regulators	 and	 found	
upregulation	of	three	factors	that	participate	in	TGF-β	signaling,	namely	the	TGFβ-ligand	
Nodal,	and	the	BMP	antagonists	Cerberus	1	(CER1)	and	Growth	and	differentiation	factor	
3	 (GDF3)217,261,262.	 Interestingly,	 Nodal/Activin	 signaling	 is	 required	 to	 maintain	 the	
undifferentiated	 state	 of	 hESCs	 via	 activation	 of	 NANOG,	 whereas	 BMP	 signaling	
antagonizes	it263,264.	This	was	in	line	with	slightly	enhanced	transcript	levels	of	NANOG	
in	BOS-iPSCs	and	ASXL1PSC/PSC	hESCs	(Figs.	 11F	 and	14F).	Furthermore,	Activin/Nodal	
signaling	and	CER1,	GDF3	and	Nodal	are	implicated	in	induction	and	specification	of	the	
definitive	 endoderm265,266.	 This	 is	 noteworthy,	 as	 levels	 of	 endoderm-related	 genes	
SOX17	or	both	SOX17	and	FOXA2267,268	increased	in	ASXL1PSC/PSC	hESCs,	and	in	short-term	
differentiation	 cultures	 overexpressing	 truncated	 ASXL1,	 respectively.	 Endoderm-
related	 pathways	 were	 classified	 among	 a	 list	 of	 tissues	 associated	 with	 upregulated	
genes	in	BOS-iPSCs	(Table	4).	Hence,	integration	of	results	obtained	with	different	BOS	
models	 indicates	 that	 expression	 of	 truncated	ASXL1	 enhances	TGFβ	 signaling,	 and	 in	
aggravated	 models	 such	 as	 homozygous	 ASXL1PSC/PSC	 hESC	 and	 the	 PB-ASXL1PSC	
overexpression	 line,	 this	 promoted	modest	 induction	 of	 endoderm-related	 genes	 (Fig.	
37A).	Analysis	of	phosphorylated	SMAD2/3	and	SMAD1/5/8	levels	should	conclusively	
prove	 this	proposition269.	While	 these	 findings	might	have	 implications	 for	progenitor	
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commitment,	 as	 I	 indeed	 also	 saw	minor	 increase	 in	NODAL,	GDF3,	CER1	 and	NANOG	
levels	in	ASXL1PSC/PSC	NC	cultures	compared	to	control	cultures	(Fig.	30B),	I	propose	that	
they	had	a	negligible,	or	potentially	enhancing	impact	on	the	stability	of	pluripotency	in	
BOS	lines.	
Another	 candidate	 from	 the	 list	 of	 upregulated	 genes	 in	 BOS-iPSC	 is	 Neuronatin	 1	
(NNAT1),	 an	 inducer	of	neuronal	differentiation	 that	 is	believed	to	participate	 in	brain	
development215,270.	 Neuronal	 features	 are	 present	 in	 all	 BOS	 patients,	 and	 analyses	 of	
neuroepithelial	ASXL1PSC/PSC	cultures	pointed	out	misregulation	of	several	genes	implied	
in	 neuronal	 differentiation,	 as	 discussed	 further	 below.	 Intriguingly,	 gene	 sets	 with	
decreased	expression	 in	BOS-iPSC	compared	to	control	cells	were	also	associated	with	
seizures,	 a	 common	 finding	 in	 BOS.	 Further	 disease-relevant	 associations	 included	
muscular	 processes	 and	 protein	 stability,	 heart	 tissue	 and	 fetal	 growth	 retardation	
(Table	4).	As	both	in	the	microarray	datasets	derived	from	undifferentiated	BOS-iPSCs,	
and	 in	 RNA-seq	 analysis	 of	 ASXL1PSC/PSC	NC	 cultures,	 downregulated	 gene	 sets	 were	
consistently	associated	with	BOS-relevant	tissues	and	BOS	symptoms,	this	conclusively	
hints	 towards	a	dominant,	 repressive	 function	of	 truncated	ASXL1	as	one	of	 the	major	
causes	of	BOS	pathogenesis.	
The	HOX	 loci	are	known	targets	of	Asxl1116,	and	my	initial	analyses	of	undifferentiated	
cells	 hinted	 an	 impaired	 induction	 of	 HOXA2	 and	 HOXB1	 in	 BOS-iPSCs	 (Fig.	 15).	
Although	HOX	genes	were	not	expressed	or	detected	only	at	low	levels	in	NC	cultures,	I	
also	 noted	 negative	 regulation	 of	 HOXB1	 in	 RNA-seq	 analyses	 of	 ASXL1PSC/PSC	 NC	
progenitors,	thus	overall	supporting	these	findings.	Strong	repression	of	HOX	genes	was	
also	reported	in	heterozygous	ASXL3	mutant	fibroblasts	isolated	from	a	BRS	patient112,	
and	 although	 the	 pathogenesis	 of	 BRS	 is	 also	 not	 entirely	 understood	 yet,	 there	 is	 a	
possibility	of	negative	HOX	regulation	being	implicated	in	the	developmental	defects	of	
both	BOS	and	BRS.		
Considering	that	ASXL1PSC/PSC	did	not	alter	the	pluripotency	characteristics	of	the	cells	or	
promote	 differentiation,	 I	 conclude	 that	ASXL1	 mutations	 contribute	 to	 the	molecular	
etiology	of	BOS	after	the	dissolution	of	pluripotency.	
	
4.6	BOS-associated	mutations	in	ASXL1	impair	NC	development	and	perturb	
ZIC1	expression	and	the	NC	regulatory	network		
The	 spectrum	 of	 BOS	 symptoms	 comprises	many	 tissues	 and	 organs	 that	 contain	 NC	
derivatives,	 including	 the	 craniofacial	 region,	 the	 heart	 and	 the	 gastrointestinal	
system35,137.	For	the	first	time,	my	study	linked	BOS-associated	mutations	in	ASXL1	with	
perturbations	 in	 NC	 specification	 and	 emigration,	 and	 provided	 initial	 molecular	
mechanisms	that	are	underlying	these	developmental	phenotypes.	
	
4.6.1	Generation	of	migrating	and	differentiating	NC	cells	in	vitro	
For	my	analyses,	I	applied	an	in	vitro	NC	differentiation	protocol	that	in	a	previous	study	
served	the	 identification	of	CHD7	as	an	important	regulator	of	NC	development33.	This	
approach	 does	 not	 rely	 on	 tightly	 controlled	 conditions	 via	 administration	 of	 BMP	 or	
WNT	signaling	modulators152,234,	but	on	self-organizing	neuroepithelial	 spheres,	which	
represent	neural	rosette	structures.	It	has	been	shown	that	early	neural	rosette	cultures	
derived	 from	 hPSCs	 are	 not	 homogenous	 but	 rather	 consist	 of	 neural	 stem	 cells,	
different	subtypes	of	neurons	and	NC	cells271.	NC	cells	generated	within	neurospheres	in	
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the	presence	of	bFGF	and	EGF	are	of	pre-migratory,	dorsal	neural	fold	identity	but	lose	
their	stemness	character	upon	detachment	 from	the	neurospheres,	when	they	migrate	
and	differentiate272.	Correspondingly,	NC-like	cells	obtained	in	this	study	proliferated	for	
10-15	passages	at	most,	expressed	p75,	a	marker	of	migrating	human	NC	cells	in	vivo184,	
and	occasionally	stained	positive	for	HNK1,	which	labels	a	subset	of	migratory	NC	cells	
in	 human	 embryos184.	 The	 loss	 of	 the	 pre-migratory	 properties	 and	 presentation	 of	
advanced	 fates	 in	 the	 isolated	 NC	 cultures	 is	 furthermore	 in	 line	 with	 the	
downregulation	of	the	bona	fide	NC	specifier	SOX10.	I	detected	SOX10	in	RNA-seq	data	at	
day	7,	 and	 in	established	cultures	at	day	10,	however	 the	 transcripts	and	protein	was	
lost	 in	 passaged	 cultures	 (Figs.	 28A	 and	 20B).	 It	 was	 shown	 that	 SOX10	 is	
downregulated	 in	 late	 migratory	 trunk	 NC	 cells223,	 and	 taken	 together	 with	 the	 low	
expression	 or	 absence	 of	HOX	 genes	 and	 detection	 of	ETS1	 in	 NC	 cultures	 at	 day	 7,	 I	
conclude	 that	 my	 differentiation	 approach	 generated	 cultures	 of	 mostly	 cranial	
identity273.	 Importantly,	 established	 NC-like	 cells	 were	 validated	 based	 on	 their	
developmental	 capacity	 to	 differentiate	 into	 MSCs	 and	 two	 of	 their	 derivatives,	
adipocytes	 and	 osteocytes.	 While	 thorough	 examination	 of	 NC	 identity	 would	 have	
required	the	additional	evidence	of	differentiation	into	neurons,	glia	and	melanocytes224,	
I	focused	on	a	potential	craniofacial	contribution	of	generated	NC	cells,	and	NC-derived	
MSCs	 are	 crucial	 for	 the	organization	of	 head	morphogenesis162.	Moreover	 supporting	
acquisition	of	 a	NC	 fate,	 the	 cultures	 exhibited	 robust	 expression	of	 the	NC	 specifying	
factor	TFAP2A,	which	 is	 found	 in	migrating	human	NC	 cells150,152,184,224.	 Since	TFAP2A	
also	marks	non-neural	ectoderm	and	is	involved	in	sensory	placode	commitment152,274,	I	
affirmed	 absence	 of	 early	 placodal	markers228	 in	 day	 7	 NC	 cultures,	 and	 furthermore	
confirmed	expression	of	a	whole	panel	of	factors	involved	in	human	NC	differentiation	in	
vitro150,152,153	(Figure	28A).		
	
4.6.2	 ASXL1	 is	 expressed	 during	 NC	 development,	 and	 truncated	 ASXL1	
dominantly	impairs	emigration	of	NC	cells		
By	 means	 of	 a	 neurosphere-based	 NC	 differentiation	 strategy,	 I	 was	 able	 to	 detect	
induction	of	ASXL1	and	ASXL3	in	human	NC	cells	and	the	presence	of	truncated	ASXL1	
variants	 in	 ASXL1PSC/PSC	 NC	 cultures	 (Fig.	 22C),	 and	 identified	 NC	 delamination	 and	
emigration	phenotypes	resulting	from	expression	of	truncated	ASXL1	(Figs.	23,	25,	26).	
The	developmental	defect	was	dramatic	 in	homozygous	ASXL1PSC/PSC	 cultures,	where	a	
very	 low	 percentage	 of	 neurospheres	 attached	 to	 the	 plate.	 In	 contrast,	 heterozygous	
BOS-iPSC	adhered	at	rates	25%-50%	lower	than	control	 iPSC.	As	discussed	before,	 the	
homozygous	hESC	model	does	not	truly	reflect	the	pathophysiological	situation	in	BOS	
patients	and	I	hypothesized	that	homozygous	truncating	mutations	would	evoke	severe	
phenotypes	not	compatible	with	sufficient	formation	of	NC	cells	in	vivo.	Interestingly,	a	
recent	 mouse	 model	 bearing	 a	 truncating	 mutation	 in	 the	 endogenous	 Asxl1	 locus	
showed	 embryonic	 lethality	 in	 homozygous	 mice,	 whereas	 heterozygous	 mice	 were	
viable127.	Unfortunately,	 these	mice	were	not	analyzed	 further	on	potential	NC-related	
defects.	 The	presence	of	 a	modest	 attachment	 and	outgrowth	phenotype	 in	BOS-iPSC-
derived	 neurospheres	 suggests	 that	ASXL1PSC/PSC	 hESC	 lines	 indeed	 presented	 disease-
relevant	phenotypes,	albeit	in	an	enhanced	manner	that	might	be	dependent	on	the	dose	
of	truncating	ASXL1	protein.	Supportive	of	this	idea,	overexpression	of	the	ASXL1PSC	on	a	
wildtype	background	nearly	abolished	neurosphere	attachment	and	delamination	of	NC	
cells.	I	conducted	further	analyses	in	NC	cells	derived	from	isogenic	hESC	lines	to	avoid	
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donor-dependent	 variability	 as	 seen	 in	BOS-iPSC	 lines	 (Fig.	 23B),	 and	 to	 examine	 the	
isolated	effects	of	truncated	ASXL1	expression.		
Diminished	attachment	of	 the	NSs	 indicated	 that	cells	within	 the	neurospheres	harbor	
immature	 cytoskeletal	 structures	 that	 do	 not	 support	 adhesion	 to	 untreated	 plastic	
dishes,	 a	 phenotype	 that	 is	 similar	 to	 the	 properties	 of	 undifferentiated	 hESCs.	
Moreover,	the	significantly	increased	number	of	(smaller)	neurospheres	in	ASXL1PSC/PSC	
cultures	 (Fig.	 23D)	 indicated	 that	 the	 integrity	of	 large	spheres	could	not	be	properly	
maintained.	Neural	rosette	structures	typically	express	N-Cadherin271,	and	interestingly,	
I	noted	a	delay	 in	 the	expected	E-	and	N-Cadherin	 switch	 in	 the	mutant	versus	control	
cultures	as	early	as	day	3,	which	showed	that	cells	residing	with	mutant	neurospheres	
retained	epithelial	 identity.	The	developmental	defect	seen	 in	BOS	model	cultures	was	
however	not	merely	an	in	vitro	artifact	of	reduced	attachment	of	neurospheres	to	plastic	
dishes,	but	was	functionally	validated	in	orthotopic	xenotransplantation	experiments	in	
chicken	embryos	(Fig.	25).	Progeny	of	transplanted	control	neurospheres	emigrated	as	
single	cells	or	 in	streams	into	the	developing	chicken	embryo,	while	this	behavior	was	
significantly	 diminished	 in	 ASXL1PSC/PSC	 neurospheres,	 similarly	 to	 what	 has	 been	
observed	 after	 transplantation	 of	 iPSCs	 derived	 from	 CHARGE	 patients,	 a	 designated	
neurocristopathy34.	Mutant	and	control	neurospheres	of	similar	size	were	transplanted	
to	 ensure	 equal	 number	 of	 starting	 populations.	 Importantly,	 ectopic	 expression	 of	
truncated	 chicken	 or	 human	 ASXL1	 impaired	 embryonic	 NC	 cells	 in	 the	 developing	
chicken	 (Fig.	 26),	 confirming	 a	 dominant,	 evolutionary	 conserved	 effect.	 It	 will	 be	
interesting	 for	 futures	 studies	 to	 examine	 chicken	 embryos	 that	 have	 been	
electroporated	with	 truncated	ASXL1	variants	 at	 later	developmental	 stages,	 to	 assess	
the	resulting	effects	on	craniofacial	morphogenesis.	
Taken	 together,	 expression	 of	 truncated	 ASXL1	 delays	 or	 impairs,	 but	 does	 not	
completely	diminish	the	induction	and/or	proliferation	of	migratory	NC	cells	in	vitro	and	
in	vivo	(Fig.	37B).	This	is	based	on	the	finding	that	ASXL1PSC/PSC	neurospheres	required	
longer	 incubation	 times	 for	 adhesion	 and	 NC	 cell	 delamination	 to	 occur	 (Fig.	 23F);	
however,	 from	 those	 mutant	 cells	 that	 did	 migrate,	 expression	 profiles	 and	
developmental	 potency	 seemed	 comparable	 to	 control	 cells	 (Fig.	 24).	 Comparison	 of	
different	 BOS-related	 models	 indicates	 that	 the	 associated	 developmental	 defects	 are	
dependent	 on	 the	 dose	 of	 truncated	 ASXL1	 that	 is	 expressed	 in	 developing	 NC	 cells,	
which	 is	 interesting	with	 regard	 to	 the	 symptomatic	 range	 that	 BOS	 patients	 display.	
‘Reverse’	 experiments,	 in	 which	 wildtype	 ASXL1	 is	 introduced	 into	 ASXL1PSC/PSC	 cells,	
should	further	investigate	this	hypothesis.		
	
4.6.3	Expression	of	truncated	ASXL1	negatively	regulates	expression	of	ZIC1	and	
NC	specifiers		
Transcriptional	analysis	of	neurospheres	at	the	attachment	stage	further	supported	the	
concept	 of	 perturbed	 NC	 induction	 and	 specification	 in	 ASXL1PSC/PSC	 cultures,	 as	 it	
revealed	deregulation	of	the	central	set	of	NC	specifiers	that	have	been	characterized	in	
Xenopus,	zebrafish	or	chicken	in	vivo,	including	most	significantly	ZIC1	(Fig.	28).	The	list	
also	 included	 strongly	 downregulated	 factors	 that	 are	 crucial	 for	 human	 NC	
differentiation	 in	 vitro,	 namely	HES1,	HES5	 and	NR2F1150,153.	 This	 conclusively	 shows	
that	 expression	 of	 truncated	 ASXL1	 can	 perturb	 human	NC	 regulatory	 networks	 (Fig.	
37B).		
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Zic	 genes	 are	 primary	 specifiers	 of	 the	neural	 plate	 border,	 and	 together	with	Pax3/7	
and	 Msx1,	 they	 are	 crucial	 factors	 for	 the	 acquisition	 of	 NC	 identity151,275.	 Xenopus	
models	have	suggested	a	minimum	circuit	of	NC	induction,	encompassing	Wnt	signaling,	
Pax3	 and	 Zic1,	 which	 cooperatively	 activate	 downstream	 effectors	 that	 control	 NC	
specification,	 proliferation,	 migration	 and	 differentiation276.	 Interestingly,	 all	 of	 these	
regulatory	 modules	 were	 represented	 by	 the	 downregulated	 gene	 cohort	 in	 the	
ASXL1PSC/PSC	NC	cultures.	This	indicates	that	ZIC1	has	a	central	role	in	NC	specification,	a	
notion	 that	 is	 supported	 also	 by	 the	 presence	 of	 ZIC1	 binding	 motifs	 at	 a	 subset	 of	
human	NC	enhancer	elements150.	According	to	its	instructive	role	in	NC	development,	I	
could	show	that	re-establishment	of	ZIC1	expression	in	ASXL1PSC/PSC	NC	cultures	rescued	
the	 attachment	 and	 delamination	 defect	 (Fig.	 29).	 This	 implies	 that	 insufficient	 ZIC1	
induction	represents	a	critical	bottleneck	for	NC	cultures	that	express	truncated	ASXL1,	
which	is	the	first	direct	evidence	for	the	significance	of	ZIC1	in	human	NC	differentiation,	
and	is	in	line	with	animal	studies	highlighting	the	importance	of	Zic	gene	dosage	during	
development277.	
I	 suggest	 that	 the	 strong	 repression	 of	 ZIC1	 is	 however	 is	 not	 the	 sole	 factor	 that	
hampers	proper	emigration	of	NC	cells	in	the	model.	This	is	based	on	the	(unquantified)	
observation	 that	 while	 ASXL1PSC/PSC	neurospheres	 overexpressing	 ZIC1	 attached	 to	 an	
extent	 that	 was	 comparable	 to	 control	 neurospheres,	 less	 prospective	 NC	 cells	 were	
emigrating	from	these	neurospheres,	indicating	that	proliferation	or	efficient	induction	
was	still	impaired	to	some	extent.	Furthermore,	the	Foxd3	gene	is	a	known	target	of	Zic1	
during	NC	development151,	but	I	did	not	find	downregulation	of	FOXD3	in	the	mutant	NC	
cultures.	This	might	owe	to	species-specific	differences,	but	it	could	also	imply	that	not	
the	 entire	 ‘ZIC1-axis’	 of	 the	 interconnected	 NC	 regulatory	 network	 was	 concurrently	
downregulated.		
Pathways	that	should	be	considered	 in	acting	upstream	or	concomitantly	 to	 inefficient	
ZIC1	 activation	 are	 BMP	 and	WNT	 signaling,	 both	 of	 which	 are	 involved	 in	 different	
stages	 of	 NC	 development.	 Induction	 of	 the	 NC	 at	 the	 NPB	 critically	 relies	 on	
intermediate	 levels	 of	 BMP	 signaling151,	 and	 the	 importance	 of	 specific	 BMP	
concentrations	 for	 human	 NC	 differentiation	 has	 been	 confirmed	 in	 vitro234.	 	 Slightly	
increased	 expression	 levels	 of	Nodal,	GDF3,	CER1,	 and	more	 pronouncedly	NANOG,	 in	
mutant	 NC	 cultures	 suggested	 enhanced	 Activin/NODAL	 signaling,	 which	 I	 had	 noted	
already	in	undifferentiated	BOS-iPSC	lines.	It	would	be	of	interest	to	determine	whether	
perturbations	in	these	pathways	contribute	to	the	developmental	phenotype	in	cultures	
expressing	truncated	ASXL1.	Particularly	regarding	increased	NANOG	levels,	they	might	
furthermore	 be	 an	 indicator	 for	 delayed	 differentiation	 in	 ASXL1PSC/PSC	 cells.	 Of	 note,	
OCT4	transcripts	could	neither	be	detected	in	control,	nor	in	mutant	NC	cultures.	
WNT	signaling	is	indispensable	for	human	NC	induction	and	specification	in	vitro152,	and	
animal	 models	 revealed	 that	 the	 Wnt	 pathway	 and	 Zic1	 are	 in	 a	 mutual	 regulatory	
relationship	 during	 NC	 development,	 with	Wnt	 activating	 Zic,	 but	 also	Gbx2,	 and	 vice	
versa275,278,279.	 The	 striking	 downregulation	 of	 a	whole	 panel	 of	 frizzled	 receptors	 and	
WNT	 ligands	 in	 ASXL1PSC/PSC	 NC	 cultures	 very	 likely	 contributes	 to	 defective	 NC	
specification	 (Fig.	 30A).	 Future	 studies	 should	 investigate	 whether	 canonical	 WNT	
pathway	 activation	 can,	 similarly	 to	 ZIC1,	 rescue	 the	 attachment	 and	 delamination	
phenotypes,	 for	 instance	 via	 application	 of	 the	 GSK3	 inhibitor	 CHIR	 during	 NC	
differentiation	from	control	and	ASXL1PSC/PSC	lines.			
Apart	 from	 identification	 of	 negatively	 regulated	 genes	 pertaining	 to	 the	 induction,	
specification	and	differentiation	modules,	my	transcriptional	analysis	also	indicated	the	
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delamination	phenotype	on	a	molecular	level.	This	includes	the	deregulated	switch	from	
E-Cadherin	 to	N-Cadherin,	 which	 presumably	 contributed	 to	 the	 impaired	 adhesion	 of	
neurospheres	 as	 discussed	 earlier,	 and	 negatively	 regulated	 Cadherin	 6,	 which	 is	
activated	during	delamination	of	NC	cells	in	vivo151	(Fig.	28C).			
I	 concluded	 from	 transcriptional	 analyses	 and	 cellular	 phenotypes	 that	 the	molecular	
network	 controlling	 NC	 induction,	 delamination	 and	 differentiation	 is	 impaired	 in	 NC	
cultures	expressing	ASXL1PSC,	and	this	 is	critically	dependent	on	negative	regulation	of	
ZIC1	 (Fig.	 37B).	 To	 conclusively	 prove	 the	 translational	 relevance	 of	 the	 uncovered	
mechanisms,	 it	would	be	important	to	show	downregulation	of	ZIC1	and	NC	specifiers,	
and	respective	rescue	experiments,	in	patient-derived	iPSCs.	
	
4.6.4	Proposed	roles	for	ASXL1	in	neuroectoderm	and	neuronal	development	
The	transcriptome	analysis	of	day	7	ASXL1PSC/PSC	NC	cultures	revealed	downregulation	of	
a	 set	 of	 genes	 that	 are	 implicated	 in	 NC	 development,	 and	 also	 more	 exclusively	 in	
neuronal	 differentiation	 and	 nervous	 system	 development	 (Table	 5).	 Detection	 of	
neuronal	specifiers	is	expected	owing	to	the	aforementioned	heterogeneity	of	cultures,	
which	 were	 comprised	 of	 neural	 rosette-like	 structures	 and	 delaminating	 NC	 cells.	
Notably,	initiation	of	NC	and	neural	induction	are	not	only	occurring	side-by-side	during	
development,	but	also	rely	on	the	same	signals	and	are	closely	linked151.	This	is	evident	
for	 instance	 in	 the	 formation	 of	 the	 birthplace	 of	 nascent	 NC	 cells,	 the	 NPB,	which	 is	
defined	by	inhibitory	actions	between	neural	and	non-neural	TFs151.	
ZIC1,	 the	 most	 significantly	 and	 highly	 repressed	 gene	 in	 ASXL1PSC/PSC	 cultures,	 is	
expressed	 in	 the	 neural	 plate	 and	 dorsal	 neural	 folds	 in	 vivo275,	 and	 besides	 being	
involved	the	NC	regulatory	program,	Zic	genes	promote	the	proliferation	of	precursors	
in	 the	 neural	 tube275,280-282.	 Interestingly,	 it	was	 shown	 that	 Zic1	 is	 important	 for	 RA-
induced	neuronal	differentiation	of	mouse	embryoid	bodies	via	induction	of	neurogenic	
genes	 such	 as	Pax3/7	 and	 Zic4	 in	 cooperation	with	 Brn2/Pou3f2283.	 Correspondingly,	
POU3F2,	PAX3	and	ZIC4,	 but	 also	ZIC1	 target	 gene	Engrailed	2275,284(EN2)	were	among	
the	 repressed	 genes	 in	 ASXL1PSC/PSC	NC	 cultures.	 I	 suggest	 that	 negative	 regulation	 of	
these	 neuronal	 factors	 evokes	 some	 of	 the	 nervous	 system-related	 symptoms	 in	 BOS.	
For	 instance,	 repression	 of	 the	 ZIC1/ZIC4	 locus	 in	 ASXL1PSC/PSC	 lines	 can	 be	 linked	 to	
reports	of	BOS	patients	exhibiting	Dandy-Walker	malformation131,137,	a	brain	defect	that	
is	 associated	 with	 the	 loss	 of	 the	 genomic	 ZIC1/ZIC4	 locus282,285.	 Analysis	 of	 neural	
progenitor/stem	 cells	 from	 the	 neurospheres	 could	 give	 indications	 on	 whether	 the	
reduction	 of	ZIC1	 (and	ZIC4)	 in	 the	mutant	 cultures	 is	 involved	 in	 the	 specification	 of	
neurons.		
Another	possibility	is	that	overactivation	of	Activin/Nodal,	which	requires	validation	on	
the	 protein	 level,	 might	 inhibit	 neuroectoderm	 formation	 in	 ASXL1PSC/PSC	 cultures	
upstream	 of	 NC	 differentiation286.	 Further	 interesting	 candidates	 among	 the	 list	 of	
downregulated	genes	in	ASXL1PSC/PSC	NC	cultures	are	the	Hes	genes,	which	are	effectors	
of	Notch	signalling	and	important	for	the	maintenance	of	neural	stem	cells287.	Similarly,	
ASCL1/Mash1	 and,	 highly	 significantly,	 the	 forkhead	 TF	 FOXP2	 were	 downregulated	
(Figs.	 27B	 and	 28B,	 Table	 5).	 Mash1	 is	 a	 neural-specific	 gene	 expressed	 in	 the	
developing	 neural	 tube,	 and	 interestingly	 also	 later	 in	 NC-derived	 enteric	 neurons288.	
Similarly,	 FOXP2	 induces	 neuronal	 differentiation	 via	 neural	 target	 genes289,290,	 and	
functional	 loss	 leads	 to	 neural	 tube	 defects291.	 Interestingly,	FOXP2	 is	 associated	with	
language	 disorders	 and	 autism	 in	 humans292,	 and	 it	 is	 tempting	 to	 speculate	 that	 the	
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speech	disorders	in	BOS	patients	are	partially	derived	from	strong	repression	of	FOXP2	
during	development.	FOXP2	expression	patterns	would	have	to	be	investigated	in	a	more	
thorough	manner	in	CNS	progenitor	populations	derived	from	ASXL1	mutant	hESC	and	
BOS-iPSC	to	delineate	a	potential	contribution	of	FOXP2	to	specific	BOS	symptoms.		
It	would	 furthermore	be	 instructive	 to	 test	by	ChIP	experiments	whether	ZIC1,	FOXP2	
and	 other	 highly	 downregulated	 gene	 in	ASXL1PSC/PSC	cultures,	which	 exhibit	 increased	
H3K27me3,	are	direct	targets	of	truncated	and	wildtype	ASXL1	(Fig.	37A).	Examination	
of	 expression	 patterns	 in	 mouse	 embryos	 (Fig.	 33C)	 and	 during	 human	 brain	
development	 (Fig.	 9F)	 suggests	 that	ASXL1	 is	 directly	 involved	 in	 neurodevelopment,	
and	 that	 this	 function	 might	 be	 conserved,	 since	 Drosophila	 Asx	 shows	 ubiquitous	
expression	 patterns	 during	 embryogenesis,	 but	 highly	 increased	 levels	 in	 the	
neuroectoderm	and	later	in	the	CNS78.	During	in	vitro	differentiation	to	neural	stem	cells,	
the	 upregulation	 of	ASXL1	 precedes	 that	 of	PAX6	 (Fig.	 9E),	 an	 important	 neuronal	TF	
that	 is	 required	 for	 neuroectoderm	 formation293.	 This	 could	 imply	 that	 ASXL1	
contributes	to	the	re-arrangement	of	chromatin	states	required	for	neural	commitment.	
To	verify	 this,	ASXL1	protein	 levels	and	recruitment	of	ASXL1	at	early	neuroectoderm	
specifiers	 would	 have	 to	 be	 tested.	 Furthermore,	 application	 of	 more	 defined	
differentiation	 protocols	 in	 futures	 studies	 might	 clarify	 distinct	 effects	 of	 ASXL1	
mutations	on	neuroectoderm	and	separately	on	the	neural	crest.	
	
4.	7	Truncated	ASXL1	in	the	global	and	local	regulation	of	histone	marks	
As	my	results	indicate	negative	regulation	of	neural	and	NC	specifiers	in	ASXL1PSC/PSC	NC	
cultures	in	correlation	to	enhanced	H3K27me3	in	affected	genes	(Fig.	32D,E),	the	next	
step	 should	 be	 the	 attempt	 to	 discover	 a	 mechanistic	 link	 between	 expression	 of	
truncated	 ASXL1	 and	 Polycomb-mediated	 transcriptional	 repression.	 To	 assess	 the	
possibility	 of	 direct	 regulation,	 the	 binding	 of	 truncated	 ASXL1	 to	 EZH2	
(Supplementary	 Fig.	 S3)	 and	 recruitment	 of	 both	 proteins	 to	 downregulated	 genes	
should	be	tested.	
Several	 observations	 are	 nonetheless	 already	 compliant	 with	 the	 notion	 of	 enhanced	
EZH2	 targeting	 by	 truncated	 ASXL1.	 It	 is	 has	 been	 shown	 that	 normal	 ASXL1	 is	
important	 for	 the	recruitment	of	PRC2	to	several	 targets	 including	the	HOX	 loci88,99,100,	
and	that	truncated	ASXL1	variants	can	also	bind	EZH2101.	Furthermore,	Ezh2	regulates	
Zic1	during	NC	 induction	 in	Xenopus160,	 and	EZH2	and	SUZ12	associate	 to	 the	bivalent	
ZIC1/ZIC4	locus	in	undifferentiated	hESCs200	(Fig.	32F).	Bivalent	or	poised	states	are	set	
up	by	Polycomb	PRC1/PRC2	and	TrxG	SET1A/B/MLL	complexes68,	and	previous	studies	
suggested	that	H3K27me3	is	important	for	the	repression	of	bivalent	lineage-regulatory	
genes	 in	 pluripotent	 stem	 cells294.	 The	 prevailing	 model	 states	 that	 developmental	
signals	tip	the	equilibrium	of	bivalent	states	by	the	recruitment	of	lineage	TFs	together	
with	 histone	 demethylases	 to	 enhancers	 and	 promoters,	 and	 thereby	 counteract	 PcG-
mediated	 repression68.	 In	 light	 of	 this	 mechanism,	 I	 hypothesize	 that	 mutant	 ASXL1	
might	 retain	 PRC2	 at	 regulatory	 genes	 such	 as	 ZIC1	 during	 NC	 induction,	 thus	
contributing	 to	 delayed	 activation	 of	 NC	 fate	 determinants.	 This	 is	 in	 line	 with	 my	
observations	 on	 the	 transcriptional	 and	 cellular	 level	 that	 suggested	 delayed	
differentiation.	 It	 is	 noteworthy	 in	 this	 context	 that	 I	 noted	 decreased	 expression	 of	
CBX8,	but	increased	levels	of	CBX7	 in	RNA-seq	analysis	of	ASXL1PSC/PSC	NC	cultures	(not	
shown).	 Presence	 of	 different	 CBX	 proteins	 discriminates	 PRC1	 complexes	 in	
developmental	 contexts,	 and	 in	 progenitors,	 CBX8/2/4	 take	 over	 the	 role	 that	 CBX7	
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plays	in	pluripotent	stem	cells57,72,295.	Thus,	the	interplay	of	the	PRC1	subunits	is	another	
mechanistic	possibility	here.	
Strikingly,	my	targeted	analysis	of	histone	modifications,	which	showed	local	increase	in	
H3K27me3	levels,	did	not	reflect	genome-wide	chromatin	landscapes	in	ASXL1PSC/PSC	NC	
cultures,	as	I	noted	reduced	global	levels	of	both	H3K27me3	and	H2AK119Ub	(Fig.	32).	
The	 latter	are	 in	 line	with	 reports	on	 somatic	mutations	of	ASXL1,	which	enhance	 the	
activity	 of	 the	 BAP1-containing	 PR-DUB	 complex,	 resulting	 in	 reduced	 H2AK119Ub	
levels69.	 It	 was	 hypothesized	 that	 the	 global	 decrease	 of	 H3K27me3	 in	 these	 settings	
might	 be	 a	 consequence	 of	 impaired	 PRC2	 targeting69	 according	 to	 the	 ‘alternative’	
model	of	PRC2	recruitment,	which	relies	on	H2AK119	ubiquitination	by	non-canonical	
PRC1	complexes	(Fig.	3A,	Fig.	6C).	I	cannot	conclusively	confirm	this	possibility	on	the	
basis	of	my	Western	Blot	results,	but	time	course	analyses	of	these	histone	modifications	
in	ASXL1PSC/PSC	NC	cultures	might	reveal	whether	the	decline	of	H2AK119	ubiquitination	
precedes	that	of	H3K27me3.	Notably,	my	results	are	the	first	to	be	obtained	in	a	human	
developmental	 model	 expressing	 physiological	 levels	 of	 truncated	 ASXL1	 protein,	 as	
opposed	 to	 the	 ectopic	 overexpression	 of	mutant	 ASXL1	 protein	 in	 the	 former	 study,	
which	used	somatic	cells69.	 Interestingly,	 in	 line	with	the	proposed	developmental	role	
of	ASXL1,	no	consistent	global	changes	in	H3K27me3	or	H2AK119	levels	were	observed	
in	undifferentiated	BOS	lines	(Fig.	19).	
Despite	the	reduction	in	total	H3K27me3	and	H2AK119Ub	in	ASXL1PSC/PSC	NC	cultures,	I	
did	not	detect	global	upregulation	of	genes,	or	de-repression	of	PRC2	targets	such	as	the	
HOX	 genes,	 which	 has	 been	 reported	 in	 a	 study	 on	 truncated	 ASXL1	 function	 in	 the	
hematopoietic	system101.	However,	Balasubramani	et	al	noted	that	the	de-ubiquitination	
activity	of	overactive	PR-DUB	seemed	to	target	specific	bivalent	genes	in	hematopoieitic	
precursor	 cells,	 and	 even	 massive	 de-ubiquitination	 did	 not	 lead	 to	 de-repression	 of	
silenced	 genes	 per	 se69.	 In	 line	 with	 this	 finding,	 it	 has	 been	 shown	 that	 the	 PRC1	
complex	can	repress	Hox	genes	independently	of	the	ubiquitination	activity	of	Ring1B296.		
The	 implications	 of	 truncated	 ASXL1	 to	 histone	modifications	 are	 likely	 broader	 than	
H3K27me3	 and	 H2AK119Ub,	 judging	 from	 the	 protein	 structure	 of	 this	 ‘epigenetic	
platform’.	 Indeed,	 a	 recent	 study	 showed	 that	 ectopically	 expressed	 truncated	 ASXL1	
binds	to	the	bromodomain-factor	BRD4,	which	is	associated	with	an	increase	in	H3K27	
and	 H3K122	 acetylation	 and	 a	 relaxed	 chromatin	 status128.	 The	 underlying	 in	 vivo	
analyses	 relied	 on	 transgene	 knock-in	 with	 unphysiological	 expression	 of	 truncated	
ASXL1,	 and	 it	 remains	 to	 be	 seen	 why	 full-length	 ASXL1	 did	 not	 bind	 BRD4;	
nevertheless,	 the	study	identified	an	 interesting	gain-of-function	of	pathological	ASXL1	
variants	 that	 could	potentially	be	 relevant	 for	BOS	pathogenesis	as	well.	Nevertheless,	
the	 highly	 context-dependent	 and	 possibly	 gene-specific	 functionality	 of	 ASXL1	 can	
impede	 inference	 from	 studies	 employing	 orthogonal	 cell	 systems,	 and	 reports	 on	
truncated	proteins	versus	knockout.	For	instance,	not	all	studies	in	Asxl1	 truncation	or	
knockout	 models	 reported	 alteration	 of	 H3K27me3	 levels128,259,260.	 In	 Asxl1-/-	 mouse	
embryonic	 fibroblasts,	 H3K27me3	 levels	 were	 unchanged	 but	 H3K9me3	 levels	 were	
reduced	by	a	half260,	 indicating	that	 in	this	particular	cell	 type,	 the	recruitment	of	HP1	
constitutes	 a	 main	 function	 of	 Asxl195.	 In	 contrast,	 Asxl1	 knockout	 decreased	 both	
H3K4me3	and	H3K27me3	levels,	but	not	H2AK19Ub	levels,	in	murine	erythroblasts	104.		
Taken	 together,	 the	 multivalent,	 context-dependent	 properties	 of	 ASXL1	 might	
complicate	the	elucidation	of	molecular	mechanisms	of	BOS.	Nevertheless,	I	have	made	
very	 important	contributions	by	discovering	 indications	 that	 truncated	ASXL1	 leads	 to	
H3K27me3	 and	 H2AK119Ub	 reduction,	 therefore	 indicating	 for	 functional	 PR-DUB	
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enhancement,	 and	 also	 identified	 discordance	 between	 local	 and	 global	 patterns	 of	
histone	 modifications	 in	 cells	 expressing	 truncated	 ASXL1	 (Fig.	 37A).	 These	 findings	
could	 be	 relevant	 to	 myloid	 disorders	 caused	 by	 truncating	 ASXL1	 mutations,	 and	
potentially	 also	 for	 truncating	mutations	 of	 ASXL2/3.	 The	 target-specific	mechanisms	
most	 importantly	 still	 have	 to	 be	 uncovered,	 and	 I	 speculate	 that	 they	might	 involve	
increased	 recruitment	 of	 EZH2	 via	 truncated	 ASXL1,	 providing	 a	 basis	 for	 developing	
therapeutic	 approaches.	 Further	 studies	 should	 also	 investigate	 other	 chromatin	
modifications,	 including	 H3K9me3,	 H3K4me3	 and	 H3	 acetylation,	 and	 interaction	 of	
truncated	 ASXL1	 with	 the	 corresponding	 histone	 modifiers.	 These	 endeavors	 should	
enhance	 understanding	 of	 ASXL/Polycomb-mediated	 regulation	 of	 embryonic	
transcription	 programs,	 and	 thus	 should	 strongly	 support	 the	 delineation	 of	 BOS	
pathogenesis.	On	a	fundamental	level,	my	studies	are	the	first	to	investigate	Polycomb-
mediated	 regulation	 of	 human	 NC	 development,	 and	 can	 be	 a	 point	 of	 departure	 to	
elucidate	 the	 still	 poorly	 understood	 epigenetic	mechanisms	 controlling	 NC	 induction	
and	specification,	in	particular	in	the	setting	of	genetic	diseases157,159.		
	
4.8	Animal	models	of	the	developmental	role	of	truncated	and	wildtype	
ASXL1		
To	 complement	my	 in	 vitro	 findings,	 I	 analyzed	 the	 expression	 of	Asxl1	 in	 a	 reporter	
mouse	model,	and	furthermore	developed	chicken	and	zebrafish	models	that	allow	for	
the	investigation	of	truncated	Asxl1	during	embryogenesis.	
While	 I	 suggest	 that	 Asxl1	 null	 mice	 are	 not	 suitable	 to	 model	 BOS	 as	 they	 lack	 the	
characteristic	 truncating	 Asxl1	 mutations,	 several	 interesting	 aspects	 arose	 from	 the	
analysis	 of	 reporter/knockout	 mouse	 mutants.	 In	 accordance	 to	 my	 in	 vitro	 NC	
differentiation	experiments,	I	detected	expression	of	Asxl1	along	the	closing	neural	tube	
and	 in	 several	 neuroectodermal	 and	NC-derived	 tissues	 during	 embryogenesis	 in	 vivo	
(Fig.	 33C).	 Transcription	 patterns	 and	 eye	 defects	 observed	 here	 and	 in	 other	
studies100,115,116,254	 (Fig.	 33B,C)	 hint	 towards	 a	 direct	 involvement	 of	 Asxl1	 in	
neuroectoderm	formation.	Expression	of	murine	Asxl2	in	the	nuclear	layer	of	the	retina	
and	 in	 cells	 of	 the	 ganglion	 layer	 has	 been	 reported119,	 indicating	 that	 both	Asxl1	 and	
Asxl2	 could	 be	 implicated	 in	 eye	 development.	 Interestingly,	 unilateral	 eye	 defects	 in	
Asxl1+/-	mice	 demonstrated	 a	 clear	 bias	 towards	 the	 right	 eye,	 an	 effect	 that	 has	 been	
noted	 in	 other	 mouse	 mutants297,	 including	 Bmp2/Bmp4	 compound	 heterozygous	
mice298.	 My	 initial	 observations	 can	 serve	 as	 a	 cornerstone	 to	 decipher	 a	 general	
neuroectodermal	 role	 of	 Asxl1,	 which	 might	 be	 relevant	 for	 the	 human	 situation	
regarding	 ophthalmic	 features	 and	 intellectual	 defects	 reported	 in	 BOS	 patients.	
Nevertheless,	 critical	 aspects	 to	 consider	 in	 the	 analysis	 of	 Asxl1	 mouse	 mutants	 are	
strain-specific	 effects,	 which	 can	 have	 an	 impact	 on	 phenotypes102,107,116.	 This	 might	
explain	 why	 I	 saw	 phenotypes	 in	 heterozygous	 mice	 on	 a	 pure	 background	 (10	
generations	of	backcrossing)	 that	where	not	observed	on	mixed	backgrounds	 in	other	
studies100,107.		
Contrary	to	the	mouse,	Asxl	functions	in	the	chicken	or	zebrafish	are	hitherto	unknown.	
Analysis	 of	 predicted	 chicken	 and	 zebrafish	 ASXL1	 protein	 sequences	 indicated	 the	
presence	 of	 the	N-and	 C-terminal	 domains	HARE-HTH,	 ASXH	 and	 PHD,	 as	well	 as	 the	
more	 centrally	 located	 NR-binding	motifs	 LVKQLL	 (chicken)	 and	 LVTQLL	 (zebrafish),	
respectively.	 This	 could	 imply	 functional	 similarities	 between	 the	 human	 and	 animal	
orthologs	in	their	wildtype	and	potentially	also	their	truncated	form,	which	I	confirmed	
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in	 electroporation	 experiments,	 where	 both	 human	 and	 chicken	 truncated	 ASXL1	
variants	 impaired	 chicken	NC	 development.	Many	 insights	 into	NC	 development	were	
gained	from	the	analysis	of	chicken	embryos151,	and	I	suggest	that	the	proposed	role	of	
Asxl1	in	neuroectoderm	and	NC	specification	could	be	further	delineated	in	this	model.	
Transplantation	 of	 neurospheres	 has,	 to	 my	 knowledge,	 only	 been	 performed	 in	 one	
neurocristopathy-related	study	thus	 far34,	and	 largely	contributed	to	the	elucidation	of	
ASXL1	mutation-related	NC	defects	in	this	work.			
Initial	analyses	of	the	putative	BOS	zebrafish	model	bearing	truncating	asxl1	mutations	
however	did	not	reveal	a	NC-specific	phenotype,	which	warrants	further,	more	detailed	
investigation.	Comparable	to	chicken,	quail	and	frog,	zebrafish	are	widely	employed	to	
decipher	 NC	 regulatory	 circuits236,299,	 which	 together	 with	 the	 ease	 of	 genetic	
manipulation	 and	 examination	 of	 embryos	 incited	 me	 to	 establish	 asxl1	 mutants.	
According	to	the	particular	situation	in	teleost	fish,	where	a	majority	of	the	genes	exists	
in	 duplicated	 form239,	 redundancy	 can	 be	 an	 impeding	 factor	 in	 genetic	 analysis.	
However,	BLAST	search	suggested	that	zebrafish	not	only	lost	duplicated	copies	of	asxl1	
and	asxl2,	but	also	the	asxl3	paralog,	which	apparently	took	place	only	in	the	teleost	fish	
(Fig.	34A),	and	might	indicate	the	adoption	of	novel	functions	for	Asxl3	in	tetrapods.	The	
identification	 of	 an	 unannotated,	 alternatively	 spliced	 exon	 in	 this	 study	 is	 not	
unexpected	 given	 the	 detection	 of	multiple	Asxl	 transcript	 variants	 in	 other	 species81.	
Closely	resembling	Drosophila	Asx	expression	kinetics78,	asxl1	and	asxl2	transcript	levels	
were	relatively	high	3	hours	post	fertilization,	then	dropped	sharply,	rose	again	slightly,	
and	remained	constant	during	larvae	development.	This	expression	pattern	is	suggestive	
of	maternal	loading	of	asxl1/2	mRNA,	which	was	reported	to	be	crucial	for	early	function	
of	Asx	in	fly	embryos73,78,	and	might	underlie	the	strong	phenotype	of	caudal	truncations	
observed	in	asxl1	mutants,	which	closely	resembles	zebrafish	no	tail	(ntl)	mutants300,301.	
Ntl	is	the	zebrafish	homolog	of	the	human/mouse	T/Brachyury,	which	is	crucial	for	the	
formation	 of	 dorsal	mesoderm300.	 This	 suggests	 a	 possible	 role	 of	asxl1	 in	mesoderm	
development	 in	 the	 zebrafish,	 but	 since	 in	 situ	 hybridization	 experiments	 did	 not	
support	mesodermal	expression	of	asxl1	 thus	 far,	 these	 intriguing	observations	clearly	
warrant	 further	 investigation	 to	 assess	 the	 specificity	 of	 the	 observed	 phenotypes302.	
Clear	signals	of	asxl1	mRNA	was	detected	in	a	very	specific	and	restricted	pattern	in	the	
otic	vesicles,	brain	(potentially	mid/hindbrain	vesicles)	and	the	retina	of	the	eye,	which	
correlated	with	neuroectoderm	expression	seen	in	the	fly78	and	the	mouse.	The	lack	of	
specific	 antibodies	 detecting	 wildtype	 and	 putative	 truncated	 fish	 asxl1	 variants	
hampered	 further	 analyses,	 and	 future	 experiments	 should	 in	 addition	 validate	 the	 in	
situ	 hybridization	 results	 with	 more	 probes,	 including	 those	 that	 detect	 the	 mutant	
mRNA	variant.		
In	all,	 I	propose	that	the	confirmation	of	asxl1/2	gene	expression	in	zebrafish	embryos	
and	 the	 establishment	of	asxl1	mutants	provides	 a	 base	 for	 the	 identification	of	 novel	
and	conserved	roles	of	ASXL	orthologs	in	developmental	contexts.	As	in	the	case	of	zic1,	
loss	of	which	does	not	affect	neural	 crest	development	 in	 the	zebrafish303,	asxl1	might	
have	 gained	 or	 lost	 functions	 in	 comparison	 to	 its	 mammalian	 counterparts.	
Nevertheless,	initial	results	indicate	that	a	neuroectodermal	role	might	is	be	conserved,	
and	 future	 studies	 should	 validate	 the	 specificity	 of	 the	 phenotypes	 I	 observed	 in	
zebrafish	mutants,	and	investigate	molecular	mechanisms.		
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Figure	 37.	Proposed	models	 for	 the	 regulation	and	role	of	 (truncated)	ASXL1	 in	pluripotent	 stem	cells,	
neuroepithelial	progenitor	cultures	and	in	putative	NC-related	defects	in	BOS.		
(A)	Expression	of	 truncated	ASXL1	does	not	 impair	maintenance	of	pluripotency	 in	hESC/BOS-iPSC,	but	
appears	to	slightly	enhance	TGFβ-signaling.	ASXL1	mutations	furthermore	affect	protein	levels	of	wildtype	
ASXL1/2	and	putative	 isoforms,	which	are	also	 regulated	according	 to	cell	density	 (upper	panel).	 In	NC	
progenitor	cultures	expressing	truncated	ASXL1	(lower	panel),	global	H3K27me3	and	H2AK119	levels	are	
reduced,	presumably	via	overactivation	of	the	PR-DUB	complex	followed	by	reduced	recruitment	of	PRC2.	
In	contrast,	 increased	 local	H3K37me3	deposition	at	 the	ZIC1/ZIC4,	ASXL1,	ASXL3	 and	FOXP2	 loci	might	
arise	 from	 increased	 targeting	 of	 PRC2	 by	 truncated	 ASXL1,	 which	 still	 needs	 to	 be	 confirmed	
experimentally.	 (B)	 In	 NC	 cultures,	 expression	 of	 truncated	 ASXL1	 leads	 to	 dramatic	 reduction	 in	 ZIC1	
levels	concomitantly	with	impaired	or	delayed	activation	of	gene	regulatory	networks	that	are	crucial	for	
NC	induction	and	EMT.	This	is	proposed	to	be	the	cause	of	reduced	emigration	of	NC	progenitors	derived	
from	BOS-iPSC	and	homozygous	ASXL1PSC/PSC	hESC,	and	 to	evoke	 the	NC-related	phenotypes	observed	 in	
BOS,	including	the	characteristic	craniofacial	features.	
	
4.9	Implications	of	ASXL1	mutant	models	for	BOS	and	related	disorders	
My	 analyses	 strongly	 indicate	 that	 truncated	 ASXL1	 proteins	 contribute	 to	 BOS	
pathogenesis,	 presumably	 via	 altered	 histone	 modifications	 and	 subsequent	
transcriptional	misregulation,	 and	 that	 at	 least	 a	 subset	 of	 BOS	 symptoms	 arises	 as	 a	
consequence	of	compromised	neuroectoderm	and	NC	development	(Fig.	37A,	B).		
Multiple	evidences	connect	the	defects	 in	the	ASXL1PSC/PSC	NC	progenitor	model	to	BOS	
and	additional	 syndromes.	First,	 loss	of	 the	ZIC1/ZIC4	 locus	 is	 associated	with	Dandy-
Walker	 malformation282,285,304,	 a	 brain	 development	 defect	 observed	 in	 some	 BOS	
patients131.	 Evaluation	 of	 ZIC1/ZIC4	 induction	 in	 BOS-iPSC-derived	 neuroepithelial	
cultures	 is	 required	 to	 conclusively	 confirm	 this	 link.	 Furthermore,	 heterozygous	
mutations	in	ZIC1	correlate	with	premature	fusion	of	the	skull	sutures284,	a	process	that	
might	 lead	 to	 trigonocephaly	 and	 associated	 hypertelorism305	 in	 BOS	 patients137.	 GO	
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terms	analysis	pointed	out	that	not	sufficiently	induced	gene	cohorts	in	ASXL1PSC/PSC	NC	
cultures	were	significantly	associated	with	additional	CNS-related	conditions	diagnosed	
in	 BOS,	 including	 ‘agenesis	 of	 corpus	 callosum’,	 ‘nervous	 system	 malformations’,		
‘seizures’	 and	 ‘communication	 disorders’.	 This	 shows	 that	 expression	 of	 truncated	
ASXL1	 in	 developmental	 models	 indeed	 provokes	misregulations	 that	 are	 relevant	 to	
BOS	disease	phenotypes.	Delineation	of	presumptive	functions	of	(truncated)	ASXL1	in	
neuroectoderm	 development	 might	 shed	 light	 on	 the	 molecular	 etiology	 of	 these	
conditions,	 and	 should	 furthermore	 elucidate	 a	 potential	 relationship	 between	ASXL1	
and	FOXP2,	which	could	be	relevant	for	neuropathological	features	in	BOS	patients.	
Defects	 in	 neural	 tube	 development	 furthermore	 present	 a	 plausible	 link	 between	
potential	 neuronal	 and	 NC-related	 features	 of	 BOS.	 Timely	 migration	 of	 NC	 cells	 is	
crucial	for	their	correct	integration	and	function	in	designated	fetal	tissues,	for	instance	
during	 head	 development162.	 Delayed	 or	 reduced	 generation	 of	migratory	NC	 cells,	 as	
suggested	by	my	observations	in	BOS	models	 in	vitro,	might	thus	evoke,	among	others,	
craniofacial	 features	 in	 BOS.	 In	 line	with	 this	 notion,	ASXL1PSC/PSC	 NC	 cultures	 showed	
significant,	8-fold	downregulation	of	DLX1,	a	gene	that	is	identified	with	anterior	dorsal	
NC	 cells,	 which	 will	 give	 rise	 to	 the	 ectomesenchyme	 that	 forms	 the	 head150,306-308.	
Cephalic	 NC	 cells	 furthermore	 have	 the	 capacity	 to	 differentiate	 into	 pericytes	 and	
smooth	muscle	cells	of	all	blood	vessels	irrigating	the	forebrain	and	facial	structures309.	
The	 majority	 of	 BOS	 patients	 display	 port-wine	 stains	 (nevus	 flammeus)	 on	 their	
forehead,	which	are	capillary	vascular	malformations,	and	plausibly,	delayed	or	reduced	
contribution	of	cranial	NC	cells	to	facial	structures	might	be	the	underlying	cause.		
Based	on	 the	assumption	 that	not	only	 cranial,	but	also	 trunk	NC	cells	 are	affected	by	
ASXL1	mutations,	frequent	reports	of	bowel	malrotation	or	obstruction	in	BOS	could	be	
a	 consequence	 of	 insufficient	 innervation	 of	 the	 enteric	 system	 due	 to	 reduced	
colonization	 by	 NC	 cells	 and	 neuronal	 derivatives166.	 Disruption	 of	 peripheral	 neuron	
development	might	 furthermore	underlie	 feeding	difficulties	emerging	 from	esophagal	
reflux,	 and	 the	 absence	 of	 tears	 in	 BOS	 patients310	 (https://bohring-
opitz.org/bosasxl1/list-of-symptoms/).	 Finally,	 malformations	 like	 palpebral	 fissures	
anomalies,	hand	and	limb	anomalies,	all	of	which	are	also	observed	in	BOS,	are	common	
to	neurocristopathies150,311.	Taken	together,	accumulating	evidence	based	on	similarities	
of	 BOS	 to	 NC-related	 disorders	 such	 as	 CHARGE	 syndrome	 or	 X-linked	 Opitz	
syndrome146,312,313	strongly	supports	my	in	vitro	and	in	vivo	results	on	the	impairment	of	
NC	 development	 by	 truncated	 ASXL1,	 and	 suggests	 that	 BOS	 should	 be	 considered	 a	
neurocristopathy.	With	respect	to	the	diversity	of	NC	derivatives	and	the	cooperation	of	
NC	 cells	with	 other	 lineages	 during	morphogenesis,	 abnormal	 development	 of	 the	NC	
results	in	organ	and	tissue	defects	with	highly	diverse	features146,	which	might	explain	
the	seemingly	unspecific	and	variable	features	reported	in	BOS	case	studies137.	Another	
interesting	aspect	 in	 this	context	 is	 the	transcriptional	regulation	of	ASXL1	 transcripts.	
While	 I	 noted	 that	 mutant	 transcripts	 escape	 NMD	 in	 BOS-iPSC,	 it	 is	 known	 that	 the	
degradation	 process	 is	 cell-	 and	 tissue-specific,	 and	 can	 largely	 modulate	 disease	
outcome255.	Generally,	when	a	 transcript	escapes	NMD,	 it	produces	 truncated	proteins	
that	exert	dominant	effects,	which	lead	to	phenotypes	that	are	more	severe	than	those	
caused	by	the	 loss	of	one	allele255.	These	mechanisms	could	account	 for	 the	variability	
between	 BOS	 patients,	 and	 are	 especially	 noteworthy	 in	 light	 of	 my	 findings	 on	
dissimilar	ASXL1	levels	in	BOS-iPSC	lines	that	were	derived	from	different	patients.	
Interestingly,	 mouse	 knockout	 phenotypes	 partly	 reflect	 clinical	 features	 of	 BOS.	 For	
example,	 both	 Asxl1	 Knockout	 mice	 and	 BOS	 patients	 display	 severely	 reduced	 birth	
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weight	and	size,	which	is	usually	re-gained	during	postnatal	development100,107,118,132,136.	
Eye	defects	that	I	and	others	noted	in	heterozygous	Asxl1+/-	mice	furthermore	correlate	
with	opththalmic	features	that	are	frequently	reported	in	BOS137.	Most	importantly,	the	
craniofacial	 malformations	 observed	 in	 homozygous	 Asxl1	 Null	 mice100	 hint	 towards	
perturbation	of	the	murine	NC	lineage	in	response	to	loss	of	Asxl1.	As	I	noted	decreased	
ASXL1	 levels	 in	my	homozygous	BOS	model	 upon	NC	differentiation,	 this	might	 argue	
towards	a	shared	pathogenic	mechanism	involving	reduction	of	ASXL1	levels.	While	the	
following	 hypothesis	 clearly	 warrants	 further	 examination,	 one	 plausible	 explanation	
that	 reconciles	 ASXL1	 loss-of-function-	 and	 truncation	 studies	 involves	 retention	 of	
H3K27me3	 (and	potentially	EZH2)	 at	 specific	 targets,	 including	 the	ASXL1/ASXL3	 loci,	
during	early	differentiation.	As	a	consequence,	expression	of	developmental	regulators	
and	 ASXL1/ASXL3	 are	 insufficient	 in	 the	 progress	 of	 induction	 and	 specification	 of	
affected	lineages.	Transcriptional	perturbations	should	thus	overlap	in	models	for	ASXL1	
loss/reduction	 and	 dominant	mutations,	 and	 lead	 to	 similar	 outcomes	 on	 the	 cellular	
level.	 Several	 lines	 of	 evidence	would	 be	 required	 to	 affirm	 this	 hypothesis,	 including	
genome-wide	 detection	 of	 ASXL1,	 EZH2	 and	 H3K27me3	 during	 differentiation	 from	
ASXL1	 mutant	 cultures,	 to	 show	 ASXL1PSC-mediated	 recruitment	 of	 the	 repressive	
complex	 to	 target	 genes,	 and	 importantly	 the	ASXL1	 locus.	 In	 a	more	 straightforward	
experiment,	 re-introduction	 of	 wildtype	 ASXL1	 into	 ASXL1PSC/PSC	 NC	 cultures	 should	
reveal	 whether	 increased	 ASXL1	 levels	 can	 rescue	 the	 differentiation	 phenotype,	 or	
whether	additional	dominant	effects	of	the	truncated	ASXL1	protein	would	prevent	this.	
My	results	obtained	in	ASXL1PSC/PSC	NC	cultures	may	also	explain	the	close	resemblance	
but	 milder	 severity	 of	 ASXL3-associated	 BRS	 compared	 to	 BOS,	 as	 truncated	 ASXL1	
negatively	 regulates	 ASXL3	 in	 tandem	 with	 ASXL1,	 implying	 a	 mechanistic	
correspondence.	 Despite	 significant	 phenotypic	 overlap,	 specific	 differences	 between	
the	 three	ASXL-related	 disorders	 lie	 in	 the	manifestation	 of	 microcephaly	 (BOS,	 BRS)	
versus	 macrocephaly	 (NDS),	 reduced	 (BOS,	 BRS)	 versus	 normal	 (NDS)	 height	 and	
weight,	severe	(BOS,	BRS)	versus	variable	intellectual	disabilities	(NDS),	presence	(BOS,	
NDS)	versus	absence	 (BRS)	of	 a	 facial	nevus	 flammeus	and	normal	 (NDS,	BRS)	versus	
specific	 (BOS)	 posture	 (Table	 2).	 These	 specifications	 indicate	 different	
neurodevelopmental	and	growth-related	roles	of	ASXL1/ASXL3	and	ASXL2,	supported	by	
expression	patterns	in	vitro	and	in	vivo	(Figs.	9F,	22A,	31A,C).	It	would	be	of	interest	to	
determine	whether	 truncated	 variants	 of	ASXL2	 and	ASXL3	 can	 also	 enhance	PR-DUB	
activity,	associating	a	unifying	molecular	mechanism	to	all	ASXL-related	disorders.		
Taken	 together,	my	study	has	 thus	uncovered	 initial	mechanisms	of	BOS	pathogenesis	
that	 involve	 NC	 defects,	 and	 taking	 into	 account	 the	 similarity	 between	 additional	
syndromes	 and	 the	 large	 homology	 between	 paralogs,	 my	 results	 may	 (partially)	 be	
applicable	to	other	NC	and	ASXL-associated	disorders.	The	latter	conditions,	as	I	suggest,	
join	 a	 group	 of	 neuronal	 disorders	 and	 intellectual	 disabilities	 arising	 from	
transcriptional	 deregulations,	 caused	 by	 heterozygous	 mutations	 in	 epigenetic	
modifiers,	 including	other	members	of	 the	Polycomb	 family144,256,314-316.	Future	studies	
will	 certainly	 uncover	 important	 functions	 of	 ASXL	 proteins	 in	 regulating	 chromatin	
processes	during	neuroectoderm	development.	
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Supplementary	 Figure	 S2.	 Detection	 of	 the	 alternatively	 spliced	 ‘NMD’-exon1	 between	
annotated	exons	2	and	3	of	human	ASXL3.	
	(A)	Sequence	of	‘NMD’	exon	based	on	sanger	sequencing	of	the	ASXL3	transcript	isolated	
from	hESC	treated	with	10	µM	RA.	Red	underlined	base	triplets	indicate	premature	STOP	
codons,	 bold	 letters	 denote	 additional	 base	 pairs	 within	 the	 transcript	 that	 were	
presumably	 spliced	 from	within	 the	 subsequent	 intron.	 (B)	Detection	 of	 ‘NMD-exon’	 by	
specific	 primer	 pair	 ‘Primer	 N-3’,	 in	 comparison	 to	 ‘Primer	 2-3’	 pair,	 which	 spans	 all	
transcripts,	including	and	excluding	the	additional	exon.	Samples	from	hESC	treated	with	
10	µM	RA	(n=2).	
A B 
ACCCCGGCATGGCTTGGAGACAGCGTTGGtGT
GTATGAAGGATCTTCCTCCAATGAAGGATTTGG
GACAACTTTCCATGATGATTATATTAGAGCCTC 
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Supplementary	 Figure	 S3.	 Preliminary	 ASXL1PSC-EZH2	 co-
immunoprecipitation	results.		
Western	Blot	of	immunoprecipitated	(IP)	EZH2	in	nuclear	extract	
samples	 from	 PB-ASXL1PSC	 neurospheres	 (day	 3)	 that	 were	 left	
untreated	 (-DOX)	or	 treated	 (+DOX)	 to	express	 truncated	ASXL1	
(red	 arrow).	 Antibodies	 towards	 ASXL1	 and	 EZH2,	 respectively,	
were	used	for	blotting	as	 indicated	on	the	 side;	FT,	 flow-through	
supernatant	after	IP.	Black	arrows	denote	a	putative	ASXL	isoform	
at	approximately	70	kDa.		
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Supplementary	 Figure	 S1.	
Detection	 of	 ASXL1	 in	 control	
hESC	 via	 Western	 Blot	 using	
monoclonal	antibody	clone	4F6.	
	Note	putative	ASXL1/2	band	at	
approximately	 170	 kDa	 (red	
arrow),	 and	 additional	 bands	
above	 300	 kDa	 (black	 arrow)	
and	at	70	kDa	(grey	arrow).	
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a.a.	 amino	acids	
ac	 acetylation	
ASX(L)	 Additional	sex	combs	(-like)	
BAP1	 BRCA1-associated	protein-1	
BMP	 Bone	Morphogenic	Protein	
BOS	 Bohring-Opitz	syndrome	
bp	 base	pair	
BRS	 Bainbridge-Ropers	syndrome	
Cas9	 Caspase	9	
cat.	#	 catalog	number	
cDNA	 Complementary	DNA	
ChIP	 Chromatin	Immunocprecipitation	
ChIP-qPCR	 Chromatin	Immunocprecipitation	paired	with	quantitative	real-time	PCR	
COMPASS	 Complex	proteins	Associated	with	Set	1	
CpG	 Cytosine-phosphate-Guanine	
CRISPR/Cas	 Clustered	Regularly	Interspaced	Short	Palindromic	Repeats/CRISPR	associated		
Ct	 Cycle	threshold	
DAPI	 4’,6-Diamidino-2-Phenylindole	
DMEM	 Dulbecco's	Modified	Eagle's	Medium	
DMSO	 Dimethyl	Sulfoxide	
Dox	 Doxycycline	
DTT	 Dithiothreitol	
EDTA	 Ethylenediaminetetraacetic	Acid	
eGFP	 enhanced	Green	Fluorescent	Protein	
EGTA	 Ethylene	Glycol-bis(β-aminoethyl	ether)-N,N,N',N'-Tetraacetic	Acid	
elfa	 elongation	factor	1	alpha		
EMT	 Epithelial-to-mesenchymal	transition	
ENCODE	 Encyclopedia	of	DNA	Elements	
FACS	 Fluorescence-Activated	Cell	Sorting	
FBS	 Fetal	Bovine	Serum	
FGF2	 Fibroblast	Growth	Factor	2	(basic	FGF,	bFGF)	
GAPDH	 Glyceraldehyde	3-phosphate	dehydrogenase	
GO-term	 Gene	Ontology	term	
GRN	 gene	regulatory	network	
gRNA	 Guide	RNA	
H2AK119	 Histone	2	Lysine	119	
H3K4/9/27	 Histone	3	Lysine	4/9/27	
HAT	 Histone	Acetyl	Transferase	
HDAC	 Histone	Deacethylase	
hESC	 	human	Embryonic	Stem	Cells	
hiPSC	 human	induced	pluripoten	stem	cell	
HP1	 Heterochromatin	Protein	1	(CBX5)	
HRP	 horseradish	peroxidase	
iCas9	hESC	 HUES9	hESC	harboring	the	inducible	Caspase	9	endonuclease	
IgG	 Immunoglobulin	G	
IP	 Immunoprecipitation	
kb	 kilo	bases	
KSR	 Knockout	Serum	Replacement	
LSD1	 Lysine-specific	histone	demethylase	1a	(KDM1A)	
me1	 Mono-Methylation	
me2	 Di-Methylation	
me3	 Tri-Methylaion	
MLL	 Mixed	Lineage	Leukemia	
mRNA	 messenger	RNA	
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NC	 Neural	crest	
NCOA1	 Nuclear	Receptor	Co-Activator	1	
NDS	 neurodevelopmental	syndrome	
NEAA	 Non	Essential	Amino	Acids	
NEB	 New	England	Biolabs	
NPB	 neural	plate	border	
NR	 Nuclear	Receptor	
PBS	 Phosphate-buffered	saline	
PBS-T	 Phosphate-	buffered	saline	containing	Tween-20	
PCA	 Principal	Component	Analysis	
PcG	 Polycomb	group	
PCGF	 Polycomb	group	ring	finger	
PHD	 Plant	Homeodomain	
PMSF	 Phenylmethane	Sulfonyl	Fluoride	
PPARγ	 peroxisome	proliferater-activated	receptor	γ		
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